data_2kv8_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kv8 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.406 HG23 HD23 ' A' ' 48' ' ' LEU . 25.2 t . . . . . 0 C--O 1.234 0.255 0 CA-C-O 120.687 0.279 . . . . 0.0 111.152 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -134.93 174.5 10.53 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.349 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 m -118.9 149.75 41.05 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.312 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.6 t -129.65 134.17 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.079 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -105.41 103.68 13.25 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.6 t -95.64 129.47 45.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.807 0.337 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -91.43 90.94 7.89 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.284 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -55.3 123.49 13.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.734 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.05 -103.17 0.1 OUTLIER Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.241 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.14 -46.4 1.94 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.536 0.208 . . . . 0.0 111.164 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -103.76 31.69 4.31 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.692 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.69 -126.77 8.3 Favored Glycine 0 C--N 1.336 0.556 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.745 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -132.88 -64.97 0.73 Allowed 'General case' 0 C--O 1.231 0.103 0 CA-C-O 120.733 0.302 . . . . 0.0 111.076 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.0 -34.53 1.31 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.925 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -65.18 179.47 0.72 Allowed 'General case' 0 CA--C 1.532 0.256 0 CA-C-O 121.064 0.459 . . . . 0.0 111.569 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.8 144.06 49.43 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.264 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.79 128.01 45.92 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.197 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 46.3 m -150.47 106.78 3.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.674 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -163.18 76.11 0.17 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.446 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -45.68 -44.71 13.63 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.736 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.547 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -114.33 -64.47 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.263 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.197 178.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.547 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 84.4 Cg_endo -89.42 91.51 0.36 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.791 2.327 . . . . 0.0 112.008 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 72.6 m -50.32 121.48 5.68 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.731 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.0 p -147.14 146.06 18.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.871 0.367 . . . . 0.0 111.724 -179.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.31 92.41 5.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.476 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.9 m -46.54 -46.29 19.22 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.867 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.0 t -171.3 158.41 5.36 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 111.431 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 50.6 t -122.13 153.23 26.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.619 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.6 mmt -103.3 100.81 10.72 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.076 0.465 . . . . 0.0 110.574 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 5.7 ptt180 -45.49 120.12 2.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.971 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 120.19 -17.81 9.73 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.542 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.415 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -85.59 166.77 28.33 Favored Pre-proline 0 CA--C 1.533 0.312 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.352 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.415 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 15.0 Cg_endo -57.13 -22.55 48.42 Favored 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 122.667 2.245 . . . . 0.0 112.748 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -68.83 -48.73 62.78 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.72 0.295 . . . . 0.0 110.913 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.36 -27.12 65.98 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.302 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-30 -57.54 -26.34 61.23 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.59 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 15.7 t -89.39 -39.39 12.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 120.794 0.33 . . . . 0.0 111.013 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 129.08 44.61 0.2 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.088 -0.577 . . . . 0.0 112.83 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.8 mt -85.22 140.9 30.52 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.788 0.328 . . . . 0.0 110.366 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.9 mtt180 -141.14 119.68 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.584 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -41.22 126.64 2.73 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.637 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.17 -26.37 5.56 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.148 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.97 114.17 3.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-O 120.661 0.267 . . . . 0.0 110.571 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -73.37 128.57 35.85 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.529 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 20.6 mt -80.93 120.17 32.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.007 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.406 HD23 HG23 ' A' ' 3' ' ' VAL . 9.3 mp -101.52 -46.7 4.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.053 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.433 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.26 139.39 52.94 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.257 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 8.8 t -132.46 111.61 17.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.003 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.405 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 77.33 29.98 0.54 Allowed 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 82.54 -2.53 1.38 Allowed 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.412 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.4 pt -114.21 132.19 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 111.487 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.433 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.6 OUTLIER -63.23 156.15 26.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.714 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 m -149.36 55.32 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.614 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -58.62 -43.25 89.6 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.723 0.297 . . . . 0.0 110.854 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -141.73 38.55 1.66 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -72.75 -178.15 2.59 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.592 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.35 137.89 32.22 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.398 0.618 . . . . 0.0 111.08 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -52.67 -43.92 65.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.942 -1.026 . . . . 0.0 111.913 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 58.1 mt-10 -65.63 -39.3 91.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.008 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -67.25 -39.37 86.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.709 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.4 t -67.44 -42.34 87.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.745 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.7 t -65.67 -39.1 83.92 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.184 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.8 mtpp -57.74 -38.95 76.24 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.3 mt -68.3 -42.54 79.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.684 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.405 ' HA ' HD23 ' A' ' 74' ' ' LEU . 6.8 mt -67.47 -36.9 77.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.884 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -81.66 10.62 50.28 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.342 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 ttpt -114.16 -5.82 13.04 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.623 0.369 . . . . 0.0 111.2 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . 0.406 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 14.0 p -47.8 -48.78 30.28 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 122.488 0.315 . . . . 0.0 111.752 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.9 t 65.65 33.34 8.5 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.069 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.16 -33.3 1.72 Allowed Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.275 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.406 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 8.0 p -172.68 138.0 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-O 121.0 0.428 . . . . 0.0 111.784 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 67' ' ' ILE . 9.1 tp -114.45 147.28 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.222 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -108.97 99.23 8.59 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.419 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.43 135.04 47.55 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.959 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.9 t -108.75 99.44 8.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.762 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -111.07 164.92 6.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.358 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.38 130.9 48.39 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.241 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.234 0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.989 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 29.9 t . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.71 0.291 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 -131.89 160.77 34.75 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.497 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.2 p -101.59 131.34 47.84 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.178 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 14.2 t -116.37 131.55 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.808 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -100.99 111.77 24.05 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.728 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.411 HG11 ' HB3' ' A' ' 15' ' ' TYR . 16.2 t -97.67 114.41 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.349 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.77 92.42 9.2 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.782 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.475 ' HG3' ' CE1' ' A' ' 15' ' ' TYR . 9.7 ttt180 -51.6 127.43 20.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.738 -0.664 . . . . 0.0 111.188 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.81 20.91 25.77 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.684 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.45 0.38 3.44 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 117.118 0.459 . . . . 0.0 111.907 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.01 24.0 1.67 Allowed 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 120.83 0.348 . . . . 0.0 111.105 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.69 -162.11 23.76 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.705 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.475 ' CE1' ' HG3' ' A' ' 10' ' ' ARG . 64.6 m-85 -131.7 -43.98 0.99 Allowed 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.36 -13.48 7.87 Favored Glycine 0 CA--C 1.522 0.507 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.18 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -108.52 174.28 5.94 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 117.039 0.419 . . . . 0.0 111.386 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.0 m -130.0 142.86 50.58 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.684 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.19 124.48 42.55 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.302 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.2 m -150.29 159.17 44.65 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.4 -29.52 2.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 121.055 -0.593 . . . . 0.0 113.157 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 64.11 21.27 12.52 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.417 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . 179.58 -63.8 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.282 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.417 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 91.0 Cg_endo -79.25 85.53 1.84 Allowed 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 122.52 2.147 . . . . 0.0 111.561 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 61.2 m -52.88 110.6 0.54 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.578 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -144.62 147.52 19.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.536 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.446 ' CD2' ' HB3' ' A' ' 41' ' ' LEU . 7.1 mp -74.4 90.8 2.18 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.3 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -43.78 61.95 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.614 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -171.17 158.09 5.36 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.984 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 14.7 t -135.77 153.34 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.92 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 16.3 ptp -104.52 105.12 15.11 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.271 0.558 . . . . 0.0 110.745 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.5 mtt180 -46.68 123.09 4.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.096 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.28 16.29 10.55 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 121.132 -0.556 . . . . 0.0 112.961 -179.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.8 164.87 17.74 Favored Pre-proline 0 C--O 1.234 0.247 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.19 -27.83 31.41 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 122.767 2.312 . . . . 0.0 112.606 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.32 -49.92 51.33 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.99 -35.23 79.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.239 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 m-30 -56.18 -32.95 64.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.714 -179.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.33 -35.05 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.62 0.247 . . . . 0.0 110.964 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.87 43.21 0.17 Allowed Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.152 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.446 ' HB3' ' CD2' ' A' ' 27' ' ' LEU . 63.5 mt -108.23 121.08 44.15 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.506 0.193 . . . . 0.0 110.53 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.92 -152.66 0.5 Allowed 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.988 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.22 130.06 44.95 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.812 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 113.68 -27.43 9.29 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.918 -0.658 . . . . 0.0 113.188 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -58.03 120.47 8.62 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.927 0.363 . . . . 0.0 111.077 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.7 125.59 30.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.741 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 23.8 mt -85.86 126.36 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.711 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.9 mp -108.22 -71.49 0.76 Allowed 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -97.07 126.89 42.53 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.756 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.0 t -119.64 103.38 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.302 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.415 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.5 t-20 76.46 31.75 0.59 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.705 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 85.01 -4.19 0.92 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.783 179.68 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.1 pp -110.58 131.96 60.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-O 120.94 0.4 . . . . 0.0 111.656 179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -71.58 145.28 49.14 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.604 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.2 m -146.11 61.14 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.376 179.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.1 -46.94 68.9 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.058 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 3.5 mtpp -140.13 37.68 1.93 Allowed 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.977 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.79 -174.96 2.32 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.446 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.8 m -91.2 145.67 24.48 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.641 0.734 . . . . 0.0 111.103 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -61.68 -44.52 96.8 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.547 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -58.84 -43.2 90.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.882 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -64.24 -44.08 92.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.492 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.402 ' HA ' HD12 ' A' ' 66' ' ' LEU . 67.5 t -64.64 -40.79 90.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.059 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.3 t -65.69 -38.84 83.25 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.37 -40.88 79.07 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.901 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.402 HD12 ' HA ' ' A' ' 63' ' ' VAL . 7.3 mt -67.27 -42.07 84.44 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.643 179.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 9.8 mt -68.03 -39.33 81.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -80.04 11.17 37.02 Favored Glycine 0 CA--C 1.524 0.595 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.585 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.21 -8.12 13.55 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.441 0.296 . . . . 0.0 111.24 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . 0.432 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 24.9 p -48.49 -49.91 33.87 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.825 0.345 . . . . 0.0 111.798 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.1 t 66.33 33.42 7.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.002 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.83 -37.41 0.95 Allowed Glycine 0 C--N 1.334 0.464 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.008 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.432 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 8.1 p -171.12 137.39 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.998 0.427 . . . . 0.0 111.922 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.406 ' N ' HG22 ' A' ' 73' ' ' VAL . 1.2 pp -112.38 155.41 24.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.363 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 68.7 m80 -110.92 98.34 7.49 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.268 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 3.0 ttm -105.07 122.74 46.52 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.052 -179.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.3 t -101.06 100.44 10.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.566 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 6.5 pt -102.53 171.76 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.427 -179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -143.13 148.04 35.94 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.416 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 . . . . . 0 C--O 1.232 0.161 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.668 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 CA--C 1.53 0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -137.35 162.59 33.16 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.219 -179.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.28 141.43 37.63 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.175 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.7 t -126.9 139.28 52.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.295 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -107.86 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.512 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.7 t -99.08 112.87 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-O 120.862 0.363 . . . . 0.0 111.187 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.79 88.82 7.42 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.343 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.471 ' HB3' ' O ' ' A' ' 71' ' ' SER . 2.1 ttt-85 -48.19 124.75 8.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.181 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.49 -87.81 0.14 Allowed Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.701 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.17 -55.85 0.45 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.615 0.245 . . . . 0.0 111.316 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.79 30.57 6.98 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.98 151.14 5.44 Favored Glycine 0 C--N 1.333 0.378 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.39 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.445 ' CE2' ' HG3' ' A' ' 10' ' ' ARG . 39.1 m-85 -77.43 -33.42 54.89 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-O 120.568 0.223 . . . . 0.0 111.086 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.84 61.77 0.83 Allowed Glycine 0 C--N 1.335 0.498 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.567 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -168.93 175.93 5.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 111.063 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -119.04 116.71 26.98 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.392 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -105.97 132.41 52.09 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.801 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.462 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 36.8 p -147.45 -176.68 5.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.819 179.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 109.4 82.27 1.35 Allowed Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 121.033 -0.604 . . . . 0.0 112.05 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.1 tp60 -45.37 -53.44 8.6 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.843 0.354 . . . . 0.0 110.594 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.521 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -98.68 -62.93 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.94 178.395 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.521 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 97.3 Cg_endo -88.11 91.85 0.45 Allowed 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.872 2.381 . . . . 0.0 112.128 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.3 p -54.73 119.78 5.83 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.659 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.5 p -141.4 151.48 19.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.83 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -81.6 91.31 6.37 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.17 -43.87 52.51 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.493 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.3 t -167.23 158.58 12.06 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.367 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.4 t -119.1 154.76 21.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.341 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 41.8 mtp -98.41 101.38 12.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 121.036 0.446 . . . . 0.0 110.33 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -50.82 124.48 11.2 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.859 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 22.87 10.97 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.488 -179.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.37 165.08 26.39 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.411 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 9.4 Cg_endo -52.59 -28.06 35.3 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.726 2.284 . . . . 0.0 112.869 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -65.36 -49.84 67.83 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.782 0.325 . . . . 0.0 110.829 179.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.36 -31.25 68.43 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.397 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.411 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.4 m-30 -61.36 -23.95 66.13 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.419 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 t -89.08 -33.73 6.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 CA-C-O 120.758 0.313 . . . . 0.0 111.167 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.45 42.51 0.31 Allowed Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.874 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -75.18 178.49 5.71 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.644 0.259 . . . . 0.0 110.62 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -171.04 130.18 0.77 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.219 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.18 111.72 3.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.479 179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 129.91 -23.96 4.62 Favored Glycine 0 CA--C 1.523 0.582 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.839 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.45 115.65 3.13 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.651 0.263 . . . . 0.0 110.518 179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.64 120.3 19.99 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.832 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 24.2 mt -78.05 124.15 35.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.537 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.2 mt -105.67 -46.46 4.15 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.776 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.532 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.5 140.43 51.45 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.996 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.9 t -134.44 110.06 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 76.65 33.56 0.49 Allowed 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -178.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 77.32 -1.86 2.68 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 112.688 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.456 HD12 HD23 ' A' ' 66' ' ' LEU . 5.0 pt -113.04 122.77 67.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 121.063 0.459 . . . . 0.0 111.315 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.532 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 6.9 t30 -63.4 128.16 34.57 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.339 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 m -136.33 54.18 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.22 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.4 mmmt -65.9 -30.0 70.52 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.25 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.4 mmtt -132.37 29.76 4.24 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.61 0.243 . . . . 0.0 111.129 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -81.75 -179.51 7.41 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.857 0.36 . . . . 0.0 111.405 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.9 m -86.18 145.26 27.07 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.58 0.705 . . . . 0.0 111.011 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 20' ' ' SER . 1.7 t-160 -59.1 -44.87 91.99 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.485 -1.234 . . . . 0.0 111.473 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.02 -38.72 89.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.546 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -42.55 92.43 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 65.2 t -65.53 -41.74 91.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.001 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 46.6 t -65.82 -38.92 83.31 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 178.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -43.09 85.72 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.234 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.456 HD23 HD12 ' A' ' 53' ' ' ILE . 56.0 mt -64.53 -41.03 96.62 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.764 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.441 ' HA ' HD21 ' A' ' 74' ' ' LEU . 44.1 mt -66.35 -43.43 91.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.499 179.383 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.64 -21.94 63.41 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.72 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.81 -34.93 72.25 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.527 0.203 . . . . 0.0 111.531 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.95 99.59 10.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.487 0.66 . . . . 0.0 110.254 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.471 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 30.3 t -88.99 -33.77 17.08 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.758 -1.11 . . . . 0.0 111.221 -179.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -65.12 -43.03 96.21 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.174 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.91 138.93 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 120.751 0.31 . . . . 0.0 111.44 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.441 HD21 ' HA ' ' A' ' 67' ' ' ILE . 0.2 OUTLIER -94.19 146.5 23.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.318 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -131.44 102.82 6.1 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.864 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.09 154.66 44.42 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.808 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.6 t -109.43 112.74 41.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.704 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.6 pp -107.24 172.18 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.387 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -145.94 129.17 16.7 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.258 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.234 0.28 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.031 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.235 0.342 0 CA-C-O 120.701 0.286 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.5 ptt-85 -153.34 166.42 32.68 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.24 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.6 m -118.16 140.96 49.01 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.2 t -115.3 138.39 45.78 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.329 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -110.69 105.78 14.78 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.987 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 73' ' ' VAL . 10.5 t -100.39 133.26 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.288 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.68 98.73 9.25 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.942 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.526 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.4 OUTLIER -53.35 126.07 19.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.978 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.82 15.14 44.29 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.706 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.8 mmt85 74.01 0.24 3.55 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.985 0.392 . . . . 0.0 111.753 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -146.28 25.57 1.23 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-O 120.77 0.319 . . . . 0.0 111.147 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 136.47 175.44 13.81 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.692 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.526 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 35.5 m-85 -114.26 -69.57 0.85 Allowed 'General case' 0 C--O 1.232 0.141 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.81 -22.25 1.8 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.988 -0.625 . . . . 0.0 113.226 -179.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.4 p90 -95.81 137.76 34.43 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.905 0.353 . . . . 0.0 110.777 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -98.08 133.25 42.8 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.201 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.0 mt -117.29 133.26 56.19 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.462 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.5 m -149.88 166.63 28.96 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.128 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.47 -34.22 4.89 Favored Glycine 0 C--N 1.336 0.568 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.897 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.515 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 79.91 -49.85 0.37 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.359 0.663 . . . . 0.0 111.552 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.436 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -97.79 -64.93 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.483 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.436 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 99.0 Cg_endo -79.74 94.86 1.03 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.402 2.068 . . . . 0.0 112.478 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 85.6 m -59.65 111.61 1.49 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.184 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -146.93 143.21 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.273 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -79.2 91.46 4.97 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.671 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.1 m -54.96 -37.64 66.75 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.347 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.2 t -167.15 155.61 9.8 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.921 0.391 . . . . 0.0 111.273 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.4 t -112.5 155.17 13.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.558 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mmt -103.31 101.92 11.86 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 121.003 0.43 . . . . 0.0 110.636 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.4 mtt85 -51.73 124.4 12.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.764 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.68 3.61 37.14 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.717 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.407 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.6 OUTLIER -108.13 167.06 9.82 Favored Pre-proline 0 C--O 1.233 0.211 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.512 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 9.8 Cg_endo -51.57 -29.51 32.54 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.924 2.416 . . . . 0.0 112.712 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.7 -49.36 73.44 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.024 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.13 -34.27 77.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -60.94 -26.79 67.76 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.492 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 t -89.56 -30.41 5.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-O 120.661 0.267 . . . . 0.0 111.144 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.06 47.11 0.67 Allowed Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.8 tp -80.22 156.45 26.88 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.965 0.412 . . . . 0.0 110.782 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.8 mmm180 -146.28 117.79 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -53.41 152.15 5.0 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.739 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.71 -28.95 13.66 Favored Glycine 0 CA--C 1.521 0.427 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.344 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -59.68 121.9 12.8 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 122.876 0.47 . . . . 0.0 111.438 179.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -78.37 130.56 36.28 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.079 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.3 mt -84.7 127.81 39.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.002 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -106.42 -43.27 4.8 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.428 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -129.95 137.2 50.21 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.504 -0.317 . . . . 0.0 111.41 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.447 ' O ' HG13 ' A' ' 53' ' ' ILE . 3.9 t -136.91 113.03 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.338 179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 76.64 31.66 0.57 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 79.15 -5.01 2.02 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.581 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 50' ' ' VAL . 1.2 pp -112.2 124.97 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-O 121.104 0.478 . . . . 0.0 111.343 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.552 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -66.19 131.41 46.1 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.307 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.5 m -129.05 53.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.309 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -55.41 -55.4 32.12 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.281 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.3 mttm -127.19 32.62 5.03 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.911 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.49 -176.84 3.88 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -85.69 133.88 34.0 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.511 0.672 . . . . 0.0 110.81 179.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.515 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 5.0 t60 -56.9 -44.31 82.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.811 -1.086 . . . . 0.0 111.882 -179.528 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.443 ' HA ' HG21 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -66.48 -33.84 76.6 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.912 179.706 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.56 -42.18 68.14 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.068 178.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 56.9 t -63.86 -44.02 97.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.083 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.443 HG21 ' HA ' ' A' ' 61' ' ' GLU . 28.6 m -66.14 -39.3 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -57.93 -42.44 84.86 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.956 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.9 mt -62.31 -43.87 97.83 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.401 HG22 ' CE2' ' A' ' 15' ' ' TYR . 53.3 mt -66.59 -41.62 88.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.677 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.38 -1.17 74.72 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.848 -0.692 . . . . 0.0 113.256 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -83.03 -34.76 26.19 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.027 0.413 . . . . 0.0 111.492 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.75 -57.3 9.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.809 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.8 34.76 5.36 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.974 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.8 -45.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.366 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 7.6 p -169.05 138.48 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-O 120.841 0.353 . . . . 0.0 111.726 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.405 ' N ' HG21 ' A' ' 73' ' ' VAL . 10.7 tp -114.33 141.87 47.05 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.26 179.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -125.27 98.41 5.63 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.977 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 15.1 ptt? -116.67 154.84 29.86 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.391 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.0 t -111.98 109.21 27.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.878 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.1 pt -102.06 163.67 3.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.509 -179.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.26 116.0 18.47 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.9 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 . . . . . 0 CA--C 1.53 0.174 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.33 -179.555 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.463 0.183 0 CA-C-O 120.719 0.295 . . . . 0.0 110.936 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -150.22 174.08 13.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.377 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -118.76 137.41 53.39 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 42.3 t -114.59 139.33 41.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.114 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -115.04 110.1 19.07 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.861 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 5.9 t -95.9 130.31 44.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.027 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.5 93.13 8.39 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.964 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 -39.38 122.7 1.34 Allowed 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.555 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.31 -90.65 0.07 OUTLIER Glycine 0 C--N 1.333 0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.907 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 ptt85 -134.98 -47.37 0.73 Allowed 'General case' 0 C--O 1.233 0.196 0 N-CA-C 111.578 0.214 . . . . 0.0 111.578 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.49 40.43 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.528 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.28 -173.96 21.43 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.826 -0.702 . . . . 0.0 113.178 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -96.56 -71.93 0.66 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.653 0.263 . . . . 0.0 111.463 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.71 -39.34 0.61 Allowed Glycine 0 CA--C 1.519 0.323 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.785 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -71.62 179.93 2.85 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.691 0.282 . . . . 0.0 111.122 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 m -135.3 151.03 50.16 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.356 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 mt -124.97 131.06 53.48 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.942 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.7 p -148.06 157.77 43.69 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 120.713 0.292 . . . . 0.0 111.561 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 126.26 -25.73 5.39 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 121.213 -0.518 . . . . 0.0 113.027 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.587 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 61.81 14.24 6.07 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.736 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.428 ' CB ' ' CD ' ' A' ' 24' ' ' PRO . . . -166.87 -65.79 0.01 OUTLIER Pre-proline 0 N--CA 1.463 0.224 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.428 ' CD ' ' CB ' ' A' ' 23' ' ' ALA . 73.8 Cg_endo -74.39 83.68 1.66 Allowed 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.381 2.054 . . . . 0.0 111.361 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.5 m -52.23 108.45 0.29 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.3 p -143.22 141.37 26.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.54 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 mp -78.98 91.95 4.89 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.408 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.24 -42.98 42.33 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.408 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.9 t -171.07 157.1 5.06 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.964 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -120.42 155.56 23.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.655 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.0 mtp -97.83 102.29 14.01 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.224 0.535 . . . . 0.0 110.572 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.34 121.6 5.17 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.967 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.21 -18.32 23.54 Favored Glycine 0 CA--C 1.522 0.499 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.291 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.79 166.74 34.16 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.654 0.227 . . . . 0.0 110.521 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -53.14 -26.74 34.32 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.101 2.534 . . . . 0.0 113.166 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -65.5 -42.27 92.3 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.53 -26.65 63.67 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.375 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -55.31 -25.59 35.37 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 111.668 0.247 . . . . 0.0 111.668 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.46 -32.51 5.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 120.612 0.244 . . . . 0.0 111.122 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.77 41.65 1.68 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.454 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.5 mt -74.79 -178.28 3.62 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.628 0.251 . . . . 0.0 110.346 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 -163.85 122.79 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.402 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -47.26 125.25 7.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.97 179.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.53 -25.66 5.89 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.595 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -56.91 122.62 12.69 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 121.018 0.437 . . . . 0.0 110.946 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.6 mp0 -76.98 117.78 18.91 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.062 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 14.0 mt -81.76 121.49 35.18 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.899 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mp -108.44 -40.59 5.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.086 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.472 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.8 133.08 55.33 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.99 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.4 t -135.3 111.29 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.22 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 76.28 32.62 0.58 Allowed 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.294 0.568 . . . . 0.0 109.717 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 76.82 -3.35 2.53 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.089 -0.96 . . . . 0.0 112.784 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.403 HG13 ' O ' ' A' ' 50' ' ' VAL . 1.1 pt -116.12 125.92 73.4 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-O 120.834 0.349 . . . . 0.0 111.16 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.472 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 18.4 p-10 -64.95 135.91 56.21 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.473 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.0 m -134.2 59.0 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.902 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 46.4 mttt -48.48 -71.44 0.07 Allowed 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.921 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 35.6 mttp -119.81 39.87 3.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.664 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -73.86 -174.87 1.94 Allowed 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.933 -179.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.99 136.24 33.12 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 121.489 0.661 . . . . 0.0 110.678 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.587 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 5.1 t60 -53.99 -44.48 70.87 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.279 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -61.17 -41.81 97.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.788 0.327 . . . . 0.0 110.737 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -66.3 -41.45 89.71 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.5 t -65.93 -39.13 83.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.606 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.5 t -65.75 -39.02 83.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 178.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -57.42 -41.26 80.05 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.887 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.2 mt -64.14 -43.62 94.66 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.46 179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 52.0 mt -66.84 -37.47 79.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.623 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -79.31 8.56 45.94 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.444 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.54 1.91 15.16 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 122.448 0.299 . . . . 0.0 110.781 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . 0.408 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 16.0 p -50.98 -44.73 60.78 Favored 'General case' 0 C--O 1.233 0.212 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.487 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.9 m 67.21 30.82 7.01 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.065 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.9 -30.93 2.78 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.152 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.408 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.1 p -163.84 138.0 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.047 0.451 . . . . 0.0 112.193 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 41.4 tp -114.35 150.41 34.59 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.164 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.4 m80 -120.01 105.82 11.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.344 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -115.45 137.18 52.32 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.168 -179.381 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 20.6 t -107.34 105.75 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.767 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -106.82 170.64 2.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.461 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -130.41 154.78 47.36 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.571 -179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.234 0.239 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.794 179.724 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.5 p . . . . . 0 C--O 1.233 0.232 0 CA-C-O 120.78 0.324 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -130.81 145.09 51.88 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.244 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -110.44 132.66 53.99 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.664 179.484 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 37.1 t -118.33 141.1 39.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.554 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -128.66 100.8 5.87 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.794 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 19.5 t -95.56 144.62 9.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-O 120.969 0.414 . . . . 0.0 111.533 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -115.14 106.44 14.09 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.625 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.7 ttt180 -50.62 120.09 4.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.12 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.97 -61.92 5.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.392 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -150.7 -76.29 0.14 Allowed 'General case' 0 C--O 1.231 0.127 0 CA-C-O 120.613 0.244 . . . . 0.0 110.564 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.39 26.46 9.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.508 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.6 173.95 46.52 Favored Glycine 0 C--N 1.336 0.57 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.897 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -111.13 -77.24 0.59 Allowed 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 120.706 0.289 . . . . 0.0 110.922 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.53 45.32 0.04 OUTLIER Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.968 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -159.03 176.77 11.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.442 0.163 . . . . 0.0 110.713 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -140.9 150.38 43.11 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.628 0.252 . . . . 0.0 111.268 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.8 mt -120.98 131.48 54.33 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.568 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.7 m -147.08 163.0 37.67 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.258 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.61 -30.65 5.07 Favored Glycine 0 C--N 1.336 0.554 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.983 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.485 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 80.97 -44.73 0.22 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.443 0.697 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.464 ' CB ' ' CD ' ' A' ' 24' ' ' PRO . . . -111.04 -68.26 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.512 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.464 ' CD ' ' CB ' ' A' ' 23' ' ' ALA . 64.0 Cg_endo -73.73 95.72 0.89 Allowed 'Trans proline' 0 C--N 1.356 0.952 0 C-N-CA 122.26 1.974 . . . . 0.0 112.446 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 84.7 m -61.73 118.5 7.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.218 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.31 145.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.86 90.99 2.95 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-O 120.846 0.355 . . . . 0.0 110.507 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.6 m -54.67 -36.67 64.86 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.417 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.2 t -164.52 157.94 17.66 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.031 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -122.54 154.61 27.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.903 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -97.45 101.28 12.78 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.279 0.561 . . . . 0.0 110.216 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -51.87 121.59 6.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.122 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.86 27.97 8.07 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.193 -0.527 . . . . 0.0 112.525 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.2 m -129.36 164.63 38.23 Favored Pre-proline 0 C--N 1.332 -0.194 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.68 -25.12 25.27 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 122.865 2.376 . . . . 0.0 112.902 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.19 -49.98 65.45 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.815 0.341 . . . . 0.0 110.704 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.03 -25.98 65.64 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.168 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.1 m-30 -57.03 -30.18 64.0 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.599 0.238 . . . . 0.0 111.388 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.8 t -89.28 -25.92 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.253 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.84 5.4 6.94 Favored Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.348 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 mp -64.67 111.45 2.76 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 117.315 0.557 . . . . 0.0 109.675 179.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -122.97 25.97 8.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.51 -179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . 72.92 159.27 0.22 Allowed 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.947 0.404 . . . . 0.0 111.636 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.15 -39.66 3.05 Favored Glycine 0 C--N 1.334 0.46 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.678 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -52.3 119.91 4.94 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.917 0.389 . . . . 0.0 110.843 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -75.22 126.22 30.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.031 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.3 mt -83.09 120.29 34.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.819 179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.4 mp -105.2 -32.87 8.45 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.624 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -137.09 137.45 39.3 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 111.018 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 6.3 t -132.25 108.15 13.39 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.407 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 4.8 t-20 77.39 33.59 0.4 Allowed 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.417 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.407 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.52 -1.08 3.1 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.517 -179.621 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.44 HD13 HD23 ' A' ' 66' ' ' LEU . 9.0 pt -113.14 119.63 61.1 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 111.176 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.476 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 10.9 m120 -62.08 120.63 11.22 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.149 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.9 m -135.14 33.71 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.747 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -61.4 -28.43 69.25 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -123.55 26.83 7.65 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 120.544 0.211 . . . . 0.0 111.3 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -92.27 -178.96 5.1 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.765 0.317 . . . . 0.0 111.505 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.23 135.36 36.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.362 0.601 . . . . 0.0 110.736 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.485 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 4.0 t60 -54.79 -44.24 73.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.927 -1.033 . . . . 0.0 111.978 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.46 ' HA ' HG23 ' A' ' 64' ' ' VAL . 20.9 mt-10 -65.64 -35.87 82.06 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.779 0.323 . . . . 0.0 110.567 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.29 -39.38 71.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.167 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.8 t -67.43 -42.31 87.09 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.162 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.46 HG23 ' HA ' ' A' ' 61' ' ' GLU . 31.4 m -65.93 -38.6 82.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.9 tttp -57.48 -40.31 78.3 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.697 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.44 HD23 HD13 ' A' ' 53' ' ' ILE . 21.2 mt -67.63 -42.42 82.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.736 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 9.5 mt -69.33 -38.38 77.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.996 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -60.1 -24.65 61.1 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.318 179.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -80.27 4.43 17.73 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.902 0.334 . . . . 0.0 111.902 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -106.18 104.01 13.62 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.356 0.598 . . . . 0.0 110.109 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.2 33.43 5.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.987 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.93 -53.91 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.088 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 p -172.03 130.96 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-O 120.99 0.424 . . . . 0.0 111.8 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -114.5 151.62 32.99 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.546 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 19.7 m170 -116.39 107.09 14.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.211 179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -108.74 145.76 34.61 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.03 -179.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.5 t -117.1 98.88 7.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 179.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 24.8 pt -101.62 172.1 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.479 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.57 146.84 52.22 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.12 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 . . . . . 0 C--O 1.232 0.16 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.118 179.912 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.07 0.462 . . . . 0.0 111.26 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 6.9 tpt180 -114.18 139.27 49.5 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.844 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.81 131.06 57.05 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.182 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.6 t -120.91 131.49 72.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.693 0.282 . . . . 0.0 110.826 179.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -116.7 115.25 25.29 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.009 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 12.2 t -108.57 138.58 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.787 0.327 . . . . 0.0 111.435 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.3 93.89 8.87 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.397 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.441 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 4.0 ttt-85 -51.81 126.41 17.9 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.445 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.92 -112.67 0.03 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.687 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -111.27 -39.33 4.75 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.468 0.175 . . . . 0.0 111.329 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -138.75 35.13 2.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.337 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 159.96 -170.45 36.1 Favored Glycine 0 C--N 1.338 0.65 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.731 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.441 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 71.5 m-85 -118.63 -69.42 0.85 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.865 0.364 . . . . 0.0 111.161 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.16 52.49 0.04 OUTLIER Glycine 0 C--N 1.332 0.315 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.317 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -162.99 155.47 18.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.549 0.214 . . . . 0.0 110.952 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.14 129.13 43.52 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.932 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -116.57 124.37 49.68 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.993 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 39.2 m -148.07 115.58 6.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.177 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -168.1 83.28 0.1 OUTLIER Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.49 -179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.25 -43.07 21.68 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.972 0.415 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.518 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -121.25 -66.69 0.02 OUTLIER Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.455 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.518 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 92.3 Cg_endo -85.23 94.88 0.64 Allowed 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 122.475 2.117 . . . . 0.0 112.214 179.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 2.6 m -51.87 117.66 2.89 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.822 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -141.51 149.41 20.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.378 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.46 91.49 5.74 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.741 179.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.08 -45.38 61.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.517 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 3.5 t -164.4 159.06 19.21 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 t -116.9 155.03 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.714 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -99.5 100.76 11.83 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.153 0.501 . . . . 0.0 110.278 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.3 mtm-85 -52.07 125.94 17.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.943 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.91 23.64 11.46 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.682 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.86 168.92 14.29 Favored Pre-proline 0 CA--C 1.531 0.218 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -50.66 -29.93 27.11 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.885 2.39 . . . . 0.0 113.051 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.444 ' CB ' HD22 ' A' ' 41' ' ' LEU . . . -65.09 -49.82 68.51 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 111.014 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -69.43 -32.79 71.98 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.243 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 16.7 m-30 -62.77 -23.78 67.38 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.455 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 38.8 t -89.32 -29.6 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.58 0.229 . . . . 0.0 111.246 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.89 39.96 0.86 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.717 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.444 HD22 ' CB ' ' A' ' 36' ' ' ALA . 4.1 tp -73.28 178.62 4.38 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.806 0.336 . . . . 0.0 110.765 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -173.92 131.17 0.41 Allowed 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.944 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.67 120.81 11.92 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.911 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 128.23 -27.57 4.48 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.804 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -58.3 123.92 17.72 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 120.927 0.394 . . . . 0.0 111.062 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -78.21 124.7 28.37 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.716 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.3 mt -95.66 122.21 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.802 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.463 ' HA ' ' HB3' ' A' ' 56' ' ' LYS . 0.3 OUTLIER -108.19 -38.32 5.79 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.016 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -119.01 138.14 53.04 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.42 ' HB ' ' CG2' ' A' ' 55' ' ' VAL . 19.3 t -141.71 115.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.773 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.403 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.7 t-20 76.89 32.78 0.49 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -178.302 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.2 -0.71 3.23 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.454 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 12.1 pt -120.47 133.42 67.23 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 111.434 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 22.9 t-20 -63.07 121.73 14.32 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.966 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.423 ' HB ' HG22 ' A' ' 63' ' ' VAL . 5.0 m -140.41 55.35 0.21 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.553 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.463 ' HB3' ' HA ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.03 14.52 31.74 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.546 179.572 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -150.89 27.95 0.7 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 122.279 0.232 . . . . 0.0 111.12 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -113.99 -167.45 1.21 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-O 120.706 0.289 . . . . 0.0 111.59 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.74 139.15 30.75 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 121.361 0.6 . . . . 0.0 110.533 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -53.69 -44.78 70.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.871 -1.058 . . . . 0.0 112.052 -179.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -60.62 -42.32 96.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.742 0.306 . . . . 0.0 110.731 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -64.79 -44.06 91.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.265 179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.423 HG22 ' HB ' ' A' ' 55' ' ' VAL . 52.4 t -63.36 -42.81 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.128 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 50.3 t -66.17 -38.91 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -57.77 -41.1 81.3 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.89 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 17.7 mt -64.05 -43.45 95.49 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.425 HG21 ' CE1' ' A' ' 15' ' ' TYR . 68.6 mt -62.42 -44.27 99.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.679 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -69.51 -22.37 76.5 Favored Glycine 0 CA--C 1.522 0.49 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.004 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.9 tptt -57.0 -34.68 68.38 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.577 0.227 . . . . 0.0 111.421 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -69.01 -57.8 4.96 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-O 120.912 0.387 . . . . 0.0 110.676 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.409 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.5 OUTLIER 65.05 36.09 7.61 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.108 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.28 -45.56 0.02 OUTLIER Glycine 0 C--N 1.332 0.313 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.196 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -165.46 138.78 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.829 0.347 . . . . 0.0 111.287 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 28.3 tp -112.29 134.65 53.71 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.286 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 55.6 m170 -119.53 98.49 6.16 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.2 179.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.97 145.15 40.12 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.327 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 22.9 t -96.67 114.0 32.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.545 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.7 pt -103.37 146.23 11.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.311 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . 0.427 ' CB ' HD21 ' A' ' 48' ' ' LEU . . . -112.94 144.57 42.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.267 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.233 0.205 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.449 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 CA--C 1.533 0.319 0 CA-C-O 120.887 0.375 . . . . 0.0 111.327 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.5 ttt85 -118.48 136.27 53.9 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.203 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.09 129.54 36.37 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.754 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.484 HG21 HD11 ' A' ' 78' ' ' ILE . 25.0 t -126.35 135.51 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.333 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -133.35 109.11 9.13 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 73' ' ' VAL . 12.2 t -102.46 144.48 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.204 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -110.23 102.96 11.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.853 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.91 120.3 5.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.211 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.52 -122.03 0.58 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.647 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -114.41 -40.7 3.58 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.514 0.197 . . . . 0.0 111.151 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -105.94 29.42 6.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 120.721 0.296 . . . . 0.0 111.52 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.96 -176.92 16.77 Favored Glycine 0 C--N 1.337 0.606 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.826 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -79.3 -71.46 0.44 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.896 0.379 . . . . 0.0 110.718 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.23 48.99 0.04 OUTLIER Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.836 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -161.01 171.59 18.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.673 0.273 . . . . 0.0 110.946 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -126.31 133.17 51.47 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.899 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.4 mt -115.27 124.59 51.72 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.204 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.4 m -136.7 16.31 3.11 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.301 -0.409 . . . . 0.0 112.101 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.44 85.19 1.57 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.071 -0.585 . . . . 0.0 112.445 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.34 -66.66 0.35 Allowed 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.691 0.281 . . . . 0.0 111.011 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.452 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -91.76 -59.06 0.23 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.103 178.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.452 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 83.9 Cg_endo -88.59 94.32 0.38 Allowed 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 122.89 2.393 . . . . 0.0 111.607 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.2 m -50.98 124.24 10.91 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.679 -179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -154.07 141.89 13.11 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.416 HD21 ' HB3' ' A' ' 41' ' ' LEU . 1.6 mp -79.71 89.53 5.18 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.771 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -56.22 -35.24 67.11 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.473 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.3 t -153.16 152.05 30.82 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.3 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.2 t -123.13 154.76 28.86 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.724 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 32.3 mtt -98.64 100.29 11.5 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.268 0.556 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.37 123.29 13.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.847 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 108.85 -19.71 30.15 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.785 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.0 166.59 25.64 Favored Pre-proline 0 CA--C 1.531 0.231 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -55.45 -24.93 46.14 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.709 2.273 . . . . 0.0 112.621 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.57 -49.11 74.7 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.993 179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.08 -28.95 65.84 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.286 179.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.7 m-30 -56.64 -33.08 65.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.687 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -89.25 -31.06 5.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.024 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.2 51.71 1.44 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.176 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.416 ' HB3' HD21 ' A' ' 27' ' ' LEU . 5.3 mt -59.32 -25.81 64.47 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 20.5 mtt85 66.7 119.49 0.03 OUTLIER 'General case' 0 C--N 1.34 0.187 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.39 89.19 0.21 Allowed 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.496 179.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.0 -12.7 5.04 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 121.208 -0.52 . . . . 0.0 112.905 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -58.22 127.49 32.38 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.711 0.291 . . . . 0.0 110.573 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.59 126.65 30.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.739 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 15.1 mt -90.63 131.06 38.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.599 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -119.06 -43.65 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.358 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.512 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.07 137.25 47.27 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.008 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.6 t -144.28 110.98 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.297 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 76.99 35.74 0.35 Allowed 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -178.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 71.55 -0.27 3.21 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.252 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 12.3 pt -120.97 125.5 74.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-O 120.81 0.338 . . . . 0.0 111.121 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.512 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -68.59 172.09 6.7 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.954 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.57 -51.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.039 -0.528 . . . . 0.0 112.121 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt 72.15 -59.41 0.56 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 123.119 0.567 . . . . 0.0 110.828 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.8 mtpt -148.23 40.26 0.94 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.75 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -72.74 -173.79 1.28 Allowed 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.859 0.362 . . . . 0.0 111.4 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -90.14 135.8 33.44 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.416 0.627 . . . . 0.0 111.174 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.4 t-160 -53.13 -44.33 67.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.486 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.448 ' O ' HG23 ' A' ' 64' ' ' VAL . 3.3 pm0 -66.21 -34.74 78.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.169 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.62 -39.43 70.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.725 0.297 . . . . 0.0 110.343 179.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -67.3 -43.87 87.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.941 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 61' ' ' GLU . 15.9 m -66.32 -38.96 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.6 mmtt -58.11 -39.73 79.42 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.059 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 25.3 mt -68.09 -41.19 82.21 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.772 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.42 ' HA ' ' CD1' ' A' ' 74' ' ' LEU . 17.7 mt -69.39 -38.49 77.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.035 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -87.77 14.33 58.72 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.102 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.57 -29.22 12.46 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.847 0.324 . . . . 0.0 111.299 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -69.71 -61.86 1.61 Allowed 'General case' 0 C--O 1.233 0.217 0 CA-C-O 120.827 0.346 . . . . 0.0 110.645 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 70.63 33.88 2.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.088 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.52 -49.4 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.126 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 7.7 p -174.73 132.56 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 111.669 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.42 ' CD1' ' HA ' ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.91 152.98 31.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.672 179.676 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.9 m170 -117.52 105.38 12.02 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.948 179.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.24 156.2 25.81 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.431 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.4 t -125.53 100.52 7.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.072 179.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.484 HD11 HG21 ' A' ' 6' ' ' VAL . 18.4 pt -101.36 158.67 4.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.388 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -114.86 116.64 28.89 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.72 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.18 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.234 0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.3 ptt180 -137.1 170.77 15.54 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.49 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.7 m -93.81 139.01 31.37 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.459 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.419 HG22 HD13 ' A' ' 78' ' ' ILE . 36.9 t -117.44 146.92 21.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.09 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -111.3 102.55 10.94 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.789 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.4 t -88.54 119.88 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.174 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.119 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.91 89.63 8.07 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.472 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.412 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 7.9 ttm-85 -53.47 122.12 9.07 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.731 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.29 -68.98 1.42 Allowed Glycine 0 C--N 1.335 0.483 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.548 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -165.32 -51.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 120.725 0.298 . . . . 0.0 110.807 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -122.53 25.04 9.0 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.596 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 150.94 171.53 19.14 Favored Glycine 0 C--N 1.336 0.58 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.795 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.412 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 5.4 m-85 -108.04 -62.85 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.667 0.27 . . . . 0.0 110.646 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.26 -33.5 0.93 Allowed Glycine 0 CA--C 1.523 0.541 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.879 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -71.48 178.59 3.39 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.021 0.439 . . . . 0.0 111.445 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 m -139.84 142.6 36.6 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.205 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -117.82 123.98 47.25 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.883 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.7 m -140.5 168.04 20.75 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.292 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 117.28 -35.2 4.24 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.877 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.438 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.35 -46.57 0.22 Allowed 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.457 0.703 . . . . 0.0 111.559 -179.829 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.438 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -101.64 -65.31 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.405 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.438 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 97.0 Cg_endo -79.77 96.04 1.04 Allowed 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.41 2.074 . . . . 0.0 112.384 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 69.8 m -61.44 114.26 3.12 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.135 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -149.0 143.72 18.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.253 -179.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.7 mp -73.13 89.75 1.51 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.655 179.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.8 m -52.49 -39.52 61.33 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.418 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -163.53 158.78 21.22 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.3 t -132.96 155.18 40.92 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.47 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 9.1 mtt -109.24 106.04 15.72 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.878 0.37 . . . . 0.0 110.477 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 32' ' ' ARG . 2.5 mtm105 -43.51 111.34 0.27 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.048 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 126.16 -16.1 6.81 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.754 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.496 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 10.0 p -80.58 162.98 58.7 Favored Pre-proline 0 CA--C 1.532 0.282 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.496 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 14.1 Cg_endo -55.84 -24.85 49.26 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 122.718 2.278 . . . . 0.0 112.751 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -68.75 -48.04 64.75 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.403 179.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.77 -30.97 72.0 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.321 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -56.03 -34.56 65.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.3 t -89.63 -29.35 5.07 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.271 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.88 -10.51 4.85 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.851 -0.69 . . . . 0.0 113.357 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 46.9 mt -54.0 116.15 2.41 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 117.016 0.408 . . . . 0.0 110.857 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.92 -153.32 0.56 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.747 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 104.02 15.97 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.424 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.94 -25.74 2.38 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.792 -0.718 . . . . 0.0 113.383 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.99 117.78 6.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.995 0.398 . . . . 0.0 111.101 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.04 132.27 35.14 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.799 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.1 mt -91.36 133.35 33.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.556 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.1 mp -117.51 -47.14 2.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.881 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.526 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -116.08 136.89 52.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.657 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.8 t -132.95 109.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.9 t30 76.83 33.62 0.46 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.642 -178.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 77.51 -2.66 2.53 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.651 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.6 pt -111.84 121.48 64.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 120.871 0.367 . . . . 0.0 111.161 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -63.59 124.01 20.29 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.063 -179.683 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.6 m -134.55 53.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.299 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 9.0 mtmt -63.45 -37.12 86.08 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.568 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -127.16 27.55 5.89 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.574 -0.284 . . . . 0.0 111.34 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -81.31 -174.02 4.68 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.694 0.283 . . . . 0.0 111.281 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 52.0 m -84.25 139.81 32.1 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.495 0.664 . . . . 0.0 110.825 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.438 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 6.1 t60 -60.8 -44.62 96.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.697 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -63.04 -42.05 99.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.437 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.79 -45.11 94.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.556 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.427 ' HA ' HD11 ' A' ' 66' ' ' LEU . 58.5 t -63.83 -41.96 94.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.8 t -65.76 -39.04 83.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 178.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.67 -39.96 78.28 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.897 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.427 HD11 ' HA ' ' A' ' 63' ' ' VAL . 13.8 mt -66.41 -43.15 86.57 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.705 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.442 ' HA ' HD12 ' A' ' 74' ' ' LEU . 25.0 mt -65.25 -37.2 79.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.759 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -83.63 12.55 51.69 Favored Glycine 0 CA--C 1.525 0.673 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.549 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -112.44 -14.73 13.22 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 122.43 0.292 . . . . 0.0 111.459 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . 0.444 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 27.2 p -45.99 -49.18 16.3 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 122.651 0.38 . . . . 0.0 111.96 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.16 33.87 9.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.974 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 151.74 -36.73 0.84 Allowed Glycine 0 C--N 1.334 0.44 0 C-N-CA 120.805 -0.712 . . . . 0.0 113.132 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.444 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.4 p -173.59 137.25 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.906 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.442 HD12 ' HA ' ' A' ' 67' ' ' ILE . 11.3 tp -112.63 142.34 45.33 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.947 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.3 m170 -107.31 98.05 7.73 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.124 179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.5 ptm -119.66 146.88 45.17 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.481 -179.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 24.6 t -102.12 112.9 36.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.963 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.419 HD13 HG22 ' A' ' 6' ' ' VAL . 19.5 pt -101.05 170.27 1.59 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.304 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -140.09 118.46 12.12 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.178 179.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.233 0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.784 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.8 t . . . . . 0 C--O 1.234 0.267 0 CA-C-O 120.616 0.246 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -121.99 140.81 52.02 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.132 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 m -97.64 127.68 43.78 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.416 HG12 ' HG ' ' A' ' 41' ' ' LEU . 38.9 t -120.08 141.8 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.137 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.9 122.6 36.5 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.158 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 73' ' ' VAL . 9.3 t -105.53 149.48 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.131 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -107.42 101.95 11.26 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.143 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -57.5 120.15 7.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.32 -110.11 0.34 Allowed Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.306 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 11.2 mtt85 -106.48 -70.94 0.77 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.65 0.262 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.52 44.52 1.24 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.172 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.55 -153.64 25.26 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.881 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.402 ' OH ' HG22 ' A' ' 67' ' ' ILE . 16.7 m-85 -131.69 -54.41 1.0 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.772 0.32 . . . . 0.0 111.184 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.27 -22.05 1.73 Allowed Glycine 0 CA--C 1.524 0.603 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.908 -179.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.84 163.01 12.79 Favored 'General case' 0 CA--C 1.53 0.203 0 CA-C-O 120.89 0.376 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.26 122.17 46.75 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -105.18 125.26 50.78 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.229 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.78 110.86 3.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.222 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -165.41 79.21 0.12 Allowed Glycine 0 N--CA 1.445 -0.74 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.893 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.89 -45.32 7.5 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.928 0.394 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.548 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -114.74 -66.42 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.402 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.548 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 95.0 Cg_endo -87.42 94.35 0.46 Allowed 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 122.606 2.204 . . . . 0.0 112.266 179.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 83.0 m -52.97 115.65 1.96 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.411 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -146.02 145.54 20.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.803 0.335 . . . . 0.0 111.796 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -73.75 90.1 1.84 Allowed 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.365 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -47.29 -51.61 18.61 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.868 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.6 t -154.45 159.36 41.01 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.475 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.5 t -125.21 154.47 33.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.597 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.2 mtp -107.6 104.72 14.32 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.211 0.529 . . . . 0.0 110.264 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -53.09 126.37 20.48 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.884 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.26 24.68 12.14 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.446 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.67 170.81 10.37 Favored Pre-proline 0 CA--C 1.532 0.252 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -47.27 -30.7 11.39 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 123.001 2.468 . . . . 0.0 113.619 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -71.3 -48.4 50.92 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 120.815 0.341 . . . . 0.0 111.029 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -69.59 -30.28 68.01 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.525 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.8 m-30 -60.13 -23.69 64.08 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 111.62 0.23 . . . . 0.0 111.62 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.9 t -89.19 -31.31 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.689 0.28 . . . . 0.0 110.897 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.8 36.3 3.26 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.522 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.416 ' HG ' HG12 ' A' ' 6' ' ' VAL . 6.4 mt -69.42 -177.99 1.29 Allowed 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.834 0.35 . . . . 0.0 110.738 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.84 131.94 7.19 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.266 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.43 98.92 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.378 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 148.51 -25.46 1.36 Allowed Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.703 -178.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -56.11 118.46 4.7 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.833 0.316 . . . . 0.0 110.718 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -77.12 123.01 25.79 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.821 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.408 HG22 HD13 ' A' ' 47' ' ' ILE . 31.0 mt -77.91 121.64 31.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.685 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 2.4 mt -100.4 -46.83 5.11 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.408 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -133.4 138.79 46.43 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.224 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.6 t -128.91 110.48 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.444 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.6 t-20 76.88 31.04 0.55 Allowed 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -178.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.444 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.62 -2.35 1.62 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.836 179.864 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.444 HG13 ' O ' ' A' ' 50' ' ' VAL . 1.2 pp -110.49 128.18 66.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.057 0.456 . . . . 0.0 111.381 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -65.27 142.96 58.1 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.609 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.2 m -145.23 62.47 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.453 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -71.16 -37.94 72.19 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.485 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -139.13 32.9 2.13 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.803 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.89 -179.97 5.79 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.558 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.16 135.61 34.19 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.421 0.629 . . . . 0.0 110.728 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 7.7 t60 -53.91 -43.88 70.09 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.974 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.454 ' HA ' HG21 ' A' ' 64' ' ' VAL . 1.5 mt-10 -62.05 -36.82 82.79 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.945 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.6 -40.66 69.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.3 t -65.59 -43.19 94.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.153 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.454 HG21 ' HA ' ' A' ' 61' ' ' GLU . 30.7 m -65.46 -38.41 82.41 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -57.98 -41.25 82.55 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.053 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 mt -68.17 -40.55 82.27 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.694 179.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.45 ' HA ' ' CD1' ' A' ' 74' ' ' LEU . 11.2 mt -69.21 -42.22 81.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.592 179.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.44 -4.26 84.11 Favored Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.923 -0.656 . . . . 0.0 113.41 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 7.1 tttt -79.34 -36.49 39.36 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 117.006 0.403 . . . . 0.0 111.647 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.32 -60.85 2.39 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.703 0.287 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 71.69 33.2 1.83 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.62 -49.92 0.01 OUTLIER Glycine 0 C--N 1.332 0.357 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.196 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 7.6 p -175.27 132.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 121.061 0.458 . . . . 0.0 111.691 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.45 ' CD1' ' HA ' ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.83 154.66 28.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.756 179.776 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -109.68 98.45 7.79 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.055 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 13.8 ttm -97.54 128.28 44.16 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.35 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.31 95.64 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.388 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.5 pp -100.35 170.82 1.45 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.486 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -123.79 143.47 50.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.251 179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 . . . . . 0 C--O 1.233 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.032 179.888 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 N--CA 1.471 0.616 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -115.39 166.87 11.4 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.26 179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -109.22 141.8 40.95 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.951 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.468 HG21 ' CD1' ' A' ' 78' ' ' ILE . 41.9 t -129.48 131.3 67.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.188 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -115.69 105.77 13.12 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.711 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.405 ' HB ' ' HG ' ' A' ' 74' ' ' LEU . 3.4 t -86.49 154.11 3.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.894 0.378 . . . . 0.0 111.035 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -112.92 104.99 12.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.935 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -48.36 110.59 0.35 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.714 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.95 -110.7 0.08 OUTLIER Glycine 0 C--N 1.333 0.378 0 C-N-CA 121.101 -0.571 . . . . 0.0 112.675 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.85 -39.89 2.91 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.83 36.68 4.35 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.815 0.34 . . . . 0.0 111.468 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.99 -129.21 5.53 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.534 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -131.88 -70.96 0.56 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.663 0.268 . . . . 0.0 111.087 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 152.58 40.62 0.03 OUTLIER Glycine 0 CA--C 1.518 0.252 0 C-N-CA 121.053 -0.594 . . . . 0.0 113.179 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -158.58 -177.76 6.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.561 0.22 . . . . 0.0 110.691 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -134.7 158.02 45.19 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-O 120.775 0.322 . . . . 0.0 111.182 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -138.96 132.07 29.68 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.0 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 p -145.93 165.09 29.98 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 111.344 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 22' ' ' GLN . . . 122.47 -22.98 7.27 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 121.186 -0.53 . . . . 0.0 113.142 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.631 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 70.04 2.52 3.96 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -179.758 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.452 ' HA ' ' O ' ' A' ' 58' ' ' ALA . . . -168.6 -61.75 0.01 OUTLIER Pre-proline 0 C--O 1.233 0.199 0 C-N-CA 122.162 0.185 . . . . 0.0 110.635 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -69.86 81.4 0.84 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.306 2.004 . . . . 0.0 110.955 178.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 62.0 m -50.39 109.29 0.29 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.071 -178.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.4 141.55 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.16 90.68 2.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.389 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 p -58.99 -38.16 78.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.189 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.1 t -168.17 154.91 7.66 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-O 120.823 0.344 . . . . 0.0 111.438 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.4 t -122.05 154.03 26.49 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.531 179.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.1 mtm -101.02 100.66 11.29 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.986 0.422 . . . . 0.0 110.52 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.0 mtt180 -51.42 125.75 15.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.749 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.52 26.61 10.67 Favored Glycine 0 CA--C 1.52 0.358 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.339 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 58.0 m -131.0 162.82 53.26 Favored Pre-proline 0 CA--C 1.529 0.163 0 N-CA-C 110.434 -0.21 . . . . 0.0 110.434 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_exo -46.75 -31.85 11.25 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.17 2.58 . . . . 0.0 113.296 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.451 ' HB3' HD11 ' A' ' 41' ' ' LEU . . . -67.01 -50.0 63.54 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-O 120.814 0.34 . . . . 0.0 110.968 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -70.66 -30.75 67.45 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.13 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 22.6 m-30 -59.58 -23.61 63.07 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.704 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 t -89.31 -32.3 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 120.652 0.263 . . . . 0.0 111.207 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.84 58.63 0.34 Allowed Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.76 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.451 HD11 ' HB3' ' A' ' 36' ' ' ALA . 17.7 mt -97.25 176.4 5.92 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.791 0.329 . . . . 0.0 110.571 179.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.45 133.39 0.81 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.909 0.385 . . . . 0.0 111.082 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.03 125.72 24.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.909 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.13 -30.59 4.29 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.389 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -62.53 121.27 12.88 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.825 0.345 . . . . 0.0 110.734 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.4 tp60 -77.9 118.09 19.88 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.928 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.9 mt -79.45 122.85 35.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.817 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mp -106.8 -41.45 5.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.605 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.483 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -113.82 152.22 30.97 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.864 0.364 . . . . 0.0 111.302 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.7 m -149.42 102.63 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.363 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 75.65 39.62 0.33 Allowed 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 74.79 -1.23 3.14 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.733 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 23.8 pt -117.27 132.1 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 111.775 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 5.0 p-10 -66.92 154.67 40.44 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 121.273 0.559 . . . . 0.0 112.123 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.47 HG12 HG22 ' A' ' 63' ' ' VAL . 9.1 m -149.58 62.9 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.295 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -55.73 -77.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.661 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -115.72 37.33 3.65 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 120.769 0.318 . . . . 0.0 110.969 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 23' ' ' ALA . . . -75.28 -172.6 1.78 Allowed 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.45 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.29 135.43 33.58 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 121.385 0.612 . . . . 0.0 110.715 179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.631 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 6.9 t60 -57.35 -44.56 84.43 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.654 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -63.27 -40.19 96.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.649 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.51 -45.34 87.68 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.451 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.47 HG22 HG12 ' A' ' 55' ' ' VAL . 48.7 t -63.49 -42.71 97.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.185 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 50.7 t -65.64 -39.45 85.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.23 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -40.05 83.51 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.046 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.4 mt -66.92 -40.16 87.56 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.918 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 7.3 mt -69.12 -41.92 81.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.482 179.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -73.77 -25.74 71.16 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.633 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 tppt? -53.98 -35.02 61.39 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 t -69.86 -54.15 14.79 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.75 0.309 . . . . 0.0 110.84 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.1 m 63.62 35.7 11.43 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.963 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.99 -43.87 0.02 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.381 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 6.5 p -162.01 134.47 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-O 120.959 0.409 . . . . 0.0 111.535 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.424 HD11 ' HG3' ' A' ' 76' ' ' MET . 3.8 pp -114.41 154.42 28.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -131.61 116.06 16.9 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.68 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.424 ' HG3' HD11 ' A' ' 74' ' ' LEU . 4.0 mtt -131.92 139.44 48.73 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.88 0.371 . . . . 0.0 111.437 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 29.3 t -103.9 112.85 39.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.977 178.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.468 ' CD1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.53 155.32 8.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.68 -179.193 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -116.85 139.01 51.1 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.285 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 CA--C 1.53 0.199 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.661 179.801 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 CA--C 1.532 0.274 0 CA-C-O 120.845 0.355 . . . . 0.0 111.065 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttt180 -115.81 142.74 46.35 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.01 -179.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 m -113.55 129.21 56.6 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.069 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 20.7 t -116.95 131.66 68.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.817 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -100.78 100.95 11.69 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.946 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 74' ' ' LEU . 13.5 t -86.09 108.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.056 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -94.82 91.82 6.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.8 ttt85 -36.55 119.12 0.6 Allowed 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.407 0.442 . . . . 0.0 111.118 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.01 -118.27 0.16 Allowed Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.746 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -113.7 -38.5 4.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.501 0.191 . . . . 0.0 111.338 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.34 28.11 8.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 124.07 -160.57 18.63 Favored Glycine 0 C--N 1.338 0.677 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.827 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 60.5 m-85 -89.82 -54.24 4.14 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.581 0.229 . . . . 0.0 111.039 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.91 65.05 0.59 Allowed Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.382 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -168.03 172.62 8.68 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.643 0.259 . . . . 0.0 111.41 179.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -122.5 159.73 27.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.28 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -149.26 130.07 14.21 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.038 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.93 158.71 38.4 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.782 0.325 . . . . 0.0 111.534 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 131.13 -27.15 3.86 Favored Glycine 0 CA--C 1.526 0.727 0 C-N-CA 121.204 -0.522 . . . . 0.0 113.114 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.53 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 62.01 13.83 5.97 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -179.825 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.432 ' CB ' ' CD ' ' A' ' 24' ' ' PRO . . . -170.74 -65.62 0.0 OUTLIER Pre-proline 0 N--CA 1.464 0.228 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.432 ' CD ' ' CB ' ' A' ' 23' ' ' ALA . 73.7 Cg_endo -75.84 83.6 1.92 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.359 2.039 . . . . 0.0 111.428 178.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 92.6 m -51.06 111.51 0.57 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.513 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.01 142.26 24.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.411 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -83.69 92.53 7.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.483 179.682 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 t -58.28 -38.62 77.33 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.281 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 3.9 t -166.09 158.93 14.9 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.893 0.378 . . . . 0.0 111.135 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 17.2 t -115.15 154.46 16.52 Favored 'Isoleucine or valine' 0 C--O 1.232 0.182 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.638 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.7 mmm -89.72 99.29 12.32 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-O 121.342 0.592 . . . . 0.0 110.327 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.28 126.24 20.43 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.966 -1.015 . . . . 0.0 111.175 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.99 27.54 12.27 Favored Glycine 0 CA--C 1.52 0.402 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.606 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.26 168.81 15.7 Favored Pre-proline 0 C--O 1.234 0.256 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.473 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 84.1 Cg_exo -48.58 -34.16 25.83 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 123.036 2.491 . . . . 0.0 113.018 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.407 ' CB ' HD23 ' A' ' 41' ' ' LEU . . . -60.16 -48.34 82.12 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.136 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -65.54 -33.2 75.36 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.473 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 14.6 m-30 -64.31 -24.8 67.78 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.411 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.27 -27.94 5.23 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.782 0.325 . . . . 0.0 110.844 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.39 32.19 2.61 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.541 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.407 HD23 ' CB ' ' A' ' 36' ' ' ALA . 6.0 tp -65.17 129.4 39.58 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 120.692 0.282 . . . . 0.0 110.446 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 71.3 mtt-85 -129.5 115.87 18.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.361 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.38 156.83 7.26 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.668 -179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.15 -13.15 63.52 Favored Glycine 0 CA--C 1.522 0.479 0 CA-C-N 115.124 -0.944 . . . . 0.0 112.211 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.83 138.34 35.12 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 110.642 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -83.47 126.42 32.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.457 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.9 mt -85.4 131.87 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.521 179.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.0 mp -107.71 -39.7 5.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.356 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.474 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -131.27 141.26 49.95 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.1 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.467 HG23 ' CG2' ' A' ' 55' ' ' VAL . 13.5 t -133.54 110.5 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.874 179.231 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.6 t30 77.07 32.34 0.48 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.82 -1.2 2.39 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.535 179.981 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.475 HD13 HG22 ' A' ' 53' ' ' ILE . 13.0 pt -115.29 126.02 72.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.98 0.419 . . . . 0.0 111.794 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.474 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -66.87 136.87 56.06 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.511 -179.626 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.467 ' CG2' HG23 ' A' ' 50' ' ' VAL . 6.4 m -147.86 63.88 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.681 -179.475 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -69.93 -31.69 69.58 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.136 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.0 mtpt -137.63 35.87 2.44 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -86.64 174.24 9.0 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 120.876 0.369 . . . . 0.0 111.534 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.27 134.75 35.64 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.399 0.619 . . . . 0.0 110.288 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.53 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 3.7 t60 -54.73 -44.46 73.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.857 -1.065 . . . . 0.0 112.14 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -61.7 -43.36 99.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.951 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.83 -41.32 91.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.507 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.9 t -65.15 -42.51 94.46 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.001 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.7 t -65.88 -39.29 84.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.68 -39.88 78.12 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.073 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.7 mt -67.71 -42.01 82.64 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.76 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 42.2 mt -66.06 -39.93 85.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.723 179.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.6 6.22 78.37 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.093 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.31 -32.69 16.41 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.857 0.328 . . . . 0.0 111.439 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.96 -61.21 2.3 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.784 0.326 . . . . 0.0 110.799 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.92 35.11 2.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.83 -47.14 0.01 OUTLIER Glycine 0 C--N 1.33 0.201 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.291 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -165.33 137.79 0.91 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.984 0.421 . . . . 0.0 111.331 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.423 ' HB3' ' HB ' ' A' ' 8' ' ' VAL . 11.1 tp -114.03 142.09 46.62 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.375 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.58 95.74 5.51 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.252 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 2.8 ttm -98.03 122.33 41.04 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.118 -179.356 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.0 t -102.23 96.64 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.464 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.7 pt -100.27 170.3 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.552 -179.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -130.83 137.2 49.29 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.234 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 . . . . . 0 C--O 1.234 0.267 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.147 179.902 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 N--CA 1.473 0.686 0 N-CA-C 112.843 0.683 . . . . 0.0 112.843 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 63.3 ttt180 -126.59 134.24 50.85 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.002 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.3 m -96.2 130.65 43.21 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.0 t -123.13 140.16 47.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.372 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -116.94 126.95 53.71 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.144 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 20.9 t -125.59 137.75 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.639 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.18 97.54 8.33 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.995 0.426 . . . . 0.0 110.603 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.482 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 2.9 ttt-85 -47.14 121.54 3.83 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.353 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.4 -130.19 1.1 Allowed Glycine 0 C--N 1.334 0.448 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.512 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.1 mtt180 -111.93 -39.57 4.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.413 0.149 . . . . 0.0 111.258 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.38 26.85 9.71 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.68 0.252 . . . . 0.0 111.68 179.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.67 -179.89 16.03 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.924 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.482 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 91.3 m-85 -83.97 -34.01 24.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.585 0.231 . . . . 0.0 111.18 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.84 47.96 0.93 Allowed Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.284 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -168.67 153.87 6.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 111.063 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.5 m -98.88 128.2 45.0 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.92 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -106.18 126.92 52.81 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.181 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.0 m -147.84 130.45 15.91 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.517 178.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.67 73.36 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.276 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.1 tp60 -44.96 -43.48 9.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.799 0.333 . . . . 0.0 110.576 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.572 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -110.98 -64.56 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.021 178.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.572 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 98.0 Cg_endo -91.74 92.7 0.21 Allowed 'Trans proline' 0 C--N 1.358 1.042 0 C-N-CA 122.943 2.428 . . . . 0.0 111.912 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 7.7 p -53.36 118.75 4.07 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.936 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -146.68 145.3 19.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.256 -179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.96 90.39 2.43 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.845 0.355 . . . . 0.0 110.496 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -53.98 -35.74 62.14 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.625 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.1 t -165.26 161.75 19.41 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.723 0.297 . . . . 0.0 110.988 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 38.0 t -131.19 152.5 37.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.877 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.4 mmt -90.24 99.66 12.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-O 121.338 0.59 . . . . 0.0 110.342 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.97 121.81 8.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.935 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.08 26.01 8.08 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.561 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -128.95 171.75 8.21 Favored Pre-proline 0 CA--C 1.532 0.269 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.409 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 77.7 Cg_exo -48.91 -30.51 17.73 Favored 'Trans proline' 0 C--N 1.352 0.737 0 C-N-CA 122.847 2.365 . . . . 0.0 113.128 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.05 -50.23 50.41 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.142 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.97 -31.86 73.3 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.42 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.409 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 17.7 m-30 -60.12 -30.71 69.45 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.198 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.72 -24.37 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.107 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.22 17.56 6.65 Favored Glycine 0 CA--C 1.523 0.57 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.153 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.4 mt -78.87 123.21 27.01 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 117.019 0.409 . . . . 0.0 110.303 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.1 mtp85 -130.48 -149.9 0.41 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -107.76 127.53 53.77 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.594 -0.275 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.7 -22.44 5.8 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 120.78 -0.724 . . . . 0.0 113.017 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -73.29 121.66 20.74 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 116.924 0.362 . . . . 0.0 110.948 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -82.45 128.04 33.87 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 6.0 mt -85.32 125.29 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -103.05 -39.41 6.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.939 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.532 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.91 145.81 50.83 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.239 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.8 t -132.97 111.72 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.926 179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 76.5 32.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.655 -178.458 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.53 -2.03 1.64 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.11 -0.95 . . . . 0.0 112.732 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.4 pt -113.73 125.58 71.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-O 120.838 0.352 . . . . 0.0 111.421 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.532 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.7 OUTLIER -60.3 125.51 23.96 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.95 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 m -146.95 40.65 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.156 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.58 -29.93 70.35 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.794 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.0 mttp -119.85 29.56 7.49 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.322 179.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -88.27 -174.13 4.5 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 111.573 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.34 140.68 29.54 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.406 0.622 . . . . 0.0 110.742 179.675 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -52.86 -44.56 66.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.721 -1.127 . . . . 0.0 111.764 -179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.61 -39.52 91.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.665 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.01 -42.46 94.42 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.584 179.252 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 44.4 t -64.82 -42.45 94.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.122 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 41.7 t -65.85 -39.19 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.2 ttmt -57.68 -40.73 80.09 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.093 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 17.7 mt -66.88 -42.82 84.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.763 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.2 mt -66.79 -40.6 86.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.97 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -70.21 -17.1 73.72 Favored Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.015 -0.612 . . . . 0.0 113.131 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -66.79 -42.09 86.55 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -67.62 -57.88 5.65 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.793 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.7 p 62.49 28.02 16.56 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.463 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -152.59 -40.48 0.03 OUTLIER Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.67 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.5 p -150.53 138.58 14.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.089 0.471 . . . . 0.0 111.333 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.434 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.5 OUTLIER -102.81 138.02 40.25 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.952 -179.866 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -130.66 95.06 3.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 3.0 mtt -117.32 140.92 48.95 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.529 -179.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 22.0 t -104.86 95.19 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.237 179.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 16.6 pt -99.17 159.97 3.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.22 -179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.82 147.83 45.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.492 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.233 0.207 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.861 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.464 0.226 0 CA-C-O 120.925 0.393 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -139.12 166.61 24.06 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.321 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -105.07 132.92 50.7 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.26 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 29.0 t -106.58 131.19 57.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.819 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.406 ' HA ' ' O ' ' A' ' 74' ' ' LEU . 1.6 mt-10 -118.83 116.57 26.8 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 3.7 t -110.01 133.97 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 111.421 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.67 94.05 9.77 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.93 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.465 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -48.47 121.03 4.08 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.176 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.45 -85.62 0.12 Allowed Glycine 0 C--N 1.335 0.501 0 C-N-CA 121.042 -0.599 . . . . 0.0 112.383 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 -145.98 -53.77 0.26 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.633 0.254 . . . . 0.0 111.013 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.18 28.91 8.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.535 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.37 164.79 11.16 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.709 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.465 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 73.3 m-85 -88.93 -66.77 0.89 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.84 0.352 . . . . 0.0 110.64 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.22 55.82 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.73 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -166.54 149.12 6.73 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.753 0.311 . . . . 0.0 110.93 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 109.43 22.12 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.03 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 6.2 tt -108.44 140.41 41.79 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.826 -179.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.427 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 22.7 m -150.35 161.44 42.48 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.457 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.78 81.35 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.313 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.5 mm100 -47.41 -40.48 17.91 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.606 0.241 . . . . 0.0 110.775 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.534 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -113.73 -63.41 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.279 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.332 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.534 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 90.9 Cg_endo -89.92 94.04 0.3 Allowed 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.812 2.341 . . . . 0.0 111.739 179.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 6.0 p -52.29 117.16 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.72 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.1 p -134.83 144.31 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.643 -179.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.58 92.74 9.22 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.084 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -57.16 -52.67 64.39 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.02 -179.308 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.4 ' HA ' ' CB ' ' A' ' 43' ' ' ALA . 0.6 OUTLIER -148.14 162.3 39.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.444 -179.594 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 10.9 t -121.19 153.73 24.82 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.129 179.304 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -94.56 99.96 12.02 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.24 0.543 . . . . 0.0 110.771 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 7.2 mtt180 -55.06 126.48 24.83 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.014 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 99.66 -16.29 58.88 Favored Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.888 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.594 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.4 m -89.64 166.38 21.22 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.841 0.32 . . . . 0.0 110.343 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.594 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 9.2 Cg_endo -51.25 -26.76 21.08 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.928 2.419 . . . . 0.0 113.441 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.19 76.76 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.849 0.357 . . . . 0.0 110.77 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.83 -26.57 63.35 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.207 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -59.43 -23.66 62.86 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.42 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.27 -30.15 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 116.662 -0.244 . . . . 0.0 111.06 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 104.71 45.4 1.41 Allowed Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.496 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 6.4 mt -72.48 -178.95 2.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-O 120.726 0.298 . . . . 0.0 110.569 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 44.9 mtp85 -142.01 112.74 7.28 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.291 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.4 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . . . -64.85 103.56 0.73 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.527 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.63 -10.55 5.77 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.266 -179.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -81.02 165.49 21.65 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.02 156.33 17.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.534 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 4.2 mt -109.11 146.25 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.589 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 mp -118.92 -57.49 2.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.893 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.502 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.08 139.28 44.19 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.008 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.9 t -138.97 110.35 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 75.97 35.86 0.47 Allowed 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 75.08 -0.39 3.33 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.808 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.419 HD11 HG22 ' A' ' 53' ' ' ILE . 8.5 pt -119.68 133.66 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-O 120.92 0.39 . . . . 0.0 111.388 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -69.74 150.84 46.5 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.67 -179.515 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 m -150.11 56.85 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.647 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.2 mmtp -60.19 -40.42 89.98 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.455 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.0 mtmp? -130.01 31.96 4.6 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.658 0.266 . . . . 0.0 111.421 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -79.6 176.51 9.64 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 120.716 0.293 . . . . 0.0 111.144 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.9 m -95.8 147.19 23.9 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.581 0.705 . . . . 0.0 111.355 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.427 ' CE1' ' HA ' ' A' ' 20' ' ' SER . 2.7 t-160 -56.11 -41.85 75.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.325 -1.307 . . . . 0.0 111.445 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.456 ' HA ' HG12 ' A' ' 64' ' ' VAL . 11.4 pt-20 -64.21 -41.09 97.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.904 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -69.79 -42.07 74.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 110.366 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.5 t -67.71 -42.35 86.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.027 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 61' ' ' GLU . 7.3 p -66.61 -39.1 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -57.94 -40.13 79.75 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.158 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 15.0 mt -66.28 -42.85 87.85 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.741 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 33.5 mt -66.62 -40.71 86.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.623 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -85.39 8.27 72.17 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.184 179.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.7 -32.63 15.36 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 116.828 0.314 . . . . 0.0 111.293 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.67 -55.04 19.61 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.963 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 m 64.5 36.17 8.89 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.859 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.87 -44.05 0.02 OUTLIER Glycine 0 C--N 1.332 0.338 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.414 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -163.39 139.13 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.129 0 CA-C-O 120.959 0.409 . . . . 0.0 111.384 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 7' ' ' GLU . 62.8 tp -103.15 136.26 43.27 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.049 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -127.13 101.37 6.49 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.411 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 13.7 ptm -132.83 141.52 48.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.47 -179.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.9 t -91.23 120.63 40.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.79 179.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 15.0 pt -99.33 170.17 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.434 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.35 148.88 30.04 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.284 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.233 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.322 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.463 0.22 0 CA-C-O 120.862 0.363 . . . . 0.0 111.296 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.8 ttt180 -123.04 126.87 47.93 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -97.8 120.84 38.9 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.754 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 20.9 t -114.2 131.58 65.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.457 ' HG2' ' CD2' ' A' ' 75' ' ' HIS . 3.1 mt-10 -115.6 112.92 22.87 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.902 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 t -94.57 134.14 33.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 CA-C-O 120.877 0.37 . . . . 0.0 111.221 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -102.17 97.64 7.91 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.687 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.442 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -47.81 118.38 2.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.006 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.92 -107.54 0.08 OUTLIER Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.553 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.8 mtt180 -123.67 -46.75 1.99 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.633 0.254 . . . . 0.0 111.046 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.01 41.79 3.45 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.651 179.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 158.4 -179.64 33.93 Favored Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.14 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.442 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 8.7 m-85 -111.41 -40.74 4.3 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.595 0.236 . . . . 0.0 111.349 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.96 23.69 5.17 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.285 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -157.26 156.24 32.15 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.997 0.398 . . . . 0.0 110.933 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.0 m -111.01 135.61 51.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.861 0.362 . . . . 0.0 111.239 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.479 HD22 ' CE1' ' A' ' 60' ' ' HIS . 0.4 OUTLIER -119.18 129.09 54.81 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.043 179.898 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.6 m -151.7 176.05 11.77 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.125 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.55 -46.32 1.13 Allowed Glycine 0 C--N 1.335 0.497 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.38 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.438 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 55.13 39.43 31.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.877 0.471 . . . . 0.0 112.09 179.489 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 174.53 -61.64 0.0 OUTLIER Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.636 179.476 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.17 -27.43 9.75 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.598 2.199 . . . . 0.0 113.127 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 18.4 m 56.79 93.44 0.03 OUTLIER 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.509 0.671 . . . . 0.0 109.788 -179.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -146.75 144.21 20.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.973 -178.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.32 122.33 16.87 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.487 179.703 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.4 m -82.42 -41.53 19.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.196 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 25.3 t -173.09 152.44 2.31 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.364 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 t -118.04 155.19 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.753 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 27.4 mmm -98.41 100.95 12.26 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.204 0.526 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mtt-85 -50.85 124.58 11.44 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.069 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.02 24.51 11.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.553 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -123.76 165.98 20.98 Favored Pre-proline 0 C--O 1.232 0.148 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.409 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 10.4 Cg_endo -53.58 -26.99 39.3 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.781 2.32 . . . . 0.0 112.747 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.48 -49.18 57.18 Favored 'General case' 0 CA--C 1.528 0.121 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.002 179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -67.05 -31.99 72.88 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.304 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.409 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 20.4 m-30 -59.47 -23.46 62.75 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.557 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.38 -30.12 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.684 0.278 . . . . 0.0 111.253 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.79 68.13 0.54 Allowed Glycine 0 C--N 1.334 0.45 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.413 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.5 mt -102.31 162.35 12.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.795 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.9 mmt180 -148.55 119.66 7.73 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.08 111.8 1.16 Allowed 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.835 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.44 -12.88 7.02 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.874 -179.49 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.499 ' HB3' ' HB ' ' A' ' 78' ' ' ILE . 0.1 OUTLIER -66.94 112.1 4.14 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.825 0.312 . . . . 0.0 110.52 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -55.45 125.7 22.04 Favored 'General case' 0 CA--C 1.53 0.173 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.71 -179.411 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 66.7 mt -82.25 123.96 38.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.574 179.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.0 mp -107.81 -41.2 5.06 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.54 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -136.46 144.4 44.38 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.73 0.3 . . . . 0.0 111.102 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 8.3 t -140.97 116.2 6.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.421 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.96 30.75 0.55 Allowed 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.421 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 80.78 -1.92 1.84 Allowed 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.239 -0.892 . . . . 0.0 112.706 179.631 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.6 pt -117.4 134.56 60.59 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.936 0.398 . . . . 0.0 111.635 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.1 m120 -63.1 152.51 36.97 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.572 -179.584 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.418 HG12 HG23 ' A' ' 63' ' ' VAL . 2.8 m -152.02 47.75 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.435 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.9 mttt -56.21 -40.12 73.53 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.215 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -137.72 31.98 2.5 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.005 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.86 -177.7 3.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.878 0.371 . . . . 0.0 111.604 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.93 135.78 33.85 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.361 0.6 . . . . 0.0 110.703 179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.479 ' CE1' HD22 ' A' ' 19' ' ' LEU . 5.5 t60 -55.9 -44.39 78.17 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.783 -1.098 . . . . 0.0 111.883 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -61.58 -39.41 91.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.439 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -67.52 -43.07 81.7 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.225 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.42 ' HA ' HD11 ' A' ' 66' ' ' LEU . 48.4 t -63.79 -40.96 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.932 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 48.8 t -65.97 -38.83 82.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 178.674 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -57.76 -42.64 84.45 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.42 HD11 ' HA ' ' A' ' 63' ' ' VAL . 12.0 mt -63.63 -42.26 98.19 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.647 179.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.433 HG12 ' CD2' ' A' ' 74' ' ' LEU . 35.8 mt -63.42 -44.18 98.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.635 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.3 -12.52 84.14 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.793 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 41.3 tptt -68.19 -37.41 80.91 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -70.7 -52.46 20.9 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.811 0.339 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m 63.8 35.73 10.96 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.742 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.22 -44.35 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.295 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -163.15 138.24 1.4 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-O 121.014 0.435 . . . . 0.0 111.335 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.433 ' CD2' HG12 ' A' ' 67' ' ' ILE . 24.2 tp -114.24 146.79 39.95 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.376 -179.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.457 ' CD2' ' HG2' ' A' ' 7' ' ' GLU . 48.1 m80 -119.6 103.22 9.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.177 179.164 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 59.0 mtp -109.14 142.09 40.41 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.671 -179.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.3 t -115.06 97.05 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.926 178.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.499 ' HB ' ' HB3' ' A' ' 45' ' ' ASP . 10.3 pt -105.78 170.74 2.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.64 -179.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -136.94 145.73 44.59 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.941 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 . . . . . 0 C--O 1.234 0.284 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.774 179.846 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.404 HG23 ' CG1' ' A' ' 77' ' ' VAL . 4.2 p . . . . . 0 N--CA 1.476 0.846 0 CA-C-O 121.386 0.612 . . . . 0.0 112.636 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.26 146.66 47.08 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.727 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.1 m -102.21 154.73 18.75 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.213 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 20.3 t -140.29 136.2 36.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.355 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -104.7 111.15 23.76 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.725 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.7 t -104.43 119.94 54.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-O 120.865 0.364 . . . . 0.0 111.475 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -90.32 92.28 8.85 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.066 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.403 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 14.3 ttt180 -49.5 125.07 10.51 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.646 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.69 -112.44 0.07 OUTLIER Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.818 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -115.39 -39.33 3.6 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.435 0.16 . . . . 0.0 111.328 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.9 30.61 6.38 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.388 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.59 -173.09 16.6 Favored Glycine 0 C--N 1.337 0.616 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.808 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.403 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 79.2 m-85 -79.34 -61.91 1.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.941 0.401 . . . . 0.0 111.013 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.43 59.22 0.26 Allowed Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.452 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 19.7 p90 -153.13 151.01 29.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 0.0 110.955 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -98.3 111.42 23.76 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.442 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.95 133.49 44.25 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.411 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 1.5 p -149.58 -174.26 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.762 179.697 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 107.28 85.43 1.77 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.3 -60.09 2.08 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.942 0.401 . . . . 0.0 110.799 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.472 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -94.41 -60.61 0.19 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.221 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.472 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 98.2 Cg_endo -87.69 95.35 0.44 Allowed 'Trans proline' 0 C--N 1.356 0.938 0 C-N-CA 122.692 2.261 . . . . 0.0 112.209 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 71.6 m -55.27 118.64 4.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.477 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.4 p -143.53 152.94 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.854 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.41 92.95 9.34 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.473 179.377 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -51.46 -39.93 58.43 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.504 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 3.6 t -169.07 161.43 10.46 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.961 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.5 t -124.8 154.35 32.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.431 179.556 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -85.58 98.0 10.4 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.227 0.537 . . . . 0.0 110.399 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.85 122.61 6.76 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.853 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.31 21.23 11.86 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.703 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.425 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -115.31 166.68 11.43 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.712 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.425 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 9.7 Cg_endo -51.75 -29.55 34.25 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.962 2.441 . . . . 0.0 112.77 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.8 -46.19 46.89 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.992 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -64.01 -32.3 73.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.069 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.408 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.1 m-30 -60.04 -28.07 67.45 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.39 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 18.3 t -89.48 -26.21 5.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-O 120.469 0.176 . . . . 0.0 111.241 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.63 1.13 7.13 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.639 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 12.0 mt -67.93 116.96 9.18 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 117.378 0.589 . . . . 0.0 110.449 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.01 -150.36 0.43 Allowed 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.006 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -105.29 146.29 29.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.636 0.255 . . . . 0.0 111.299 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.82 -16.97 33.22 Favored Glycine 0 CA--C 1.523 0.56 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.152 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.57 128.31 34.53 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 117.122 0.461 . . . . 0.0 110.822 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -82.38 134.01 35.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.486 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 22.7 mt -85.82 122.57 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.798 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -106.57 -47.55 3.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -124.08 136.25 54.11 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.993 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 3.0 t -135.51 105.71 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.096 179.553 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 75.92 37.8 0.37 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 72.32 -0.56 3.23 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.834 -179.628 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 8.0 pt -113.96 119.39 61.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 120.955 0.407 . . . . 0.0 111.01 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.482 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.0 m120 -68.53 130.32 42.53 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.081 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 24.3 m -124.03 52.3 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.095 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.0 mttm -55.45 -45.65 76.83 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.543 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -136.48 32.42 2.8 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.095 179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.37 177.85 7.62 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 120.805 0.336 . . . . 0.0 111.275 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -80.73 133.67 35.71 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 121.418 0.628 . . . . 0.0 110.665 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.411 ' CE1' ' HA ' ' A' ' 20' ' ' SER . 1.4 t-160 -54.49 -44.78 72.95 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.772 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -65.13 -41.91 94.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.693 179.547 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -64.34 -42.47 96.25 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.712 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 54.9 t -63.5 -43.34 98.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.124 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.1 t -66.03 -39.73 85.34 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.162 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.79 -40.46 84.11 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.01 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.1 mt -65.53 -40.86 93.4 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.195 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 26.2 mt -69.55 -40.48 79.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.866 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -59.83 -27.82 64.87 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.278 179.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.69 -19.79 62.02 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.51 0.324 . . . . 0.0 111.668 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -98.54 100.89 12.18 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.408 0.623 . . . . 0.0 110.219 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.2 m -99.64 -29.16 12.83 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.975 -1.011 . . . . 0.0 111.663 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.05 -50.93 7.25 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.139 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.5 p -177.12 134.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.841 0.353 . . . . 0.0 111.487 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.2 tp -114.32 141.29 47.79 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.073 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -114.01 104.67 12.37 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.163 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.19 148.5 28.8 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.211 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.404 ' CG1' HG23 ' A' ' 3' ' ' VAL . 21.8 t -109.33 105.43 18.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.721 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.8 pt -100.98 173.58 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.208 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -155.86 124.73 6.05 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.666 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.375 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.639 179.206 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 120.702 0.287 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -139.2 169.24 18.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.402 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -116.66 144.57 44.25 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.99 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 20.6 t -113.39 140.44 33.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.31 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.8 mt-10 -112.68 108.05 16.94 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.973 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.7 t -102.66 126.23 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 111.277 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.39 92.24 8.03 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.979 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.457 ' HG3' ' CZ ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -52.92 122.53 9.44 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.972 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.83 -65.93 3.08 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 121.162 -0.542 . . . . 0.0 112.665 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -163.54 -48.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.568 0.223 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -131.93 26.36 4.62 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.455 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 179.71 164.69 32.49 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.607 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.457 ' CZ ' ' HG3' ' A' ' 10' ' ' ARG . 40.1 m-85 -107.91 -73.72 0.68 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.65 0.262 . . . . 0.0 111.373 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.39 50.83 0.04 OUTLIER Glycine 0 C--N 1.33 0.242 0 C-N-CA 121.142 -0.552 . . . . 0.0 112.425 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 37.6 p90 -167.14 -177.08 3.57 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.428 0.156 . . . . 0.0 110.754 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -133.68 145.1 49.62 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 120.822 0.344 . . . . 0.0 111.353 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.4 mt -128.72 123.48 33.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.945 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.5 m -135.83 14.81 3.36 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.26 -0.427 . . . . 0.0 112.101 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -84.86 85.2 1.57 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.035 -0.603 . . . . 0.0 112.131 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.02 -63.24 0.9 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.837 0.351 . . . . 0.0 111.074 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.459 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -94.24 -61.04 0.18 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.146 178.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.459 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 98.5 Cg_endo -86.75 93.26 0.53 Allowed 'Trans proline' 0 C--N 1.353 0.793 0 C-N-CA 122.825 2.35 . . . . 0.0 111.764 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.5 m -54.46 121.14 7.71 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.884 0.373 . . . . 0.0 110.806 -179.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.4 p -145.79 146.74 19.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.85 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -81.55 92.24 6.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.707 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.83 -34.82 63.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.317 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.3 t -169.72 160.47 8.77 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 111.242 179.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.52 154.1 18.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.745 179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 12.1 mmm -99.22 99.24 10.18 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.101 0.477 . . . . 0.0 110.818 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -50.2 126.85 15.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.118 -0.946 . . . . 0.0 111.276 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.05 24.2 13.37 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.028 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.449 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -127.52 169.58 12.05 Favored Pre-proline 0 C--N 1.33 -0.253 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.265 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.449 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 19.3 Cg_endo -58.13 -17.7 33.19 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.673 2.248 . . . . 0.0 113.043 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.59 -50.91 32.18 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -72.07 -29.83 64.52 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.229 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.406 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.7 m-30 -59.18 -27.5 65.75 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.616 -0.266 . . . . 0.0 110.973 179.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.64 -50.31 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.762 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 146.65 46.77 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.068 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.31 134.25 34.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.665 0.269 . . . . 0.0 110.412 179.511 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.4 mmt180 -144.91 120.38 10.34 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -45.97 125.74 6.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.449 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.33 -26.95 5.4 Favored Glycine 0 CA--C 1.517 0.189 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.322 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -67.1 121.1 14.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 120.593 0.235 . . . . 0.0 110.682 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.43 127.69 32.96 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.77 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 18.9 mt -82.65 119.31 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.569 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -97.11 -42.22 7.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.548 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.84 140.85 51.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.007 179.691 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 53' ' ' ILE . 21.5 t -133.14 112.52 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.13 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.4 t30 76.34 31.06 0.64 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.672 -178.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.77 -3.76 1.57 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 115.174 -0.921 . . . . 0.0 112.713 179.64 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.434 ' CD1' HD12 ' A' ' 66' ' ' LEU . 1.1 pp -114.45 128.93 71.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.016 0.436 . . . . 0.0 111.397 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.1 m120 -64.27 132.69 51.0 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.439 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.8 m -136.36 58.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.452 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -62.51 -40.2 95.98 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.422 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -132.92 31.11 3.94 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.208 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.04 179.92 6.5 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.771 0.32 . . . . 0.0 111.548 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.14 135.47 33.42 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.305 0.574 . . . . 0.0 110.951 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 7.4 t60 -54.46 -44.63 72.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.815 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -62.63 -43.35 99.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.504 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.22 -41.38 97.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.543 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.0 t -64.94 -43.52 96.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.988 179.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.0 t -65.76 -39.34 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -57.97 -40.98 81.94 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.01 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.434 HD12 ' CD1' ' A' ' 53' ' ' ILE . 4.5 mt -66.22 -42.43 88.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.668 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 18.5 mt -65.52 -42.92 94.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.51 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.98 -15.04 81.66 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.945 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -65.13 -39.79 93.56 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -62.72 -55.25 28.42 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 65.94 35.03 6.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.903 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.29 -44.24 0.02 OUTLIER Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.554 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -160.72 138.86 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.784 0.326 . . . . 0.0 111.642 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 33.0 tp -105.8 143.18 34.31 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -128.56 96.8 4.5 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.191 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -121.66 154.59 36.62 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.43 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.1 t -111.63 110.87 33.77 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.746 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.6 pt -105.51 145.38 13.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.322 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -111.23 134.35 52.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.291 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 . . . . . 0 C--O 1.233 0.207 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.852 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.465 0.28 0 CA-C-O 120.725 0.298 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -135.96 162.25 33.38 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.448 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.38 125.32 53.04 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.785 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.4 HG13 ' CD1' ' A' ' 41' ' ' LEU . 20.8 t -111.33 134.07 54.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.105 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -105.71 112.87 26.11 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 4.9 t -87.77 116.85 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-O 120.84 0.352 . . . . 0.0 111.28 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -81.54 89.72 6.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.861 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.414 ' HG3' ' CE2' ' A' ' 15' ' ' TYR . 5.3 ttp180 -56.14 120.97 8.38 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.116 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.97 -88.1 0.29 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.738 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -121.33 -73.5 0.65 Allowed 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.64 0.257 . . . . 0.0 110.76 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -121.11 31.96 6.15 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.111 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -178.26 -169.61 39.31 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.582 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.414 ' CE2' ' HG3' ' A' ' 10' ' ' ARG . 24.4 m-85 -133.17 -64.42 0.73 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.655 0.264 . . . . 0.0 111.27 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.03 47.24 0.08 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.814 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -156.73 172.31 18.83 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 120.708 0.289 . . . . 0.0 110.813 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -117.56 110.72 18.29 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.954 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.5 126.15 49.46 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.119 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 73.5 m -152.06 107.56 3.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.55 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.95 79.63 0.15 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.704 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.85 -45.88 30.57 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.03 0.443 . . . . 0.0 110.018 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.532 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -115.57 -67.35 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.24 178.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.532 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 90.3 Cg_endo -85.1 95.55 0.65 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 122.605 2.204 . . . . 0.0 112.155 179.158 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 80.8 m -53.27 118.91 4.16 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.679 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 p -146.79 149.63 15.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.393 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -87.48 93.61 9.46 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.319 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -46.91 -43.98 19.38 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.485 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.7 t -172.37 158.53 4.38 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.173 179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.5 t -126.04 154.95 35.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.616 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mtp -100.33 101.59 12.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 121.153 0.501 . . . . 0.0 110.66 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.1 mtm-85 -49.96 123.95 9.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.39 16.7 10.75 Favored Glycine 0 CA--C 1.523 0.583 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.75 -179.176 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -120.98 166.68 15.03 Favored Pre-proline 0 CA--C 1.531 0.221 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.486 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -49.27 -31.39 22.25 Favored 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.989 2.46 . . . . 0.0 113.346 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.61 -49.06 51.63 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.587 -0.278 . . . . 0.0 111.139 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.36 -32.47 73.88 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.486 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.9 m-30 -58.06 -29.25 65.24 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.457 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 18.7 t -89.53 -32.73 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.696 0.284 . . . . 0.0 110.948 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.45 51.39 0.16 Allowed Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.123 -0.56 . . . . 0.0 112.66 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.4 ' CD1' HG13 ' A' ' 6' ' ' VAL . 2.8 mt -116.55 129.3 56.1 Favored 'General case' 0 C--O 1.231 0.098 0 CA-C-O 120.574 0.226 . . . . 0.0 110.817 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -137.6 -152.9 0.46 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -99.58 148.14 24.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.799 179.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.3 -21.33 46.08 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.975 -0.631 . . . . 0.0 113.214 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -69.9 116.86 10.77 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.883 0.341 . . . . 0.0 110.827 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.53 132.09 37.06 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.425 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 27.2 mt -84.34 120.42 35.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.74 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.0 -40.37 5.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.402 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.457 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -128.88 135.99 49.83 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.626 0.25 . . . . 0.0 111.097 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.441 ' O ' HG13 ' A' ' 53' ' ' ILE . 4.8 t -135.73 110.09 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.186 179.53 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 75.99 33.71 0.58 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 77.6 -5.13 2.18 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 115.15 -0.932 . . . . 0.0 112.706 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.441 HG13 ' O ' ' A' ' 50' ' ' VAL . 2.2 pp -116.71 130.82 70.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 111.403 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.457 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -67.11 141.62 57.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.691 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.2 m -142.68 51.16 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.413 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.2 mtpp -58.16 -35.27 71.31 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.657 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -137.2 34.62 2.55 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.694 0.283 . . . . 0.0 111.03 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.13 -172.9 2.96 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.843 0.354 . . . . 0.0 111.556 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.55 141.0 29.11 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.275 0.56 . . . . 0.0 110.791 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.1 t-160 -52.86 -43.29 65.98 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.443 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.496 ' O ' HG22 ' A' ' 64' ' ' VAL . 2.7 mt-10 -66.53 -35.06 79.32 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.457 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.59 -38.39 70.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.798 0.332 . . . . 0.0 110.286 179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.6 t -66.47 -44.89 90.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.042 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.496 HG22 ' O ' ' A' ' 61' ' ' GLU . 2.9 m -66.42 -39.19 83.45 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.39 -39.18 82.57 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.972 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.3 mt -66.03 -41.99 90.19 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.864 179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.424 ' HA ' ' CD1' ' A' ' 74' ' ' LEU . 31.5 mt -68.11 -41.41 84.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.762 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.74 8.73 19.64 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.954 178.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 2.0 tttp -111.61 -4.0 14.9 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 116.943 0.371 . . . . 0.0 111.071 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . 0.446 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 26.4 p -50.62 -47.56 58.23 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 122.536 0.334 . . . . 0.0 111.71 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.74 31.71 4.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.004 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 150.02 -37.51 0.94 Allowed Glycine 0 C--N 1.335 0.499 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.062 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.446 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.8 p -172.05 138.07 0.35 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.234 0 CA-C-O 120.894 0.378 . . . . 0.0 112.012 -179.657 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.424 ' CD1' ' HA ' ' A' ' 67' ' ' ILE . 3.8 tp -111.04 139.77 46.12 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.111 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -100.95 101.52 12.33 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.29 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 35.5 ttm -103.44 125.1 49.84 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 40.5 t -97.86 103.61 14.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.511 179.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 14.7 pt -106.72 168.31 3.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.468 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.91 155.2 39.58 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.703 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.235 0.298 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.234 0.279 0 CA-C-O 120.64 0.257 . . . . 0.0 111.369 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.98 167.5 21.99 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.657 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 m -102.94 135.19 45.07 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.1 t -115.69 131.84 66.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.109 179.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -113.05 120.51 41.59 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.105 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.461 HG12 ' HB3' ' A' ' 15' ' ' TYR . 12.7 t -104.92 134.18 47.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.179 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -103.55 98.79 8.62 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.039 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -48.84 124.11 8.04 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.268 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.41 118.43 0.45 Allowed Glycine 0 CA--C 1.52 0.353 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER 78.51 90.0 0.06 Allowed 'General case' 0 C--O 1.235 0.34 0 CA-C-O 121.393 0.616 . . . . 0.0 110.396 -179.22 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 71.15 34.26 1.85 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.548 -1.206 . . . . 0.0 111.569 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 -113.1 3.6 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.837 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . 0.461 ' HB3' HG12 ' A' ' 8' ' ' VAL . 79.3 m-85 -110.64 -66.32 1.08 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.414 0.149 . . . . 0.0 111.171 -179.546 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.17 61.14 0.2 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.894 -0.67 . . . . 0.0 113.351 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -166.41 167.79 15.46 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 120.556 0.217 . . . . 0.0 111.183 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -120.34 150.84 40.11 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.007 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -137.62 124.32 21.08 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.363 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 m -140.15 15.74 2.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.092 -0.503 . . . . 0.0 112.021 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.65 84.36 1.59 Allowed Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.417 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -44.2 -61.98 1.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.795 0.331 . . . . 0.0 110.783 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.473 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -94.29 -62.81 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.881 178.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.473 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 92.0 Cg_endo -85.84 96.45 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.925 0 C-N-CA 122.76 2.307 . . . . 0.0 111.915 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.0 m -55.8 124.95 19.25 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.567 -179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.16 143.8 17.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.395 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -80.81 90.62 5.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.462 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 5.8 p -53.8 -38.44 64.52 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.473 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 8.1 t -161.75 153.41 18.89 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.836 0.351 . . . . 0.0 111.447 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.3 t -116.23 155.38 17.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.554 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.3 mtp -97.79 100.35 11.72 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.236 0.541 . . . . 0.0 110.791 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.4 mtm-85 -53.74 124.23 14.61 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.892 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.13 -24.04 21.88 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.534 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.407 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.4 OUTLIER -82.5 166.61 35.36 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 110.533 179.722 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 11.0 Cg_endo -53.95 -23.53 28.35 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 123.19 2.593 . . . . 0.0 113.186 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.59 76.91 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.887 0.375 . . . . 0.0 110.731 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -68.24 -27.1 66.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.194 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -55.97 -24.31 37.6 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 112.141 0.422 . . . . 0.0 112.141 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.8 t -89.09 -29.21 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 111.034 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.86 43.95 2.17 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.518 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -74.25 176.42 6.67 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 120.913 0.387 . . . . 0.0 110.762 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 4.1 mtp85 -139.0 116.95 11.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.44 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.53 101.03 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.801 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.35 -21.26 3.47 Favored Glycine 0 CA--C 1.524 0.606 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.407 -179.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -58.24 123.31 15.62 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 120.633 0.254 . . . . 0.0 110.8 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -66.68 127.87 34.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.089 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 21.2 mt -85.27 125.89 40.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.573 179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.9 mp -98.76 -70.27 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.575 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.502 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -99.99 143.94 29.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.739 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.6 t -135.84 113.94 15.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.411 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.1 t-20 76.38 33.05 0.55 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -177.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.74 -1.78 2.37 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 115.189 -0.914 . . . . 0.0 113.074 179.72 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 5.4 pt -115.65 133.0 63.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-O 120.817 0.342 . . . . 0.0 111.827 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 42.8 t30 -66.83 130.22 42.45 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.143 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 15.3 m -137.28 59.57 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.965 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.9 mmtm -51.91 -72.46 0.05 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.999 -179.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.2 mttt -111.72 39.55 2.34 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.255 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -73.86 -175.93 2.29 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.515 -179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.44 134.67 33.78 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.443 0.639 . . . . 0.0 110.865 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -53.04 -44.76 67.64 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.689 -1.142 . . . . 0.0 111.419 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.456 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.7 pm0 -66.36 -34.7 78.56 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.184 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.6 -39.31 70.6 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.728 0.299 . . . . 0.0 110.443 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.4 t -67.02 -43.36 89.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.456 HG22 ' HA ' ' A' ' 61' ' ' GLU . 29.8 m -65.93 -38.71 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 1.9 mtmp? -57.87 -39.38 77.67 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.881 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.5 mt -67.41 -43.28 81.65 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.761 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 13.8 mt -65.66 -38.03 81.36 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.981 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -86.61 3.77 86.76 Favored Glycine 0 CA--C 1.524 0.645 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.015 179.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.6 tptm -86.91 -34.88 19.23 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.824 0.312 . . . . 0.0 111.25 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -71.66 -57.86 4.01 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.809 0.338 . . . . 0.0 110.86 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.1 m 64.65 36.02 8.61 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.072 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.13 -44.13 0.02 OUTLIER Glycine 0 C--N 1.331 0.296 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.434 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 7.1 p -162.12 137.08 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 CA-C-O 120.985 0.421 . . . . 0.0 111.385 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -112.6 134.37 54.17 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.523 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -117.09 96.36 5.41 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.999 179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 16.5 ptt? -122.01 156.31 33.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.791 -179.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.7 t -111.42 109.73 29.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.735 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 pt -106.1 139.39 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.304 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -105.86 125.15 50.65 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.154 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 . . . . . 0 C--O 1.232 0.139 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.696 179.715 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 CA--C 1.534 0.345 0 CA-C-O 120.495 0.188 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.0 ttt85 -114.05 141.21 47.74 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 120.883 0.373 . . . . 0.0 111.1 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.0 m -110.9 137.16 48.88 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.664 179.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 16.7 t -111.8 136.01 49.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.756 -179.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -134.59 100.84 4.76 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.535 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.2 t -106.47 150.51 9.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.276 -179.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -99.4 98.54 9.45 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.988 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 50.9 ttp85 -50.71 120.67 4.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.696 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.73 -107.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.705 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -118.28 -39.94 2.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.419 0.152 . . . . 0.0 111.249 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -111.3 32.19 5.53 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.668 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.11 -137.96 14.57 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.828 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 80.2 m-85 -116.17 -83.33 0.63 Allowed 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.633 0.254 . . . . 0.0 111.19 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.61 55.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.265 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 14.3 p90 -143.31 166.83 23.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.631 0.253 . . . . 0.0 110.756 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.1 m -113.92 142.03 46.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.943 0.401 . . . . 0.0 111.479 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 mt -133.89 122.87 23.78 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.943 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.8 m -146.92 169.37 19.29 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.31 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.91 -37.51 2.88 Favored Glycine 0 C--N 1.336 0.532 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.509 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 81.55 -48.92 0.24 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.286 0.635 . . . . 0.0 111.493 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.453 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -100.97 -65.09 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.438 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.453 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 91.5 Cg_endo -80.55 96.21 1.0 Allowed 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.292 1.994 . . . . 0.0 112.318 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.0 m -61.37 115.66 4.04 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.334 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.84 142.46 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.154 -179.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -75.87 90.98 2.96 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.468 179.743 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 69.4 p -53.2 -36.59 61.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.308 -179.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 3.0 t -167.22 158.63 12.13 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.237 179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.8 t -119.08 154.97 21.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.858 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 30.8 mtt -98.28 101.85 13.42 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 121.21 0.529 . . . . 0.0 110.623 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 26.8 mtt-85 -51.84 123.69 10.82 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.22 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.07 -22.3 31.72 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 120.938 -0.649 . . . . 0.0 113.071 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.41 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.6 m -83.47 168.01 25.04 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.711 0.255 . . . . 0.0 110.658 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.41 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 73.6 Cg_exo -50.43 -25.51 14.23 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 123.033 2.489 . . . . 0.0 113.448 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.26 -47.8 82.74 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 120.868 0.366 . . . . 0.0 111.024 179.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.96 -26.73 65.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.31 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.4 m-30 -54.98 -28.71 53.79 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 111.674 0.249 . . . . 0.0 111.674 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.6 t -89.43 -34.4 6.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 CA-C-O 120.83 0.347 . . . . 0.0 111.037 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.6 -11.81 15.88 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.747 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -64.58 127.59 32.16 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -115.51 -146.52 0.4 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.249 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.11 159.19 15.13 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.926 0.393 . . . . 0.0 110.908 179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.24 -33.52 6.1 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.577 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -61.39 118.56 7.11 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.79 0.328 . . . . 0.0 110.989 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.02 131.44 35.31 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.679 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 8.3 mm -87.38 124.55 40.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.5 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -105.49 -46.51 4.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.352 -179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.548 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.49 139.2 53.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.195 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 53' ' ' ILE . 9.0 t -140.79 109.27 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.487 179.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 76.54 34.21 0.48 Allowed 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 76.02 -3.4 2.57 Favored 'General case' 0 CA--C 1.537 0.481 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.773 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.452 HG13 ' O ' ' A' ' 50' ' ' VAL . 1.1 pt -114.27 120.5 64.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-O 121.047 0.451 . . . . 0.0 111.312 179.501 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -64.71 131.84 47.98 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.054 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.8 m -131.11 55.97 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.355 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.9 mtmt -59.88 -40.5 88.94 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.188 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.0 mttp -136.35 30.84 2.92 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.061 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.93 -169.22 1.05 Allowed 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.272 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.01 135.0 34.3 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.47 0.652 . . . . 0.0 110.616 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 4.9 t60 -54.44 -44.6 72.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.818 -1.083 . . . . 0.0 111.957 -179.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -63.41 -38.11 89.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.811 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.4 -42.9 82.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.541 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.9 t -65.29 -42.18 93.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.754 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.5 t -65.8 -39.08 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.475 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.6 mttt -57.64 -39.41 76.92 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.45 -0.796 . . . . 0.0 110.89 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 11.3 mt -66.57 -43.7 84.26 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.773 179.444 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 54.0 mt -63.16 -37.96 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.642 179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.47 11.98 57.02 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.316 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.5 ttpm? -110.32 -16.23 13.77 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 122.406 0.282 . . . . 0.0 111.264 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 23.3 p -44.2 -50.85 8.61 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 122.576 0.351 . . . . 0.0 111.6 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.5 p 63.26 32.22 14.97 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.454 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.17 -36.73 0.6 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.993 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -172.46 136.58 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-O 120.995 0.426 . . . . 0.0 111.917 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 9.8 tp -114.45 145.0 42.41 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.827 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -119.37 107.11 12.96 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.16 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 1.1 ptp -122.71 135.04 54.46 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.012 0.434 . . . . 0.0 111.239 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 41.3 t -94.37 115.1 32.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.642 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 3.7 pt -107.06 167.05 3.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.551 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.82 128.22 26.36 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.331 -0.207 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.471 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.488 1.169 0 CA-C-O 120.933 0.305 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.44 -173.16 4.47 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.848 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.406 HG23 HD23 ' A' ' 48' ' ' LEU . 25.2 t -99.31 136.29 31.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.152 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -134.93 174.5 10.53 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.349 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 m -118.9 149.75 41.05 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.312 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.6 t -129.65 134.17 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.079 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -105.41 103.68 13.25 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.6 t -95.64 129.47 45.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.807 0.337 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -91.43 90.94 7.89 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.284 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -55.3 123.49 13.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.734 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.05 -103.17 0.1 OUTLIER Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.241 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.14 -46.4 1.94 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.536 0.208 . . . . 0.0 111.164 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -103.76 31.69 4.31 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.692 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.69 -126.77 8.3 Favored Glycine 0 C--N 1.336 0.556 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.745 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -132.88 -64.97 0.73 Allowed 'General case' 0 C--O 1.231 0.103 0 CA-C-O 120.733 0.302 . . . . 0.0 111.076 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.0 -34.53 1.31 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.925 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -65.18 179.47 0.72 Allowed 'General case' 0 CA--C 1.532 0.256 0 CA-C-O 121.064 0.459 . . . . 0.0 111.569 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.8 144.06 49.43 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.264 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.79 128.01 45.92 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.197 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 46.3 m -150.47 106.78 3.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.674 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -163.18 76.11 0.17 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.446 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -45.68 -44.71 13.63 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.736 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.547 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -114.33 -64.47 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.263 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.197 178.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.547 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 84.4 Cg_endo -89.42 91.51 0.36 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.791 2.327 . . . . 0.0 112.008 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 72.6 m -50.32 121.48 5.68 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.731 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.0 p -147.14 146.06 18.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.871 0.367 . . . . 0.0 111.724 -179.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.31 92.41 5.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.476 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.9 m -46.54 -46.29 19.22 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.867 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.0 t -171.3 158.41 5.36 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 111.431 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 50.6 t -122.13 153.23 26.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.619 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.6 mmt -103.3 100.81 10.72 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.076 0.465 . . . . 0.0 110.574 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 5.7 ptt180 -45.49 120.12 2.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.971 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 120.19 -17.81 9.73 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.542 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.415 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -85.59 166.77 28.33 Favored Pre-proline 0 CA--C 1.533 0.312 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.352 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.415 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 15.0 Cg_endo -57.13 -22.55 48.42 Favored 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 122.667 2.245 . . . . 0.0 112.748 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -68.83 -48.73 62.78 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.72 0.295 . . . . 0.0 110.913 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.36 -27.12 65.98 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.302 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-30 -57.54 -26.34 61.23 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.59 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 15.7 t -89.39 -39.39 12.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 120.794 0.33 . . . . 0.0 111.013 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 129.08 44.61 0.2 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.088 -0.577 . . . . 0.0 112.83 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.8 mt -85.22 140.9 30.52 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.788 0.328 . . . . 0.0 110.366 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.9 mtt180 -141.14 119.68 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.584 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -41.22 126.64 2.73 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.637 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.17 -26.37 5.56 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.148 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.97 114.17 3.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-O 120.661 0.267 . . . . 0.0 110.571 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -73.37 128.57 35.85 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.529 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 20.6 mt -80.93 120.17 32.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.007 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.406 HD23 HG23 ' A' ' 3' ' ' VAL . 9.3 mp -101.52 -46.7 4.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.053 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.433 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.26 139.39 52.94 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.257 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 8.8 t -132.46 111.61 17.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.003 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.405 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 77.33 29.98 0.54 Allowed 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 82.54 -2.53 1.38 Allowed 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.412 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.4 pt -114.21 132.19 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 111.487 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.433 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.6 OUTLIER -63.23 156.15 26.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.714 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 m -149.36 55.32 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.614 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -58.62 -43.25 89.6 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.723 0.297 . . . . 0.0 110.854 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -141.73 38.55 1.66 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -72.75 -178.15 2.59 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.592 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.35 137.89 32.22 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.398 0.618 . . . . 0.0 111.08 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -52.67 -43.92 65.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.942 -1.026 . . . . 0.0 111.913 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 58.1 mt-10 -65.63 -39.3 91.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.008 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -67.25 -39.37 86.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.709 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.4 t -67.44 -42.34 87.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.745 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.7 t -65.67 -39.1 83.92 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.184 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.8 mtpp -57.74 -38.95 76.24 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.3 mt -68.3 -42.54 79.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.684 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.405 ' HA ' HD23 ' A' ' 74' ' ' LEU . 6.8 mt -67.47 -36.9 77.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.884 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -81.66 10.62 50.28 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.342 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 ttpt -114.16 -5.82 13.04 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.623 0.369 . . . . 0.0 111.2 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . 0.406 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 14.0 p -47.8 -48.78 30.28 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 122.488 0.315 . . . . 0.0 111.752 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.9 t 65.65 33.34 8.5 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.069 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.16 -33.3 1.72 Allowed Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.275 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.406 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 8.0 p -172.68 138.0 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-O 121.0 0.428 . . . . 0.0 111.784 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 67' ' ' ILE . 9.1 tp -114.45 147.28 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.222 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -108.97 99.23 8.59 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.419 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.43 135.04 47.55 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.959 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.9 t -108.75 99.44 8.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.762 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -111.07 164.92 6.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.358 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.38 130.9 48.39 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.241 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -82.79 121.69 27.23 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -87.23 -46.68 4.93 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.911 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.1 t -104.77 118.43 52.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.83 0.348 . . . . 0.0 111.116 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.333 -179.887 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.49 1.321 0 CA-C-O 120.721 0.217 . . . . 0.0 111.995 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.79 -50.98 4.03 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.253 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 29.9 t -71.22 123.09 24.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.865 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 -131.89 160.77 34.75 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.497 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.2 p -101.59 131.34 47.84 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.178 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 14.2 t -116.37 131.55 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.808 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -100.99 111.77 24.05 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.728 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.411 HG11 ' HB3' ' A' ' 15' ' ' TYR . 16.2 t -97.67 114.41 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.349 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.77 92.42 9.2 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.782 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.475 ' HG3' ' CE1' ' A' ' 15' ' ' TYR . 9.7 ttt180 -51.6 127.43 20.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.738 -0.664 . . . . 0.0 111.188 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.81 20.91 25.77 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.684 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.45 0.38 3.44 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 117.118 0.459 . . . . 0.0 111.907 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.01 24.0 1.67 Allowed 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 120.83 0.348 . . . . 0.0 111.105 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.69 -162.11 23.76 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.705 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.475 ' CE1' ' HG3' ' A' ' 10' ' ' ARG . 64.6 m-85 -131.7 -43.98 0.99 Allowed 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.36 -13.48 7.87 Favored Glycine 0 CA--C 1.522 0.507 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.18 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -108.52 174.28 5.94 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 117.039 0.419 . . . . 0.0 111.386 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.0 m -130.0 142.86 50.58 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.684 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.19 124.48 42.55 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.302 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.2 m -150.29 159.17 44.65 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.4 -29.52 2.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 121.055 -0.593 . . . . 0.0 113.157 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 64.11 21.27 12.52 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.417 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . 179.58 -63.8 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.282 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.417 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 91.0 Cg_endo -79.25 85.53 1.84 Allowed 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 122.52 2.147 . . . . 0.0 111.561 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 61.2 m -52.88 110.6 0.54 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.578 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -144.62 147.52 19.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.536 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.446 ' CD2' ' HB3' ' A' ' 41' ' ' LEU . 7.1 mp -74.4 90.8 2.18 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.3 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -43.78 61.95 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.614 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -171.17 158.09 5.36 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.984 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 14.7 t -135.77 153.34 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.92 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 16.3 ptp -104.52 105.12 15.11 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.271 0.558 . . . . 0.0 110.745 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.5 mtt180 -46.68 123.09 4.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.096 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.28 16.29 10.55 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 121.132 -0.556 . . . . 0.0 112.961 -179.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.8 164.87 17.74 Favored Pre-proline 0 C--O 1.234 0.247 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.19 -27.83 31.41 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 122.767 2.312 . . . . 0.0 112.606 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.32 -49.92 51.33 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.99 -35.23 79.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.239 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 m-30 -56.18 -32.95 64.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.714 -179.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.33 -35.05 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.62 0.247 . . . . 0.0 110.964 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.87 43.21 0.17 Allowed Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.152 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.446 ' HB3' ' CD2' ' A' ' 27' ' ' LEU . 63.5 mt -108.23 121.08 44.15 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.506 0.193 . . . . 0.0 110.53 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.92 -152.66 0.5 Allowed 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.988 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.22 130.06 44.95 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.812 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 113.68 -27.43 9.29 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.918 -0.658 . . . . 0.0 113.188 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -58.03 120.47 8.62 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.927 0.363 . . . . 0.0 111.077 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.7 125.59 30.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.741 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 23.8 mt -85.86 126.36 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.711 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.9 mp -108.22 -71.49 0.76 Allowed 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -97.07 126.89 42.53 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.756 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.0 t -119.64 103.38 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.302 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.415 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.5 t-20 76.46 31.75 0.59 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.705 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 85.01 -4.19 0.92 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.783 179.68 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.1 pp -110.58 131.96 60.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-O 120.94 0.4 . . . . 0.0 111.656 179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -71.58 145.28 49.14 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.604 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.2 m -146.11 61.14 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.376 179.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.1 -46.94 68.9 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.058 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 3.5 mtpp -140.13 37.68 1.93 Allowed 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.977 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.79 -174.96 2.32 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.446 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.8 m -91.2 145.67 24.48 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.641 0.734 . . . . 0.0 111.103 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -61.68 -44.52 96.8 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.547 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -58.84 -43.2 90.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.882 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -64.24 -44.08 92.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.492 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.402 ' HA ' HD12 ' A' ' 66' ' ' LEU . 67.5 t -64.64 -40.79 90.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.059 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.3 t -65.69 -38.84 83.25 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.37 -40.88 79.07 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.901 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.402 HD12 ' HA ' ' A' ' 63' ' ' VAL . 7.3 mt -67.27 -42.07 84.44 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.643 179.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 9.8 mt -68.03 -39.33 81.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -80.04 11.17 37.02 Favored Glycine 0 CA--C 1.524 0.595 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.585 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.21 -8.12 13.55 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.441 0.296 . . . . 0.0 111.24 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . 0.432 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 24.9 p -48.49 -49.91 33.87 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.825 0.345 . . . . 0.0 111.798 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.1 t 66.33 33.42 7.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.002 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.83 -37.41 0.95 Allowed Glycine 0 C--N 1.334 0.464 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.008 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.432 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 8.1 p -171.12 137.39 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.998 0.427 . . . . 0.0 111.922 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.406 ' N ' HG22 ' A' ' 73' ' ' VAL . 1.2 pp -112.38 155.41 24.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.363 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 68.7 m80 -110.92 98.34 7.49 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.268 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 3.0 ttm -105.07 122.74 46.52 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.052 -179.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.3 t -101.06 100.44 10.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.566 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 6.5 pt -102.53 171.76 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.427 -179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -143.13 148.04 35.94 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.416 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -97.86 135.12 40.06 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -147.4 108.57 0.44 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.218 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 33.4 t -72.18 93.24 0.52 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.307 0 CA-C-O 120.838 0.351 . . . . 0.0 110.585 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.979 0 CA-C-O 118.299 -1.279 . . . . 0.0 112.255 -179.575 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo . . . . . 0 N--CA 1.49 1.304 0 CA-C-O 120.592 0.164 . . . . 0.0 111.801 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -96.76 -68.12 0.82 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.683 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 10.7 p -85.06 118.6 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.641 179.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -137.35 162.59 33.16 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.219 -179.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.28 141.43 37.63 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.175 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.7 t -126.9 139.28 52.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.295 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -107.86 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.512 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.7 t -99.08 112.87 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-O 120.862 0.363 . . . . 0.0 111.187 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.79 88.82 7.42 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.343 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.471 ' HB3' ' O ' ' A' ' 71' ' ' SER . 2.1 ttt-85 -48.19 124.75 8.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.181 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.49 -87.81 0.14 Allowed Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.701 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.17 -55.85 0.45 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.615 0.245 . . . . 0.0 111.316 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.79 30.57 6.98 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.98 151.14 5.44 Favored Glycine 0 C--N 1.333 0.378 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.39 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.445 ' CE2' ' HG3' ' A' ' 10' ' ' ARG . 39.1 m-85 -77.43 -33.42 54.89 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-O 120.568 0.223 . . . . 0.0 111.086 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.84 61.77 0.83 Allowed Glycine 0 C--N 1.335 0.498 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.567 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -168.93 175.93 5.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 111.063 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -119.04 116.71 26.98 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.392 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -105.97 132.41 52.09 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.801 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.462 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 36.8 p -147.45 -176.68 5.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.819 179.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 109.4 82.27 1.35 Allowed Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 121.033 -0.604 . . . . 0.0 112.05 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.1 tp60 -45.37 -53.44 8.6 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.843 0.354 . . . . 0.0 110.594 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.521 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -98.68 -62.93 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.94 178.395 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.521 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 97.3 Cg_endo -88.11 91.85 0.45 Allowed 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.872 2.381 . . . . 0.0 112.128 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.3 p -54.73 119.78 5.83 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.659 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.5 p -141.4 151.48 19.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.83 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -81.6 91.31 6.37 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.17 -43.87 52.51 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.493 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.3 t -167.23 158.58 12.06 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.367 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.4 t -119.1 154.76 21.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.341 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 41.8 mtp -98.41 101.38 12.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 121.036 0.446 . . . . 0.0 110.33 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -50.82 124.48 11.2 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.859 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 22.87 10.97 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.488 -179.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.37 165.08 26.39 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.411 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 9.4 Cg_endo -52.59 -28.06 35.3 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.726 2.284 . . . . 0.0 112.869 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -65.36 -49.84 67.83 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.782 0.325 . . . . 0.0 110.829 179.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.36 -31.25 68.43 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.397 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.411 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.4 m-30 -61.36 -23.95 66.13 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.419 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 t -89.08 -33.73 6.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 CA-C-O 120.758 0.313 . . . . 0.0 111.167 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.45 42.51 0.31 Allowed Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.874 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -75.18 178.49 5.71 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.644 0.259 . . . . 0.0 110.62 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -171.04 130.18 0.77 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.219 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.18 111.72 3.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.479 179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 129.91 -23.96 4.62 Favored Glycine 0 CA--C 1.523 0.582 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.839 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.45 115.65 3.13 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.651 0.263 . . . . 0.0 110.518 179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.64 120.3 19.99 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.832 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 24.2 mt -78.05 124.15 35.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.537 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.2 mt -105.67 -46.46 4.15 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.776 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.532 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.5 140.43 51.45 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.996 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.9 t -134.44 110.06 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 76.65 33.56 0.49 Allowed 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -178.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 77.32 -1.86 2.68 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 112.688 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.456 HD12 HD23 ' A' ' 66' ' ' LEU . 5.0 pt -113.04 122.77 67.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 121.063 0.459 . . . . 0.0 111.315 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.532 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 6.9 t30 -63.4 128.16 34.57 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.339 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 m -136.33 54.18 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.22 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.4 mmmt -65.9 -30.0 70.52 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.25 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.4 mmtt -132.37 29.76 4.24 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.61 0.243 . . . . 0.0 111.129 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -81.75 -179.51 7.41 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.857 0.36 . . . . 0.0 111.405 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.9 m -86.18 145.26 27.07 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.58 0.705 . . . . 0.0 111.011 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 20' ' ' SER . 1.7 t-160 -59.1 -44.87 91.99 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.485 -1.234 . . . . 0.0 111.473 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.02 -38.72 89.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.546 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -42.55 92.43 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 65.2 t -65.53 -41.74 91.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.001 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 46.6 t -65.82 -38.92 83.31 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 178.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -43.09 85.72 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.234 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.456 HD23 HD12 ' A' ' 53' ' ' ILE . 56.0 mt -64.53 -41.03 96.62 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.764 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.441 ' HA ' HD21 ' A' ' 74' ' ' LEU . 44.1 mt -66.35 -43.43 91.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.499 179.383 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.64 -21.94 63.41 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.72 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.81 -34.93 72.25 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.527 0.203 . . . . 0.0 111.531 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.95 99.59 10.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.487 0.66 . . . . 0.0 110.254 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.471 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 30.3 t -88.99 -33.77 17.08 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.758 -1.11 . . . . 0.0 111.221 -179.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -65.12 -43.03 96.21 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.174 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.91 138.93 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 120.751 0.31 . . . . 0.0 111.44 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.441 HD21 ' HA ' ' A' ' 67' ' ' ILE . 0.2 OUTLIER -94.19 146.5 23.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.318 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -131.44 102.82 6.1 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.864 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.09 154.66 44.42 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.808 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.6 t -109.43 112.74 41.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.704 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.6 pp -107.24 172.18 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.387 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -145.94 129.17 16.7 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.258 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.08 169.86 10.82 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.031 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -157.07 -97.6 0.13 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.911 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m -67.09 109.37 1.33 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.283 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.46 -1.189 . . . . 0.0 112.343 -179.952 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo . . . . . 0 N--CA 1.49 1.308 0 CA-C-O 120.852 0.272 . . . . 0.0 111.92 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -165.23 -51.84 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.832 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 p -97.6 138.3 22.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.247 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.5 ptt-85 -153.34 166.42 32.68 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.24 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.6 m -118.16 140.96 49.01 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.2 t -115.3 138.39 45.78 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.329 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -110.69 105.78 14.78 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.987 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 73' ' ' VAL . 10.5 t -100.39 133.26 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.288 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.68 98.73 9.25 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.942 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.526 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.4 OUTLIER -53.35 126.07 19.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.978 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.82 15.14 44.29 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.706 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.8 mmt85 74.01 0.24 3.55 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.985 0.392 . . . . 0.0 111.753 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -146.28 25.57 1.23 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-O 120.77 0.319 . . . . 0.0 111.147 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 136.47 175.44 13.81 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.692 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.526 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 35.5 m-85 -114.26 -69.57 0.85 Allowed 'General case' 0 C--O 1.232 0.141 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.81 -22.25 1.8 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.988 -0.625 . . . . 0.0 113.226 -179.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.4 p90 -95.81 137.76 34.43 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.905 0.353 . . . . 0.0 110.777 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -98.08 133.25 42.8 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.201 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.0 mt -117.29 133.26 56.19 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.462 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.5 m -149.88 166.63 28.96 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.128 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.47 -34.22 4.89 Favored Glycine 0 C--N 1.336 0.568 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.897 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.515 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 79.91 -49.85 0.37 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.359 0.663 . . . . 0.0 111.552 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.436 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -97.79 -64.93 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.483 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.436 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 99.0 Cg_endo -79.74 94.86 1.03 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.402 2.068 . . . . 0.0 112.478 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 85.6 m -59.65 111.61 1.49 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.184 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -146.93 143.21 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.273 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -79.2 91.46 4.97 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.671 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.1 m -54.96 -37.64 66.75 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.347 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.2 t -167.15 155.61 9.8 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.921 0.391 . . . . 0.0 111.273 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.4 t -112.5 155.17 13.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.558 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mmt -103.31 101.92 11.86 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 121.003 0.43 . . . . 0.0 110.636 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.4 mtt85 -51.73 124.4 12.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.764 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.68 3.61 37.14 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.717 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.407 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.6 OUTLIER -108.13 167.06 9.82 Favored Pre-proline 0 C--O 1.233 0.211 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.512 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 9.8 Cg_endo -51.57 -29.51 32.54 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.924 2.416 . . . . 0.0 112.712 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.7 -49.36 73.44 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.024 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.13 -34.27 77.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -60.94 -26.79 67.76 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.492 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 t -89.56 -30.41 5.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-O 120.661 0.267 . . . . 0.0 111.144 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.06 47.11 0.67 Allowed Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.8 tp -80.22 156.45 26.88 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.965 0.412 . . . . 0.0 110.782 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.8 mmm180 -146.28 117.79 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -53.41 152.15 5.0 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.739 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.71 -28.95 13.66 Favored Glycine 0 CA--C 1.521 0.427 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.344 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -59.68 121.9 12.8 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 122.876 0.47 . . . . 0.0 111.438 179.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -78.37 130.56 36.28 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.079 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.3 mt -84.7 127.81 39.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.002 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -106.42 -43.27 4.8 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.428 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -129.95 137.2 50.21 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.504 -0.317 . . . . 0.0 111.41 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.447 ' O ' HG13 ' A' ' 53' ' ' ILE . 3.9 t -136.91 113.03 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.338 179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 76.64 31.66 0.57 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 79.15 -5.01 2.02 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.581 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 50' ' ' VAL . 1.2 pp -112.2 124.97 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-O 121.104 0.478 . . . . 0.0 111.343 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.552 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -66.19 131.41 46.1 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.307 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.5 m -129.05 53.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.309 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -55.41 -55.4 32.12 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.281 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.3 mttm -127.19 32.62 5.03 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.911 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.49 -176.84 3.88 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -85.69 133.88 34.0 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.511 0.672 . . . . 0.0 110.81 179.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.515 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 5.0 t60 -56.9 -44.31 82.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.811 -1.086 . . . . 0.0 111.882 -179.528 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.443 ' HA ' HG21 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -66.48 -33.84 76.6 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.912 179.706 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.56 -42.18 68.14 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.068 178.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 56.9 t -63.86 -44.02 97.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.083 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.443 HG21 ' HA ' ' A' ' 61' ' ' GLU . 28.6 m -66.14 -39.3 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -57.93 -42.44 84.86 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.956 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.9 mt -62.31 -43.87 97.83 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.401 HG22 ' CE2' ' A' ' 15' ' ' TYR . 53.3 mt -66.59 -41.62 88.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.677 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.38 -1.17 74.72 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.848 -0.692 . . . . 0.0 113.256 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -83.03 -34.76 26.19 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.027 0.413 . . . . 0.0 111.492 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.75 -57.3 9.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.809 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.8 34.76 5.36 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.974 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.8 -45.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.366 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 7.6 p -169.05 138.48 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-O 120.841 0.353 . . . . 0.0 111.726 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.405 ' N ' HG21 ' A' ' 73' ' ' VAL . 10.7 tp -114.33 141.87 47.05 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.26 179.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -125.27 98.41 5.63 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.977 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 15.1 ptt? -116.67 154.84 29.86 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.391 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.0 t -111.98 109.21 27.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.878 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.1 pt -102.06 163.67 3.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.509 -179.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.26 116.0 18.47 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.9 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -71.49 117.42 13.02 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.33 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -106.13 -30.6 4.41 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.924 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 17.8 t -92.47 134.29 31.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 120.823 0.344 . . . . 0.0 110.868 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.163 0 CA-C-O 118.685 -1.064 . . . . 0.0 113.104 -179.928 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo . . . . . 0 N--CA 1.489 1.227 0 CA-C-O 120.536 0.14 . . . . 0.0 112.162 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -176.99 -42.54 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.466 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 21.4 t -72.64 120.44 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.936 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -150.22 174.08 13.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.377 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -118.76 137.41 53.39 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 42.3 t -114.59 139.33 41.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.114 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -115.04 110.1 19.07 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.861 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 5.9 t -95.9 130.31 44.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.027 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.5 93.13 8.39 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.964 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 -39.38 122.7 1.34 Allowed 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.555 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.31 -90.65 0.07 OUTLIER Glycine 0 C--N 1.333 0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.907 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 ptt85 -134.98 -47.37 0.73 Allowed 'General case' 0 C--O 1.233 0.196 0 N-CA-C 111.578 0.214 . . . . 0.0 111.578 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.49 40.43 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.528 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.28 -173.96 21.43 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.826 -0.702 . . . . 0.0 113.178 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -96.56 -71.93 0.66 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.653 0.263 . . . . 0.0 111.463 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.71 -39.34 0.61 Allowed Glycine 0 CA--C 1.519 0.323 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.785 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -71.62 179.93 2.85 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.691 0.282 . . . . 0.0 111.122 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 m -135.3 151.03 50.16 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.356 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 mt -124.97 131.06 53.48 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.942 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.7 p -148.06 157.77 43.69 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 120.713 0.292 . . . . 0.0 111.561 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 126.26 -25.73 5.39 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 121.213 -0.518 . . . . 0.0 113.027 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.587 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 61.81 14.24 6.07 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.736 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.428 ' CB ' ' CD ' ' A' ' 24' ' ' PRO . . . -166.87 -65.79 0.01 OUTLIER Pre-proline 0 N--CA 1.463 0.224 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.428 ' CD ' ' CB ' ' A' ' 23' ' ' ALA . 73.8 Cg_endo -74.39 83.68 1.66 Allowed 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.381 2.054 . . . . 0.0 111.361 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.5 m -52.23 108.45 0.29 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.3 p -143.22 141.37 26.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.54 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 mp -78.98 91.95 4.89 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.408 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.24 -42.98 42.33 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.408 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.9 t -171.07 157.1 5.06 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.964 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -120.42 155.56 23.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.655 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.0 mtp -97.83 102.29 14.01 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.224 0.535 . . . . 0.0 110.572 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.34 121.6 5.17 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.967 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.21 -18.32 23.54 Favored Glycine 0 CA--C 1.522 0.499 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.291 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.79 166.74 34.16 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.654 0.227 . . . . 0.0 110.521 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -53.14 -26.74 34.32 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.101 2.534 . . . . 0.0 113.166 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -65.5 -42.27 92.3 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.53 -26.65 63.67 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.375 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -55.31 -25.59 35.37 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 111.668 0.247 . . . . 0.0 111.668 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.46 -32.51 5.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 120.612 0.244 . . . . 0.0 111.122 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.77 41.65 1.68 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.454 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.5 mt -74.79 -178.28 3.62 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.628 0.251 . . . . 0.0 110.346 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 -163.85 122.79 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.402 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -47.26 125.25 7.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.97 179.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.53 -25.66 5.89 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.595 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -56.91 122.62 12.69 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 121.018 0.437 . . . . 0.0 110.946 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.6 mp0 -76.98 117.78 18.91 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.062 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 14.0 mt -81.76 121.49 35.18 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.899 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mp -108.44 -40.59 5.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.086 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.472 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.8 133.08 55.33 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.99 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.4 t -135.3 111.29 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.22 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 76.28 32.62 0.58 Allowed 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.294 0.568 . . . . 0.0 109.717 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 76.82 -3.35 2.53 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.089 -0.96 . . . . 0.0 112.784 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.403 HG13 ' O ' ' A' ' 50' ' ' VAL . 1.1 pt -116.12 125.92 73.4 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-O 120.834 0.349 . . . . 0.0 111.16 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.472 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 18.4 p-10 -64.95 135.91 56.21 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.473 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.0 m -134.2 59.0 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.902 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 46.4 mttt -48.48 -71.44 0.07 Allowed 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.921 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 35.6 mttp -119.81 39.87 3.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.664 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -73.86 -174.87 1.94 Allowed 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.933 -179.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.99 136.24 33.12 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 121.489 0.661 . . . . 0.0 110.678 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.587 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 5.1 t60 -53.99 -44.48 70.87 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.279 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -61.17 -41.81 97.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.788 0.327 . . . . 0.0 110.737 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -66.3 -41.45 89.71 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.5 t -65.93 -39.13 83.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.606 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.5 t -65.75 -39.02 83.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 178.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -57.42 -41.26 80.05 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.887 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.2 mt -64.14 -43.62 94.66 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.46 179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 52.0 mt -66.84 -37.47 79.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.623 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -79.31 8.56 45.94 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.444 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.54 1.91 15.16 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 122.448 0.299 . . . . 0.0 110.781 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . 0.408 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 16.0 p -50.98 -44.73 60.78 Favored 'General case' 0 C--O 1.233 0.212 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.487 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.9 m 67.21 30.82 7.01 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.065 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.9 -30.93 2.78 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.152 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.408 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.1 p -163.84 138.0 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.047 0.451 . . . . 0.0 112.193 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 41.4 tp -114.35 150.41 34.59 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.164 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.4 m80 -120.01 105.82 11.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.344 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -115.45 137.18 52.32 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.168 -179.381 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 20.6 t -107.34 105.75 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.767 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -106.82 170.64 2.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.461 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -130.41 154.78 47.36 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.571 -179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -105.7 151.12 24.83 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.794 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.33 162.32 20.21 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.2 108.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.937 0.398 . . . . 0.0 111.0 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.44 -1.2 . . . . 0.0 112.273 -179.46 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo . . . . . 0 N--CA 1.493 1.467 0 CA-C-O 120.42 0.092 . . . . 0.0 112.317 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 25.7 ptt85 38.18 39.42 0.26 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.765 0.426 . . . . 0.0 112.068 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.5 p -111.61 132.18 60.92 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.181 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -130.81 145.09 51.88 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.244 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -110.44 132.66 53.99 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.664 179.484 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 37.1 t -118.33 141.1 39.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.554 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -128.66 100.8 5.87 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.794 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 19.5 t -95.56 144.62 9.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-O 120.969 0.414 . . . . 0.0 111.533 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -115.14 106.44 14.09 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.625 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.7 ttt180 -50.62 120.09 4.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.12 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.97 -61.92 5.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.392 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -150.7 -76.29 0.14 Allowed 'General case' 0 C--O 1.231 0.127 0 CA-C-O 120.613 0.244 . . . . 0.0 110.564 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.39 26.46 9.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.508 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.6 173.95 46.52 Favored Glycine 0 C--N 1.336 0.57 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.897 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -111.13 -77.24 0.59 Allowed 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 120.706 0.289 . . . . 0.0 110.922 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.53 45.32 0.04 OUTLIER Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.968 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -159.03 176.77 11.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.442 0.163 . . . . 0.0 110.713 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -140.9 150.38 43.11 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.628 0.252 . . . . 0.0 111.268 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.8 mt -120.98 131.48 54.33 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.568 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.7 m -147.08 163.0 37.67 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.258 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.61 -30.65 5.07 Favored Glycine 0 C--N 1.336 0.554 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.983 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.485 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 80.97 -44.73 0.22 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.443 0.697 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.464 ' CB ' ' CD ' ' A' ' 24' ' ' PRO . . . -111.04 -68.26 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.512 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.464 ' CD ' ' CB ' ' A' ' 23' ' ' ALA . 64.0 Cg_endo -73.73 95.72 0.89 Allowed 'Trans proline' 0 C--N 1.356 0.952 0 C-N-CA 122.26 1.974 . . . . 0.0 112.446 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 84.7 m -61.73 118.5 7.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.218 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.31 145.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.86 90.99 2.95 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-O 120.846 0.355 . . . . 0.0 110.507 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.6 m -54.67 -36.67 64.86 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.417 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.2 t -164.52 157.94 17.66 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.031 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.1 t -122.54 154.61 27.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.903 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -97.45 101.28 12.78 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.279 0.561 . . . . 0.0 110.216 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -51.87 121.59 6.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.122 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.86 27.97 8.07 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.193 -0.527 . . . . 0.0 112.525 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.2 m -129.36 164.63 38.23 Favored Pre-proline 0 C--N 1.332 -0.194 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.68 -25.12 25.27 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 122.865 2.376 . . . . 0.0 112.902 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.19 -49.98 65.45 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.815 0.341 . . . . 0.0 110.704 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.03 -25.98 65.64 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.168 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.1 m-30 -57.03 -30.18 64.0 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.599 0.238 . . . . 0.0 111.388 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.8 t -89.28 -25.92 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.253 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.84 5.4 6.94 Favored Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.348 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 mp -64.67 111.45 2.76 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 117.315 0.557 . . . . 0.0 109.675 179.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -122.97 25.97 8.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.51 -179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . 72.92 159.27 0.22 Allowed 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.947 0.404 . . . . 0.0 111.636 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.15 -39.66 3.05 Favored Glycine 0 C--N 1.334 0.46 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.678 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -52.3 119.91 4.94 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.917 0.389 . . . . 0.0 110.843 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -75.22 126.22 30.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.031 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.3 mt -83.09 120.29 34.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.819 179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.4 mp -105.2 -32.87 8.45 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.624 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -137.09 137.45 39.3 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 111.018 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 6.3 t -132.25 108.15 13.39 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.407 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 4.8 t-20 77.39 33.59 0.4 Allowed 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.417 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.407 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.52 -1.08 3.1 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.517 -179.621 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.44 HD13 HD23 ' A' ' 66' ' ' LEU . 9.0 pt -113.14 119.63 61.1 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 111.176 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.476 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 10.9 m120 -62.08 120.63 11.22 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.149 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.9 m -135.14 33.71 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.747 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -61.4 -28.43 69.25 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -123.55 26.83 7.65 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 120.544 0.211 . . . . 0.0 111.3 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -92.27 -178.96 5.1 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.765 0.317 . . . . 0.0 111.505 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.23 135.36 36.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.362 0.601 . . . . 0.0 110.736 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.485 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 4.0 t60 -54.79 -44.24 73.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.927 -1.033 . . . . 0.0 111.978 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.46 ' HA ' HG23 ' A' ' 64' ' ' VAL . 20.9 mt-10 -65.64 -35.87 82.06 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.779 0.323 . . . . 0.0 110.567 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.29 -39.38 71.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.167 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.8 t -67.43 -42.31 87.09 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.162 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.46 HG23 ' HA ' ' A' ' 61' ' ' GLU . 31.4 m -65.93 -38.6 82.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.9 tttp -57.48 -40.31 78.3 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.697 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.44 HD23 HD13 ' A' ' 53' ' ' ILE . 21.2 mt -67.63 -42.42 82.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.736 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 9.5 mt -69.33 -38.38 77.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.996 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -60.1 -24.65 61.1 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.318 179.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -80.27 4.43 17.73 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.902 0.334 . . . . 0.0 111.902 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -106.18 104.01 13.62 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.356 0.598 . . . . 0.0 110.109 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.2 33.43 5.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.987 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.93 -53.91 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.088 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 p -172.03 130.96 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-O 120.99 0.424 . . . . 0.0 111.8 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -114.5 151.62 32.99 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.546 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 19.7 m170 -116.39 107.09 14.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.211 179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -108.74 145.76 34.61 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.03 -179.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.5 t -117.1 98.88 7.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 179.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 24.8 pt -101.62 172.1 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.479 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.57 146.84 52.22 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.12 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -61.28 120.96 11.42 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.118 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 175.55 120.87 0.62 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.247 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.1 p -159.25 136.49 2.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.815 0.34 . . . . 0.0 111.204 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.303 -1.276 . . . . 0.0 112.75 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo . . . . . 0 N--CA 1.491 1.343 0 CA-C-O 120.653 0.189 . . . . 0.0 112.348 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 4.6 mtt-85 -178.9 95.11 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.811 0.339 . . . . 0.0 110.68 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -85.83 105.47 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.07 0.462 . . . . 0.0 111.26 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 6.9 tpt180 -114.18 139.27 49.5 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.844 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.81 131.06 57.05 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.182 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.6 t -120.91 131.49 72.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.693 0.282 . . . . 0.0 110.826 179.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -116.7 115.25 25.29 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.009 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 12.2 t -108.57 138.58 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.787 0.327 . . . . 0.0 111.435 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.3 93.89 8.87 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.397 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.441 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 4.0 ttt-85 -51.81 126.41 17.9 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.445 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.92 -112.67 0.03 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.687 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -111.27 -39.33 4.75 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.468 0.175 . . . . 0.0 111.329 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -138.75 35.13 2.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.337 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 159.96 -170.45 36.1 Favored Glycine 0 C--N 1.338 0.65 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.731 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.441 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 71.5 m-85 -118.63 -69.42 0.85 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.865 0.364 . . . . 0.0 111.161 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.16 52.49 0.04 OUTLIER Glycine 0 C--N 1.332 0.315 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.317 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -162.99 155.47 18.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.549 0.214 . . . . 0.0 110.952 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.14 129.13 43.52 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.932 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -116.57 124.37 49.68 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.993 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 39.2 m -148.07 115.58 6.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.177 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -168.1 83.28 0.1 OUTLIER Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.49 -179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.25 -43.07 21.68 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.972 0.415 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.518 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -121.25 -66.69 0.02 OUTLIER Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.455 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.518 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 92.3 Cg_endo -85.23 94.88 0.64 Allowed 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 122.475 2.117 . . . . 0.0 112.214 179.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 2.6 m -51.87 117.66 2.89 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.822 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -141.51 149.41 20.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.378 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.46 91.49 5.74 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.741 179.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.08 -45.38 61.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.517 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 3.5 t -164.4 159.06 19.21 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 t -116.9 155.03 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.714 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -99.5 100.76 11.83 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.153 0.501 . . . . 0.0 110.278 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.3 mtm-85 -52.07 125.94 17.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.943 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.91 23.64 11.46 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.682 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.86 168.92 14.29 Favored Pre-proline 0 CA--C 1.531 0.218 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -50.66 -29.93 27.11 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.885 2.39 . . . . 0.0 113.051 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.444 ' CB ' HD22 ' A' ' 41' ' ' LEU . . . -65.09 -49.82 68.51 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 111.014 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -69.43 -32.79 71.98 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.243 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 16.7 m-30 -62.77 -23.78 67.38 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.455 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 38.8 t -89.32 -29.6 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.58 0.229 . . . . 0.0 111.246 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.89 39.96 0.86 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.717 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.444 HD22 ' CB ' ' A' ' 36' ' ' ALA . 4.1 tp -73.28 178.62 4.38 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.806 0.336 . . . . 0.0 110.765 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -173.92 131.17 0.41 Allowed 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.944 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.67 120.81 11.92 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.911 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 128.23 -27.57 4.48 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.804 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -58.3 123.92 17.72 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 120.927 0.394 . . . . 0.0 111.062 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -78.21 124.7 28.37 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.716 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.3 mt -95.66 122.21 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.802 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.463 ' HA ' ' HB3' ' A' ' 56' ' ' LYS . 0.3 OUTLIER -108.19 -38.32 5.79 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.016 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -119.01 138.14 53.04 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.42 ' HB ' ' CG2' ' A' ' 55' ' ' VAL . 19.3 t -141.71 115.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.773 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.403 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.7 t-20 76.89 32.78 0.49 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -178.302 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.2 -0.71 3.23 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.454 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 12.1 pt -120.47 133.42 67.23 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 111.434 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 22.9 t-20 -63.07 121.73 14.32 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.966 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.423 ' HB ' HG22 ' A' ' 63' ' ' VAL . 5.0 m -140.41 55.35 0.21 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.553 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.463 ' HB3' ' HA ' ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.03 14.52 31.74 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.546 179.572 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -150.89 27.95 0.7 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 122.279 0.232 . . . . 0.0 111.12 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -113.99 -167.45 1.21 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-O 120.706 0.289 . . . . 0.0 111.59 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.74 139.15 30.75 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 121.361 0.6 . . . . 0.0 110.533 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -53.69 -44.78 70.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.871 -1.058 . . . . 0.0 112.052 -179.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -60.62 -42.32 96.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.742 0.306 . . . . 0.0 110.731 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -64.79 -44.06 91.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.265 179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.423 HG22 ' HB ' ' A' ' 55' ' ' VAL . 52.4 t -63.36 -42.81 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.128 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 50.3 t -66.17 -38.91 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -57.77 -41.1 81.3 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.89 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 17.7 mt -64.05 -43.45 95.49 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.425 HG21 ' CE1' ' A' ' 15' ' ' TYR . 68.6 mt -62.42 -44.27 99.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.679 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -69.51 -22.37 76.5 Favored Glycine 0 CA--C 1.522 0.49 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.004 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.9 tptt -57.0 -34.68 68.38 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.577 0.227 . . . . 0.0 111.421 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -69.01 -57.8 4.96 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-O 120.912 0.387 . . . . 0.0 110.676 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.409 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.5 OUTLIER 65.05 36.09 7.61 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.108 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.28 -45.56 0.02 OUTLIER Glycine 0 C--N 1.332 0.313 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.196 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -165.46 138.78 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.829 0.347 . . . . 0.0 111.287 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 28.3 tp -112.29 134.65 53.71 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.286 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 55.6 m170 -119.53 98.49 6.16 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.2 179.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.97 145.15 40.12 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.327 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 22.9 t -96.67 114.0 32.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.545 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.7 pt -103.37 146.23 11.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.311 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . 0.427 ' CB ' HD21 ' A' ' 48' ' ' LEU . . . -112.94 144.57 42.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.267 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -91.91 119.05 31.32 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.449 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -83.89 -122.27 0.91 Allowed Glycine 0 C--N 1.333 0.412 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.636 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 21.3 t -83.28 81.54 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-O 120.981 0.42 . . . . 0.0 110.372 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.465 -1.186 . . . . 0.0 112.322 -179.878 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 120.575 0.156 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -119.37 161.14 20.99 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.953 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.9 p -114.44 112.31 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 120.887 0.375 . . . . 0.0 111.327 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.5 ttt85 -118.48 136.27 53.9 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.203 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.09 129.54 36.37 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.754 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.484 HG21 HD11 ' A' ' 78' ' ' ILE . 25.0 t -126.35 135.51 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.333 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -133.35 109.11 9.13 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 73' ' ' VAL . 12.2 t -102.46 144.48 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.204 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -110.23 102.96 11.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.853 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.91 120.3 5.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.211 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.52 -122.03 0.58 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.647 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -114.41 -40.7 3.58 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.514 0.197 . . . . 0.0 111.151 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -105.94 29.42 6.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 120.721 0.296 . . . . 0.0 111.52 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.96 -176.92 16.77 Favored Glycine 0 C--N 1.337 0.606 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.826 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -79.3 -71.46 0.44 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.896 0.379 . . . . 0.0 110.718 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.23 48.99 0.04 OUTLIER Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.836 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -161.01 171.59 18.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.673 0.273 . . . . 0.0 110.946 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -126.31 133.17 51.47 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.899 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.4 mt -115.27 124.59 51.72 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.204 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.4 m -136.7 16.31 3.11 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.301 -0.409 . . . . 0.0 112.101 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.44 85.19 1.57 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.071 -0.585 . . . . 0.0 112.445 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.34 -66.66 0.35 Allowed 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.691 0.281 . . . . 0.0 111.011 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.452 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -91.76 -59.06 0.23 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.103 178.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.452 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 83.9 Cg_endo -88.59 94.32 0.38 Allowed 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 122.89 2.393 . . . . 0.0 111.607 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.2 m -50.98 124.24 10.91 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.679 -179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -154.07 141.89 13.11 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.416 HD21 ' HB3' ' A' ' 41' ' ' LEU . 1.6 mp -79.71 89.53 5.18 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.771 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -56.22 -35.24 67.11 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.473 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.3 t -153.16 152.05 30.82 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.3 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.2 t -123.13 154.76 28.86 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.724 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 32.3 mtt -98.64 100.29 11.5 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.268 0.556 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.37 123.29 13.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.847 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 108.85 -19.71 30.15 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.785 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.0 166.59 25.64 Favored Pre-proline 0 CA--C 1.531 0.231 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -55.45 -24.93 46.14 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.709 2.273 . . . . 0.0 112.621 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.57 -49.11 74.7 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.993 179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.08 -28.95 65.84 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.286 179.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.7 m-30 -56.64 -33.08 65.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.687 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -89.25 -31.06 5.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.024 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.2 51.71 1.44 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.176 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.416 ' HB3' HD21 ' A' ' 27' ' ' LEU . 5.3 mt -59.32 -25.81 64.47 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 20.5 mtt85 66.7 119.49 0.03 OUTLIER 'General case' 0 C--N 1.34 0.187 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.39 89.19 0.21 Allowed 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.496 179.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.0 -12.7 5.04 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 121.208 -0.52 . . . . 0.0 112.905 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -58.22 127.49 32.38 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.711 0.291 . . . . 0.0 110.573 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.59 126.65 30.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.739 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 15.1 mt -90.63 131.06 38.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.599 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -119.06 -43.65 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.358 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.512 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.07 137.25 47.27 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.008 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.6 t -144.28 110.98 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.297 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 76.99 35.74 0.35 Allowed 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -178.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 71.55 -0.27 3.21 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.252 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 12.3 pt -120.97 125.5 74.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-O 120.81 0.338 . . . . 0.0 111.121 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.512 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -68.59 172.09 6.7 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.954 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.57 -51.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.039 -0.528 . . . . 0.0 112.121 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt 72.15 -59.41 0.56 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 123.119 0.567 . . . . 0.0 110.828 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.8 mtpt -148.23 40.26 0.94 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.75 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -72.74 -173.79 1.28 Allowed 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.859 0.362 . . . . 0.0 111.4 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -90.14 135.8 33.44 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.416 0.627 . . . . 0.0 111.174 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.4 t-160 -53.13 -44.33 67.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.486 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.448 ' O ' HG23 ' A' ' 64' ' ' VAL . 3.3 pm0 -66.21 -34.74 78.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.169 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.62 -39.43 70.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.725 0.297 . . . . 0.0 110.343 179.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -67.3 -43.87 87.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.941 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 61' ' ' GLU . 15.9 m -66.32 -38.96 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.6 mmtt -58.11 -39.73 79.42 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.059 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 25.3 mt -68.09 -41.19 82.21 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.772 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.42 ' HA ' ' CD1' ' A' ' 74' ' ' LEU . 17.7 mt -69.39 -38.49 77.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.035 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -87.77 14.33 58.72 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.102 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.57 -29.22 12.46 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.847 0.324 . . . . 0.0 111.299 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -69.71 -61.86 1.61 Allowed 'General case' 0 C--O 1.233 0.217 0 CA-C-O 120.827 0.346 . . . . 0.0 110.645 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 70.63 33.88 2.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.088 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.52 -49.4 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.126 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 7.7 p -174.73 132.56 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 111.669 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.42 ' CD1' ' HA ' ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.91 152.98 31.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.672 179.676 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.9 m170 -117.52 105.38 12.02 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.948 179.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.24 156.2 25.81 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.431 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.4 t -125.53 100.52 7.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.072 179.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.484 HD11 HG21 ' A' ' 6' ' ' VAL . 18.4 pt -101.36 158.67 4.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.388 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -114.86 116.64 28.89 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.72 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.44 120.83 18.6 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -168.89 43.26 0.22 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.397 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.61 104.33 15.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-O 120.667 0.27 . . . . 0.0 110.735 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.191 0 CA-C-O 118.675 -1.069 . . . . 0.0 112.937 -179.912 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo . . . . . 0 N--CA 1.492 1.395 0 CA-C-O 120.384 0.077 . . . . 0.0 112.072 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 70.78 131.47 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.837 0.455 . . . . 0.0 111.358 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 p -65.78 121.05 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.3 ptt180 -137.1 170.77 15.54 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.49 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.7 m -93.81 139.01 31.37 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.459 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.419 HG22 HD13 ' A' ' 78' ' ' ILE . 36.9 t -117.44 146.92 21.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.09 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -111.3 102.55 10.94 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.789 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.4 t -88.54 119.88 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.174 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.119 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.91 89.63 8.07 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.472 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.412 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 7.9 ttm-85 -53.47 122.12 9.07 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.731 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.29 -68.98 1.42 Allowed Glycine 0 C--N 1.335 0.483 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.548 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -165.32 -51.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 120.725 0.298 . . . . 0.0 110.807 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -122.53 25.04 9.0 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.596 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 150.94 171.53 19.14 Favored Glycine 0 C--N 1.336 0.58 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.795 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.412 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 5.4 m-85 -108.04 -62.85 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.667 0.27 . . . . 0.0 110.646 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.26 -33.5 0.93 Allowed Glycine 0 CA--C 1.523 0.541 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.879 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -71.48 178.59 3.39 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.021 0.439 . . . . 0.0 111.445 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 m -139.84 142.6 36.6 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.205 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -117.82 123.98 47.25 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.883 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.7 m -140.5 168.04 20.75 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.292 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 117.28 -35.2 4.24 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.877 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.438 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.35 -46.57 0.22 Allowed 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.457 0.703 . . . . 0.0 111.559 -179.829 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.438 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -101.64 -65.31 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.405 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.438 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 97.0 Cg_endo -79.77 96.04 1.04 Allowed 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.41 2.074 . . . . 0.0 112.384 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 69.8 m -61.44 114.26 3.12 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.135 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -149.0 143.72 18.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.253 -179.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.7 mp -73.13 89.75 1.51 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.655 179.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.8 m -52.49 -39.52 61.33 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.418 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -163.53 158.78 21.22 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.3 t -132.96 155.18 40.92 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.47 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 9.1 mtt -109.24 106.04 15.72 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.878 0.37 . . . . 0.0 110.477 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 32' ' ' ARG . 2.5 mtm105 -43.51 111.34 0.27 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.048 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 126.16 -16.1 6.81 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.754 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.496 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 10.0 p -80.58 162.98 58.7 Favored Pre-proline 0 CA--C 1.532 0.282 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.496 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 14.1 Cg_endo -55.84 -24.85 49.26 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 122.718 2.278 . . . . 0.0 112.751 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -68.75 -48.04 64.75 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.403 179.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.77 -30.97 72.0 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.321 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -56.03 -34.56 65.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.3 t -89.63 -29.35 5.07 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.271 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.88 -10.51 4.85 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.851 -0.69 . . . . 0.0 113.357 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 46.9 mt -54.0 116.15 2.41 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 117.016 0.408 . . . . 0.0 110.857 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.92 -153.32 0.56 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.747 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 104.02 15.97 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.424 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.94 -25.74 2.38 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.792 -0.718 . . . . 0.0 113.383 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.99 117.78 6.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.995 0.398 . . . . 0.0 111.101 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.04 132.27 35.14 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.799 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.1 mt -91.36 133.35 33.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.556 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.1 mp -117.51 -47.14 2.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.881 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.526 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -116.08 136.89 52.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.657 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.8 t -132.95 109.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.9 t30 76.83 33.62 0.46 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.642 -178.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 77.51 -2.66 2.53 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.651 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.6 pt -111.84 121.48 64.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 120.871 0.367 . . . . 0.0 111.161 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -63.59 124.01 20.29 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.063 -179.683 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.6 m -134.55 53.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.299 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 9.0 mtmt -63.45 -37.12 86.08 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.568 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -127.16 27.55 5.89 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.574 -0.284 . . . . 0.0 111.34 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -81.31 -174.02 4.68 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.694 0.283 . . . . 0.0 111.281 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 52.0 m -84.25 139.81 32.1 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.495 0.664 . . . . 0.0 110.825 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.438 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 6.1 t60 -60.8 -44.62 96.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.697 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -63.04 -42.05 99.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.437 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.79 -45.11 94.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.556 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.427 ' HA ' HD11 ' A' ' 66' ' ' LEU . 58.5 t -63.83 -41.96 94.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.8 t -65.76 -39.04 83.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 178.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.67 -39.96 78.28 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.897 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.427 HD11 ' HA ' ' A' ' 63' ' ' VAL . 13.8 mt -66.41 -43.15 86.57 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.705 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.442 ' HA ' HD12 ' A' ' 74' ' ' LEU . 25.0 mt -65.25 -37.2 79.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.759 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -83.63 12.55 51.69 Favored Glycine 0 CA--C 1.525 0.673 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.549 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -112.44 -14.73 13.22 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 122.43 0.292 . . . . 0.0 111.459 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . 0.444 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 27.2 p -45.99 -49.18 16.3 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 122.651 0.38 . . . . 0.0 111.96 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.16 33.87 9.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.974 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 151.74 -36.73 0.84 Allowed Glycine 0 C--N 1.334 0.44 0 C-N-CA 120.805 -0.712 . . . . 0.0 113.132 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.444 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.4 p -173.59 137.25 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.906 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.442 HD12 ' HA ' ' A' ' 67' ' ' ILE . 11.3 tp -112.63 142.34 45.33 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.947 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.3 m170 -107.31 98.05 7.73 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.124 179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.5 ptm -119.66 146.88 45.17 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.481 -179.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 24.6 t -102.12 112.9 36.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.963 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.419 HD13 HG22 ' A' ' 6' ' ' VAL . 19.5 pt -101.05 170.27 1.59 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.304 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -140.09 118.46 12.12 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.178 179.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.35 118.98 12.91 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.784 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -88.62 -174.37 47.12 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.783 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 m -64.37 -33.62 63.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.868 -0.962 . . . . 0.0 113.207 179.805 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo . . . . . 0 N--CA 1.491 1.374 0 CA-C-O 120.934 0.306 . . . . 0.0 112.141 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 7.0 ttt85 -92.71 151.18 20.21 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.8 t -91.94 128.72 43.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.972 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -121.99 140.81 52.02 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.132 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 m -97.64 127.68 43.78 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.416 HG12 ' HG ' ' A' ' 41' ' ' LEU . 38.9 t -120.08 141.8 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.137 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.9 122.6 36.5 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.158 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 73' ' ' VAL . 9.3 t -105.53 149.48 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.131 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -107.42 101.95 11.26 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.143 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -57.5 120.15 7.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.32 -110.11 0.34 Allowed Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.306 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 11.2 mtt85 -106.48 -70.94 0.77 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.65 0.262 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.52 44.52 1.24 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.172 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.55 -153.64 25.26 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.881 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.402 ' OH ' HG22 ' A' ' 67' ' ' ILE . 16.7 m-85 -131.69 -54.41 1.0 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.772 0.32 . . . . 0.0 111.184 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.27 -22.05 1.73 Allowed Glycine 0 CA--C 1.524 0.603 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.908 -179.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.84 163.01 12.79 Favored 'General case' 0 CA--C 1.53 0.203 0 CA-C-O 120.89 0.376 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.26 122.17 46.75 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -105.18 125.26 50.78 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.229 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.78 110.86 3.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.222 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -165.41 79.21 0.12 Allowed Glycine 0 N--CA 1.445 -0.74 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.893 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.89 -45.32 7.5 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.928 0.394 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.548 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -114.74 -66.42 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.402 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.548 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 95.0 Cg_endo -87.42 94.35 0.46 Allowed 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 122.606 2.204 . . . . 0.0 112.266 179.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 83.0 m -52.97 115.65 1.96 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.411 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -146.02 145.54 20.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.803 0.335 . . . . 0.0 111.796 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -73.75 90.1 1.84 Allowed 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.365 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -47.29 -51.61 18.61 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.868 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.6 t -154.45 159.36 41.01 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.475 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.5 t -125.21 154.47 33.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.597 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.2 mtp -107.6 104.72 14.32 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.211 0.529 . . . . 0.0 110.264 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -53.09 126.37 20.48 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.884 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.26 24.68 12.14 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.446 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.67 170.81 10.37 Favored Pre-proline 0 CA--C 1.532 0.252 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -47.27 -30.7 11.39 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 123.001 2.468 . . . . 0.0 113.619 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -71.3 -48.4 50.92 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 120.815 0.341 . . . . 0.0 111.029 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -69.59 -30.28 68.01 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.525 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.8 m-30 -60.13 -23.69 64.08 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 111.62 0.23 . . . . 0.0 111.62 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.9 t -89.19 -31.31 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.689 0.28 . . . . 0.0 110.897 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.8 36.3 3.26 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.522 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.416 ' HG ' HG12 ' A' ' 6' ' ' VAL . 6.4 mt -69.42 -177.99 1.29 Allowed 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.834 0.35 . . . . 0.0 110.738 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.84 131.94 7.19 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.266 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.43 98.92 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.378 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 148.51 -25.46 1.36 Allowed Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.703 -178.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -56.11 118.46 4.7 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.833 0.316 . . . . 0.0 110.718 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -77.12 123.01 25.79 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.821 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.408 HG22 HD13 ' A' ' 47' ' ' ILE . 31.0 mt -77.91 121.64 31.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.685 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 2.4 mt -100.4 -46.83 5.11 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.408 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -133.4 138.79 46.43 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.224 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.6 t -128.91 110.48 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.444 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.6 t-20 76.88 31.04 0.55 Allowed 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -178.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.444 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.62 -2.35 1.62 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.836 179.864 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.444 HG13 ' O ' ' A' ' 50' ' ' VAL . 1.2 pp -110.49 128.18 66.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.057 0.456 . . . . 0.0 111.381 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -65.27 142.96 58.1 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.609 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.2 m -145.23 62.47 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.453 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -71.16 -37.94 72.19 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.485 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -139.13 32.9 2.13 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.803 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.89 -179.97 5.79 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.558 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.16 135.61 34.19 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.421 0.629 . . . . 0.0 110.728 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 7.7 t60 -53.91 -43.88 70.09 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.974 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.454 ' HA ' HG21 ' A' ' 64' ' ' VAL . 1.5 mt-10 -62.05 -36.82 82.79 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.945 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.6 -40.66 69.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.3 t -65.59 -43.19 94.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.153 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.454 HG21 ' HA ' ' A' ' 61' ' ' GLU . 30.7 m -65.46 -38.41 82.41 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -57.98 -41.25 82.55 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.053 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 mt -68.17 -40.55 82.27 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.694 179.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.45 ' HA ' ' CD1' ' A' ' 74' ' ' LEU . 11.2 mt -69.21 -42.22 81.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.592 179.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.44 -4.26 84.11 Favored Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.923 -0.656 . . . . 0.0 113.41 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 7.1 tttt -79.34 -36.49 39.36 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 117.006 0.403 . . . . 0.0 111.647 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.32 -60.85 2.39 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.703 0.287 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 71.69 33.2 1.83 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.62 -49.92 0.01 OUTLIER Glycine 0 C--N 1.332 0.357 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.196 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 7.6 p -175.27 132.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 121.061 0.458 . . . . 0.0 111.691 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.45 ' CD1' ' HA ' ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.83 154.66 28.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.756 179.776 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -109.68 98.45 7.79 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.055 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 13.8 ttm -97.54 128.28 44.16 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.35 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.31 95.64 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.388 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.5 pp -100.35 170.82 1.45 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.486 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -123.79 143.47 50.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.251 179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -98.83 167.25 10.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.032 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -144.98 72.25 0.35 Allowed Glycine 0 C--N 1.332 0.317 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.376 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 m -62.75 109.89 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.789 0.328 . . . . 0.0 111.417 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.704 -1.053 . . . . 0.0 112.766 -179.66 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.486 1.084 0 CA-C-O 120.419 0.091 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 69.89 -66.56 0.26 Allowed 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 122.759 0.424 . . . . 0.0 111.409 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 p 42.81 100.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.745 0.818 . . . . 0.0 112.634 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -115.39 166.87 11.4 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.26 179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -109.22 141.8 40.95 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.951 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.468 HG21 ' CD1' ' A' ' 78' ' ' ILE . 41.9 t -129.48 131.3 67.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.188 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -115.69 105.77 13.12 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.711 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.405 ' HB ' ' HG ' ' A' ' 74' ' ' LEU . 3.4 t -86.49 154.11 3.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.894 0.378 . . . . 0.0 111.035 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -112.92 104.99 12.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.935 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -48.36 110.59 0.35 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.714 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.95 -110.7 0.08 OUTLIER Glycine 0 C--N 1.333 0.378 0 C-N-CA 121.101 -0.571 . . . . 0.0 112.675 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.85 -39.89 2.91 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.83 36.68 4.35 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.815 0.34 . . . . 0.0 111.468 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.99 -129.21 5.53 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.534 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -131.88 -70.96 0.56 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.663 0.268 . . . . 0.0 111.087 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 152.58 40.62 0.03 OUTLIER Glycine 0 CA--C 1.518 0.252 0 C-N-CA 121.053 -0.594 . . . . 0.0 113.179 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -158.58 -177.76 6.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.561 0.22 . . . . 0.0 110.691 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -134.7 158.02 45.19 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-O 120.775 0.322 . . . . 0.0 111.182 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -138.96 132.07 29.68 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.0 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 p -145.93 165.09 29.98 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 111.344 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 22' ' ' GLN . . . 122.47 -22.98 7.27 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 121.186 -0.53 . . . . 0.0 113.142 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.631 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 70.04 2.52 3.96 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -179.758 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.452 ' HA ' ' O ' ' A' ' 58' ' ' ALA . . . -168.6 -61.75 0.01 OUTLIER Pre-proline 0 C--O 1.233 0.199 0 C-N-CA 122.162 0.185 . . . . 0.0 110.635 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -69.86 81.4 0.84 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.306 2.004 . . . . 0.0 110.955 178.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 62.0 m -50.39 109.29 0.29 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.071 -178.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.4 141.55 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.16 90.68 2.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.389 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 p -58.99 -38.16 78.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.189 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.1 t -168.17 154.91 7.66 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-O 120.823 0.344 . . . . 0.0 111.438 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 3.4 t -122.05 154.03 26.49 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.531 179.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.1 mtm -101.02 100.66 11.29 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.986 0.422 . . . . 0.0 110.52 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.0 mtt180 -51.42 125.75 15.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.749 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.52 26.61 10.67 Favored Glycine 0 CA--C 1.52 0.358 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.339 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 58.0 m -131.0 162.82 53.26 Favored Pre-proline 0 CA--C 1.529 0.163 0 N-CA-C 110.434 -0.21 . . . . 0.0 110.434 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_exo -46.75 -31.85 11.25 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.17 2.58 . . . . 0.0 113.296 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.451 ' HB3' HD11 ' A' ' 41' ' ' LEU . . . -67.01 -50.0 63.54 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-O 120.814 0.34 . . . . 0.0 110.968 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -70.66 -30.75 67.45 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.13 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 22.6 m-30 -59.58 -23.61 63.07 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.704 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 t -89.31 -32.3 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 120.652 0.263 . . . . 0.0 111.207 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.84 58.63 0.34 Allowed Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.76 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.451 HD11 ' HB3' ' A' ' 36' ' ' ALA . 17.7 mt -97.25 176.4 5.92 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.791 0.329 . . . . 0.0 110.571 179.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.45 133.39 0.81 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.909 0.385 . . . . 0.0 111.082 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.03 125.72 24.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.909 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.13 -30.59 4.29 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.389 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -62.53 121.27 12.88 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.825 0.345 . . . . 0.0 110.734 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.4 tp60 -77.9 118.09 19.88 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.928 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.9 mt -79.45 122.85 35.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.817 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mp -106.8 -41.45 5.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.605 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.483 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -113.82 152.22 30.97 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.864 0.364 . . . . 0.0 111.302 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.7 m -149.42 102.63 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.363 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 75.65 39.62 0.33 Allowed 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 74.79 -1.23 3.14 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.733 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 23.8 pt -117.27 132.1 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 111.775 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 5.0 p-10 -66.92 154.67 40.44 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 121.273 0.559 . . . . 0.0 112.123 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.47 HG12 HG22 ' A' ' 63' ' ' VAL . 9.1 m -149.58 62.9 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.295 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -55.73 -77.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.661 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -115.72 37.33 3.65 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 120.769 0.318 . . . . 0.0 110.969 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 23' ' ' ALA . . . -75.28 -172.6 1.78 Allowed 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.45 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.29 135.43 33.58 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 121.385 0.612 . . . . 0.0 110.715 179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.631 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 6.9 t60 -57.35 -44.56 84.43 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.654 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -63.27 -40.19 96.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.649 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.51 -45.34 87.68 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.451 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.47 HG22 HG12 ' A' ' 55' ' ' VAL . 48.7 t -63.49 -42.71 97.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.185 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 50.7 t -65.64 -39.45 85.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.23 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -40.05 83.51 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.046 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.4 mt -66.92 -40.16 87.56 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.918 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 7.3 mt -69.12 -41.92 81.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.482 179.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -73.77 -25.74 71.16 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.633 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 tppt? -53.98 -35.02 61.39 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 t -69.86 -54.15 14.79 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.75 0.309 . . . . 0.0 110.84 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.1 m 63.62 35.7 11.43 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.963 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.99 -43.87 0.02 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.381 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 6.5 p -162.01 134.47 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-O 120.959 0.409 . . . . 0.0 111.535 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.424 HD11 ' HG3' ' A' ' 76' ' ' MET . 3.8 pp -114.41 154.42 28.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -131.61 116.06 16.9 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.68 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.424 ' HG3' HD11 ' A' ' 74' ' ' LEU . 4.0 mtt -131.92 139.44 48.73 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.88 0.371 . . . . 0.0 111.437 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 29.3 t -103.9 112.85 39.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.977 178.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.468 ' CD1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.53 155.32 8.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.68 -179.193 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -116.85 139.01 51.1 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.285 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -105.38 119.85 40.11 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.661 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -122.73 66.14 0.5 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.449 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -114.18 21.08 6.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 120.89 0.376 . . . . 0.0 111.45 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.388 -1.229 . . . . 0.0 112.62 179.783 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.49 1.273 0 CA-C-O 120.624 0.177 . . . . 0.0 111.935 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.47 161.11 14.51 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.096 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p -111.23 115.57 50.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttt180 -115.81 142.74 46.35 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.01 -179.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 m -113.55 129.21 56.6 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.069 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 20.7 t -116.95 131.66 68.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.817 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -100.78 100.95 11.69 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.946 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 74' ' ' LEU . 13.5 t -86.09 108.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.056 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -94.82 91.82 6.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.8 ttt85 -36.55 119.12 0.6 Allowed 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.407 0.442 . . . . 0.0 111.118 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.01 -118.27 0.16 Allowed Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.746 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -113.7 -38.5 4.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.501 0.191 . . . . 0.0 111.338 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.34 28.11 8.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 124.07 -160.57 18.63 Favored Glycine 0 C--N 1.338 0.677 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.827 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 60.5 m-85 -89.82 -54.24 4.14 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.581 0.229 . . . . 0.0 111.039 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.91 65.05 0.59 Allowed Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.382 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -168.03 172.62 8.68 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.643 0.259 . . . . 0.0 111.41 179.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -122.5 159.73 27.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.28 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -149.26 130.07 14.21 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.038 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.93 158.71 38.4 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.782 0.325 . . . . 0.0 111.534 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 131.13 -27.15 3.86 Favored Glycine 0 CA--C 1.526 0.727 0 C-N-CA 121.204 -0.522 . . . . 0.0 113.114 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.53 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 62.01 13.83 5.97 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -179.825 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.432 ' CB ' ' CD ' ' A' ' 24' ' ' PRO . . . -170.74 -65.62 0.0 OUTLIER Pre-proline 0 N--CA 1.464 0.228 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.432 ' CD ' ' CB ' ' A' ' 23' ' ' ALA . 73.7 Cg_endo -75.84 83.6 1.92 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.359 2.039 . . . . 0.0 111.428 178.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 92.6 m -51.06 111.51 0.57 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.513 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.01 142.26 24.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.411 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -83.69 92.53 7.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.483 179.682 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 t -58.28 -38.62 77.33 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.281 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 3.9 t -166.09 158.93 14.9 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.893 0.378 . . . . 0.0 111.135 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 17.2 t -115.15 154.46 16.52 Favored 'Isoleucine or valine' 0 C--O 1.232 0.182 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.638 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.7 mmm -89.72 99.29 12.32 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-O 121.342 0.592 . . . . 0.0 110.327 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.28 126.24 20.43 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.966 -1.015 . . . . 0.0 111.175 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.99 27.54 12.27 Favored Glycine 0 CA--C 1.52 0.402 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.606 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.26 168.81 15.7 Favored Pre-proline 0 C--O 1.234 0.256 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.473 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 84.1 Cg_exo -48.58 -34.16 25.83 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 123.036 2.491 . . . . 0.0 113.018 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.407 ' CB ' HD23 ' A' ' 41' ' ' LEU . . . -60.16 -48.34 82.12 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.136 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -65.54 -33.2 75.36 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.473 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 14.6 m-30 -64.31 -24.8 67.78 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.411 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.27 -27.94 5.23 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.782 0.325 . . . . 0.0 110.844 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.39 32.19 2.61 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.541 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.407 HD23 ' CB ' ' A' ' 36' ' ' ALA . 6.0 tp -65.17 129.4 39.58 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 120.692 0.282 . . . . 0.0 110.446 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 71.3 mtt-85 -129.5 115.87 18.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.361 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.38 156.83 7.26 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.668 -179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.15 -13.15 63.52 Favored Glycine 0 CA--C 1.522 0.479 0 CA-C-N 115.124 -0.944 . . . . 0.0 112.211 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.83 138.34 35.12 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 110.642 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -83.47 126.42 32.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.457 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.9 mt -85.4 131.87 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.521 179.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.0 mp -107.71 -39.7 5.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.356 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.474 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -131.27 141.26 49.95 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.1 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.467 HG23 ' CG2' ' A' ' 55' ' ' VAL . 13.5 t -133.54 110.5 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.874 179.231 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.6 t30 77.07 32.34 0.48 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.82 -1.2 2.39 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.535 179.981 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.475 HD13 HG22 ' A' ' 53' ' ' ILE . 13.0 pt -115.29 126.02 72.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.98 0.419 . . . . 0.0 111.794 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.474 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -66.87 136.87 56.06 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.511 -179.626 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.467 ' CG2' HG23 ' A' ' 50' ' ' VAL . 6.4 m -147.86 63.88 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.681 -179.475 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -69.93 -31.69 69.58 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.136 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.0 mtpt -137.63 35.87 2.44 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -86.64 174.24 9.0 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 120.876 0.369 . . . . 0.0 111.534 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.27 134.75 35.64 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.399 0.619 . . . . 0.0 110.288 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.53 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 3.7 t60 -54.73 -44.46 73.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.857 -1.065 . . . . 0.0 112.14 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -61.7 -43.36 99.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.951 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.83 -41.32 91.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.507 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.9 t -65.15 -42.51 94.46 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.001 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.7 t -65.88 -39.29 84.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.68 -39.88 78.12 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.073 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.7 mt -67.71 -42.01 82.64 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.76 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 42.2 mt -66.06 -39.93 85.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.723 179.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.6 6.22 78.37 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.093 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.31 -32.69 16.41 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.857 0.328 . . . . 0.0 111.439 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.96 -61.21 2.3 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.784 0.326 . . . . 0.0 110.799 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.92 35.11 2.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.83 -47.14 0.01 OUTLIER Glycine 0 C--N 1.33 0.201 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.291 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -165.33 137.79 0.91 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.984 0.421 . . . . 0.0 111.331 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.423 ' HB3' ' HB ' ' A' ' 8' ' ' VAL . 11.1 tp -114.03 142.09 46.62 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.375 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.58 95.74 5.51 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.252 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 2.8 ttm -98.03 122.33 41.04 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.118 -179.356 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.0 t -102.23 96.64 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.464 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.7 pt -100.27 170.3 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.552 -179.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -130.83 137.2 49.29 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.234 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -61.55 112.0 2.04 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.147 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -164.12 52.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.504 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.5 m -66.61 103.55 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.237 0 CA-C-O 120.807 0.337 . . . . 0.0 111.4 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.471 -1.183 . . . . 0.0 112.563 -179.927 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.488 1.172 0 CA-C-O 120.638 0.182 . . . . 0.0 111.828 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? 68.43 122.75 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.26 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p 31.58 100.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.086 0.954 . . . . 0.0 112.843 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 63.3 ttt180 -126.59 134.24 50.85 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.002 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.3 m -96.2 130.65 43.21 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.0 t -123.13 140.16 47.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.372 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -116.94 126.95 53.71 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.144 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 20.9 t -125.59 137.75 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.639 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.18 97.54 8.33 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.995 0.426 . . . . 0.0 110.603 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.482 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 2.9 ttt-85 -47.14 121.54 3.83 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.353 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.4 -130.19 1.1 Allowed Glycine 0 C--N 1.334 0.448 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.512 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.1 mtt180 -111.93 -39.57 4.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.413 0.149 . . . . 0.0 111.258 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.38 26.85 9.71 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.68 0.252 . . . . 0.0 111.68 179.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.67 -179.89 16.03 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.924 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.482 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 91.3 m-85 -83.97 -34.01 24.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.585 0.231 . . . . 0.0 111.18 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.84 47.96 0.93 Allowed Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.284 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -168.67 153.87 6.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 111.063 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.5 m -98.88 128.2 45.0 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.92 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -106.18 126.92 52.81 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.181 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.0 m -147.84 130.45 15.91 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.517 178.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.67 73.36 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.276 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.1 tp60 -44.96 -43.48 9.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.799 0.333 . . . . 0.0 110.576 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.572 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -110.98 -64.56 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.021 178.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.572 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 98.0 Cg_endo -91.74 92.7 0.21 Allowed 'Trans proline' 0 C--N 1.358 1.042 0 C-N-CA 122.943 2.428 . . . . 0.0 111.912 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 7.7 p -53.36 118.75 4.07 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.936 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -146.68 145.3 19.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.256 -179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.96 90.39 2.43 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.845 0.355 . . . . 0.0 110.496 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -53.98 -35.74 62.14 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.625 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.1 t -165.26 161.75 19.41 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.723 0.297 . . . . 0.0 110.988 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 38.0 t -131.19 152.5 37.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.877 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.4 mmt -90.24 99.66 12.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-O 121.338 0.59 . . . . 0.0 110.342 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.97 121.81 8.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.935 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.08 26.01 8.08 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.561 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -128.95 171.75 8.21 Favored Pre-proline 0 CA--C 1.532 0.269 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.409 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 77.7 Cg_exo -48.91 -30.51 17.73 Favored 'Trans proline' 0 C--N 1.352 0.737 0 C-N-CA 122.847 2.365 . . . . 0.0 113.128 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.05 -50.23 50.41 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.142 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.97 -31.86 73.3 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.42 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.409 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 17.7 m-30 -60.12 -30.71 69.45 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.198 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.72 -24.37 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.107 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.22 17.56 6.65 Favored Glycine 0 CA--C 1.523 0.57 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.153 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.4 mt -78.87 123.21 27.01 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 117.019 0.409 . . . . 0.0 110.303 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.1 mtp85 -130.48 -149.9 0.41 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -107.76 127.53 53.77 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.594 -0.275 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.7 -22.44 5.8 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 120.78 -0.724 . . . . 0.0 113.017 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -73.29 121.66 20.74 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 116.924 0.362 . . . . 0.0 110.948 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -82.45 128.04 33.87 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 6.0 mt -85.32 125.29 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -103.05 -39.41 6.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.939 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.532 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.91 145.81 50.83 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.239 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.8 t -132.97 111.72 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.926 179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 76.5 32.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.655 -178.458 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.53 -2.03 1.64 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.11 -0.95 . . . . 0.0 112.732 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.4 pt -113.73 125.58 71.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-O 120.838 0.352 . . . . 0.0 111.421 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.532 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.7 OUTLIER -60.3 125.51 23.96 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.95 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 m -146.95 40.65 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.156 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.58 -29.93 70.35 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.794 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.0 mttp -119.85 29.56 7.49 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.322 179.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -88.27 -174.13 4.5 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 111.573 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.34 140.68 29.54 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.406 0.622 . . . . 0.0 110.742 179.675 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -52.86 -44.56 66.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.721 -1.127 . . . . 0.0 111.764 -179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.61 -39.52 91.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.665 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.01 -42.46 94.42 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.584 179.252 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 44.4 t -64.82 -42.45 94.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.122 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 41.7 t -65.85 -39.19 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.2 ttmt -57.68 -40.73 80.09 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.093 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 17.7 mt -66.88 -42.82 84.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.763 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.2 mt -66.79 -40.6 86.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.97 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -70.21 -17.1 73.72 Favored Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.015 -0.612 . . . . 0.0 113.131 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -66.79 -42.09 86.55 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -67.62 -57.88 5.65 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.793 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.7 p 62.49 28.02 16.56 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.463 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -152.59 -40.48 0.03 OUTLIER Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.67 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 6.5 p -150.53 138.58 14.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.089 0.471 . . . . 0.0 111.333 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.434 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.5 OUTLIER -102.81 138.02 40.25 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.952 -179.866 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -130.66 95.06 3.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 3.0 mtt -117.32 140.92 48.95 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.529 -179.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 22.0 t -104.86 95.19 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.237 179.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 16.6 pt -99.17 159.97 3.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.22 -179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.82 147.83 45.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.492 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.84 111.38 23.59 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.861 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -148.41 50.77 0.57 Allowed Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.379 179.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.2 p -131.26 145.14 35.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.63 0.252 . . . . 0.0 111.12 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.718 -1.046 . . . . 0.0 113.054 -179.863 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.407 ' HD2' ' O ' ' A' ' 80' ' ' GLU . 3.4 Cg_endo . . . . . 0 N--CA 1.488 1.199 0 CA-C-O 120.435 0.098 . . . . 0.0 111.877 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 57.56 52.13 8.78 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.077 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.3 p -60.51 122.98 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.078 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -139.12 166.61 24.06 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.321 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -105.07 132.92 50.7 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.26 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 29.0 t -106.58 131.19 57.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.819 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.406 ' HA ' ' O ' ' A' ' 74' ' ' LEU . 1.6 mt-10 -118.83 116.57 26.8 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 3.7 t -110.01 133.97 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 111.421 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.67 94.05 9.77 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.93 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.465 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -48.47 121.03 4.08 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.176 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.45 -85.62 0.12 Allowed Glycine 0 C--N 1.335 0.501 0 C-N-CA 121.042 -0.599 . . . . 0.0 112.383 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 -145.98 -53.77 0.26 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.633 0.254 . . . . 0.0 111.013 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.18 28.91 8.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.535 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.37 164.79 11.16 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.709 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.465 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 73.3 m-85 -88.93 -66.77 0.89 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.84 0.352 . . . . 0.0 110.64 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.22 55.82 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.73 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -166.54 149.12 6.73 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.753 0.311 . . . . 0.0 110.93 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 109.43 22.12 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.03 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 6.2 tt -108.44 140.41 41.79 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.826 -179.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.427 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 22.7 m -150.35 161.44 42.48 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.457 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.78 81.35 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.313 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.5 mm100 -47.41 -40.48 17.91 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.606 0.241 . . . . 0.0 110.775 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.534 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -113.73 -63.41 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.279 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.332 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.534 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 90.9 Cg_endo -89.92 94.04 0.3 Allowed 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.812 2.341 . . . . 0.0 111.739 179.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 6.0 p -52.29 117.16 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.72 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.1 p -134.83 144.31 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.643 -179.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.58 92.74 9.22 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.084 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -57.16 -52.67 64.39 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.02 -179.308 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.4 ' HA ' ' CB ' ' A' ' 43' ' ' ALA . 0.6 OUTLIER -148.14 162.3 39.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.444 -179.594 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 10.9 t -121.19 153.73 24.82 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.129 179.304 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -94.56 99.96 12.02 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.24 0.543 . . . . 0.0 110.771 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 7.2 mtt180 -55.06 126.48 24.83 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.014 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 99.66 -16.29 58.88 Favored Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.888 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.594 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.4 m -89.64 166.38 21.22 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.841 0.32 . . . . 0.0 110.343 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.594 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 9.2 Cg_endo -51.25 -26.76 21.08 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.928 2.419 . . . . 0.0 113.441 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.19 76.76 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.849 0.357 . . . . 0.0 110.77 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.83 -26.57 63.35 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.207 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -59.43 -23.66 62.86 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.42 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.27 -30.15 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 116.662 -0.244 . . . . 0.0 111.06 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 104.71 45.4 1.41 Allowed Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.496 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 6.4 mt -72.48 -178.95 2.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-O 120.726 0.298 . . . . 0.0 110.569 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 44.9 mtp85 -142.01 112.74 7.28 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.291 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.4 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . . . -64.85 103.56 0.73 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.527 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.63 -10.55 5.77 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.266 -179.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -81.02 165.49 21.65 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.02 156.33 17.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.534 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 4.2 mt -109.11 146.25 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.589 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 mp -118.92 -57.49 2.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.893 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.502 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.08 139.28 44.19 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.008 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.9 t -138.97 110.35 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 75.97 35.86 0.47 Allowed 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 75.08 -0.39 3.33 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.808 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.419 HD11 HG22 ' A' ' 53' ' ' ILE . 8.5 pt -119.68 133.66 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-O 120.92 0.39 . . . . 0.0 111.388 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -69.74 150.84 46.5 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.67 -179.515 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 m -150.11 56.85 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.647 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.2 mmtp -60.19 -40.42 89.98 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.455 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.0 mtmp? -130.01 31.96 4.6 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.658 0.266 . . . . 0.0 111.421 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -79.6 176.51 9.64 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 120.716 0.293 . . . . 0.0 111.144 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.9 m -95.8 147.19 23.9 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.581 0.705 . . . . 0.0 111.355 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.427 ' CE1' ' HA ' ' A' ' 20' ' ' SER . 2.7 t-160 -56.11 -41.85 75.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.325 -1.307 . . . . 0.0 111.445 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.456 ' HA ' HG12 ' A' ' 64' ' ' VAL . 11.4 pt-20 -64.21 -41.09 97.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.904 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -69.79 -42.07 74.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 110.366 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.5 t -67.71 -42.35 86.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.027 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 61' ' ' GLU . 7.3 p -66.61 -39.1 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -57.94 -40.13 79.75 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.158 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 15.0 mt -66.28 -42.85 87.85 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.741 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 33.5 mt -66.62 -40.71 86.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.623 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -85.39 8.27 72.17 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.184 179.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.7 -32.63 15.36 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 116.828 0.314 . . . . 0.0 111.293 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.67 -55.04 19.61 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.963 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 m 64.5 36.17 8.89 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.859 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.87 -44.05 0.02 OUTLIER Glycine 0 C--N 1.332 0.338 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.414 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -163.39 139.13 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.129 0 CA-C-O 120.959 0.409 . . . . 0.0 111.384 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 7' ' ' GLU . 62.8 tp -103.15 136.26 43.27 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.049 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -127.13 101.37 6.49 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.411 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 13.7 ptm -132.83 141.52 48.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.47 -179.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.9 t -91.23 120.63 40.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.79 179.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 15.0 pt -99.33 170.17 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.434 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.35 148.88 30.04 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.284 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.407 ' O ' ' HD2' ' A' ' 1' ' ' PRO . 0.6 OUTLIER -98.21 163.84 12.56 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.322 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -154.61 31.98 0.69 Allowed Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.793 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.4 t -136.53 34.12 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-O 121.056 0.455 . . . . 0.0 110.939 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.284 -1.286 . . . . 0.0 112.703 -179.842 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.489 1.22 0 CA-C-O 120.85 0.271 . . . . 0.0 111.882 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 48.7 mtp180 -111.93 155.63 23.38 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.097 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.3 p -90.66 128.3 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.296 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.8 ttt180 -123.04 126.87 47.93 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -97.8 120.84 38.9 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.754 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 20.9 t -114.2 131.58 65.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.457 ' HG2' ' CD2' ' A' ' 75' ' ' HIS . 3.1 mt-10 -115.6 112.92 22.87 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.902 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 t -94.57 134.14 33.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 CA-C-O 120.877 0.37 . . . . 0.0 111.221 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -102.17 97.64 7.91 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.687 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.442 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -47.81 118.38 2.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.006 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.92 -107.54 0.08 OUTLIER Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.553 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.8 mtt180 -123.67 -46.75 1.99 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.633 0.254 . . . . 0.0 111.046 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.01 41.79 3.45 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.651 179.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 158.4 -179.64 33.93 Favored Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.14 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.442 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 8.7 m-85 -111.41 -40.74 4.3 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.595 0.236 . . . . 0.0 111.349 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.96 23.69 5.17 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.285 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -157.26 156.24 32.15 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.997 0.398 . . . . 0.0 110.933 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.0 m -111.01 135.61 51.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.861 0.362 . . . . 0.0 111.239 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.479 HD22 ' CE1' ' A' ' 60' ' ' HIS . 0.4 OUTLIER -119.18 129.09 54.81 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.043 179.898 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.6 m -151.7 176.05 11.77 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.125 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.55 -46.32 1.13 Allowed Glycine 0 C--N 1.335 0.497 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.38 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.438 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 55.13 39.43 31.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.877 0.471 . . . . 0.0 112.09 179.489 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 174.53 -61.64 0.0 OUTLIER Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.636 179.476 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.17 -27.43 9.75 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.598 2.199 . . . . 0.0 113.127 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 18.4 m 56.79 93.44 0.03 OUTLIER 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.509 0.671 . . . . 0.0 109.788 -179.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -146.75 144.21 20.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.973 -178.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.32 122.33 16.87 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.487 179.703 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.4 m -82.42 -41.53 19.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.196 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 25.3 t -173.09 152.44 2.31 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.364 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 t -118.04 155.19 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.753 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 27.4 mmm -98.41 100.95 12.26 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.204 0.526 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mtt-85 -50.85 124.58 11.44 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.069 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.02 24.51 11.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.553 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -123.76 165.98 20.98 Favored Pre-proline 0 C--O 1.232 0.148 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.409 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 10.4 Cg_endo -53.58 -26.99 39.3 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.781 2.32 . . . . 0.0 112.747 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.48 -49.18 57.18 Favored 'General case' 0 CA--C 1.528 0.121 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.002 179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -67.05 -31.99 72.88 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.304 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.409 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 20.4 m-30 -59.47 -23.46 62.75 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.557 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.38 -30.12 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.684 0.278 . . . . 0.0 111.253 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.79 68.13 0.54 Allowed Glycine 0 C--N 1.334 0.45 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.413 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.5 mt -102.31 162.35 12.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.795 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.9 mmt180 -148.55 119.66 7.73 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.08 111.8 1.16 Allowed 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.835 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.44 -12.88 7.02 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.874 -179.49 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.499 ' HB3' ' HB ' ' A' ' 78' ' ' ILE . 0.1 OUTLIER -66.94 112.1 4.14 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.825 0.312 . . . . 0.0 110.52 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -55.45 125.7 22.04 Favored 'General case' 0 CA--C 1.53 0.173 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.71 -179.411 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 66.7 mt -82.25 123.96 38.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.574 179.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.0 mp -107.81 -41.2 5.06 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.54 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -136.46 144.4 44.38 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.73 0.3 . . . . 0.0 111.102 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 8.3 t -140.97 116.2 6.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.421 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.96 30.75 0.55 Allowed 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.421 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 80.78 -1.92 1.84 Allowed 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.239 -0.892 . . . . 0.0 112.706 179.631 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.6 pt -117.4 134.56 60.59 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.936 0.398 . . . . 0.0 111.635 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.1 m120 -63.1 152.51 36.97 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.572 -179.584 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.418 HG12 HG23 ' A' ' 63' ' ' VAL . 2.8 m -152.02 47.75 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.435 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.9 mttt -56.21 -40.12 73.53 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.215 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -137.72 31.98 2.5 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.005 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.86 -177.7 3.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.878 0.371 . . . . 0.0 111.604 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.93 135.78 33.85 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.361 0.6 . . . . 0.0 110.703 179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.479 ' CE1' HD22 ' A' ' 19' ' ' LEU . 5.5 t60 -55.9 -44.39 78.17 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.783 -1.098 . . . . 0.0 111.883 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -61.58 -39.41 91.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.439 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -67.52 -43.07 81.7 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.225 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.42 ' HA ' HD11 ' A' ' 66' ' ' LEU . 48.4 t -63.79 -40.96 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.932 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 48.8 t -65.97 -38.83 82.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 178.674 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -57.76 -42.64 84.45 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.42 HD11 ' HA ' ' A' ' 63' ' ' VAL . 12.0 mt -63.63 -42.26 98.19 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.647 179.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.433 HG12 ' CD2' ' A' ' 74' ' ' LEU . 35.8 mt -63.42 -44.18 98.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.635 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.3 -12.52 84.14 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.793 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 41.3 tptt -68.19 -37.41 80.91 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -70.7 -52.46 20.9 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.811 0.339 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m 63.8 35.73 10.96 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.742 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.22 -44.35 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.295 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -163.15 138.24 1.4 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-O 121.014 0.435 . . . . 0.0 111.335 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.433 ' CD2' HG12 ' A' ' 67' ' ' ILE . 24.2 tp -114.24 146.79 39.95 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.376 -179.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.457 ' CD2' ' HG2' ' A' ' 7' ' ' GLU . 48.1 m80 -119.6 103.22 9.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.177 179.164 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 59.0 mtp -109.14 142.09 40.41 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.671 -179.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.3 t -115.06 97.05 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.926 178.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.499 ' HB ' ' HB3' ' A' ' 45' ' ' ASP . 10.3 pt -105.78 170.74 2.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.64 -179.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -136.94 145.73 44.59 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.941 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -86.43 112.89 21.92 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.774 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -106.45 46.31 1.19 Allowed Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.456 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -119.41 131.85 70.87 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-O 120.734 0.302 . . . . 0.0 110.858 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.694 -1.059 . . . . 0.0 112.976 -179.804 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.493 1.499 0 CA-C-O 120.419 0.091 . . . . 0.0 112.221 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.61 -46.93 3.72 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.533 -179.74 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.404 HG23 ' CG1' ' A' ' 77' ' ' VAL . 4.2 p 44.33 101.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.955 0.902 . . . . 0.0 112.636 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.26 146.66 47.08 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.727 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.1 m -102.21 154.73 18.75 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.213 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 20.3 t -140.29 136.2 36.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.355 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -104.7 111.15 23.76 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.725 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.7 t -104.43 119.94 54.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-O 120.865 0.364 . . . . 0.0 111.475 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -90.32 92.28 8.85 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.066 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.403 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 14.3 ttt180 -49.5 125.07 10.51 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.646 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.69 -112.44 0.07 OUTLIER Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.818 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -115.39 -39.33 3.6 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.435 0.16 . . . . 0.0 111.328 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.9 30.61 6.38 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.388 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.59 -173.09 16.6 Favored Glycine 0 C--N 1.337 0.616 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.808 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.403 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 79.2 m-85 -79.34 -61.91 1.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.941 0.401 . . . . 0.0 111.013 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.43 59.22 0.26 Allowed Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.452 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 19.7 p90 -153.13 151.01 29.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 0.0 110.955 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -98.3 111.42 23.76 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.442 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.95 133.49 44.25 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.411 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 1.5 p -149.58 -174.26 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.762 179.697 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 107.28 85.43 1.77 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.3 -60.09 2.08 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.942 0.401 . . . . 0.0 110.799 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.472 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -94.41 -60.61 0.19 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.221 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.472 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 98.2 Cg_endo -87.69 95.35 0.44 Allowed 'Trans proline' 0 C--N 1.356 0.938 0 C-N-CA 122.692 2.261 . . . . 0.0 112.209 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 71.6 m -55.27 118.64 4.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.477 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.4 p -143.53 152.94 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.854 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.41 92.95 9.34 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.473 179.377 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -51.46 -39.93 58.43 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.504 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 3.6 t -169.07 161.43 10.46 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.961 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.5 t -124.8 154.35 32.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.431 179.556 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -85.58 98.0 10.4 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.227 0.537 . . . . 0.0 110.399 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.85 122.61 6.76 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.853 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.31 21.23 11.86 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.703 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.425 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -115.31 166.68 11.43 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.712 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.425 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 9.7 Cg_endo -51.75 -29.55 34.25 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.962 2.441 . . . . 0.0 112.77 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.8 -46.19 46.89 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.992 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -64.01 -32.3 73.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.069 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.408 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.1 m-30 -60.04 -28.07 67.45 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.39 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 18.3 t -89.48 -26.21 5.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-O 120.469 0.176 . . . . 0.0 111.241 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.63 1.13 7.13 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.639 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 12.0 mt -67.93 116.96 9.18 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 117.378 0.589 . . . . 0.0 110.449 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.01 -150.36 0.43 Allowed 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.006 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -105.29 146.29 29.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.636 0.255 . . . . 0.0 111.299 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.82 -16.97 33.22 Favored Glycine 0 CA--C 1.523 0.56 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.152 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.57 128.31 34.53 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 117.122 0.461 . . . . 0.0 110.822 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -82.38 134.01 35.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.486 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 22.7 mt -85.82 122.57 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.798 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -106.57 -47.55 3.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -124.08 136.25 54.11 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.993 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 3.0 t -135.51 105.71 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.096 179.553 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 75.92 37.8 0.37 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 72.32 -0.56 3.23 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.834 -179.628 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 8.0 pt -113.96 119.39 61.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 120.955 0.407 . . . . 0.0 111.01 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.482 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.0 m120 -68.53 130.32 42.53 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.081 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 24.3 m -124.03 52.3 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.095 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.0 mttm -55.45 -45.65 76.83 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.543 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -136.48 32.42 2.8 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.095 179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.37 177.85 7.62 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 120.805 0.336 . . . . 0.0 111.275 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -80.73 133.67 35.71 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 121.418 0.628 . . . . 0.0 110.665 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.411 ' CE1' ' HA ' ' A' ' 20' ' ' SER . 1.4 t-160 -54.49 -44.78 72.95 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.772 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -65.13 -41.91 94.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.693 179.547 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -64.34 -42.47 96.25 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.712 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 54.9 t -63.5 -43.34 98.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.124 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.1 t -66.03 -39.73 85.34 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.162 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.79 -40.46 84.11 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.01 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.1 mt -65.53 -40.86 93.4 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.195 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 26.2 mt -69.55 -40.48 79.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.866 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -59.83 -27.82 64.87 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.278 179.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.69 -19.79 62.02 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.51 0.324 . . . . 0.0 111.668 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -98.54 100.89 12.18 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.408 0.623 . . . . 0.0 110.219 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.2 m -99.64 -29.16 12.83 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.975 -1.011 . . . . 0.0 111.663 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.05 -50.93 7.25 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.139 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.5 p -177.12 134.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.841 0.353 . . . . 0.0 111.487 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.2 tp -114.32 141.29 47.79 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.073 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -114.01 104.67 12.37 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.163 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.19 148.5 28.8 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.211 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.404 ' CG1' HG23 ' A' ' 3' ' ' VAL . 21.8 t -109.33 105.43 18.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.721 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.8 pt -100.98 173.58 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.208 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -155.86 124.73 6.05 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.666 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.32 120.84 41.16 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.639 179.206 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 128.27 -114.98 1.94 Allowed Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.187 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.6 t 57.2 90.39 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-O 121.034 0.445 . . . . 0.0 111.819 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.369 -1.239 . . . . 0.0 112.481 179.722 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo . . . . . 0 N--CA 1.49 1.272 0 N-CA-C 112.415 0.121 . . . . 0.0 112.415 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -61.72 89.21 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.925 0.393 . . . . 0.0 111.2 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.4 t -138.27 138.67 42.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.12 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -139.2 169.24 18.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.402 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -116.66 144.57 44.25 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.99 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 20.6 t -113.39 140.44 33.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.31 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.8 mt-10 -112.68 108.05 16.94 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.973 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.7 t -102.66 126.23 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 111.277 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.39 92.24 8.03 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.979 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.457 ' HG3' ' CZ ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -52.92 122.53 9.44 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.972 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.83 -65.93 3.08 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 121.162 -0.542 . . . . 0.0 112.665 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -163.54 -48.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.568 0.223 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -131.93 26.36 4.62 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.455 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 179.71 164.69 32.49 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.607 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.457 ' CZ ' ' HG3' ' A' ' 10' ' ' ARG . 40.1 m-85 -107.91 -73.72 0.68 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.65 0.262 . . . . 0.0 111.373 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.39 50.83 0.04 OUTLIER Glycine 0 C--N 1.33 0.242 0 C-N-CA 121.142 -0.552 . . . . 0.0 112.425 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 37.6 p90 -167.14 -177.08 3.57 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.428 0.156 . . . . 0.0 110.754 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -133.68 145.1 49.62 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 120.822 0.344 . . . . 0.0 111.353 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.4 mt -128.72 123.48 33.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.945 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.5 m -135.83 14.81 3.36 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.26 -0.427 . . . . 0.0 112.101 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -84.86 85.2 1.57 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.035 -0.603 . . . . 0.0 112.131 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.02 -63.24 0.9 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.837 0.351 . . . . 0.0 111.074 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.459 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -94.24 -61.04 0.18 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.146 178.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.459 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 98.5 Cg_endo -86.75 93.26 0.53 Allowed 'Trans proline' 0 C--N 1.353 0.793 0 C-N-CA 122.825 2.35 . . . . 0.0 111.764 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.5 m -54.46 121.14 7.71 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.884 0.373 . . . . 0.0 110.806 -179.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.4 p -145.79 146.74 19.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.85 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -81.55 92.24 6.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.707 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.83 -34.82 63.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.317 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.3 t -169.72 160.47 8.77 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 111.242 179.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.52 154.1 18.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.745 179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 12.1 mmm -99.22 99.24 10.18 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.101 0.477 . . . . 0.0 110.818 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -50.2 126.85 15.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.118 -0.946 . . . . 0.0 111.276 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.05 24.2 13.37 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.028 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.449 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -127.52 169.58 12.05 Favored Pre-proline 0 C--N 1.33 -0.253 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.265 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.449 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 19.3 Cg_endo -58.13 -17.7 33.19 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.673 2.248 . . . . 0.0 113.043 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.59 -50.91 32.18 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -72.07 -29.83 64.52 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.229 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.406 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.7 m-30 -59.18 -27.5 65.75 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.616 -0.266 . . . . 0.0 110.973 179.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.64 -50.31 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.762 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 146.65 46.77 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.068 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.31 134.25 34.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.665 0.269 . . . . 0.0 110.412 179.511 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.4 mmt180 -144.91 120.38 10.34 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -45.97 125.74 6.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.449 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.33 -26.95 5.4 Favored Glycine 0 CA--C 1.517 0.189 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.322 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -67.1 121.1 14.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 120.593 0.235 . . . . 0.0 110.682 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.43 127.69 32.96 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.77 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 18.9 mt -82.65 119.31 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.569 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -97.11 -42.22 7.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.548 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.84 140.85 51.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.007 179.691 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 53' ' ' ILE . 21.5 t -133.14 112.52 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.13 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.4 t30 76.34 31.06 0.64 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.672 -178.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.77 -3.76 1.57 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 115.174 -0.921 . . . . 0.0 112.713 179.64 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.434 ' CD1' HD12 ' A' ' 66' ' ' LEU . 1.1 pp -114.45 128.93 71.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.016 0.436 . . . . 0.0 111.397 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.1 m120 -64.27 132.69 51.0 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.439 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.8 m -136.36 58.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.452 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -62.51 -40.2 95.98 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.422 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -132.92 31.11 3.94 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.208 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.04 179.92 6.5 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.771 0.32 . . . . 0.0 111.548 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.14 135.47 33.42 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.305 0.574 . . . . 0.0 110.951 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 7.4 t60 -54.46 -44.63 72.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.815 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -62.63 -43.35 99.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.504 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.22 -41.38 97.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.543 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.0 t -64.94 -43.52 96.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.988 179.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.0 t -65.76 -39.34 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -57.97 -40.98 81.94 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.01 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.434 HD12 ' CD1' ' A' ' 53' ' ' ILE . 4.5 mt -66.22 -42.43 88.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.668 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 18.5 mt -65.52 -42.92 94.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.51 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.98 -15.04 81.66 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.945 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -65.13 -39.79 93.56 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -62.72 -55.25 28.42 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 65.94 35.03 6.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.903 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.29 -44.24 0.02 OUTLIER Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.554 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -160.72 138.86 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.784 0.326 . . . . 0.0 111.642 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 33.0 tp -105.8 143.18 34.31 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -128.56 96.8 4.5 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.191 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -121.66 154.59 36.62 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.43 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.1 t -111.63 110.87 33.77 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.746 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.6 pt -105.51 145.38 13.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.322 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -111.23 134.35 52.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.291 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -103.08 133.83 47.54 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 69.65 85.24 0.14 Allowed Glycine 0 C--N 1.333 0.404 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.459 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 21.7 t -67.54 116.2 6.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-O 120.711 0.291 . . . . 0.0 110.923 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.338 -1.257 . . . . 0.0 112.192 -179.842 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo . . . . . 0 N--CA 1.488 1.155 0 N-CA-C 111.565 -0.206 . . . . 0.0 111.565 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.91 148.52 0.09 Allowed 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 120.812 0.339 . . . . 0.0 111.062 -179.665 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.1 t -112.05 142.56 24.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -135.96 162.25 33.38 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.448 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.38 125.32 53.04 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.785 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.4 HG13 ' CD1' ' A' ' 41' ' ' LEU . 20.8 t -111.33 134.07 54.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.105 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -105.71 112.87 26.11 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 4.9 t -87.77 116.85 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-O 120.84 0.352 . . . . 0.0 111.28 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -81.54 89.72 6.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.861 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.414 ' HG3' ' CE2' ' A' ' 15' ' ' TYR . 5.3 ttp180 -56.14 120.97 8.38 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.116 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.97 -88.1 0.29 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.738 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -121.33 -73.5 0.65 Allowed 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.64 0.257 . . . . 0.0 110.76 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -121.11 31.96 6.15 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.111 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -178.26 -169.61 39.31 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.582 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.414 ' CE2' ' HG3' ' A' ' 10' ' ' ARG . 24.4 m-85 -133.17 -64.42 0.73 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.655 0.264 . . . . 0.0 111.27 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.03 47.24 0.08 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.814 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -156.73 172.31 18.83 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 120.708 0.289 . . . . 0.0 110.813 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -117.56 110.72 18.29 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.954 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.5 126.15 49.46 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.119 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 73.5 m -152.06 107.56 3.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.55 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.95 79.63 0.15 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.704 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.85 -45.88 30.57 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.03 0.443 . . . . 0.0 110.018 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.532 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -115.57 -67.35 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.24 178.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.532 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 90.3 Cg_endo -85.1 95.55 0.65 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 122.605 2.204 . . . . 0.0 112.155 179.158 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 80.8 m -53.27 118.91 4.16 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.679 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 p -146.79 149.63 15.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.393 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -87.48 93.61 9.46 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.319 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -46.91 -43.98 19.38 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.485 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.7 t -172.37 158.53 4.38 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.173 179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.5 t -126.04 154.95 35.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.616 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mtp -100.33 101.59 12.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 121.153 0.501 . . . . 0.0 110.66 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.1 mtm-85 -49.96 123.95 9.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.39 16.7 10.75 Favored Glycine 0 CA--C 1.523 0.583 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.75 -179.176 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -120.98 166.68 15.03 Favored Pre-proline 0 CA--C 1.531 0.221 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.486 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -49.27 -31.39 22.25 Favored 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.989 2.46 . . . . 0.0 113.346 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.61 -49.06 51.63 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.587 -0.278 . . . . 0.0 111.139 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.36 -32.47 73.88 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.486 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.9 m-30 -58.06 -29.25 65.24 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.457 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 18.7 t -89.53 -32.73 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.696 0.284 . . . . 0.0 110.948 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.45 51.39 0.16 Allowed Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.123 -0.56 . . . . 0.0 112.66 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.4 ' CD1' HG13 ' A' ' 6' ' ' VAL . 2.8 mt -116.55 129.3 56.1 Favored 'General case' 0 C--O 1.231 0.098 0 CA-C-O 120.574 0.226 . . . . 0.0 110.817 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -137.6 -152.9 0.46 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -99.58 148.14 24.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.799 179.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.3 -21.33 46.08 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.975 -0.631 . . . . 0.0 113.214 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -69.9 116.86 10.77 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.883 0.341 . . . . 0.0 110.827 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.53 132.09 37.06 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.425 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 27.2 mt -84.34 120.42 35.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.74 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.0 -40.37 5.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.402 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.457 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -128.88 135.99 49.83 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.626 0.25 . . . . 0.0 111.097 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.441 ' O ' HG13 ' A' ' 53' ' ' ILE . 4.8 t -135.73 110.09 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.186 179.53 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 75.99 33.71 0.58 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 77.6 -5.13 2.18 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 115.15 -0.932 . . . . 0.0 112.706 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.441 HG13 ' O ' ' A' ' 50' ' ' VAL . 2.2 pp -116.71 130.82 70.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 111.403 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.457 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -67.11 141.62 57.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.691 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.2 m -142.68 51.16 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.413 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.2 mtpp -58.16 -35.27 71.31 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.657 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -137.2 34.62 2.55 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.694 0.283 . . . . 0.0 111.03 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.13 -172.9 2.96 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.843 0.354 . . . . 0.0 111.556 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.55 141.0 29.11 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.275 0.56 . . . . 0.0 110.791 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.1 t-160 -52.86 -43.29 65.98 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.443 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.496 ' O ' HG22 ' A' ' 64' ' ' VAL . 2.7 mt-10 -66.53 -35.06 79.32 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.457 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.59 -38.39 70.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.798 0.332 . . . . 0.0 110.286 179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.6 t -66.47 -44.89 90.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.042 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.496 HG22 ' O ' ' A' ' 61' ' ' GLU . 2.9 m -66.42 -39.19 83.45 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.39 -39.18 82.57 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.972 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.3 mt -66.03 -41.99 90.19 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.864 179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.424 ' HA ' ' CD1' ' A' ' 74' ' ' LEU . 31.5 mt -68.11 -41.41 84.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.762 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.74 8.73 19.64 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.954 178.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 2.0 tttp -111.61 -4.0 14.9 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 116.943 0.371 . . . . 0.0 111.071 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . 0.446 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 26.4 p -50.62 -47.56 58.23 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 122.536 0.334 . . . . 0.0 111.71 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.74 31.71 4.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.004 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 150.02 -37.51 0.94 Allowed Glycine 0 C--N 1.335 0.499 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.062 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.446 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.8 p -172.05 138.07 0.35 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.234 0 CA-C-O 120.894 0.378 . . . . 0.0 112.012 -179.657 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.424 ' CD1' ' HA ' ' A' ' 67' ' ' ILE . 3.8 tp -111.04 139.77 46.12 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.111 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -100.95 101.52 12.33 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.29 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 35.5 ttm -103.44 125.1 49.84 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 40.5 t -97.86 103.61 14.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.511 179.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 14.7 pt -106.72 168.31 3.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.468 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.91 155.2 39.58 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.703 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.34 135.37 42.95 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -141.61 -87.98 0.12 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.449 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.0 t -86.3 -35.49 9.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.496 0.188 . . . . 0.0 110.975 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.27 -1.294 . . . . 0.0 112.624 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo . . . . . 0 N--CA 1.486 1.07 0 CA-C-O 120.147 -0.022 . . . . 0.0 112.087 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.39 178.83 0.13 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 120.869 0.366 . . . . 0.0 111.501 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 20.4 t -131.44 148.93 32.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.98 167.5 21.99 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.657 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 m -102.94 135.19 45.07 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.1 t -115.69 131.84 66.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.109 179.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -113.05 120.51 41.59 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.105 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.461 HG12 ' HB3' ' A' ' 15' ' ' TYR . 12.7 t -104.92 134.18 47.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.179 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -103.55 98.79 8.62 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.039 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -48.84 124.11 8.04 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.268 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.41 118.43 0.45 Allowed Glycine 0 CA--C 1.52 0.353 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER 78.51 90.0 0.06 Allowed 'General case' 0 C--O 1.235 0.34 0 CA-C-O 121.393 0.616 . . . . 0.0 110.396 -179.22 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 71.15 34.26 1.85 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.548 -1.206 . . . . 0.0 111.569 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 -113.1 3.6 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.837 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.461 ' HB3' HG12 ' A' ' 8' ' ' VAL . 79.3 m-85 -110.64 -66.32 1.08 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.414 0.149 . . . . 0.0 111.171 -179.546 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.17 61.14 0.2 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.894 -0.67 . . . . 0.0 113.351 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -166.41 167.79 15.46 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 120.556 0.217 . . . . 0.0 111.183 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -120.34 150.84 40.11 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.007 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -137.62 124.32 21.08 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.363 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 m -140.15 15.74 2.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.092 -0.503 . . . . 0.0 112.021 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.65 84.36 1.59 Allowed Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.417 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -44.2 -61.98 1.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.795 0.331 . . . . 0.0 110.783 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.473 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -94.29 -62.81 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.881 178.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.473 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 92.0 Cg_endo -85.84 96.45 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.925 0 C-N-CA 122.76 2.307 . . . . 0.0 111.915 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.0 m -55.8 124.95 19.25 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.567 -179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.16 143.8 17.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.395 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -80.81 90.62 5.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.462 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 5.8 p -53.8 -38.44 64.52 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.473 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 8.1 t -161.75 153.41 18.89 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.836 0.351 . . . . 0.0 111.447 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.3 t -116.23 155.38 17.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.554 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.3 mtp -97.79 100.35 11.72 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.236 0.541 . . . . 0.0 110.791 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.4 mtm-85 -53.74 124.23 14.61 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.892 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.13 -24.04 21.88 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.534 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.407 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.4 OUTLIER -82.5 166.61 35.36 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 110.533 179.722 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 11.0 Cg_endo -53.95 -23.53 28.35 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 123.19 2.593 . . . . 0.0 113.186 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.59 76.91 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.887 0.375 . . . . 0.0 110.731 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -68.24 -27.1 66.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.194 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -55.97 -24.31 37.6 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 112.141 0.422 . . . . 0.0 112.141 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.8 t -89.09 -29.21 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 111.034 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.86 43.95 2.17 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.518 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -74.25 176.42 6.67 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 120.913 0.387 . . . . 0.0 110.762 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 4.1 mtp85 -139.0 116.95 11.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.44 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.53 101.03 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.801 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.35 -21.26 3.47 Favored Glycine 0 CA--C 1.524 0.606 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.407 -179.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -58.24 123.31 15.62 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 120.633 0.254 . . . . 0.0 110.8 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -66.68 127.87 34.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.089 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 21.2 mt -85.27 125.89 40.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.573 179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.9 mp -98.76 -70.27 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.575 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.502 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -99.99 143.94 29.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.739 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.6 t -135.84 113.94 15.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.411 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.1 t-20 76.38 33.05 0.55 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -177.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.74 -1.78 2.37 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 115.189 -0.914 . . . . 0.0 113.074 179.72 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 5.4 pt -115.65 133.0 63.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-O 120.817 0.342 . . . . 0.0 111.827 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 42.8 t30 -66.83 130.22 42.45 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.143 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 15.3 m -137.28 59.57 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.965 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.9 mmtm -51.91 -72.46 0.05 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.999 -179.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.2 mttt -111.72 39.55 2.34 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.255 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -73.86 -175.93 2.29 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.515 -179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.44 134.67 33.78 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.443 0.639 . . . . 0.0 110.865 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -53.04 -44.76 67.64 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.689 -1.142 . . . . 0.0 111.419 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.456 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.7 pm0 -66.36 -34.7 78.56 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.184 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.6 -39.31 70.6 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.728 0.299 . . . . 0.0 110.443 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.4 t -67.02 -43.36 89.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.456 HG22 ' HA ' ' A' ' 61' ' ' GLU . 29.8 m -65.93 -38.71 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 1.9 mtmp? -57.87 -39.38 77.67 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.881 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.5 mt -67.41 -43.28 81.65 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.761 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 13.8 mt -65.66 -38.03 81.36 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.981 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -86.61 3.77 86.76 Favored Glycine 0 CA--C 1.524 0.645 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.015 179.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.6 tptm -86.91 -34.88 19.23 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.824 0.312 . . . . 0.0 111.25 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -71.66 -57.86 4.01 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.809 0.338 . . . . 0.0 110.86 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.1 m 64.65 36.02 8.61 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.072 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.13 -44.13 0.02 OUTLIER Glycine 0 C--N 1.331 0.296 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.434 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 8' ' ' VAL . 7.1 p -162.12 137.08 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 CA-C-O 120.985 0.421 . . . . 0.0 111.385 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -112.6 134.37 54.17 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.523 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -117.09 96.36 5.41 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.999 179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 16.5 ptt? -122.01 156.31 33.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.791 -179.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.7 t -111.42 109.73 29.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.735 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 pt -106.1 139.39 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.304 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -105.86 125.15 50.65 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.154 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -87.31 122.55 31.23 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.696 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.55 145.7 4.85 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.428 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m -67.82 95.1 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 120.976 0.417 . . . . 0.0 111.169 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.435 -1.203 . . . . 0.0 112.179 -179.624 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_endo . . . . . 0 N--CA 1.492 1.398 0 CA-C-O 120.943 0.31 . . . . 0.0 112.183 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 15.4 ttm-85 -105.6 -43.72 4.86 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.832 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -118.56 156.84 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.0 ttt85 -114.05 141.21 47.74 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 120.883 0.373 . . . . 0.0 111.1 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.0 m -110.9 137.16 48.88 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.664 179.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 16.7 t -111.8 136.01 49.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.756 -179.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -134.59 100.84 4.76 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.535 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.2 t -106.47 150.51 9.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.276 -179.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -99.4 98.54 9.45 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.988 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 50.9 ttp85 -50.71 120.67 4.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.696 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.73 -107.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.705 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -118.28 -39.94 2.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.419 0.152 . . . . 0.0 111.249 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -111.3 32.19 5.53 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.668 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.11 -137.96 14.57 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.828 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 80.2 m-85 -116.17 -83.33 0.63 Allowed 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.633 0.254 . . . . 0.0 111.19 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.61 55.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.265 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 14.3 p90 -143.31 166.83 23.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.631 0.253 . . . . 0.0 110.756 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.1 m -113.92 142.03 46.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.943 0.401 . . . . 0.0 111.479 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 mt -133.89 122.87 23.78 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.943 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.8 m -146.92 169.37 19.29 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.31 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.91 -37.51 2.88 Favored Glycine 0 C--N 1.336 0.532 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.509 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 81.55 -48.92 0.24 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.286 0.635 . . . . 0.0 111.493 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.453 ' CB ' ' HD3' ' A' ' 24' ' ' PRO . . . -100.97 -65.09 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.438 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.453 ' HD3' ' CB ' ' A' ' 23' ' ' ALA . 91.5 Cg_endo -80.55 96.21 1.0 Allowed 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.292 1.994 . . . . 0.0 112.318 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.0 m -61.37 115.66 4.04 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.334 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.84 142.46 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.154 -179.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -75.87 90.98 2.96 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.468 179.743 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 69.4 p -53.2 -36.59 61.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.308 -179.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 3.0 t -167.22 158.63 12.13 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.237 179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.8 t -119.08 154.97 21.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.858 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 30.8 mtt -98.28 101.85 13.42 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 121.21 0.529 . . . . 0.0 110.623 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 26.8 mtt-85 -51.84 123.69 10.82 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.22 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.07 -22.3 31.72 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 120.938 -0.649 . . . . 0.0 113.071 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.41 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.6 m -83.47 168.01 25.04 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.711 0.255 . . . . 0.0 110.658 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.41 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 73.6 Cg_exo -50.43 -25.51 14.23 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 123.033 2.489 . . . . 0.0 113.448 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.26 -47.8 82.74 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 120.868 0.366 . . . . 0.0 111.024 179.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.96 -26.73 65.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.31 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.4 m-30 -54.98 -28.71 53.79 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 111.674 0.249 . . . . 0.0 111.674 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.6 t -89.43 -34.4 6.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 CA-C-O 120.83 0.347 . . . . 0.0 111.037 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.6 -11.81 15.88 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.747 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -64.58 127.59 32.16 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -115.51 -146.52 0.4 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.249 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.11 159.19 15.13 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.926 0.393 . . . . 0.0 110.908 179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.24 -33.52 6.1 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.577 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -61.39 118.56 7.11 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.79 0.328 . . . . 0.0 110.989 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.02 131.44 35.31 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.679 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 8.3 mm -87.38 124.55 40.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.5 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -105.49 -46.51 4.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.352 -179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.548 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.49 139.2 53.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.195 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 53' ' ' ILE . 9.0 t -140.79 109.27 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.487 179.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 76.54 34.21 0.48 Allowed 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 76.02 -3.4 2.57 Favored 'General case' 0 CA--C 1.537 0.481 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.773 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.452 HG13 ' O ' ' A' ' 50' ' ' VAL . 1.1 pt -114.27 120.5 64.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-O 121.047 0.451 . . . . 0.0 111.312 179.501 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -64.71 131.84 47.98 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.054 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.8 m -131.11 55.97 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.355 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.9 mtmt -59.88 -40.5 88.94 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.188 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.0 mttp -136.35 30.84 2.92 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.061 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.93 -169.22 1.05 Allowed 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.272 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.01 135.0 34.3 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.47 0.652 . . . . 0.0 110.616 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 4.9 t60 -54.44 -44.6 72.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.818 -1.083 . . . . 0.0 111.957 -179.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -63.41 -38.11 89.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.811 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.4 -42.9 82.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.541 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.9 t -65.29 -42.18 93.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.754 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.5 t -65.8 -39.08 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.475 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.6 mttt -57.64 -39.41 76.92 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.45 -0.796 . . . . 0.0 110.89 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 11.3 mt -66.57 -43.7 84.26 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.773 179.444 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 54.0 mt -63.16 -37.96 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.642 179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.47 11.98 57.02 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.316 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.5 ttpm? -110.32 -16.23 13.77 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 122.406 0.282 . . . . 0.0 111.264 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 23.3 p -44.2 -50.85 8.61 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 122.576 0.351 . . . . 0.0 111.6 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.5 p 63.26 32.22 14.97 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.454 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.17 -36.73 0.6 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.993 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -172.46 136.58 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-O 120.995 0.426 . . . . 0.0 111.917 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 9.8 tp -114.45 145.0 42.41 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.827 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -119.37 107.11 12.96 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.16 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 1.1 ptp -122.71 135.04 54.46 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.012 0.434 . . . . 0.0 111.239 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 41.3 t -94.37 115.1 32.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.642 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 3.7 pt -107.06 167.05 3.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.551 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.82 128.22 26.36 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -74.25 109.82 8.05 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.471 179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 134.72 125.14 2.52 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.287 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m -65.09 120.25 11.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-O 120.814 0.34 . . . . 0.0 111.495 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.219 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.62 -179.91 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.636 HG22 ' HB2' ' A' ' 79' ' ' ALA . 25.2 t . . . . . 0 C--O 1.234 0.255 0 CA-C-O 120.687 0.279 . . . . 0.0 111.152 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -134.93 174.5 10.53 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.349 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 m -118.9 149.75 41.05 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.312 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.658 HG23 HD11 ' A' ' 78' ' ' ILE . 54.6 t -129.65 134.17 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.079 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -105.41 103.68 13.25 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 73' ' ' VAL . 14.6 t -95.64 129.47 45.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.807 0.337 . . . . 0.0 111.229 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -91.43 90.94 7.89 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.284 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -55.3 123.49 13.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.734 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.05 -103.17 0.1 OUTLIER Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.241 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.14 -46.4 1.94 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.536 0.208 . . . . 0.0 111.164 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -103.76 31.69 4.31 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.692 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.69 -126.77 8.3 Favored Glycine 0 C--N 1.336 0.556 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.745 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -132.88 -64.97 0.73 Allowed 'General case' 0 C--O 1.231 0.103 0 CA-C-O 120.733 0.302 . . . . 0.0 111.076 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.0 -34.53 1.31 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.925 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.578 ' CD1' HD21 ' A' ' 27' ' ' LEU . 41.6 p90 -65.18 179.47 0.72 Allowed 'General case' 0 CA--C 1.532 0.256 0 CA-C-O 121.064 0.459 . . . . 0.0 111.569 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.8 144.06 49.43 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.264 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.79 128.01 45.92 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.197 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 46.3 m -150.47 106.78 3.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.674 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -163.18 76.11 0.17 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.446 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -45.68 -44.71 13.63 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.736 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.976 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -114.33 -64.47 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.263 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.197 178.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.976 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 84.4 Cg_endo -89.42 91.51 0.36 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.791 2.327 . . . . 0.0 112.008 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.67 ' SG ' HG21 ' A' ' 63' ' ' VAL . 72.6 m -50.32 121.48 5.68 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.731 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.0 p -147.14 146.06 18.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.871 0.367 . . . . 0.0 111.724 -179.462 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.627 HD13 HD22 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -80.31 92.41 5.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.476 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.9 m -46.54 -46.29 19.22 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.867 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.68 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.0 t -171.3 158.41 5.36 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 111.431 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' A' ' 41' ' ' LEU . 50.6 t -122.13 153.23 26.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.619 179.61 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.6 mmt -103.3 100.81 10.72 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.076 0.465 . . . . 0.0 110.574 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 5.7 ptt180 -45.49 120.12 2.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.971 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 120.19 -17.81 9.73 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.542 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.413 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -85.59 166.77 28.33 Favored Pre-proline 0 CA--C 1.533 0.312 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.352 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 15.0 Cg_endo -57.13 -22.55 48.42 Favored 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 122.667 2.245 . . . . 0.0 112.748 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.825 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -68.83 -48.73 62.78 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.72 0.295 . . . . 0.0 110.913 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.36 -27.12 65.98 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.302 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-30 -57.54 -26.34 61.23 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.59 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.617 HG11 HG13 ' A' ' 6' ' ' VAL . 15.7 t -89.39 -39.39 12.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 120.794 0.33 . . . . 0.0 111.013 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 129.08 44.61 0.2 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.088 -0.577 . . . . 0.0 112.83 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.825 HD12 ' HB1' ' A' ' 36' ' ' ALA . 13.8 mt -85.22 140.9 30.52 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.788 0.328 . . . . 0.0 110.366 179.655 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.9 mtt180 -141.14 119.68 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.584 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.68 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -41.22 126.64 2.73 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.637 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.17 -26.37 5.56 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.148 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.97 114.17 3.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-O 120.661 0.267 . . . . 0.0 110.571 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -73.37 128.57 35.85 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.529 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.894 ' HA ' HG22 ' A' ' 78' ' ' ILE . 20.6 mt -80.93 120.17 32.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.007 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 mp -101.52 -46.7 4.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.053 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.605 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -127.26 139.39 52.94 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.257 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.458 HG21 HG13 ' A' ' 63' ' ' VAL . 8.8 t -132.46 111.61 17.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.003 179.358 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 77.33 29.98 0.54 Allowed 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.959 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.419 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 82.54 -2.53 1.38 Allowed 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.412 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.646 HD11 ' CD1' ' A' ' 66' ' ' LEU . 20.4 pt -114.21 132.19 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 111.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.6 OUTLIER -63.23 156.15 26.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.714 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.447 HG21 HG23 ' A' ' 50' ' ' VAL . 2.6 m -149.36 55.32 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.614 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -58.62 -43.25 89.6 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.723 0.297 . . . . 0.0 110.854 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.492 ' HE3' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -141.73 38.55 1.66 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.308 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.437 ' CB ' HG12 ' A' ' 55' ' ' VAL . . . -72.75 -178.15 2.59 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.592 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.593 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -93.35 137.89 32.22 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.398 0.618 . . . . 0.0 111.08 -179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.794 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.6 t-80 -52.67 -43.92 65.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.942 -1.026 . . . . 0.0 111.913 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 58.1 mt-10 -65.63 -39.3 91.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.008 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -67.25 -39.37 86.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.709 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.67 HG21 ' SG ' ' A' ' 25' ' ' CYS . 46.4 t -67.44 -42.34 87.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.745 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 60' ' ' HIS . 42.7 t -65.67 -39.1 83.92 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.184 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.8 mtpp -57.74 -38.95 76.24 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.646 ' CD1' HD11 ' A' ' 53' ' ' ILE . 13.3 mt -68.3 -42.54 79.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.684 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.63 HG23 HD22 ' A' ' 74' ' ' LEU . 6.8 mt -67.47 -36.9 77.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.884 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -81.66 10.62 50.28 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.342 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 ttpt -114.16 -5.82 13.04 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.623 0.369 . . . . 0.0 111.2 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.433 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 14.0 p -47.8 -48.78 30.28 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 122.488 0.315 . . . . 0.0 111.752 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.9 t 65.65 33.34 8.5 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.069 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.16 -33.3 1.72 Allowed Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.275 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 8' ' ' VAL . 8.0 p -172.68 138.0 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-O 121.0 0.428 . . . . 0.0 111.784 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.63 HD22 HG23 ' A' ' 67' ' ' ILE . 9.1 tp -114.45 147.28 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.222 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -108.97 99.23 8.59 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.419 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.577 ' CG ' HD23 ' A' ' 74' ' ' LEU . 0.0 OUTLIER -105.43 135.04 47.55 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.959 -179.618 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.605 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 21.9 t -108.75 99.44 8.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.762 179.76 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.894 HG22 ' HA ' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -111.07 164.92 6.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.358 -179.747 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.636 ' HB2' HG22 ' A' ' 3' ' ' VAL . . . -128.38 130.9 48.39 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.241 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.234 0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.989 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 29.9 t . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.71 0.291 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 -131.89 160.77 34.75 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.497 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.2 p -101.59 131.34 47.84 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.178 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.609 HG13 ' CG1' ' A' ' 39' ' ' VAL . 14.2 t -116.37 131.55 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.808 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -100.99 111.77 24.05 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.728 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.5 ' O ' HG23 ' A' ' 73' ' ' VAL . 16.2 t -97.67 114.41 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.349 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.77 92.42 9.2 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.782 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.463 ' HG3' ' CE1' ' A' ' 15' ' ' TYR . 9.7 ttt180 -51.6 127.43 20.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.738 -0.664 . . . . 0.0 111.188 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.81 20.91 25.77 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.684 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.45 0.38 3.44 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 117.118 0.459 . . . . 0.0 111.907 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.01 24.0 1.67 Allowed 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 120.83 0.348 . . . . 0.0 111.105 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.69 -162.11 23.76 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.705 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.463 ' CE1' ' HG3' ' A' ' 10' ' ' ARG . 64.6 m-85 -131.7 -43.98 0.99 Allowed 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.36 -13.48 7.87 Favored Glycine 0 CA--C 1.522 0.507 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.18 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -108.52 174.28 5.94 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 117.039 0.419 . . . . 0.0 111.386 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.0 m -130.0 142.86 50.58 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.684 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.665 HD21 HD12 ' A' ' 47' ' ' ILE . 0.8 OUTLIER -124.19 124.48 42.55 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.302 -179.63 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.2 m -150.29 159.17 44.65 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.4 -29.52 2.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 121.055 -0.593 . . . . 0.0 113.157 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.403 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 64.11 21.27 12.52 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.94 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.834 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . 179.58 -63.8 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.282 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.834 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 91.0 Cg_endo -79.25 85.53 1.84 Allowed 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 122.52 2.147 . . . . 0.0 111.561 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.643 ' SG ' HG21 ' A' ' 63' ' ' VAL . 61.2 m -52.88 110.6 0.54 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.578 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -144.62 147.52 19.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.536 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.464 HD12 ' CG1' ' A' ' 47' ' ' ILE . 7.1 mp -74.4 90.8 2.18 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.3 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -43.78 61.95 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.614 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -171.17 158.09 5.36 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.984 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 14.7 t -135.77 153.34 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.92 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 16.3 ptp -104.52 105.12 15.11 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.271 0.558 . . . . 0.0 110.745 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.5 mtt180 -46.68 123.09 4.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.096 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.28 16.29 10.55 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 121.132 -0.556 . . . . 0.0 112.961 -179.356 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.8 164.87 17.74 Favored Pre-proline 0 C--O 1.234 0.247 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.19 -27.83 31.41 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 122.767 2.312 . . . . 0.0 112.606 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.32 -49.92 51.33 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.99 -35.23 79.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.239 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 m-30 -56.18 -32.95 64.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.714 -179.661 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.609 ' CG1' HG13 ' A' ' 6' ' ' VAL . 14.7 t -89.33 -35.05 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.62 0.247 . . . . 0.0 110.964 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.87 43.21 0.17 Allowed Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.152 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.512 HD21 HG21 ' A' ' 6' ' ' VAL . 63.5 mt -108.23 121.08 44.15 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.506 0.193 . . . . 0.0 110.53 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.92 -152.66 0.5 Allowed 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.988 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.22 130.06 44.95 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.812 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 113.68 -27.43 9.29 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.918 -0.658 . . . . 0.0 113.188 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -58.03 120.47 8.62 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.927 0.363 . . . . 0.0 111.077 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.7 125.59 30.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.741 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.665 HD12 HD21 ' A' ' 19' ' ' LEU . 23.8 mt -85.86 126.36 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.711 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.9 mp -108.22 -71.49 0.76 Allowed 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.495 ' HB3' ' CG2' ' A' ' 77' ' ' VAL . . . -97.07 126.89 42.53 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.756 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.599 HG21 HG13 ' A' ' 63' ' ' VAL . 11.0 t -119.64 103.38 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.302 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.423 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.5 t-20 76.46 31.75 0.59 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.705 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.423 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 85.01 -4.19 0.92 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.783 179.68 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 66' ' ' LEU . 1.1 pp -110.58 131.96 60.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-O 120.94 0.4 . . . . 0.0 111.656 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -71.58 145.28 49.14 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.604 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.507 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.2 m -146.11 61.14 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.376 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.1 -46.94 68.9 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.058 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 3.5 mtpp -140.13 37.68 1.93 Allowed 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.977 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.507 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -74.79 -174.96 2.32 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.446 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 3.8 m -91.2 145.67 24.48 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.641 0.734 . . . . 0.0 111.103 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.753 ' O ' HG23 ' A' ' 64' ' ' VAL . 2.5 t60 -61.68 -44.52 96.8 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.547 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -58.84 -43.2 90.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.882 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -64.24 -44.08 92.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.492 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.643 HG21 ' SG ' ' A' ' 25' ' ' CYS . 67.5 t -64.64 -40.79 90.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.059 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.753 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.3 t -65.69 -38.84 83.25 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 178.654 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.37 -40.88 79.07 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.901 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.743 HD11 HD11 ' A' ' 53' ' ' ILE . 7.3 mt -67.27 -42.07 84.44 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.643 179.432 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.975 HG23 HD22 ' A' ' 74' ' ' LEU . 9.8 mt -68.03 -39.33 81.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -80.04 11.17 37.02 Favored Glycine 0 CA--C 1.524 0.595 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.585 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.21 -8.12 13.55 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.441 0.296 . . . . 0.0 111.24 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.459 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 24.9 p -48.49 -49.91 33.87 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.825 0.345 . . . . 0.0 111.798 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.1 t 66.33 33.42 7.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.002 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.83 -37.41 0.95 Allowed Glycine 0 C--N 1.334 0.464 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.008 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 8' ' ' VAL . 8.1 p -171.12 137.39 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.998 0.427 . . . . 0.0 111.922 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.975 HD22 HG23 ' A' ' 67' ' ' ILE . 1.2 pp -112.38 155.41 24.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.363 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 68.7 m80 -110.92 98.34 7.49 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.268 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.475 ' HG2' HG23 ' A' ' 47' ' ' ILE . 3.0 ttm -105.07 122.74 46.52 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.052 -179.366 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.495 ' CG2' ' HB3' ' A' ' 49' ' ' ALA . 21.3 t -101.06 100.44 10.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.566 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.469 HG22 ' HA ' ' A' ' 47' ' ' ILE . 6.5 pt -102.53 171.76 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.427 -179.69 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -143.13 148.04 35.94 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.416 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 . . . . . 0 C--O 1.232 0.161 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.668 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.422 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.7 p . . . . . 0 CA--C 1.53 0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.641 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.471 ' HG3' HD11 ' A' ' 78' ' ' ILE . 14.8 ptm180 -137.35 162.59 33.16 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.219 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.28 141.43 37.63 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.175 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.624 HG11 HD22 ' A' ' 41' ' ' LEU . 21.7 t -126.9 139.28 52.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.295 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.792 ' O ' HG21 ' A' ' 39' ' ' VAL . 13.0 mt-10 -107.86 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.512 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.41 HG12 ' HD2' ' A' ' 15' ' ' TYR . 6.7 t -99.08 112.87 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-O 120.862 0.363 . . . . 0.0 111.187 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.79 88.82 7.42 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.343 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.491 ' HB3' ' O ' ' A' ' 71' ' ' SER . 2.1 ttt-85 -48.19 124.75 8.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.181 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.49 -87.81 0.14 Allowed Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.701 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.17 -55.85 0.45 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.615 0.245 . . . . 0.0 111.316 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.79 30.57 6.98 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.98 151.14 5.44 Favored Glycine 0 C--N 1.333 0.378 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.39 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.448 ' CE2' ' HG3' ' A' ' 10' ' ' ARG . 39.1 m-85 -77.43 -33.42 54.89 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-O 120.568 0.223 . . . . 0.0 111.086 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.84 61.77 0.83 Allowed Glycine 0 C--N 1.335 0.498 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.567 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.403 ' CD1' ' HB2' ' A' ' 15' ' ' TYR . 6.1 p90 -168.93 175.93 5.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 111.063 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -119.04 116.71 26.98 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.392 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.4 HD23 ' N ' ' A' ' 20' ' ' SER . 0.6 OUTLIER -105.97 132.41 52.09 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.801 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.4 ' N ' HD23 ' A' ' 19' ' ' LEU . 36.8 p -147.45 -176.68 5.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.819 179.333 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 109.4 82.27 1.35 Allowed Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 121.033 -0.604 . . . . 0.0 112.05 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -45.37 -53.44 8.6 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.843 0.354 . . . . 0.0 110.594 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.956 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -98.68 -62.93 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.94 178.395 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.956 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 97.3 Cg_endo -88.11 91.85 0.45 Allowed 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.872 2.381 . . . . 0.0 112.128 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.3 p -54.73 119.78 5.83 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.659 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.508 HG23 ' HA ' ' A' ' 46' ' ' GLN . 12.5 p -141.4 151.48 19.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.83 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -81.6 91.31 6.37 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.17 -43.87 52.51 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.493 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.44 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.3 t -167.23 158.58 12.06 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.367 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.632 HG21 ' HB3' ' A' ' 41' ' ' LEU . 12.4 t -119.1 154.76 21.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.341 179.462 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 41.8 mtp -98.41 101.38 12.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 121.036 0.446 . . . . 0.0 110.33 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -50.82 124.48 11.2 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.859 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 22.87 10.97 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.488 -179.465 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.37 165.08 26.39 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.621 ' O ' HG23 ' A' ' 39' ' ' VAL . 9.4 Cg_endo -52.59 -28.06 35.3 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.726 2.284 . . . . 0.0 112.869 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.655 ' O ' HD23 ' A' ' 41' ' ' LEU . . . -65.36 -49.84 67.83 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.782 0.325 . . . . 0.0 110.829 179.464 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.36 -31.25 68.43 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.397 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.427 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.4 m-30 -61.36 -23.95 66.13 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.419 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.792 HG21 ' O ' ' A' ' 7' ' ' GLU . 23.5 t -89.08 -33.73 6.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 CA-C-O 120.758 0.313 . . . . 0.0 111.167 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.45 42.51 0.31 Allowed Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.874 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.655 HD23 ' O ' ' A' ' 36' ' ' ALA . 1.7 mm? -75.18 178.49 5.71 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.644 0.259 . . . . 0.0 110.62 179.557 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -171.04 130.18 0.77 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.219 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.44 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -65.18 111.72 3.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.479 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 129.91 -23.96 4.62 Favored Glycine 0 CA--C 1.523 0.582 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.839 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.45 115.65 3.13 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.651 0.263 . . . . 0.0 110.518 179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLN . . . . . 0.508 ' HA ' HG23 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -74.64 120.3 19.99 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.832 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.639 ' HA ' HG22 ' A' ' 78' ' ' ILE . 24.2 mt -78.05 124.15 35.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.537 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.716 HD11 ' HB2' ' A' ' 79' ' ' ALA . 3.2 mt -105.67 -46.46 4.15 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.776 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.5 140.43 51.45 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.996 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.461 HG23 ' CG2' ' A' ' 55' ' ' VAL . 13.9 t -134.44 110.06 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.402 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.9 t-20 76.65 33.56 0.49 Allowed 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -178.441 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 77.32 -1.86 2.68 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 112.688 -179.869 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.587 HD11 HD13 ' A' ' 66' ' ' LEU . 5.0 pt -113.04 122.77 67.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 121.063 0.459 . . . . 0.0 111.315 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.541 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 6.9 t30 -63.4 128.16 34.57 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.339 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.575 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 13.1 m -136.33 54.18 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.22 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.409 ' HD3' HD22 ' A' ' 48' ' ' LEU . 2.4 mmmt -65.9 -30.0 70.52 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.25 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.4 mmtt -132.37 29.76 4.24 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.61 0.243 . . . . 0.0 111.129 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.575 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -81.75 -179.51 7.41 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.857 0.36 . . . . 0.0 111.405 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.627 ' O ' HG23 ' A' ' 63' ' ' VAL . 3.9 m -86.18 145.26 27.07 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.58 0.705 . . . . 0.0 111.011 179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.721 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.5 t-80 -59.1 -44.87 91.99 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.485 -1.234 . . . . 0.0 111.473 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.02 -38.72 89.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.546 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -42.55 92.43 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.627 HG23 ' O ' ' A' ' 59' ' ' SER . 65.2 t -65.53 -41.74 91.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.001 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 60' ' ' HIS . 46.6 t -65.82 -38.92 83.31 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 178.569 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -43.09 85.72 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.234 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.587 HD13 HD11 ' A' ' 53' ' ' ILE . 56.0 mt -64.53 -41.03 96.62 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.764 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.763 HG23 ' HG ' ' A' ' 74' ' ' LEU . 44.1 mt -66.35 -43.43 91.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.499 179.383 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.64 -21.94 63.41 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.72 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.81 -34.93 72.25 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.527 0.203 . . . . 0.0 111.531 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.527 ' HB3' HD22 ' A' ' 74' ' ' LEU . 0.1 OUTLIER -97.95 99.59 10.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.487 0.66 . . . . 0.0 110.254 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.491 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 30.3 t -88.99 -33.77 17.08 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.758 -1.11 . . . . 0.0 111.221 -179.665 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -65.12 -43.03 96.21 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.174 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.91 138.93 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 120.751 0.31 . . . . 0.0 111.44 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.763 ' HG ' HG23 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -94.19 146.5 23.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.318 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 -131.44 102.82 6.1 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.864 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.09 154.66 44.42 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.808 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.6 t -109.43 112.74 41.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.704 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.639 HG22 ' HA ' ' A' ' 47' ' ' ILE . 1.6 pp -107.24 172.18 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.387 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.716 ' HB2' HD11 ' A' ' 48' ' ' LEU . . . -145.94 129.17 16.7 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.258 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.234 0.28 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.031 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.235 0.342 0 CA-C-O 120.701 0.286 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.5 ptt-85 -153.34 166.42 32.68 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.24 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.6 m -118.16 140.96 49.01 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.801 HG21 ' CD1' ' A' ' 41' ' ' LEU . 25.2 t -115.3 138.39 45.78 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.329 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -110.69 105.78 14.78 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.987 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.488 ' O ' HG23 ' A' ' 73' ' ' VAL . 10.5 t -100.39 133.26 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.288 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.68 98.73 9.25 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.942 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.526 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.4 OUTLIER -53.35 126.07 19.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.978 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.82 15.14 44.29 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.706 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.8 mmt85 74.01 0.24 3.55 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.985 0.392 . . . . 0.0 111.753 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -146.28 25.57 1.23 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-O 120.77 0.319 . . . . 0.0 111.147 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 136.47 175.44 13.81 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.692 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.623 ' CE2' HG22 ' A' ' 67' ' ' ILE . 35.5 m-85 -114.26 -69.57 0.85 Allowed 'General case' 0 C--O 1.232 0.141 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.81 -22.25 1.8 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.988 -0.625 . . . . 0.0 113.226 -179.621 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.53 ' HB2' HD21 ' A' ' 27' ' ' LEU . 51.4 p90 -95.81 137.76 34.43 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.905 0.353 . . . . 0.0 110.777 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -98.08 133.25 42.8 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.201 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.674 HD21 HD12 ' A' ' 47' ' ' ILE . 3.0 mt -117.29 133.26 56.19 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.462 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.5 m -149.88 166.63 28.96 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.128 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.47 -34.22 4.89 Favored Glycine 0 C--N 1.336 0.568 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.897 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.523 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 79.91 -49.85 0.37 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.359 0.663 . . . . 0.0 111.552 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.889 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -97.79 -64.93 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.483 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.889 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 99.0 Cg_endo -79.74 94.86 1.03 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.402 2.068 . . . . 0.0 112.478 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 85.6 m -59.65 111.61 1.49 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.184 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -146.93 143.21 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.273 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.726 HD22 HG22 ' A' ' 30' ' ' VAL . 0.1 OUTLIER -79.2 91.46 4.97 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.671 179.655 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.1 m -54.96 -37.64 66.75 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.347 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.549 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.2 t -167.15 155.61 9.8 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.921 0.391 . . . . 0.0 111.273 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.726 HG22 HD22 ' A' ' 27' ' ' LEU . 2.4 t -112.5 155.17 13.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.558 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mmt -103.31 101.92 11.86 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 121.003 0.43 . . . . 0.0 110.636 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.4 mtt85 -51.73 124.4 12.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.764 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.68 3.61 37.14 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.717 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.413 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.6 OUTLIER -108.13 167.06 9.82 Favored Pre-proline 0 C--O 1.233 0.211 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.512 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.546 ' O ' HG23 ' A' ' 39' ' ' VAL . 9.8 Cg_endo -51.57 -29.51 32.54 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.924 2.416 . . . . 0.0 112.712 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.603 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -63.7 -49.36 73.44 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.024 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.13 -34.27 77.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -60.94 -26.79 67.76 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.492 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 35' ' ' PRO . 35.3 t -89.56 -30.41 5.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-O 120.661 0.267 . . . . 0.0 111.144 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.06 47.11 0.67 Allowed Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.801 ' CD1' HG21 ' A' ' 6' ' ' VAL . 2.8 tp -80.22 156.45 26.88 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.965 0.412 . . . . 0.0 110.782 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.8 mmm180 -146.28 117.79 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.549 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -53.41 152.15 5.0 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.739 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.71 -28.95 13.66 Favored Glycine 0 CA--C 1.521 0.427 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.344 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.451 ' OD2' HD13 ' A' ' 78' ' ' ILE . 19.0 p-10 -59.68 121.9 12.8 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 122.876 0.47 . . . . 0.0 111.438 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -78.37 130.56 36.28 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.079 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.674 HD12 HD21 ' A' ' 19' ' ' LEU . 17.3 mt -84.7 127.81 39.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.002 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.445 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.3 mm? -106.42 -43.27 4.8 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.428 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.556 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -129.95 137.2 50.21 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.504 -0.317 . . . . 0.0 111.41 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.585 HG11 HD11 ' A' ' 67' ' ' ILE . 3.9 t -136.91 113.03 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.338 179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 76.64 31.66 0.57 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 79.15 -5.01 2.02 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.581 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.827 HD11 HD13 ' A' ' 66' ' ' LEU . 1.2 pp -112.2 124.97 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-O 121.104 0.478 . . . . 0.0 111.343 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.556 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -66.19 131.41 46.1 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.307 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.604 HG11 HG22 ' A' ' 63' ' ' VAL . 17.5 m -129.05 53.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.309 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -55.41 -55.4 32.12 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.281 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.3 mttm -127.19 32.62 5.03 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.911 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.49 -176.84 3.88 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.669 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -85.69 133.88 34.0 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.511 0.672 . . . . 0.0 110.81 179.699 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.523 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 5.0 t60 -56.9 -44.31 82.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.811 -1.086 . . . . 0.0 111.882 -179.528 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.47 ' HA ' HG22 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -66.48 -33.84 76.6 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.912 179.706 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.56 -42.18 68.14 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.068 178.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.669 HG23 ' O ' ' A' ' 59' ' ' SER . 56.9 t -63.86 -44.02 97.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.083 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.47 HG22 ' HA ' ' A' ' 61' ' ' GLU . 28.6 m -66.14 -39.3 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -57.93 -42.44 84.86 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.956 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.827 HD13 HD11 ' A' ' 53' ' ' ILE . 5.9 mt -62.31 -43.87 97.83 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.623 HG22 ' CE2' ' A' ' 15' ' ' TYR . 53.3 mt -66.59 -41.62 88.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.677 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.38 -1.17 74.72 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.848 -0.692 . . . . 0.0 113.256 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -83.03 -34.76 26.19 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.027 0.413 . . . . 0.0 111.492 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.75 -57.3 9.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.809 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.8 34.76 5.36 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.974 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.8 -45.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.366 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.6 p -169.05 138.48 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-O 120.841 0.353 . . . . 0.0 111.726 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.464 HD11 HG12 ' A' ' 50' ' ' VAL . 10.7 tp -114.33 141.87 47.05 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.26 179.595 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -125.27 98.41 5.63 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.977 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 15.1 ptt? -116.67 154.84 29.86 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.391 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.0 t -111.98 109.21 27.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.878 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.451 HD13 ' OD2' ' A' ' 45' ' ' ASP . 1.1 pt -102.06 163.67 3.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.509 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.26 116.0 18.47 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.9 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 . . . . . 0 CA--C 1.53 0.174 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.33 -179.555 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.463 0.183 0 CA-C-O 120.719 0.295 . . . . 0.0 110.936 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -150.22 174.08 13.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.377 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -118.76 137.41 53.39 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.765 HG13 HG11 ' A' ' 39' ' ' VAL . 42.3 t -114.59 139.33 41.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.114 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -115.04 110.1 19.07 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.861 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 73' ' ' VAL . 5.9 t -95.9 130.31 44.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.027 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.5 93.13 8.39 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.964 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 -39.38 122.7 1.34 Allowed 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.555 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.31 -90.65 0.07 OUTLIER Glycine 0 C--N 1.333 0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.907 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 ptt85 -134.98 -47.37 0.73 Allowed 'General case' 0 C--O 1.233 0.196 0 N-CA-C 111.578 0.214 . . . . 0.0 111.578 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.49 40.43 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.528 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.28 -173.96 21.43 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.826 -0.702 . . . . 0.0 113.178 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -96.56 -71.93 0.66 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.653 0.263 . . . . 0.0 111.463 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.71 -39.34 0.61 Allowed Glycine 0 CA--C 1.519 0.323 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.785 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -71.62 179.93 2.85 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.691 0.282 . . . . 0.0 111.122 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 m -135.3 151.03 50.16 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.356 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 mt -124.97 131.06 53.48 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.942 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.7 p -148.06 157.77 43.69 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 120.713 0.292 . . . . 0.0 111.561 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 126.26 -25.73 5.39 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 121.213 -0.518 . . . . 0.0 113.027 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 61.81 14.24 6.07 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.736 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.801 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -166.87 -65.79 0.01 OUTLIER Pre-proline 0 N--CA 1.463 0.224 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.801 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.8 Cg_endo -74.39 83.68 1.66 Allowed 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.381 2.054 . . . . 0.0 111.361 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.5 m -52.23 108.45 0.29 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.3 p -143.22 141.37 26.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.54 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 1.003 HD12 HD11 ' A' ' 47' ' ' ILE . 2.1 mp -78.98 91.95 4.89 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.408 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.24 -42.98 42.33 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.408 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.59 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.9 t -171.07 157.1 5.06 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.964 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -120.42 155.56 23.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.655 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.0 mtp -97.83 102.29 14.01 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.224 0.535 . . . . 0.0 110.572 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.34 121.6 5.17 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.967 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.21 -18.32 23.54 Favored Glycine 0 CA--C 1.522 0.499 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.291 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.79 166.74 34.16 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.654 0.227 . . . . 0.0 110.521 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -53.14 -26.74 34.32 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.101 2.534 . . . . 0.0 113.166 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -65.5 -42.27 92.3 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.53 -26.65 63.67 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.375 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -55.31 -25.59 35.37 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 111.668 0.247 . . . . 0.0 111.668 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.765 HG11 HG13 ' A' ' 6' ' ' VAL . 21.4 t -89.46 -32.51 5.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 120.612 0.244 . . . . 0.0 111.122 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.77 41.65 1.68 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.454 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.5 mt -74.79 -178.28 3.62 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.628 0.251 . . . . 0.0 110.346 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 -163.85 122.79 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.402 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.59 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -47.26 125.25 7.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.97 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.53 -25.66 5.89 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.595 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.627 ' OD2' HG21 ' A' ' 78' ' ' ILE . 11.3 p-10 -56.91 122.62 12.69 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 121.018 0.437 . . . . 0.0 110.946 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.6 mp0 -76.98 117.78 18.91 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.062 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 1.003 HD11 HD12 ' A' ' 27' ' ' LEU . 14.0 mt -81.76 121.49 35.18 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.899 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mp -108.44 -40.59 5.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.086 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.558 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -120.8 133.08 55.33 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.99 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.4 t -135.3 111.29 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.22 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.28 32.62 0.58 Allowed 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.294 0.568 . . . . 0.0 109.717 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 76.82 -3.35 2.53 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.089 -0.96 . . . . 0.0 112.784 179.869 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.78 HD11 ' CD1' ' A' ' 66' ' ' LEU . 1.1 pt -116.12 125.92 73.4 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-O 120.834 0.349 . . . . 0.0 111.16 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.481 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 18.4 p-10 -64.95 135.91 56.21 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.473 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.0 m -134.2 59.0 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.902 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 46.4 mttt -48.48 -71.44 0.07 Allowed 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.921 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 35.6 mttp -119.81 39.87 3.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.664 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -73.86 -174.87 1.94 Allowed 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.933 -179.353 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.529 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.99 136.24 33.12 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 121.489 0.661 . . . . 0.0 110.678 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.742 ' O ' HG23 ' A' ' 64' ' ' VAL . 5.1 t60 -53.99 -44.48 70.87 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.279 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -61.17 -41.81 97.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.788 0.327 . . . . 0.0 110.737 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -66.3 -41.45 89.71 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 59' ' ' SER . 61.5 t -65.93 -39.13 83.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.606 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.5 t -65.75 -39.02 83.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 178.381 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -57.42 -41.26 80.05 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.887 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.78 ' CD1' HD11 ' A' ' 53' ' ' ILE . 14.2 mt -64.14 -43.62 94.66 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.46 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.782 HG23 HD22 ' A' ' 74' ' ' LEU . 52.0 mt -66.84 -37.47 79.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.623 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -79.31 8.56 45.94 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.444 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.54 1.91 15.16 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 122.448 0.299 . . . . 0.0 110.781 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.439 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 16.0 p -50.98 -44.73 60.78 Favored 'General case' 0 C--O 1.233 0.212 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.487 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.9 m 67.21 30.82 7.01 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.065 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.9 -30.93 2.78 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.152 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.439 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.1 p -163.84 138.0 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.047 0.451 . . . . 0.0 112.193 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.782 HD22 HG23 ' A' ' 67' ' ' ILE . 41.4 tp -114.35 150.41 34.59 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.164 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.4 m80 -120.01 105.82 11.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.344 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.506 ' SD ' HD23 ' A' ' 74' ' ' LEU . 0.9 OUTLIER -115.45 137.18 52.32 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.168 -179.381 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.558 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 20.6 t -107.34 105.75 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.767 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.638 HG22 ' HA ' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -106.82 170.64 2.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.461 -179.821 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -130.41 154.78 47.36 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.571 -179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.234 0.239 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.794 179.724 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.5 p . . . . . 0 C--O 1.233 0.232 0 CA-C-O 120.78 0.324 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -130.81 145.09 51.88 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.244 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -110.44 132.66 53.99 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.664 179.484 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.672 HG13 HG11 ' A' ' 39' ' ' VAL . 37.1 t -118.33 141.1 39.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.554 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -128.66 100.8 5.87 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.794 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.632 ' O ' HG23 ' A' ' 73' ' ' VAL . 19.5 t -95.56 144.62 9.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-O 120.969 0.414 . . . . 0.0 111.533 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -115.14 106.44 14.09 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.625 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.424 ' HD3' ' HA ' ' A' ' 71' ' ' SER . 17.7 ttt180 -50.62 120.09 4.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.12 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.97 -61.92 5.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.392 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -150.7 -76.29 0.14 Allowed 'General case' 0 C--O 1.231 0.127 0 CA-C-O 120.613 0.244 . . . . 0.0 110.564 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.39 26.46 9.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.508 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.6 173.95 46.52 Favored Glycine 0 C--N 1.336 0.57 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.897 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -111.13 -77.24 0.59 Allowed 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 120.706 0.289 . . . . 0.0 110.922 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.53 45.32 0.04 OUTLIER Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.968 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -159.03 176.77 11.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.442 0.163 . . . . 0.0 110.713 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -140.9 150.38 43.11 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.628 0.252 . . . . 0.0 111.268 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.628 HD21 HD12 ' A' ' 47' ' ' ILE . 2.8 mt -120.98 131.48 54.33 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.568 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.7 m -147.08 163.0 37.67 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.258 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.61 -30.65 5.07 Favored Glycine 0 C--N 1.336 0.554 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.983 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.487 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 80.97 -44.73 0.22 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.443 0.697 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.799 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -111.04 -68.26 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.512 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.799 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 64.0 Cg_endo -73.73 95.72 0.89 Allowed 'Trans proline' 0 C--N 1.356 0.952 0 C-N-CA 122.26 1.974 . . . . 0.0 112.446 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.455 ' SG ' HG21 ' A' ' 63' ' ' VAL . 84.7 m -61.73 118.5 7.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.218 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.31 145.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.396 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.583 HD21 HD23 ' A' ' 41' ' ' LEU . 0.6 OUTLIER -75.86 90.99 2.95 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-O 120.846 0.355 . . . . 0.0 110.507 179.758 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.6 m -54.67 -36.67 64.86 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.417 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.474 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.2 t -164.52 157.94 17.66 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.031 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.419 HG21 ' O ' ' A' ' 41' ' ' LEU . 4.1 t -122.54 154.61 27.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.903 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -97.45 101.28 12.78 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.279 0.561 . . . . 0.0 110.216 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -51.87 121.59 6.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.122 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.86 27.97 8.07 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.193 -0.527 . . . . 0.0 112.525 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.2 m -129.36 164.63 38.23 Favored Pre-proline 0 C--N 1.332 -0.194 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.68 -25.12 25.27 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 122.865 2.376 . . . . 0.0 112.902 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.19 -49.98 65.45 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.815 0.341 . . . . 0.0 110.704 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.03 -25.98 65.64 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.168 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.1 m-30 -57.03 -30.18 64.0 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.599 0.238 . . . . 0.0 111.388 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.672 HG11 HG13 ' A' ' 6' ' ' VAL . 20.8 t -89.28 -25.92 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.253 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.84 5.4 6.94 Favored Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.348 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.617 HD11 HG11 ' A' ' 6' ' ' VAL . 7.3 mp -64.67 111.45 2.76 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 117.315 0.557 . . . . 0.0 109.675 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.482 ' O ' ' HB3' ' A' ' 43' ' ' ALA . 18.0 mmm180 -122.97 25.97 8.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.51 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 42' ' ' ARG . . . 72.92 159.27 0.22 Allowed 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.947 0.404 . . . . 0.0 111.636 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.15 -39.66 3.05 Favored Glycine 0 C--N 1.334 0.46 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.678 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.535 ' OD2' HD13 ' A' ' 27' ' ' LEU . 2.9 p-10 -52.3 119.91 4.94 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.917 0.389 . . . . 0.0 110.843 179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLN . . . . . 0.483 ' O ' HD12 ' A' ' 48' ' ' LEU . 11.0 mt-30 -75.22 126.22 30.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.031 -179.442 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.628 HD12 HD21 ' A' ' 19' ' ' LEU . 19.3 mt -83.09 120.29 34.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.819 179.696 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.483 HD12 ' O ' ' A' ' 46' ' ' GLN . 5.4 mp -105.2 -32.87 8.45 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.624 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.552 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -137.09 137.45 39.3 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 111.018 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.438 HG23 ' CG2' ' A' ' 55' ' ' VAL . 6.3 t -132.25 108.15 13.39 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.424 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 4.8 t-20 77.39 33.59 0.4 Allowed 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.417 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.52 -1.08 3.1 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.517 -179.621 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.655 HD11 HD13 ' A' ' 66' ' ' LEU . 9.0 pt -113.14 119.63 61.1 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 111.176 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 10.9 m120 -62.08 120.63 11.22 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.149 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.457 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 11.9 m -135.14 33.71 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.747 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -61.4 -28.43 69.25 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -123.55 26.83 7.65 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 120.544 0.211 . . . . 0.0 111.3 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.457 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -92.27 -178.96 5.1 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.765 0.317 . . . . 0.0 111.505 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.654 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.3 OUTLIER -80.23 135.36 36.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.362 0.601 . . . . 0.0 110.736 179.688 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.487 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 4.0 t60 -54.79 -44.24 73.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.927 -1.033 . . . . 0.0 111.978 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.469 ' HA ' HG22 ' A' ' 64' ' ' VAL . 20.9 mt-10 -65.64 -35.87 82.06 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.779 0.323 . . . . 0.0 110.567 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.29 -39.38 71.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.167 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 59' ' ' SER . 60.8 t -67.43 -42.31 87.09 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.162 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.469 HG22 ' HA ' ' A' ' 61' ' ' GLU . 31.4 m -65.93 -38.6 82.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.9 tttp -57.48 -40.31 78.3 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.697 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.655 HD13 HD11 ' A' ' 53' ' ' ILE . 21.2 mt -67.63 -42.42 82.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.736 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.508 HG23 HD13 ' A' ' 74' ' ' LEU . 9.5 mt -69.33 -38.38 77.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.996 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -60.1 -24.65 61.1 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.318 179.18 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -80.27 4.43 17.73 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.902 0.334 . . . . 0.0 111.902 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.607 ' HB2' HD12 ' A' ' 74' ' ' LEU . 0.1 OUTLIER -106.18 104.01 13.62 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.356 0.598 . . . . 0.0 110.109 179.708 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.424 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.1 OUTLIER -116.2 33.43 5.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.987 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.93 -53.91 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.088 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 8' ' ' VAL . 4.0 p -172.03 130.96 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-O 120.99 0.424 . . . . 0.0 111.8 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.607 HD12 ' HB2' ' A' ' 70' ' ' CYS . 0.5 OUTLIER -114.5 151.62 32.99 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.546 -179.878 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.522 ' N ' HD23 ' A' ' 74' ' ' LEU . 19.7 m170 -116.39 107.09 14.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.211 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.412 ' HG3' HD22 ' A' ' 74' ' ' LEU . 1.6 mpt? -108.74 145.76 34.61 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.03 -179.323 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.552 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 19.5 t -117.1 98.88 7.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.522 HG22 ' HA ' ' A' ' 47' ' ' ILE . 24.8 pt -101.62 172.1 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.479 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.57 146.84 52.22 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.12 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 . . . . . 0 C--O 1.232 0.16 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.118 179.912 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 3' ' ' VAL . 9.2 p . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.07 0.462 . . . . 0.0 111.26 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.73 ' HG2' HD11 ' A' ' 78' ' ' ILE . 6.9 tpt180 -114.18 139.27 49.5 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.844 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.81 131.06 57.05 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.182 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.825 HG11 HD13 ' A' ' 41' ' ' LEU . 25.6 t -120.91 131.49 72.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.693 0.282 . . . . 0.0 110.826 179.485 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.644 ' O ' HG21 ' A' ' 39' ' ' VAL . 25.6 mt-10 -116.7 115.25 25.29 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.009 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.448 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.2 t -108.57 138.58 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.787 0.327 . . . . 0.0 111.435 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.3 93.89 8.87 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.397 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.436 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 4.0 ttt-85 -51.81 126.41 17.9 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.445 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.92 -112.67 0.03 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.687 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -111.27 -39.33 4.75 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.468 0.175 . . . . 0.0 111.329 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -138.75 35.13 2.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.337 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 159.96 -170.45 36.1 Favored Glycine 0 C--N 1.338 0.65 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.731 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.436 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 71.5 m-85 -118.63 -69.42 0.85 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.865 0.364 . . . . 0.0 111.161 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.16 52.49 0.04 OUTLIER Glycine 0 C--N 1.332 0.315 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.317 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.525 ' HB2' HD21 ' A' ' 27' ' ' LEU . 51.0 p90 -162.99 155.47 18.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.549 0.214 . . . . 0.0 110.952 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.14 129.13 43.52 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.932 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -116.57 124.37 49.68 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.993 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 39.2 m -148.07 115.58 6.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.177 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -168.1 83.28 0.1 OUTLIER Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.49 -179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.25 -43.07 21.68 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.972 0.415 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.96 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -121.25 -66.69 0.02 OUTLIER Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.455 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.96 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 92.3 Cg_endo -85.23 94.88 0.64 Allowed 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 122.475 2.117 . . . . 0.0 112.214 179.269 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 2.6 m -51.87 117.66 2.89 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.822 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -141.51 149.41 20.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.378 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.612 HD11 HD21 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -80.46 91.49 5.74 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.741 179.661 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.08 -45.38 61.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.517 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.503 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.5 t -164.4 159.06 19.21 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.59 HG22 HD22 ' A' ' 27' ' ' LEU . 5.2 t -116.9 155.03 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.714 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -99.5 100.76 11.83 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.153 0.501 . . . . 0.0 110.278 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.3 mtm-85 -52.07 125.94 17.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.943 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.91 23.64 11.46 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.682 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.86 168.92 14.29 Favored Pre-proline 0 CA--C 1.531 0.218 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.669 ' O ' HG23 ' A' ' 39' ' ' VAL . 78.4 Cg_exo -50.66 -29.93 27.11 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.885 2.39 . . . . 0.0 113.051 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.796 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -65.09 -49.82 68.51 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 111.014 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -69.43 -32.79 71.98 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.243 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 16.7 m-30 -62.77 -23.78 67.38 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.455 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.669 HG23 ' O ' ' A' ' 35' ' ' PRO . 38.8 t -89.32 -29.6 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.58 0.229 . . . . 0.0 111.246 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.89 39.96 0.86 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.717 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.825 HD13 HG11 ' A' ' 6' ' ' VAL . 4.1 tp -73.28 178.62 4.38 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.806 0.336 . . . . 0.0 110.765 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -173.92 131.17 0.41 Allowed 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.944 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.503 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -62.67 120.81 11.92 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.911 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 128.23 -27.57 4.48 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.804 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -58.3 123.92 17.72 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 120.927 0.394 . . . . 0.0 111.062 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -78.21 124.7 28.37 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.716 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.3 mt -95.66 122.21 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.802 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.76 HD12 ' HD2' ' A' ' 56' ' ' LYS . 0.3 OUTLIER -108.19 -38.32 5.79 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.016 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.523 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -119.01 138.14 53.04 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.569 ' HB ' HG21 ' A' ' 55' ' ' VAL . 19.3 t -141.71 115.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.773 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.417 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.7 t-20 76.89 32.78 0.49 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -178.302 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.417 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.2 -0.71 3.23 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.454 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.71 HD11 HD13 ' A' ' 66' ' ' LEU . 12.1 pt -120.47 133.42 67.23 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 111.434 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.523 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 22.9 t-20 -63.07 121.73 14.32 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.966 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.569 HG21 ' HB ' ' A' ' 50' ' ' VAL . 5.0 m -140.41 55.35 0.21 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.553 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.76 ' HD2' HD12 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.03 14.52 31.74 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.546 179.572 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -150.89 27.95 0.7 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 122.279 0.232 . . . . 0.0 111.12 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -113.99 -167.45 1.21 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-O 120.706 0.289 . . . . 0.0 111.59 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.591 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.4 OUTLIER -88.74 139.15 30.75 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 121.361 0.6 . . . . 0.0 110.533 179.672 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.727 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.3 t60 -53.69 -44.78 70.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.871 -1.058 . . . . 0.0 112.052 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -60.62 -42.32 96.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.742 0.306 . . . . 0.0 110.731 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -64.79 -44.06 91.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.265 179.033 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 59' ' ' SER . 52.4 t -63.36 -42.81 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.128 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.727 HG23 ' O ' ' A' ' 60' ' ' HIS . 50.3 t -66.17 -38.91 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -57.77 -41.1 81.3 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.89 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.71 HD13 HD11 ' A' ' 53' ' ' ILE . 17.7 mt -64.05 -43.45 95.49 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.566 HG23 HD22 ' A' ' 74' ' ' LEU . 68.6 mt -62.42 -44.27 99.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.679 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -69.51 -22.37 76.5 Favored Glycine 0 CA--C 1.522 0.49 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.004 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.9 tptt -57.0 -34.68 68.38 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.577 0.227 . . . . 0.0 111.421 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -69.01 -57.8 4.96 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-O 120.912 0.387 . . . . 0.0 110.676 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.416 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.5 OUTLIER 65.05 36.09 7.61 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.108 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.28 -45.56 0.02 OUTLIER Glycine 0 C--N 1.332 0.313 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.196 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.2 p -165.46 138.78 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.829 0.347 . . . . 0.0 111.287 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.566 HD22 HG23 ' A' ' 67' ' ' ILE . 28.3 tp -112.29 134.65 53.71 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.286 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 55.6 m170 -119.53 98.49 6.16 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.2 179.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.97 145.15 40.12 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.327 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 22.9 t -96.67 114.0 32.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.545 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.73 HD11 ' HG2' ' A' ' 4' ' ' ARG . 1.7 pt -103.37 146.23 11.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.311 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -112.94 144.57 42.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.267 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.233 0.205 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.449 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.498 ' O ' HG13 ' A' ' 3' ' ' VAL . 11.9 p . . . . . 0 CA--C 1.533 0.319 0 CA-C-O 120.887 0.375 . . . . 0.0 111.327 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.5 ttt85 -118.48 136.27 53.9 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.203 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.09 129.54 36.37 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.754 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.405 HG11 ' CD2' ' A' ' 41' ' ' LEU . 25.0 t -126.35 135.51 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.333 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -133.35 109.11 9.13 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.515 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.2 t -102.46 144.48 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.204 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -110.23 102.96 11.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.853 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.91 120.3 5.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.211 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.52 -122.03 0.58 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.647 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -114.41 -40.7 3.58 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.514 0.197 . . . . 0.0 111.151 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -105.94 29.42 6.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 120.721 0.296 . . . . 0.0 111.52 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.96 -176.92 16.77 Favored Glycine 0 C--N 1.337 0.606 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.826 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CE2' HG22 ' A' ' 67' ' ' ILE . 61.8 m-85 -79.3 -71.46 0.44 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.896 0.379 . . . . 0.0 110.718 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.23 48.99 0.04 OUTLIER Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.836 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.743 ' HB2' HD23 ' A' ' 27' ' ' LEU . 50.5 p90 -161.01 171.59 18.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.673 0.273 . . . . 0.0 110.946 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -126.31 133.17 51.47 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.899 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.531 HD21 ' CD1' ' A' ' 47' ' ' ILE . 3.4 mt -115.27 124.59 51.72 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.204 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.4 m -136.7 16.31 3.11 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.301 -0.409 . . . . 0.0 112.101 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.44 85.19 1.57 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.071 -0.585 . . . . 0.0 112.445 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.34 -66.66 0.35 Allowed 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.691 0.281 . . . . 0.0 111.011 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.883 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -91.76 -59.06 0.23 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.103 178.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.883 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 83.9 Cg_endo -88.59 94.32 0.38 Allowed 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 122.89 2.393 . . . . 0.0 111.607 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.57 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.2 m -50.98 124.24 10.91 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.679 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 45' ' ' ASP . 7.3 p -154.07 141.89 13.11 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.743 HD23 ' HB2' ' A' ' 17' ' ' PHE . 1.6 mp -79.71 89.53 5.18 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.771 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -56.22 -35.24 67.11 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.473 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.3 t -153.16 152.05 30.82 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.3 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.2 t -123.13 154.76 28.86 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.724 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 32.3 mtt -98.64 100.29 11.5 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.268 0.556 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.37 123.29 13.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.847 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 108.85 -19.71 30.15 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.785 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.0 166.59 25.64 Favored Pre-proline 0 CA--C 1.531 0.231 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -55.45 -24.93 46.14 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.709 2.273 . . . . 0.0 112.621 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.769 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -63.57 -49.11 74.7 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.993 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.08 -28.95 65.84 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.286 179.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.7 m-30 -56.64 -33.08 65.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.687 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -89.25 -31.06 5.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.024 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.2 51.71 1.44 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.176 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.769 HD12 ' HB1' ' A' ' 36' ' ' ALA . 5.3 mt -59.32 -25.81 64.47 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 20.5 mtt85 66.7 119.49 0.03 OUTLIER 'General case' 0 C--N 1.34 0.187 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.39 89.19 0.21 Allowed 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.496 179.249 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.0 -12.7 5.04 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 121.208 -0.52 . . . . 0.0 112.905 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.542 ' HB3' HD12 ' A' ' 78' ' ' ILE . 1.3 t70 -58.22 127.49 32.38 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.711 0.291 . . . . 0.0 110.573 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.59 126.65 30.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.739 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.812 ' HA ' HG22 ' A' ' 78' ' ' ILE . 15.1 mt -90.63 131.06 38.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.599 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -119.06 -43.65 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.358 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.07 137.25 47.27 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.008 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.6 t -144.28 110.98 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.297 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.413 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.3 t-20 76.99 35.74 0.35 Allowed 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -178.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.2 OUTLIER 71.55 -0.27 3.21 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.252 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 12.3 pt -120.97 125.5 74.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-O 120.81 0.338 . . . . 0.0 111.121 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.524 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -68.59 172.09 6.7 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.954 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.476 HG11 HG22 ' A' ' 63' ' ' VAL . 3.7 m -138.57 -51.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.039 -0.528 . . . . 0.0 112.121 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt 72.15 -59.41 0.56 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 123.119 0.567 . . . . 0.0 110.828 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.8 mtpt -148.23 40.26 0.94 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.75 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -72.74 -173.79 1.28 Allowed 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.859 0.362 . . . . 0.0 111.4 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.569 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -90.14 135.8 33.44 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.416 0.627 . . . . 0.0 111.174 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.539 ' O ' HG22 ' A' ' 64' ' ' VAL . 2.4 t-160 -53.13 -44.33 67.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.486 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.465 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.3 pm0 -66.21 -34.74 78.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.169 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.62 -39.43 70.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.725 0.297 . . . . 0.0 110.343 179.251 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.57 HG21 ' SG ' ' A' ' 25' ' ' CYS . 48.0 t -67.3 -43.87 87.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.941 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 60' ' ' HIS . 15.9 m -66.32 -38.96 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.6 mmtt -58.11 -39.73 79.42 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.059 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 25.3 mt -68.09 -41.19 82.21 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.772 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.557 HG23 HD22 ' A' ' 74' ' ' LEU . 17.7 mt -69.39 -38.49 77.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.035 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -87.77 14.33 58.72 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.102 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.57 -29.22 12.46 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.847 0.324 . . . . 0.0 111.299 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.426 ' HB2' HD12 ' A' ' 74' ' ' LEU . 0.5 OUTLIER -69.71 -61.86 1.61 Allowed 'General case' 0 C--O 1.233 0.217 0 CA-C-O 120.827 0.346 . . . . 0.0 110.645 -179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 70.63 33.88 2.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.088 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.52 -49.4 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.126 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -174.73 132.56 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 111.669 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.557 HD22 HG23 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.91 152.98 31.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.672 179.676 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.9 m170 -117.52 105.38 12.02 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.948 179.211 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.24 156.2 25.81 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.431 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.456 ' CG1' HG23 ' A' ' 3' ' ' VAL . 26.4 t -125.53 100.52 7.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.072 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.812 HG22 ' HA ' ' A' ' 47' ' ' ILE . 18.4 pt -101.36 158.67 4.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.388 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -114.86 116.64 28.89 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.72 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.18 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.466 HG22 ' CG1' ' A' ' 77' ' ' VAL . 11.5 p . . . . . 0 C--O 1.234 0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.935 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.3 ptt180 -137.1 170.77 15.54 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.49 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.7 m -93.81 139.01 31.37 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.459 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.818 HG13 HG11 ' A' ' 39' ' ' VAL . 36.9 t -117.44 146.92 21.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.09 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -111.3 102.55 10.94 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.789 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 73' ' ' VAL . 13.4 t -88.54 119.88 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.174 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.119 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.91 89.63 8.07 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.472 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.405 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 7.9 ttm-85 -53.47 122.12 9.07 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.731 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.29 -68.98 1.42 Allowed Glycine 0 C--N 1.335 0.483 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.548 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -165.32 -51.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 120.725 0.298 . . . . 0.0 110.807 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -122.53 25.04 9.0 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.596 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 150.94 171.53 19.14 Favored Glycine 0 C--N 1.336 0.58 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.795 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.405 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 5.4 m-85 -108.04 -62.85 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.667 0.27 . . . . 0.0 110.646 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.26 -33.5 0.93 Allowed Glycine 0 CA--C 1.523 0.541 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.879 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -71.48 178.59 3.39 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.021 0.439 . . . . 0.0 111.445 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 m -139.84 142.6 36.6 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.205 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.62 HD21 HD12 ' A' ' 47' ' ' ILE . 0.7 OUTLIER -117.82 123.98 47.25 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.883 179.924 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.7 m -140.5 168.04 20.75 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.292 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 117.28 -35.2 4.24 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.877 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.44 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.35 -46.57 0.22 Allowed 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.457 0.703 . . . . 0.0 111.559 -179.829 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -101.64 -65.31 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.405 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.88 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 97.0 Cg_endo -79.77 96.04 1.04 Allowed 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.41 2.074 . . . . 0.0 112.384 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.419 ' SG ' HG11 ' A' ' 63' ' ' VAL . 69.8 m -61.44 114.26 3.12 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.135 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -149.0 143.72 18.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.253 -179.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.674 HD12 HD11 ' A' ' 47' ' ' ILE . 3.7 mp -73.13 89.75 1.51 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.655 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.8 m -52.49 -39.52 61.33 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.418 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -163.53 158.78 21.22 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.581 HG22 HD23 ' A' ' 27' ' ' LEU . 5.3 t -132.96 155.18 40.92 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.47 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 9.1 mtt -109.24 106.04 15.72 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.878 0.37 . . . . 0.0 110.477 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 32' ' ' ARG . 2.5 mtm105 -43.51 111.34 0.27 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.048 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 126.16 -16.1 6.81 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.754 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.502 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 10.0 p -80.58 162.98 58.7 Favored Pre-proline 0 CA--C 1.532 0.282 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.502 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 14.1 Cg_endo -55.84 -24.85 49.26 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 122.718 2.278 . . . . 0.0 112.751 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.546 ' HA ' HD12 ' A' ' 41' ' ' LEU . . . -68.75 -48.04 64.75 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.403 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.77 -30.97 72.0 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.321 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -56.03 -34.56 65.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.818 HG11 HG13 ' A' ' 6' ' ' VAL . 20.3 t -89.63 -29.35 5.07 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.271 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.88 -10.51 4.85 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.851 -0.69 . . . . 0.0 113.357 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.72 ' CD2' HD13 ' A' ' 78' ' ' ILE . 46.9 mt -54.0 116.15 2.41 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 117.016 0.408 . . . . 0.0 110.857 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.92 -153.32 0.56 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.747 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 104.02 15.97 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.424 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.94 -25.74 2.38 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.792 -0.718 . . . . 0.0 113.383 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.99 117.78 6.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.995 0.398 . . . . 0.0 111.101 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.04 132.27 35.14 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.799 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.674 HD11 HD12 ' A' ' 27' ' ' LEU . 17.1 mt -91.36 133.35 33.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.556 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.533 HD11 ' CB ' ' A' ' 79' ' ' ALA . 3.1 mp -117.51 -47.14 2.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.881 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.536 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -116.08 136.89 52.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.657 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.524 HG21 HG13 ' A' ' 63' ' ' VAL . 21.8 t -132.95 109.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.402 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 7.9 t30 76.83 33.62 0.46 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.642 -178.33 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 77.51 -2.66 2.53 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.651 -179.868 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.662 HD11 ' CD1' ' A' ' 66' ' ' LEU . 13.6 pt -111.84 121.48 64.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 120.871 0.367 . . . . 0.0 111.161 179.587 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.536 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -63.59 124.01 20.29 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.063 -179.683 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.689 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.6 m -134.55 53.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.299 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 9.0 mtmt -63.45 -37.12 86.08 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.568 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -127.16 27.55 5.89 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.574 -0.284 . . . . 0.0 111.34 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.689 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -81.31 -174.02 4.68 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.694 0.283 . . . . 0.0 111.281 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.661 ' O ' HG23 ' A' ' 63' ' ' VAL . 52.0 m -84.25 139.81 32.1 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.495 0.664 . . . . 0.0 110.825 179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.719 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.1 t60 -60.8 -44.62 96.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.697 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -63.04 -42.05 99.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.437 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.79 -45.11 94.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.556 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 59' ' ' SER . 58.5 t -63.83 -41.96 94.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.8 t -65.76 -39.04 83.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 178.753 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.67 -39.96 78.28 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.897 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.662 ' CD1' HD11 ' A' ' 53' ' ' ILE . 13.8 mt -66.41 -43.15 86.57 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.705 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.431 HG12 HD22 ' A' ' 74' ' ' LEU . 25.0 mt -65.25 -37.2 79.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.759 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -83.63 12.55 51.69 Favored Glycine 0 CA--C 1.525 0.673 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.549 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -112.44 -14.73 13.22 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 122.43 0.292 . . . . 0.0 111.459 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.471 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 27.2 p -45.99 -49.18 16.3 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 122.651 0.38 . . . . 0.0 111.96 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.16 33.87 9.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.974 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 151.74 -36.73 0.84 Allowed Glycine 0 C--N 1.334 0.44 0 C-N-CA 120.805 -0.712 . . . . 0.0 113.132 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.4 p -173.59 137.25 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.906 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.444 HD21 HG13 ' A' ' 50' ' ' VAL . 11.3 tp -112.63 142.34 45.33 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.947 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.3 m170 -107.31 98.05 7.73 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.124 179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.5 ptm -119.66 146.88 45.17 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.481 -179.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.466 ' CG1' HG22 ' A' ' 3' ' ' VAL . 24.6 t -102.12 112.9 36.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.963 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.72 HD13 ' CD2' ' A' ' 41' ' ' LEU . 19.5 pt -101.05 170.27 1.59 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.304 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.533 ' CB ' HD11 ' A' ' 48' ' ' LEU . . . -140.09 118.46 12.12 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.178 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.233 0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.784 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.8 t . . . . . 0 C--O 1.234 0.267 0 CA-C-O 120.616 0.246 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -121.99 140.81 52.02 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.132 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 m -97.64 127.68 43.78 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.849 HG13 HG11 ' A' ' 39' ' ' VAL . 38.9 t -120.08 141.8 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.137 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.9 122.6 36.5 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.158 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.534 ' O ' HG23 ' A' ' 73' ' ' VAL . 9.3 t -105.53 149.48 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.131 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -107.42 101.95 11.26 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.143 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -57.5 120.15 7.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.32 -110.11 0.34 Allowed Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.306 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 11.2 mtt85 -106.48 -70.94 0.77 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.65 0.262 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.52 44.52 1.24 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.172 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.55 -153.64 25.26 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.881 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.641 ' OH ' HG22 ' A' ' 67' ' ' ILE . 16.7 m-85 -131.69 -54.41 1.0 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.772 0.32 . . . . 0.0 111.184 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.27 -22.05 1.73 Allowed Glycine 0 CA--C 1.524 0.603 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.908 -179.38 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.84 163.01 12.79 Favored 'General case' 0 CA--C 1.53 0.203 0 CA-C-O 120.89 0.376 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.26 122.17 46.75 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD21 HD12 ' A' ' 47' ' ' ILE . 0.4 OUTLIER -105.18 125.26 50.78 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.229 -179.844 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.78 110.86 3.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.222 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -165.41 79.21 0.12 Allowed Glycine 0 N--CA 1.445 -0.74 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.893 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.89 -45.32 7.5 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.928 0.394 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.963 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -114.74 -66.42 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.402 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.963 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 95.0 Cg_endo -87.42 94.35 0.46 Allowed 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 122.606 2.204 . . . . 0.0 112.266 179.285 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 83.0 m -52.97 115.65 1.96 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.411 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -146.02 145.54 20.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.803 0.335 . . . . 0.0 111.796 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -73.75 90.1 1.84 Allowed 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.365 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -47.29 -51.61 18.61 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.868 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.6 t -154.45 159.36 41.01 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.475 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.5 t -125.21 154.47 33.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.597 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.2 mtp -107.6 104.72 14.32 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.211 0.529 . . . . 0.0 110.264 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -53.09 126.37 20.48 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.884 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.26 24.68 12.14 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.446 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.67 170.81 10.37 Favored Pre-proline 0 CA--C 1.532 0.252 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -47.27 -30.7 11.39 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 123.001 2.468 . . . . 0.0 113.619 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -71.3 -48.4 50.92 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 120.815 0.341 . . . . 0.0 111.029 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -69.59 -30.28 68.01 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.525 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.8 m-30 -60.13 -23.69 64.08 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 111.62 0.23 . . . . 0.0 111.62 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.849 HG11 HG13 ' A' ' 6' ' ' VAL . 22.9 t -89.19 -31.31 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.689 0.28 . . . . 0.0 110.897 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.8 36.3 3.26 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.522 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 6.4 mt -69.42 -177.99 1.29 Allowed 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.834 0.35 . . . . 0.0 110.738 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.84 131.94 7.19 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.266 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.43 98.92 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.378 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 148.51 -25.46 1.36 Allowed Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.703 -178.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.558 ' CG ' HD13 ' A' ' 78' ' ' ILE . 12.7 m-20 -56.11 118.46 4.7 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.833 0.316 . . . . 0.0 110.718 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -77.12 123.01 25.79 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.821 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.792 ' HA ' HG22 ' A' ' 78' ' ' ILE . 31.0 mt -77.91 121.64 31.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.685 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.977 HD11 ' HB2' ' A' ' 79' ' ' ALA . 2.4 mt -100.4 -46.83 5.11 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.408 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -133.4 138.79 46.43 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.224 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.6 t -128.91 110.48 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.458 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.8 t30 76.88 31.04 0.55 Allowed 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -178.345 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.62 -2.35 1.62 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.836 179.864 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.754 HD11 HD13 ' A' ' 66' ' ' LEU . 1.2 pp -110.49 128.18 66.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.057 0.456 . . . . 0.0 111.381 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.4 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -65.27 142.96 58.1 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.609 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.2 m -145.23 62.47 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.453 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -71.16 -37.94 72.19 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.485 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -139.13 32.9 2.13 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.803 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.89 -179.97 5.79 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.558 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.604 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.5 OUTLIER -93.16 135.61 34.19 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.421 0.629 . . . . 0.0 110.728 179.868 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 7.7 t60 -53.91 -43.88 70.09 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.974 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.471 ' HA ' HG22 ' A' ' 64' ' ' VAL . 1.5 mt-10 -62.05 -36.82 82.79 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.945 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.6 -40.66 69.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 59' ' ' SER . 46.3 t -65.59 -43.19 94.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.153 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.532 ' HA ' HD12 ' A' ' 67' ' ' ILE . 30.7 m -65.46 -38.41 82.41 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -57.98 -41.25 82.55 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.053 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.754 HD13 HD11 ' A' ' 53' ' ' ILE . 4.4 mt -68.17 -40.55 82.27 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.694 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.641 HG22 ' OH ' ' A' ' 15' ' ' TYR . 11.2 mt -69.21 -42.22 81.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.592 179.575 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.44 -4.26 84.11 Favored Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.923 -0.656 . . . . 0.0 113.41 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 7.1 tttt -79.34 -36.49 39.36 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 117.006 0.403 . . . . 0.0 111.647 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.32 -60.85 2.39 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.703 0.287 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 71.69 33.2 1.83 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.62 -49.92 0.01 OUTLIER Glycine 0 C--N 1.332 0.357 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.196 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.6 p -175.27 132.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 121.061 0.458 . . . . 0.0 111.691 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.464 HD22 HG12 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.83 154.66 28.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.756 179.776 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -109.68 98.45 7.79 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.055 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.49 ' HG2' HG23 ' A' ' 47' ' ' ILE . 13.8 ttm -97.54 128.28 44.16 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.35 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.31 95.64 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.388 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.792 HG22 ' HA ' ' A' ' 47' ' ' ILE . 2.5 pp -100.35 170.82 1.45 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.486 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.977 ' HB2' HD11 ' A' ' 48' ' ' LEU . . . -123.79 143.47 50.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.251 179.55 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 . . . . . 0 C--O 1.233 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.032 179.888 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 N--CA 1.471 0.616 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.497 HH21 HG22 ' A' ' 6' ' ' VAL . 4.8 ptm180 -115.39 166.87 11.4 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.26 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -109.22 141.8 40.95 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.951 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.642 HG23 HD11 ' A' ' 78' ' ' ILE . 41.9 t -129.48 131.3 67.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.188 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -115.69 105.77 13.12 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.711 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.695 HG11 ' HB3' ' A' ' 15' ' ' TYR . 3.4 t -86.49 154.11 3.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.894 0.378 . . . . 0.0 111.035 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -112.92 104.99 12.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.935 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -48.36 110.59 0.35 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.714 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.95 -110.7 0.08 OUTLIER Glycine 0 C--N 1.333 0.378 0 C-N-CA 121.101 -0.571 . . . . 0.0 112.675 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.85 -39.89 2.91 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.83 36.68 4.35 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.815 0.34 . . . . 0.0 111.468 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.99 -129.21 5.53 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.534 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.695 ' HB3' HG11 ' A' ' 8' ' ' VAL . 98.8 m-85 -131.88 -70.96 0.56 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.663 0.268 . . . . 0.0 111.087 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 152.58 40.62 0.03 OUTLIER Glycine 0 CA--C 1.518 0.252 0 C-N-CA 121.053 -0.594 . . . . 0.0 113.179 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -158.58 -177.76 6.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.561 0.22 . . . . 0.0 110.691 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -134.7 158.02 45.19 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-O 120.775 0.322 . . . . 0.0 111.182 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -138.96 132.07 29.68 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.0 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 p -145.93 165.09 29.98 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 111.344 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 22' ' ' GLN . . . 122.47 -22.98 7.27 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 121.186 -0.53 . . . . 0.0 113.142 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.651 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 70.04 2.52 3.96 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -179.758 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.652 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -168.6 -61.75 0.01 OUTLIER Pre-proline 0 C--O 1.233 0.199 0 C-N-CA 122.162 0.185 . . . . 0.0 110.635 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.652 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 58.4 Cg_endo -69.86 81.4 0.84 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.306 2.004 . . . . 0.0 110.955 178.817 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.617 ' SG ' HG11 ' A' ' 63' ' ' VAL . 62.0 m -50.39 109.29 0.29 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.071 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.4 141.55 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.717 HD21 HD13 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -75.16 90.68 2.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.389 179.575 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 p -58.99 -38.16 78.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.189 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.1 t -168.17 154.91 7.66 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-O 120.823 0.344 . . . . 0.0 111.438 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.638 HG22 HD23 ' A' ' 27' ' ' LEU . 3.4 t -122.05 154.03 26.49 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.531 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.1 mtm -101.02 100.66 11.29 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.986 0.422 . . . . 0.0 110.52 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.0 mtt180 -51.42 125.75 15.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.749 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.52 26.61 10.67 Favored Glycine 0 CA--C 1.52 0.358 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.339 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.409 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 58.0 m -131.0 162.82 53.26 Favored Pre-proline 0 CA--C 1.529 0.163 0 N-CA-C 110.434 -0.21 . . . . 0.0 110.434 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.512 ' O ' HG23 ' A' ' 39' ' ' VAL . 83.2 Cg_exo -46.75 -31.85 11.25 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.17 2.58 . . . . 0.0 113.296 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.694 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -67.01 -50.0 63.54 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-O 120.814 0.34 . . . . 0.0 110.968 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -70.66 -30.75 67.45 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.13 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 22.6 m-30 -59.58 -23.61 63.07 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.704 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.575 ' CG1' HG13 ' A' ' 6' ' ' VAL . 20.1 t -89.31 -32.3 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 120.652 0.263 . . . . 0.0 111.207 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.84 58.63 0.34 Allowed Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.76 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.717 HD13 HD21 ' A' ' 27' ' ' LEU . 17.7 mt -97.25 176.4 5.92 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.791 0.329 . . . . 0.0 110.571 179.631 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.45 133.39 0.81 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.909 0.385 . . . . 0.0 111.082 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.03 125.72 24.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.909 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.13 -30.59 4.29 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.389 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -62.53 121.27 12.88 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.825 0.345 . . . . 0.0 110.734 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.4 tp60 -77.9 118.09 19.88 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.928 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.552 HD11 HD12 ' A' ' 27' ' ' LEU . 19.9 mt -79.45 122.85 35.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.817 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mp -106.8 -41.45 5.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.605 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.497 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -113.82 152.22 30.97 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.864 0.364 . . . . 0.0 111.302 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.81 HG21 HG13 ' A' ' 63' ' ' VAL . 2.7 m -149.42 102.63 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.363 179.463 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 75.65 39.62 0.33 Allowed 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 74.79 -1.23 3.14 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.733 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.653 HD11 HD13 ' A' ' 66' ' ' LEU . 23.8 pt -117.27 132.1 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 111.775 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.497 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 5.0 p-10 -66.92 154.67 40.44 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 121.273 0.559 . . . . 0.0 112.123 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.47 HG11 HG22 ' A' ' 63' ' ' VAL . 9.1 m -149.58 62.9 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.295 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -55.73 -77.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.661 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -115.72 37.33 3.65 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 120.769 0.318 . . . . 0.0 110.969 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' ALA . . . -75.28 -172.6 1.78 Allowed 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.45 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -89.29 135.43 33.58 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 121.385 0.612 . . . . 0.0 110.715 179.759 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.759 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.9 t60 -57.35 -44.56 84.43 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.654 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -63.27 -40.19 96.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.649 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.51 -45.34 87.68 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.451 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.81 HG13 HG21 ' A' ' 50' ' ' VAL . 48.7 t -63.49 -42.71 97.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.185 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 60' ' ' HIS . 50.7 t -65.64 -39.45 85.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.23 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -40.05 83.51 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.046 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.653 HD13 HD11 ' A' ' 53' ' ' ILE . 6.4 mt -66.92 -40.16 87.56 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.918 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.682 HD12 ' HA ' ' A' ' 64' ' ' VAL . 7.3 mt -69.12 -41.92 81.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.482 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -73.77 -25.74 71.16 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.633 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 tppt? -53.98 -35.02 61.39 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 t -69.86 -54.15 14.79 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.75 0.309 . . . . 0.0 110.84 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.1 m 63.62 35.7 11.43 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.963 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.99 -43.87 0.02 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.381 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 8' ' ' VAL . 6.5 p -162.01 134.47 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-O 120.959 0.409 . . . . 0.0 111.535 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.596 HD23 ' CE1' ' A' ' 15' ' ' TYR . 3.8 pp -114.41 154.42 28.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -131.61 116.06 16.9 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.68 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.446 ' CE ' HD13 ' A' ' 74' ' ' LEU . 4.0 mtt -131.92 139.44 48.73 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.88 0.371 . . . . 0.0 111.437 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 29.3 t -103.9 112.85 39.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.977 178.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.642 HD11 HG23 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.53 155.32 8.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.68 -179.193 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -116.85 139.01 51.1 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.285 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 CA--C 1.53 0.199 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.661 179.801 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.7 p . . . . . 0 CA--C 1.532 0.274 0 CA-C-O 120.845 0.355 . . . . 0.0 111.065 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttt180 -115.81 142.74 46.35 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.01 -179.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 m -113.55 129.21 56.6 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.069 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.874 HG11 HD13 ' A' ' 41' ' ' LEU . 20.7 t -116.95 131.66 68.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.817 179.736 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -100.78 100.95 11.69 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.946 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.505 ' O ' HG23 ' A' ' 73' ' ' VAL . 13.5 t -86.09 108.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.056 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -94.82 91.82 6.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.8 ttt85 -36.55 119.12 0.6 Allowed 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.407 0.442 . . . . 0.0 111.118 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.01 -118.27 0.16 Allowed Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.746 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -113.7 -38.5 4.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.501 0.191 . . . . 0.0 111.338 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.34 28.11 8.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 124.07 -160.57 18.63 Favored Glycine 0 C--N 1.338 0.677 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.827 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 60.5 m-85 -89.82 -54.24 4.14 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.581 0.229 . . . . 0.0 111.039 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.91 65.05 0.59 Allowed Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.382 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.787 ' HB2' HD21 ' A' ' 27' ' ' LEU . 20.5 p90 -168.03 172.62 8.68 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.643 0.259 . . . . 0.0 111.41 179.645 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -122.5 159.73 27.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.28 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -149.26 130.07 14.21 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.038 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.93 158.71 38.4 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.782 0.325 . . . . 0.0 111.534 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 131.13 -27.15 3.86 Favored Glycine 0 CA--C 1.526 0.727 0 C-N-CA 121.204 -0.522 . . . . 0.0 113.114 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.529 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 62.01 13.83 5.97 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -179.825 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.832 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -170.74 -65.62 0.0 OUTLIER Pre-proline 0 N--CA 1.464 0.228 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.832 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.7 Cg_endo -75.84 83.6 1.92 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.359 2.039 . . . . 0.0 111.428 178.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 92.6 m -51.06 111.51 0.57 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.513 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.01 142.26 24.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.411 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.787 HD21 ' HB2' ' A' ' 17' ' ' PHE . 0.1 OUTLIER -83.69 92.53 7.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.483 179.682 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 t -58.28 -38.62 77.33 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.281 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.487 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.9 t -166.09 158.93 14.9 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.893 0.378 . . . . 0.0 111.135 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.599 HG22 HD22 ' A' ' 27' ' ' LEU . 17.2 t -115.15 154.46 16.52 Favored 'Isoleucine or valine' 0 C--O 1.232 0.182 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.638 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.7 mmm -89.72 99.29 12.32 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-O 121.342 0.592 . . . . 0.0 110.327 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.28 126.24 20.43 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.966 -1.015 . . . . 0.0 111.175 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.99 27.54 12.27 Favored Glycine 0 CA--C 1.52 0.402 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.606 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.26 168.81 15.7 Favored Pre-proline 0 C--O 1.234 0.256 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.518 ' O ' HG23 ' A' ' 39' ' ' VAL . 84.1 Cg_exo -48.58 -34.16 25.83 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 123.036 2.491 . . . . 0.0 113.018 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.595 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -60.16 -48.34 82.12 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.136 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -65.54 -33.2 75.36 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.501 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 14.6 m-30 -64.31 -24.8 67.78 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.411 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 35' ' ' PRO . 21.9 t -89.27 -27.94 5.23 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.782 0.325 . . . . 0.0 110.844 179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.39 32.19 2.61 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.541 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.874 HD13 HG11 ' A' ' 6' ' ' VAL . 6.0 tp -65.17 129.4 39.58 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 120.692 0.282 . . . . 0.0 110.446 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 71.3 mtt-85 -129.5 115.87 18.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.361 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.487 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -57.38 156.83 7.26 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.668 -179.405 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.15 -13.15 63.52 Favored Glycine 0 CA--C 1.522 0.479 0 CA-C-N 115.124 -0.944 . . . . 0.0 112.211 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.83 138.34 35.12 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 110.642 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -83.47 126.42 32.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.457 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.499 HG23 ' HG2' ' A' ' 76' ' ' MET . 12.9 mt -85.4 131.87 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.521 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.525 HD11 ' CB ' ' A' ' 79' ' ' ALA . 5.0 mp -107.71 -39.7 5.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.356 -179.815 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.487 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -131.27 141.26 49.95 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.1 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.424 HG11 HD11 ' A' ' 67' ' ' ILE . 13.5 t -133.54 110.5 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.874 179.231 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.413 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.6 t30 77.07 32.34 0.48 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.82 -1.2 2.39 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.535 179.981 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.784 HD11 HD13 ' A' ' 66' ' ' LEU . 13.0 pt -115.29 126.02 72.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.98 0.419 . . . . 0.0 111.794 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -66.87 136.87 56.06 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.511 -179.626 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.455 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.4 m -147.86 63.88 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.681 -179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -69.93 -31.69 69.58 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.136 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.0 mtpt -137.63 35.87 2.44 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.455 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -86.64 174.24 9.0 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 120.876 0.369 . . . . 0.0 111.534 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.661 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -81.27 134.75 35.64 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.399 0.619 . . . . 0.0 110.288 179.509 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.73 ' O ' HG23 ' A' ' 64' ' ' VAL . 3.7 t60 -54.73 -44.46 73.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.857 -1.065 . . . . 0.0 112.14 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -61.7 -43.36 99.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.951 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.83 -41.32 91.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.507 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 59' ' ' SER . 55.9 t -65.15 -42.51 94.46 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.001 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 60' ' ' HIS . 60.7 t -65.88 -39.29 84.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.708 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.68 -39.88 78.12 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.073 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.784 HD13 HD11 ' A' ' 53' ' ' ILE . 5.7 mt -67.71 -42.01 82.64 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.76 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.592 HG23 HD13 ' A' ' 74' ' ' LEU . 42.2 mt -66.06 -39.93 85.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.723 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.6 6.22 78.37 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.093 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.31 -32.69 16.41 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.857 0.328 . . . . 0.0 111.439 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.96 -61.21 2.3 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.784 0.326 . . . . 0.0 110.799 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.92 35.11 2.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.83 -47.14 0.01 OUTLIER Glycine 0 C--N 1.33 0.201 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.291 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -165.33 137.79 0.91 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.984 0.421 . . . . 0.0 111.331 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.592 HD13 HG23 ' A' ' 67' ' ' ILE . 11.1 tp -114.03 142.09 46.62 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.375 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.58 95.74 5.51 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.252 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.499 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.8 ttm -98.03 122.33 41.04 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.118 -179.356 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 21.0 t -102.23 96.64 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.464 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.492 HG22 ' HA ' ' A' ' 47' ' ' ILE . 2.7 pt -100.27 170.3 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.552 -179.55 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.525 ' CB ' HD11 ' A' ' 48' ' ' LEU . . . -130.83 137.2 49.29 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.234 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 . . . . . 0 C--O 1.234 0.267 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.147 179.902 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.507 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.7 p . . . . . 0 N--CA 1.473 0.686 0 N-CA-C 112.843 0.683 . . . . 0.0 112.843 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 63.3 ttt180 -126.59 134.24 50.85 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.002 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.3 m -96.2 130.65 43.21 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.503 HG13 HG11 ' A' ' 39' ' ' VAL . 25.0 t -123.13 140.16 47.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.372 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.514 ' O ' HG21 ' A' ' 39' ' ' VAL . 4.2 mt-10 -116.94 126.95 53.71 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.144 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 73' ' ' VAL . 20.9 t -125.59 137.75 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.639 179.581 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.18 97.54 8.33 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.995 0.426 . . . . 0.0 110.603 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.471 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 2.9 ttt-85 -47.14 121.54 3.83 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.353 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.4 -130.19 1.1 Allowed Glycine 0 C--N 1.334 0.448 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.512 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.1 mtt180 -111.93 -39.57 4.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.413 0.149 . . . . 0.0 111.258 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.38 26.85 9.71 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.68 0.252 . . . . 0.0 111.68 179.355 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.67 -179.89 16.03 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.924 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.471 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 91.3 m-85 -83.97 -34.01 24.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.585 0.231 . . . . 0.0 111.18 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.84 47.96 0.93 Allowed Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.284 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.416 ' HA ' ' HA ' ' A' ' 30' ' ' VAL . 20.6 p90 -168.67 153.87 6.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 111.063 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.5 m -98.88 128.2 45.0 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.92 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -106.18 126.92 52.81 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.181 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.0 m -147.84 130.45 15.91 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.517 178.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.67 73.36 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.276 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.1 tp60 -44.96 -43.48 9.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.799 0.333 . . . . 0.0 110.576 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.966 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -110.98 -64.56 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.021 178.317 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.966 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.0 Cg_endo -91.74 92.7 0.21 Allowed 'Trans proline' 0 C--N 1.358 1.042 0 C-N-CA 122.943 2.428 . . . . 0.0 111.912 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 7.7 p -53.36 118.75 4.07 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.936 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 45' ' ' ASP . 7.1 p -146.68 145.3 19.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.256 -179.285 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.568 HD12 HD11 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -74.96 90.39 2.43 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.845 0.355 . . . . 0.0 110.496 179.603 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -53.98 -35.74 62.14 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.625 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.1 t -165.26 161.75 19.41 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.723 0.297 . . . . 0.0 110.988 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.45 HG22 HD23 ' A' ' 27' ' ' LEU . 38.0 t -131.19 152.5 37.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.877 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.4 mmt -90.24 99.66 12.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-O 121.338 0.59 . . . . 0.0 110.342 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.97 121.81 8.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.935 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.08 26.01 8.08 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.561 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -128.95 171.75 8.21 Favored Pre-proline 0 CA--C 1.532 0.269 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.441 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 77.7 Cg_exo -48.91 -30.51 17.73 Favored 'Trans proline' 0 C--N 1.352 0.737 0 C-N-CA 122.847 2.365 . . . . 0.0 113.128 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.05 -50.23 50.41 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.142 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.97 -31.86 73.3 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.42 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.441 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 17.7 m-30 -60.12 -30.71 69.45 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.198 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.514 HG21 ' O ' ' A' ' 7' ' ' GLU . 22.3 t -89.72 -24.37 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.107 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.22 17.56 6.65 Favored Glycine 0 CA--C 1.523 0.57 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.153 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.56 HD21 HD13 ' A' ' 78' ' ' ILE . 3.4 mt -78.87 123.21 27.01 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 117.019 0.409 . . . . 0.0 110.303 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.1 mtp85 -130.48 -149.9 0.41 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -107.76 127.53 53.77 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.594 -0.275 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.7 -22.44 5.8 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 120.78 -0.724 . . . . 0.0 113.017 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.403 ' HB3' HD12 ' A' ' 78' ' ' ILE . 6.5 m-20 -73.29 121.66 20.74 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 116.924 0.362 . . . . 0.0 110.948 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -82.45 128.04 33.87 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.696 ' HA ' HG22 ' A' ' 78' ' ' ILE . 6.0 mt -85.32 125.29 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.445 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.7 mm? -103.05 -39.41 6.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.939 -179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.535 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.91 145.81 50.83 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.239 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.669 HG21 HG13 ' A' ' 63' ' ' VAL . 42.8 t -132.97 111.72 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.926 179.257 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.415 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 76.5 32.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.655 -178.458 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.53 -2.03 1.64 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.11 -0.95 . . . . 0.0 112.732 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.678 HD11 HD13 ' A' ' 66' ' ' LEU . 20.4 pt -113.73 125.58 71.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-O 120.838 0.352 . . . . 0.0 111.421 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.535 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.7 OUTLIER -60.3 125.51 23.96 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.95 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.497 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 3.7 m -146.95 40.65 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.415 ' HB3' ' HA ' ' A' ' 48' ' ' LEU . 0.0 OUTLIER -61.58 -29.93 70.35 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.794 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.0 mttp -119.85 29.56 7.49 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.322 179.645 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.497 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -88.27 -174.13 4.5 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 111.573 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.615 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -91.34 140.68 29.54 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.406 0.622 . . . . 0.0 110.742 179.675 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.766 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.5 t-80 -52.86 -44.56 66.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.721 -1.127 . . . . 0.0 111.764 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.61 -39.52 91.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.665 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.01 -42.46 94.42 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.584 179.252 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.669 HG13 HG21 ' A' ' 50' ' ' VAL . 44.4 t -64.82 -42.45 94.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.122 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.766 HG23 ' O ' ' A' ' 60' ' ' HIS . 41.7 t -65.85 -39.19 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.688 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.2 ttmt -57.68 -40.73 80.09 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.093 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.678 HD13 HD11 ' A' ' 53' ' ' ILE . 17.7 mt -66.88 -42.82 84.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.763 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.702 HG23 ' HG ' ' A' ' 74' ' ' LEU . 25.2 mt -66.79 -40.6 86.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.97 179.745 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -70.21 -17.1 73.72 Favored Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.015 -0.612 . . . . 0.0 113.131 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -66.79 -42.09 86.55 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -67.62 -57.88 5.65 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.793 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.7 p 62.49 28.02 16.56 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.463 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -152.59 -40.48 0.03 OUTLIER Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.67 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 8' ' ' VAL . 6.5 p -150.53 138.58 14.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.089 0.471 . . . . 0.0 111.333 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.702 ' HG ' HG23 ' A' ' 67' ' ' ILE . 0.5 OUTLIER -102.81 138.02 40.25 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.952 -179.866 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -130.66 95.06 3.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 3.0 mtt -117.32 140.92 48.95 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.529 -179.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.505 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 22.0 t -104.86 95.19 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.237 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.696 HG22 ' HA ' ' A' ' 47' ' ' ILE . 16.6 pt -99.17 159.97 3.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.22 -179.659 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.82 147.83 45.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.492 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.233 0.207 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.861 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.464 0.226 0 CA-C-O 120.925 0.393 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -139.12 166.61 24.06 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.321 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -105.07 132.92 50.7 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.26 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.576 HG23 HG12 ' A' ' 78' ' ' ILE . 29.0 t -106.58 131.19 57.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.819 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 74' ' ' LEU . 1.6 mt-10 -118.83 116.57 26.8 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.543 HG11 ' HB3' ' A' ' 15' ' ' TYR . 3.7 t -110.01 133.97 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 111.421 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.67 94.05 9.77 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.93 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.455 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -48.47 121.03 4.08 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.176 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.45 -85.62 0.12 Allowed Glycine 0 C--N 1.335 0.501 0 C-N-CA 121.042 -0.599 . . . . 0.0 112.383 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 -145.98 -53.77 0.26 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.633 0.254 . . . . 0.0 111.013 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.18 28.91 8.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.535 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.37 164.79 11.16 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.709 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.543 ' HB3' HG11 ' A' ' 8' ' ' VAL . 73.3 m-85 -88.93 -66.77 0.89 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.84 0.352 . . . . 0.0 110.64 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.22 55.82 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.73 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -166.54 149.12 6.73 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.753 0.311 . . . . 0.0 110.93 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 109.43 22.12 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.03 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 6.2 tt -108.44 140.41 41.79 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.826 -179.753 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.7 m -150.35 161.44 42.48 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.457 179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.78 81.35 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.313 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.5 mm100 -47.41 -40.48 17.91 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.606 0.241 . . . . 0.0 110.775 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.949 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -113.73 -63.41 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.279 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.332 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.949 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 90.9 Cg_endo -89.92 94.04 0.3 Allowed 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.812 2.341 . . . . 0.0 111.739 179.128 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.593 ' SG ' HG23 ' A' ' 55' ' ' VAL . 6.0 p -52.29 117.16 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.72 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.1 p -134.83 144.31 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.643 -179.295 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.58 92.74 9.22 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.084 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -57.16 -52.67 64.39 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.02 -179.308 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.546 ' HA ' ' HB1' ' A' ' 43' ' ' ALA . 0.6 OUTLIER -148.14 162.3 39.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.444 -179.594 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 10.9 t -121.19 153.73 24.82 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.129 179.304 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -94.56 99.96 12.02 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.24 0.543 . . . . 0.0 110.771 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 7.2 mtt180 -55.06 126.48 24.83 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.014 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 99.66 -16.29 58.88 Favored Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.888 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.614 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.4 m -89.64 166.38 21.22 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.841 0.32 . . . . 0.0 110.343 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.614 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 9.2 Cg_endo -51.25 -26.76 21.08 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.928 2.419 . . . . 0.0 113.441 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.19 76.76 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.849 0.357 . . . . 0.0 110.77 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.83 -26.57 63.35 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.207 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -59.43 -23.66 62.86 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.42 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.542 HG11 HG13 ' A' ' 6' ' ' VAL . 21.4 t -89.27 -30.15 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 116.662 -0.244 . . . . 0.0 111.06 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 104.71 45.4 1.41 Allowed Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.496 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.452 ' HG ' HG11 ' A' ' 6' ' ' VAL . 6.4 mt -72.48 -178.95 2.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-O 120.726 0.298 . . . . 0.0 110.569 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 44.9 mtp85 -142.01 112.74 7.28 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.291 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.546 ' HB1' ' HA ' ' A' ' 29' ' ' CYS . . . -64.85 103.56 0.73 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.527 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.63 -10.55 5.77 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.266 -179.414 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -81.02 165.49 21.65 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.02 156.33 17.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.534 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 4.2 mt -109.11 146.25 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.589 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 mp -118.92 -57.49 2.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.893 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.08 139.28 44.19 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.008 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.42 HG23 ' CG2' ' A' ' 55' ' ' VAL . 2.9 t -138.97 110.35 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.406 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.9 t-20 75.97 35.86 0.47 Allowed 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.406 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.08 -0.39 3.33 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.808 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.618 HD11 HD22 ' A' ' 66' ' ' LEU . 8.5 pt -119.68 133.66 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-O 120.92 0.39 . . . . 0.0 111.388 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -69.74 150.84 46.5 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.67 -179.515 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.607 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 2.4 m -150.11 56.85 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.2 mmtp -60.19 -40.42 89.98 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.455 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.0 mtmp? -130.01 31.96 4.6 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.658 0.266 . . . . 0.0 111.421 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.607 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -79.6 176.51 9.64 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 120.716 0.293 . . . . 0.0 111.144 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 2.9 m -95.8 147.19 23.9 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.581 0.705 . . . . 0.0 111.355 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -56.11 -41.85 75.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.325 -1.307 . . . . 0.0 111.445 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.474 ' HA ' HG12 ' A' ' 64' ' ' VAL . 11.4 pt-20 -64.21 -41.09 97.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.904 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -69.79 -42.07 74.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 110.366 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.619 HG23 ' O ' ' A' ' 59' ' ' SER . 55.5 t -67.71 -42.35 86.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.027 179.573 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.474 HG12 ' HA ' ' A' ' 61' ' ' GLU . 7.3 p -66.61 -39.1 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -57.94 -40.13 79.75 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.158 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.618 HD22 HD11 ' A' ' 53' ' ' ILE . 15.0 mt -66.28 -42.85 87.85 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.741 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.627 HG23 HD13 ' A' ' 74' ' ' LEU . 33.5 mt -66.62 -40.71 86.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.623 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -85.39 8.27 72.17 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.184 179.368 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.7 -32.63 15.36 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 116.828 0.314 . . . . 0.0 111.293 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.67 -55.04 19.61 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.963 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 m 64.5 36.17 8.89 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.859 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.87 -44.05 0.02 OUTLIER Glycine 0 C--N 1.332 0.338 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.414 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -163.39 139.13 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.129 0 CA-C-O 120.959 0.409 . . . . 0.0 111.384 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.627 HD13 HG23 ' A' ' 67' ' ' ILE . 62.8 tp -103.15 136.26 43.27 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.049 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -127.13 101.37 6.49 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.411 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.595 ' SD ' HD21 ' A' ' 74' ' ' LEU . 13.7 ptm -132.83 141.52 48.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.47 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.9 t -91.23 120.63 40.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.79 179.695 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.576 HG12 HG23 ' A' ' 6' ' ' VAL . 15.0 pt -99.33 170.17 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.35 148.88 30.04 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.284 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.233 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.322 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.463 0.22 0 CA-C-O 120.862 0.363 . . . . 0.0 111.296 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.8 ttt180 -123.04 126.87 47.93 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -97.8 120.84 38.9 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.754 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.771 HG11 ' HG ' ' A' ' 41' ' ' LEU . 20.9 t -114.2 131.58 65.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.512 ' O ' HG21 ' A' ' 39' ' ' VAL . 3.1 mt-10 -115.6 112.92 22.87 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.902 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 t -94.57 134.14 33.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 CA-C-O 120.877 0.37 . . . . 0.0 111.221 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -102.17 97.64 7.91 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.687 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.431 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -47.81 118.38 2.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.006 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.92 -107.54 0.08 OUTLIER Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.553 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.8 mtt180 -123.67 -46.75 1.99 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.633 0.254 . . . . 0.0 111.046 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.01 41.79 3.45 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.651 179.692 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 158.4 -179.64 33.93 Favored Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.14 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.431 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 8.7 m-85 -111.41 -40.74 4.3 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.595 0.236 . . . . 0.0 111.349 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.96 23.69 5.17 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.285 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -157.26 156.24 32.15 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.997 0.398 . . . . 0.0 110.933 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.0 m -111.01 135.61 51.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.861 0.362 . . . . 0.0 111.239 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.484 HD22 ' CE1' ' A' ' 60' ' ' HIS . 0.4 OUTLIER -119.18 129.09 54.81 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.043 179.898 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.6 m -151.7 176.05 11.77 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.125 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.55 -46.32 1.13 Allowed Glycine 0 C--N 1.335 0.497 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.38 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.437 ' O ' ' HB2' ' A' ' 23' ' ' ALA . 0.0 OUTLIER 55.13 39.43 31.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.877 0.471 . . . . 0.0 112.09 179.489 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.758 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . 174.53 -61.64 0.0 OUTLIER Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.636 179.476 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.758 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.1 Cg_endo -75.17 -27.43 9.75 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.598 2.199 . . . . 0.0 113.127 179.758 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.401 ' CB ' ' HB ' ' A' ' 47' ' ' ILE . 18.4 m 56.79 93.44 0.03 OUTLIER 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.509 0.671 . . . . 0.0 109.788 -179.002 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.834 HG13 ' HA ' ' A' ' 46' ' ' GLN . 0.8 OUTLIER -146.75 144.21 20.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.973 -178.95 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.32 122.33 16.87 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.487 179.703 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.4 m -82.42 -41.53 19.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.196 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.559 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 25.3 t -173.09 152.44 2.31 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.364 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.413 HG21 ' HB3' ' A' ' 41' ' ' LEU . 5.2 t -118.04 155.19 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.753 179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 27.4 mmm -98.41 100.95 12.26 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.204 0.526 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mtt-85 -50.85 124.58 11.44 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.069 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.02 24.51 11.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.553 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -123.76 165.98 20.98 Favored Pre-proline 0 C--O 1.232 0.148 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.432 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 10.4 Cg_endo -53.58 -26.99 39.3 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.781 2.32 . . . . 0.0 112.747 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.691 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -69.48 -49.18 57.18 Favored 'General case' 0 CA--C 1.528 0.121 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.002 179.667 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -67.05 -31.99 72.88 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.304 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.432 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 20.4 m-30 -59.47 -23.46 62.75 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.557 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.512 HG21 ' O ' ' A' ' 7' ' ' GLU . 21.9 t -89.38 -30.12 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.684 0.278 . . . . 0.0 111.253 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.79 68.13 0.54 Allowed Glycine 0 C--N 1.334 0.45 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.413 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.771 ' HG ' HG11 ' A' ' 6' ' ' VAL . 5.5 mt -102.31 162.35 12.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.795 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.9 mmt180 -148.55 119.66 7.73 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.559 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -57.08 111.8 1.16 Allowed 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.835 179.546 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.44 -12.88 7.02 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.874 -179.49 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.562 ' CB ' HD12 ' A' ' 78' ' ' ILE . 0.1 OUTLIER -66.94 112.1 4.14 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.825 0.312 . . . . 0.0 110.52 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLN . . . . . 0.834 ' HA ' HG13 ' A' ' 26' ' ' VAL . 1.1 tt0 -55.45 125.7 22.04 Favored 'General case' 0 CA--C 1.53 0.173 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.71 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.643 ' HA ' HG22 ' A' ' 78' ' ' ILE . 66.7 mt -82.25 123.96 38.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.574 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.0 mp -107.81 -41.2 5.06 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.54 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -136.46 144.4 44.38 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.73 0.3 . . . . 0.0 111.102 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.493 HG13 ' HG2' ' A' ' 76' ' ' MET . 8.3 t -140.97 116.2 6.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.434 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.96 30.75 0.55 Allowed 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.773 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.434 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 80.78 -1.92 1.84 Allowed 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.239 -0.892 . . . . 0.0 112.706 179.631 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.822 HD11 ' CD1' ' A' ' 66' ' ' LEU . 1.6 pt -117.4 134.56 60.59 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.936 0.398 . . . . 0.0 111.635 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.1 m120 -63.1 152.51 36.97 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.572 -179.584 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.58 HG11 HG22 ' A' ' 63' ' ' VAL . 2.8 m -152.02 47.75 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.435 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.9 mttt -56.21 -40.12 73.53 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.215 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -137.72 31.98 2.5 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.005 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.452 ' CB ' HG12 ' A' ' 55' ' ' VAL . . . -75.86 -177.7 3.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.878 0.371 . . . . 0.0 111.604 -179.723 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.654 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -92.93 135.78 33.85 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.361 0.6 . . . . 0.0 110.703 179.705 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.747 ' O ' HG23 ' A' ' 64' ' ' VAL . 5.5 t60 -55.9 -44.39 78.17 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.783 -1.098 . . . . 0.0 111.883 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -61.58 -39.41 91.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.439 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -67.52 -43.07 81.7 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.225 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 59' ' ' SER . 48.4 t -63.79 -40.96 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.932 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.747 HG23 ' O ' ' A' ' 60' ' ' HIS . 48.8 t -65.97 -38.83 82.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 178.674 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -57.76 -42.64 84.45 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.822 ' CD1' HD11 ' A' ' 53' ' ' ILE . 12.0 mt -63.63 -42.26 98.19 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.647 179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.63 HG23 HD22 ' A' ' 74' ' ' LEU . 35.8 mt -63.42 -44.18 98.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.635 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.3 -12.52 84.14 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.793 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 41.3 tptt -68.19 -37.41 80.91 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -70.7 -52.46 20.9 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.811 0.339 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m 63.8 35.73 10.96 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.742 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.22 -44.35 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.295 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -163.15 138.24 1.4 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-O 121.014 0.435 . . . . 0.0 111.335 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.63 HD22 HG23 ' A' ' 67' ' ' ILE . 24.2 tp -114.24 146.79 39.95 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.376 -179.799 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 33.3 m-70 -119.6 103.22 9.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.177 179.164 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.493 ' HG2' HG13 ' A' ' 50' ' ' VAL . 59.0 mtp -109.14 142.09 40.41 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.671 -179.272 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.3 t -115.06 97.05 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.926 178.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.643 HG22 ' HA ' ' A' ' 47' ' ' ILE . 10.3 pt -105.78 170.74 2.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.64 -179.084 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -136.94 145.73 44.59 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.941 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 . . . . . 0 C--O 1.234 0.284 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.774 179.846 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.476 0.846 0 CA-C-O 121.386 0.612 . . . . 0.0 112.636 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.26 146.66 47.08 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.727 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.1 m -102.21 154.73 18.75 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.213 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.699 HG11 ' HG ' ' A' ' 41' ' ' LEU . 20.3 t -140.29 136.2 36.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.355 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.428 ' O ' HG21 ' A' ' 39' ' ' VAL . 25.6 mt-10 -104.7 111.15 23.76 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.725 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.605 ' O ' HG23 ' A' ' 73' ' ' VAL . 6.7 t -104.43 119.94 54.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-O 120.865 0.364 . . . . 0.0 111.475 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -90.32 92.28 8.85 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.066 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -49.5 125.07 10.51 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.646 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.69 -112.44 0.07 OUTLIER Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.818 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -115.39 -39.33 3.6 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.435 0.16 . . . . 0.0 111.328 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.9 30.61 6.38 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.388 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.59 -173.09 16.6 Favored Glycine 0 C--N 1.337 0.616 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.808 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.524 ' HD1' HG12 ' A' ' 8' ' ' VAL . 79.2 m-85 -79.34 -61.91 1.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.941 0.401 . . . . 0.0 111.013 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.43 59.22 0.26 Allowed Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.452 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.507 ' CD1' HD21 ' A' ' 27' ' ' LEU . 19.7 p90 -153.13 151.01 29.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 0.0 110.955 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -98.3 111.42 23.76 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.442 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.465 HD23 ' N ' ' A' ' 20' ' ' SER . 0.8 OUTLIER -99.95 133.49 44.25 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.465 ' N ' HD23 ' A' ' 19' ' ' LEU . 1.5 p -149.58 -174.26 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.762 179.697 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 107.28 85.43 1.77 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.3 -60.09 2.08 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.942 0.401 . . . . 0.0 110.799 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.892 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.41 -60.61 0.19 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.221 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.892 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.2 Cg_endo -87.69 95.35 0.44 Allowed 'Trans proline' 0 C--N 1.356 0.938 0 C-N-CA 122.692 2.261 . . . . 0.0 112.209 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 71.6 m -55.27 118.64 4.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.477 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.4 p -143.53 152.94 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.854 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.551 HD11 ' CE ' ' A' ' 76' ' ' MET . 1.0 OUTLIER -89.41 92.95 9.34 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.473 179.377 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -51.46 -39.93 58.43 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.504 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.67 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.6 t -169.07 161.43 10.46 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.961 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.432 HG13 ' HB3' ' A' ' 17' ' ' PHE . 18.5 t -124.8 154.35 32.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.431 179.556 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -85.58 98.0 10.4 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.227 0.537 . . . . 0.0 110.399 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.85 122.61 6.76 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.853 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.31 21.23 11.86 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.703 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.42 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -115.31 166.68 11.43 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.712 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.443 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 9.7 Cg_endo -51.75 -29.55 34.25 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.962 2.441 . . . . 0.0 112.77 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.8 -46.19 46.89 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.992 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -64.01 -32.3 73.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.069 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.443 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.1 m-30 -60.04 -28.07 67.45 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.39 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.439 HG11 HG13 ' A' ' 6' ' ' VAL . 18.3 t -89.48 -26.21 5.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-O 120.469 0.176 . . . . 0.0 111.241 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.63 1.13 7.13 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.639 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.699 ' HG ' HG11 ' A' ' 6' ' ' VAL . 12.0 mt -67.93 116.96 9.18 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 117.378 0.589 . . . . 0.0 110.449 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.01 -150.36 0.43 Allowed 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.006 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.67 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -105.29 146.29 29.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.636 0.255 . . . . 0.0 111.299 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.82 -16.97 33.22 Favored Glycine 0 CA--C 1.523 0.56 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.152 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.434 ' CG ' HD12 ' A' ' 78' ' ' ILE . 1.3 m-20 -84.57 128.31 34.53 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 117.122 0.461 . . . . 0.0 110.822 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -82.38 134.01 35.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.486 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.42 ' CG2' HG22 ' A' ' 50' ' ' VAL . 22.7 mt -85.82 122.57 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.798 179.776 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -106.57 -47.55 3.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -124.08 136.25 54.11 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.993 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.42 HG22 ' CG2' ' A' ' 47' ' ' ILE . 3.0 t -135.51 105.71 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.096 179.553 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 75.92 37.8 0.37 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.394 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 72.32 -0.56 3.23 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.834 -179.628 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.665 ' CD1' HD22 ' A' ' 66' ' ' LEU . 8.0 pt -113.96 119.39 61.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 120.955 0.407 . . . . 0.0 111.01 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.493 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.0 m120 -68.53 130.32 42.53 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.081 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 63' ' ' VAL . 24.3 m -124.03 52.3 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.095 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.0 mttm -55.45 -45.65 76.83 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.543 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -136.48 32.42 2.8 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.095 179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.37 177.85 7.62 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 120.805 0.336 . . . . 0.0 111.275 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.676 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.7 OUTLIER -80.73 133.67 35.71 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 121.418 0.628 . . . . 0.0 110.665 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.704 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.4 t-160 -54.49 -44.78 72.95 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.772 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -65.13 -41.91 94.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.693 179.547 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -64.34 -42.47 96.25 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.712 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 59' ' ' SER . 54.9 t -63.5 -43.34 98.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.124 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.704 HG23 ' O ' ' A' ' 60' ' ' HIS . 47.1 t -66.03 -39.73 85.34 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.162 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.79 -40.46 84.11 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.01 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.665 HD22 ' CD1' ' A' ' 53' ' ' ILE . 7.1 mt -65.53 -40.86 93.4 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.195 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 26.2 mt -69.55 -40.48 79.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.866 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -59.83 -27.82 64.87 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.278 179.212 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.69 -19.79 62.02 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.51 0.324 . . . . 0.0 111.668 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -98.54 100.89 12.18 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.408 0.623 . . . . 0.0 110.219 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.2 m -99.64 -29.16 12.83 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.975 -1.011 . . . . 0.0 111.663 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.05 -50.93 7.25 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.139 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.5 p -177.12 134.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.841 0.353 . . . . 0.0 111.487 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.408 ' HB2' ' OH ' ' A' ' 15' ' ' TYR . 1.2 tp -114.32 141.29 47.79 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.073 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -114.01 104.67 12.37 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.163 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.551 ' CE ' HD11 ' A' ' 27' ' ' LEU . 0.8 OUTLIER -107.19 148.5 28.8 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.211 -179.543 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.33 105.43 18.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.721 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.434 HD12 ' CG ' ' A' ' 45' ' ' ASP . 7.8 pt -100.98 173.58 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.208 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -155.86 124.73 6.05 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.666 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.375 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.639 179.206 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 120.702 0.287 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -139.2 169.24 18.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.402 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -116.66 144.57 44.25 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.99 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.778 HG11 ' CD1' ' A' ' 41' ' ' LEU . 20.6 t -113.39 140.44 33.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.31 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.702 ' O ' HG21 ' A' ' 39' ' ' VAL . 30.8 mt-10 -112.68 108.05 16.94 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.973 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.7 t -102.66 126.23 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 111.277 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.39 92.24 8.03 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.979 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.468 ' HG3' ' CZ ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -52.92 122.53 9.44 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.972 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.83 -65.93 3.08 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 121.162 -0.542 . . . . 0.0 112.665 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -163.54 -48.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.568 0.223 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -131.93 26.36 4.62 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.455 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 179.71 164.69 32.49 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.607 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.674 ' CE2' HG22 ' A' ' 67' ' ' ILE . 40.1 m-85 -107.91 -73.72 0.68 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.65 0.262 . . . . 0.0 111.373 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.39 50.83 0.04 OUTLIER Glycine 0 C--N 1.33 0.242 0 C-N-CA 121.142 -0.552 . . . . 0.0 112.425 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.4 ' HB2' ' CD2' ' A' ' 27' ' ' LEU . 37.6 p90 -167.14 -177.08 3.57 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.428 0.156 . . . . 0.0 110.754 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -133.68 145.1 49.62 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 120.822 0.344 . . . . 0.0 111.353 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.4 mt -128.72 123.48 33.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.945 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.5 m -135.83 14.81 3.36 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.26 -0.427 . . . . 0.0 112.101 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -84.86 85.2 1.57 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.035 -0.603 . . . . 0.0 112.131 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.02 -63.24 0.9 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.837 0.351 . . . . 0.0 111.074 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.24 -61.04 0.18 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.146 178.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.88 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.5 Cg_endo -86.75 93.26 0.53 Allowed 'Trans proline' 0 C--N 1.353 0.793 0 C-N-CA 122.825 2.35 . . . . 0.0 111.764 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.503 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.5 m -54.46 121.14 7.71 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.884 0.373 . . . . 0.0 110.806 -179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.4 p -145.79 146.74 19.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.85 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.589 HD22 HD23 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -81.55 92.24 6.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.707 179.843 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.83 -34.82 63.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.317 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.732 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 1.3 t -169.72 160.47 8.77 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 111.242 179.612 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.416 HG21 ' HB3' ' A' ' 41' ' ' LEU . 4.7 t -116.52 154.1 18.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.745 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 12.1 mmm -99.22 99.24 10.18 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.101 0.477 . . . . 0.0 110.818 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -50.2 126.85 15.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.118 -0.946 . . . . 0.0 111.276 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.05 24.2 13.37 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.028 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.458 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -127.52 169.58 12.05 Favored Pre-proline 0 C--N 1.33 -0.253 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.265 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.552 ' O ' HG23 ' A' ' 39' ' ' VAL . 19.3 Cg_endo -58.13 -17.7 33.19 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.673 2.248 . . . . 0.0 113.043 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.951 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -70.59 -50.91 32.18 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -72.07 -29.83 64.52 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.229 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.433 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.7 m-30 -59.18 -27.5 65.75 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.616 -0.266 . . . . 0.0 110.973 179.594 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.702 HG21 ' O ' ' A' ' 7' ' ' GLU . 22.4 t -89.64 -50.31 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.762 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 146.65 46.77 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.068 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.951 HD22 ' HB1' ' A' ' 36' ' ' ALA . 1.0 OUTLIER -89.31 134.25 34.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.665 0.269 . . . . 0.0 110.412 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.4 mmt180 -144.91 120.38 10.34 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.732 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -45.97 125.74 6.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.449 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.33 -26.95 5.4 Favored Glycine 0 CA--C 1.517 0.189 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.322 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.4 ' CG ' HD12 ' A' ' 78' ' ' ILE . 0.7 OUTLIER -67.1 121.1 14.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 120.593 0.235 . . . . 0.0 110.682 179.731 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.43 127.69 32.96 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.77 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.478 HG21 HG22 ' A' ' 50' ' ' VAL . 18.9 mt -82.65 119.31 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.569 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -97.11 -42.22 7.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.84 140.85 51.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.007 179.691 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.504 HG23 ' CG2' ' A' ' 55' ' ' VAL . 21.5 t -133.14 112.52 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.13 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.411 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.4 t30 76.34 31.06 0.64 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.672 -178.597 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.77 -3.76 1.57 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 115.174 -0.921 . . . . 0.0 112.713 179.64 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.501 HD12 HG13 ' A' ' 55' ' ' VAL . 1.1 pp -114.45 128.93 71.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.016 0.436 . . . . 0.0 111.397 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.561 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.1 m120 -64.27 132.69 51.0 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.439 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.58 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 7.8 m -136.36 58.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.452 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -62.51 -40.2 95.98 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.422 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -132.92 31.11 3.94 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.208 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.58 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -78.04 179.92 6.5 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.771 0.32 . . . . 0.0 111.548 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.734 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.14 135.47 33.42 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.305 0.574 . . . . 0.0 110.951 179.881 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.76 ' O ' HG23 ' A' ' 64' ' ' VAL . 7.4 t60 -54.46 -44.63 72.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.815 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -62.63 -43.35 99.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.504 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.22 -41.38 97.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.543 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 59' ' ' SER . 47.0 t -64.94 -43.52 96.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.988 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.76 HG23 ' O ' ' A' ' 60' ' ' HIS . 45.0 t -65.76 -39.34 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -57.97 -40.98 81.94 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.01 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.625 HD12 ' HA ' ' A' ' 63' ' ' VAL . 4.5 mt -66.22 -42.43 88.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.668 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.799 HG23 HD13 ' A' ' 74' ' ' LEU . 18.5 mt -65.52 -42.92 94.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.51 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.98 -15.04 81.66 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.945 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -65.13 -39.79 93.56 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -62.72 -55.25 28.42 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.4 ' HA ' ' NH1' ' A' ' 10' ' ' ARG . 0.3 OUTLIER 65.94 35.03 6.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.903 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.29 -44.24 0.02 OUTLIER Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.554 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -160.72 138.86 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.784 0.326 . . . . 0.0 111.642 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.799 HD13 HG23 ' A' ' 67' ' ' ILE . 33.0 tp -105.8 143.18 34.31 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -128.56 96.8 4.5 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.191 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -121.66 154.59 36.62 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.43 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.1 t -111.63 110.87 33.77 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.746 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.428 HG12 HG23 ' A' ' 6' ' ' VAL . 7.6 pt -105.51 145.38 13.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.322 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -111.23 134.35 52.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.291 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 . . . . . 0 C--O 1.233 0.207 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.852 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.465 0.28 0 CA-C-O 120.725 0.298 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -135.96 162.25 33.38 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.448 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.38 125.32 53.04 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.785 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.516 HG13 ' HB ' ' A' ' 39' ' ' VAL . 20.8 t -111.33 134.07 54.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.105 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.584 ' O ' HG21 ' A' ' 39' ' ' VAL . 16.9 mt-10 -105.71 112.87 26.11 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.404 ' O ' HG23 ' A' ' 73' ' ' VAL . 4.9 t -87.77 116.85 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-O 120.84 0.352 . . . . 0.0 111.28 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.813 ' HB3' ' HB3' ' A' ' 35' ' ' PRO . . . -81.54 89.72 6.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.861 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.404 ' HG3' ' CE2' ' A' ' 15' ' ' TYR . 5.3 ttp180 -56.14 120.97 8.38 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.116 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.97 -88.1 0.29 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.738 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -121.33 -73.5 0.65 Allowed 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.64 0.257 . . . . 0.0 110.76 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -121.11 31.96 6.15 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.111 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -178.26 -169.61 39.31 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.582 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.56 ' OH ' HG22 ' A' ' 67' ' ' ILE . 24.4 m-85 -133.17 -64.42 0.73 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.655 0.264 . . . . 0.0 111.27 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.03 47.24 0.08 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.814 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -156.73 172.31 18.83 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 120.708 0.289 . . . . 0.0 110.813 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -117.56 110.72 18.29 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.954 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.5 126.15 49.46 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.119 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 73.5 m -152.06 107.56 3.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.55 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.95 79.63 0.15 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.704 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.85 -45.88 30.57 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.03 0.443 . . . . 0.0 110.018 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.944 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -115.57 -67.35 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.24 178.523 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.944 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 90.3 Cg_endo -85.1 95.55 0.65 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 122.605 2.204 . . . . 0.0 112.155 179.158 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.635 ' SG ' HG21 ' A' ' 63' ' ' VAL . 80.8 m -53.27 118.91 4.16 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.679 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 p -146.79 149.63 15.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.393 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.463 HD22 HD22 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -87.48 93.61 9.46 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.319 179.401 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -46.91 -43.98 19.38 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.485 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.509 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 1.7 t -172.37 158.53 4.38 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.173 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.5 t -126.04 154.95 35.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.616 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mtp -100.33 101.59 12.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 121.153 0.501 . . . . 0.0 110.66 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.1 mtm-85 -49.96 123.95 9.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.39 16.7 10.75 Favored Glycine 0 CA--C 1.523 0.583 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.75 -179.176 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -120.98 166.68 15.03 Favored Pre-proline 0 CA--C 1.531 0.221 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.486 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.813 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 71.0 Cg_exo -49.27 -31.39 22.25 Favored 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.989 2.46 . . . . 0.0 113.346 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.61 -49.06 51.63 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.587 -0.278 . . . . 0.0 111.139 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.36 -32.47 73.88 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.486 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.9 m-30 -58.06 -29.25 65.24 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.457 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.584 HG21 ' O ' ' A' ' 7' ' ' GLU . 18.7 t -89.53 -32.73 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.696 0.284 . . . . 0.0 110.948 179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.45 51.39 0.16 Allowed Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.123 -0.56 . . . . 0.0 112.66 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.682 ' CD2' HD13 ' A' ' 78' ' ' ILE . 2.8 mt -116.55 129.3 56.1 Favored 'General case' 0 C--O 1.231 0.098 0 CA-C-O 120.574 0.226 . . . . 0.0 110.817 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -137.6 -152.9 0.46 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -99.58 148.14 24.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.799 179.6 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.3 -21.33 46.08 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.975 -0.631 . . . . 0.0 113.214 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.65 ' CG ' HD12 ' A' ' 78' ' ' ILE . 0.9 OUTLIER -69.9 116.86 10.77 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.883 0.341 . . . . 0.0 110.827 -179.853 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.53 132.09 37.06 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.425 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 27.2 mt -84.34 120.42 35.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.74 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.0 -40.37 5.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.402 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.512 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -128.88 135.99 49.83 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.626 0.25 . . . . 0.0 111.097 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.448 ' O ' HG13 ' A' ' 53' ' ' ILE . 4.8 t -135.73 110.09 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.186 179.53 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 75.99 33.71 0.58 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 77.6 -5.13 2.18 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 115.15 -0.932 . . . . 0.0 112.706 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.796 HD11 ' CD1' ' A' ' 66' ' ' LEU . 2.2 pp -116.71 130.82 70.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 111.403 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -67.11 141.62 57.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.691 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.604 HG13 HD12 ' A' ' 53' ' ' ILE . 4.2 m -142.68 51.16 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.413 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.2 mtpp -58.16 -35.27 71.31 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.657 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -137.2 34.62 2.55 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.694 0.283 . . . . 0.0 111.03 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.537 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -78.13 -172.9 2.96 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.843 0.354 . . . . 0.0 111.556 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.616 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.4 OUTLIER -94.55 141.0 29.11 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.275 0.56 . . . . 0.0 110.791 179.738 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.697 ' O ' HG22 ' A' ' 64' ' ' VAL . 1.1 t-160 -52.86 -43.29 65.98 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.443 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.429 ' HA ' ' CG2' ' A' ' 64' ' ' VAL . 2.7 mt-10 -66.53 -35.06 79.32 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.457 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.59 -38.39 70.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.798 0.332 . . . . 0.0 110.286 179.178 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.635 HG21 ' SG ' ' A' ' 25' ' ' CYS . 46.6 t -66.47 -44.89 90.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.042 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.697 HG22 ' O ' ' A' ' 60' ' ' HIS . 2.9 m -66.42 -39.19 83.45 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.39 -39.18 82.57 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.972 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.796 ' CD1' HD11 ' A' ' 53' ' ' ILE . 14.3 mt -66.03 -41.99 90.19 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.864 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.924 ' HA ' HD13 ' A' ' 74' ' ' LEU . 31.5 mt -68.11 -41.41 84.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.762 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.74 8.73 19.64 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.954 178.807 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 2.0 tttp -111.61 -4.0 14.9 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 116.943 0.371 . . . . 0.0 111.071 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.469 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 26.4 p -50.62 -47.56 58.23 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 122.536 0.334 . . . . 0.0 111.71 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.74 31.71 4.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.004 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 150.02 -37.51 0.94 Allowed Glycine 0 C--N 1.335 0.499 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.062 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.469 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.8 p -172.05 138.07 0.35 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.234 0 CA-C-O 120.894 0.378 . . . . 0.0 112.012 -179.657 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.924 HD13 ' HA ' ' A' ' 67' ' ' ILE . 3.8 tp -111.04 139.77 46.12 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.111 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -100.95 101.52 12.33 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.29 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 35.5 ttm -103.44 125.1 49.84 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.512 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 40.5 t -97.86 103.61 14.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.511 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.682 HD13 ' CD2' ' A' ' 41' ' ' LEU . 14.7 pt -106.72 168.31 3.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.468 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.91 155.2 39.58 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.703 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.235 0.298 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.234 0.279 0 CA-C-O 120.64 0.257 . . . . 0.0 111.369 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.98 167.5 21.99 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.657 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 m -102.94 135.19 45.07 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.919 HG11 HD12 ' A' ' 41' ' ' LEU . 25.1 t -115.69 131.84 66.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.109 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -113.05 120.51 41.59 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.105 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.7 t -104.92 134.18 47.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.179 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -103.55 98.79 8.62 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.039 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -48.84 124.11 8.04 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.268 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.41 118.43 0.45 Allowed Glycine 0 CA--C 1.52 0.353 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER 78.51 90.0 0.06 Allowed 'General case' 0 C--O 1.235 0.34 0 CA-C-O 121.393 0.616 . . . . 0.0 110.396 -179.22 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 71.15 34.26 1.85 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.548 -1.206 . . . . 0.0 111.569 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 -113.1 3.6 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.837 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.45 ' HB3' HG11 ' A' ' 8' ' ' VAL . 79.3 m-85 -110.64 -66.32 1.08 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.414 0.149 . . . . 0.0 111.171 -179.546 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.17 61.14 0.2 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.894 -0.67 . . . . 0.0 113.351 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -166.41 167.79 15.46 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 120.556 0.217 . . . . 0.0 111.183 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -120.34 150.84 40.11 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.007 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -137.62 124.32 21.08 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.363 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 m -140.15 15.74 2.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.092 -0.503 . . . . 0.0 112.021 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.65 84.36 1.59 Allowed Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.417 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -44.2 -61.98 1.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.795 0.331 . . . . 0.0 110.783 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.904 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.29 -62.81 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.881 178.574 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.904 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 92.0 Cg_endo -85.84 96.45 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.925 0 C-N-CA 122.76 2.307 . . . . 0.0 111.915 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.524 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.0 m -55.8 124.95 19.25 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.567 -179.642 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.16 143.8 17.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.395 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.771 HD22 HD22 ' A' ' 41' ' ' LEU . 0.4 OUTLIER -80.81 90.62 5.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.462 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 5.8 p -53.8 -38.44 64.52 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.473 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 8.1 t -161.75 153.41 18.89 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.836 0.351 . . . . 0.0 111.447 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.3 t -116.23 155.38 17.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.554 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.3 mtp -97.79 100.35 11.72 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.236 0.541 . . . . 0.0 110.791 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.4 mtm-85 -53.74 124.23 14.61 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.892 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.13 -24.04 21.88 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.534 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.414 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.4 OUTLIER -82.5 166.61 35.36 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 110.533 179.722 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 11.0 Cg_endo -53.95 -23.53 28.35 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 123.19 2.593 . . . . 0.0 113.186 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.59 76.91 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.887 0.375 . . . . 0.0 110.731 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -68.24 -27.1 66.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.194 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -55.97 -24.31 37.6 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 112.141 0.422 . . . . 0.0 112.141 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.748 HG11 HG13 ' A' ' 6' ' ' VAL . 34.8 t -89.09 -29.21 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 111.034 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.86 43.95 2.17 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.518 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.919 HD12 HG11 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -74.25 176.42 6.67 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 120.913 0.387 . . . . 0.0 110.762 179.857 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.519 ' H ' HD23 ' A' ' 41' ' ' LEU . 4.1 mtp85 -139.0 116.95 11.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.44 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.53 101.03 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.801 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.35 -21.26 3.47 Favored Glycine 0 CA--C 1.524 0.606 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.407 -179.062 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -58.24 123.31 15.62 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 120.633 0.254 . . . . 0.0 110.8 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -66.68 127.87 34.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.089 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.72 HD11 HD12 ' A' ' 27' ' ' LEU . 21.2 mt -85.27 125.89 40.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.573 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.492 ' N ' HD12 ' A' ' 48' ' ' LEU . 6.9 mp -98.76 -70.27 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.575 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.504 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -99.99 143.94 29.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.739 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.445 HG23 ' CG2' ' A' ' 55' ' ' VAL . 18.6 t -135.84 113.94 15.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.428 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 76.38 33.05 0.55 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -177.837 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.74 -1.78 2.37 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 115.189 -0.914 . . . . 0.0 113.074 179.72 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.794 HD11 ' CD1' ' A' ' 66' ' ' LEU . 5.4 pt -115.65 133.0 63.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-O 120.817 0.342 . . . . 0.0 111.827 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.504 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 42.8 t30 -66.83 130.22 42.45 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.143 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.472 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 15.3 m -137.28 59.57 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.965 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.9 mmtm -51.91 -72.46 0.05 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.999 -179.532 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.2 mttt -111.72 39.55 2.34 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.255 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.472 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -73.86 -175.93 2.29 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.515 -179.462 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.632 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.44 134.67 33.78 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.443 0.639 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -53.04 -44.76 67.64 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.689 -1.142 . . . . 0.0 111.419 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.472 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.7 pm0 -66.36 -34.7 78.56 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.184 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.6 -39.31 70.6 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.728 0.299 . . . . 0.0 110.443 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 59' ' ' SER . 41.4 t -67.02 -43.36 89.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.497 ' HA ' HD12 ' A' ' 67' ' ' ILE . 29.8 m -65.93 -38.71 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.699 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 1.9 mtmp? -57.87 -39.38 77.67 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.881 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.794 ' CD1' HD11 ' A' ' 53' ' ' ILE . 7.5 mt -67.41 -43.28 81.65 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.761 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.83 HG23 ' HG ' ' A' ' 74' ' ' LEU . 13.8 mt -65.66 -38.03 81.36 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.981 179.564 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -86.61 3.77 86.76 Favored Glycine 0 CA--C 1.524 0.645 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.015 179.393 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.6 tptm -86.91 -34.88 19.23 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.824 0.312 . . . . 0.0 111.25 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -71.66 -57.86 4.01 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.809 0.338 . . . . 0.0 110.86 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.1 m 64.65 36.02 8.61 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.072 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.13 -44.13 0.02 OUTLIER Glycine 0 C--N 1.331 0.296 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.434 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.1 p -162.12 137.08 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 CA-C-O 120.985 0.421 . . . . 0.0 111.385 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.83 ' HG ' HG23 ' A' ' 67' ' ' ILE . 1.9 mm? -112.6 134.37 54.17 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.523 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -117.09 96.36 5.41 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.999 179.446 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 16.5 ptt? -122.01 156.31 33.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.791 -179.155 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.7 t -111.42 109.73 29.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.735 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 pt -106.1 139.39 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.304 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -105.86 125.15 50.65 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.154 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 . . . . . 0 C--O 1.232 0.139 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.696 179.715 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 CA--C 1.534 0.345 0 CA-C-O 120.495 0.188 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.566 ' HD3' HD11 ' A' ' 78' ' ' ILE . 4.0 ttt85 -114.05 141.21 47.74 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 120.883 0.373 . . . . 0.0 111.1 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.0 m -110.9 137.16 48.88 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.664 179.518 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.756 HG11 HD22 ' A' ' 41' ' ' LEU . 16.7 t -111.8 136.01 49.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.756 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -134.59 100.84 4.76 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.535 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.645 ' O ' HG23 ' A' ' 73' ' ' VAL . 11.2 t -106.47 150.51 9.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.276 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -99.4 98.54 9.45 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.988 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 50.9 ttp85 -50.71 120.67 4.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.696 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.73 -107.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.705 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -118.28 -39.94 2.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.419 0.152 . . . . 0.0 111.249 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -111.3 32.19 5.53 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.668 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.11 -137.96 14.57 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.828 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.41 ' O ' ' HD2' ' A' ' 35' ' ' PRO . 80.2 m-85 -116.17 -83.33 0.63 Allowed 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.633 0.254 . . . . 0.0 111.19 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.61 55.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.265 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.525 ' HZ ' HG21 ' A' ' 67' ' ' ILE . 14.3 p90 -143.31 166.83 23.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.631 0.253 . . . . 0.0 110.756 179.743 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.1 m -113.92 142.03 46.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.943 0.401 . . . . 0.0 111.479 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 mt -133.89 122.87 23.78 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.943 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.8 m -146.92 169.37 19.29 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.31 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.91 -37.51 2.88 Favored Glycine 0 C--N 1.336 0.532 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.509 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.404 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.55 -48.92 0.24 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.286 0.635 . . . . 0.0 111.493 -179.817 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.896 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -100.97 -65.09 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.438 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.896 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 91.5 Cg_endo -80.55 96.21 1.0 Allowed 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.292 1.994 . . . . 0.0 112.318 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.0 m -61.37 115.66 4.04 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.334 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.84 142.46 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.154 -179.302 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.648 HD12 HD11 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -75.87 90.98 2.96 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.468 179.743 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 69.4 p -53.2 -36.59 61.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.308 -179.715 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.443 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.0 t -167.22 158.63 12.13 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.237 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.592 HG21 ' HA ' ' A' ' 42' ' ' ARG . 11.8 t -119.08 154.97 21.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.858 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 30.8 mtt -98.28 101.85 13.42 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 121.21 0.529 . . . . 0.0 110.623 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 26.8 mtt-85 -51.84 123.69 10.82 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.22 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.07 -22.3 31.72 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 120.938 -0.649 . . . . 0.0 113.071 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.448 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.6 m -83.47 168.01 25.04 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.711 0.255 . . . . 0.0 110.658 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.448 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 73.6 Cg_exo -50.43 -25.51 14.23 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 123.033 2.489 . . . . 0.0 113.448 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.26 -47.8 82.74 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 120.868 0.366 . . . . 0.0 111.024 179.628 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.96 -26.73 65.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.31 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.4 m-30 -54.98 -28.71 53.79 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 111.674 0.249 . . . . 0.0 111.674 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.763 ' HB ' HD23 ' A' ' 41' ' ' LEU . 22.6 t -89.43 -34.4 6.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 CA-C-O 120.83 0.347 . . . . 0.0 111.037 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.6 -11.81 15.88 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.747 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.763 HD23 ' HB ' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -64.58 127.59 32.16 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 179.918 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.592 ' HA ' HG21 ' A' ' 30' ' ' VAL . 1.7 mmm180 -115.51 -146.52 0.4 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.249 -179.687 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.443 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -95.11 159.19 15.13 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.926 0.393 . . . . 0.0 110.908 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.24 -33.52 6.1 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.577 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -61.39 118.56 7.11 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.79 0.328 . . . . 0.0 110.989 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.02 131.44 35.31 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.679 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.648 HD11 HD12 ' A' ' 27' ' ' LEU . 8.3 mm -87.38 124.55 40.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.5 179.68 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.439 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.5 mm? -105.49 -46.51 4.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.352 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.561 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -120.49 139.2 53.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.195 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 53' ' ' ILE . 9.0 t -140.79 109.27 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.487 179.407 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.405 ' HB2' ' HB3' ' A' ' 66' ' ' LEU . 0.1 OUTLIER 76.54 34.21 0.48 Allowed 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.878 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 76.02 -3.4 2.57 Favored 'General case' 0 CA--C 1.537 0.481 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.773 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.882 HD11 HD11 ' A' ' 66' ' ' LEU . 1.1 pt -114.27 120.5 64.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-O 121.047 0.451 . . . . 0.0 111.312 179.501 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.559 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -64.71 131.84 47.98 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.054 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.503 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 5.8 m -131.11 55.97 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.355 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.9 mtmt -59.88 -40.5 88.94 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.188 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.0 mttp -136.35 30.84 2.92 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.061 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.503 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -75.93 -169.22 1.05 Allowed 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.272 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -92.01 135.0 34.3 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.47 0.652 . . . . 0.0 110.616 179.713 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.742 ' O ' HG23 ' A' ' 64' ' ' VAL . 4.9 t60 -54.44 -44.6 72.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.818 -1.083 . . . . 0.0 111.957 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -63.41 -38.11 89.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.811 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.4 -42.9 82.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.541 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 59' ' ' SER . 42.9 t -65.29 -42.18 93.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.754 179.644 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 60' ' ' HIS . 47.5 t -65.8 -39.08 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.6 mttt -57.64 -39.41 76.92 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.45 -0.796 . . . . 0.0 110.89 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.882 HD11 HD11 ' A' ' 53' ' ' ILE . 11.3 mt -66.57 -43.7 84.26 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.773 179.444 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.757 HG23 HD22 ' A' ' 74' ' ' LEU . 54.0 mt -63.16 -37.96 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.642 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.47 11.98 57.02 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.316 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.5 ttpm? -110.32 -16.23 13.77 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 122.406 0.282 . . . . 0.0 111.264 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' CYS . . . . . 0.403 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 23.3 p -44.2 -50.85 8.61 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 122.576 0.351 . . . . 0.0 111.6 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.5 p 63.26 32.22 14.97 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.454 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.17 -36.73 0.6 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.993 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -172.46 136.58 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-O 120.995 0.426 . . . . 0.0 111.917 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.757 HD22 HG23 ' A' ' 67' ' ' ILE . 9.8 tp -114.45 145.0 42.41 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.827 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -119.37 107.11 12.96 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.16 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 1.1 ptp -122.71 135.04 54.46 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.012 0.434 . . . . 0.0 111.239 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.561 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 41.3 t -94.37 115.1 32.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.642 179.741 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.566 HD11 ' HD3' ' A' ' 4' ' ' ARG . 3.7 pt -107.06 167.05 3.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.551 -179.66 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.82 128.22 26.36 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.331 -0.207 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.471 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.488 1.169 0 CA-C-O 120.933 0.305 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.44 -173.16 4.47 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.848 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.636 HG22 ' HB2' ' A' ' 79' ' ' ALA . 25.2 t -99.31 136.29 31.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.152 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -134.93 174.5 10.53 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.349 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 m -118.9 149.75 41.05 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.312 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.658 HG23 HD11 ' A' ' 78' ' ' ILE . 54.6 t -129.65 134.17 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.079 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -105.41 103.68 13.25 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 73' ' ' VAL . 14.6 t -95.64 129.47 45.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.807 0.337 . . . . 0.0 111.229 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -91.43 90.94 7.89 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.284 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -55.3 123.49 13.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.734 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.05 -103.17 0.1 OUTLIER Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.241 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.14 -46.4 1.94 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.536 0.208 . . . . 0.0 111.164 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -103.76 31.69 4.31 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.692 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.69 -126.77 8.3 Favored Glycine 0 C--N 1.336 0.556 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.745 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -132.88 -64.97 0.73 Allowed 'General case' 0 C--O 1.231 0.103 0 CA-C-O 120.733 0.302 . . . . 0.0 111.076 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.0 -34.53 1.31 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.925 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.578 ' CD1' HD21 ' A' ' 27' ' ' LEU . 41.6 p90 -65.18 179.47 0.72 Allowed 'General case' 0 CA--C 1.532 0.256 0 CA-C-O 121.064 0.459 . . . . 0.0 111.569 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.8 144.06 49.43 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.264 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.79 128.01 45.92 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.197 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 46.3 m -150.47 106.78 3.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.674 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -163.18 76.11 0.17 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.446 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -45.68 -44.71 13.63 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.736 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.976 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -114.33 -64.47 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.263 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.197 178.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.976 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 84.4 Cg_endo -89.42 91.51 0.36 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.791 2.327 . . . . 0.0 112.008 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.67 ' SG ' HG21 ' A' ' 63' ' ' VAL . 72.6 m -50.32 121.48 5.68 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.731 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.0 p -147.14 146.06 18.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.871 0.367 . . . . 0.0 111.724 -179.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.627 HD13 HD22 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -80.31 92.41 5.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.476 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.9 m -46.54 -46.29 19.22 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.867 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.68 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.0 t -171.3 158.41 5.36 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 111.431 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' A' ' 41' ' ' LEU . 50.6 t -122.13 153.23 26.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.619 179.61 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.6 mmt -103.3 100.81 10.72 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.076 0.465 . . . . 0.0 110.574 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 5.7 ptt180 -45.49 120.12 2.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.971 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 120.19 -17.81 9.73 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.542 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.413 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -85.59 166.77 28.33 Favored Pre-proline 0 CA--C 1.533 0.312 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.352 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 15.0 Cg_endo -57.13 -22.55 48.42 Favored 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 122.667 2.245 . . . . 0.0 112.748 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.825 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -68.83 -48.73 62.78 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.72 0.295 . . . . 0.0 110.913 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.36 -27.12 65.98 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.302 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-30 -57.54 -26.34 61.23 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.59 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.617 HG11 HG13 ' A' ' 6' ' ' VAL . 15.7 t -89.39 -39.39 12.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 120.794 0.33 . . . . 0.0 111.013 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 129.08 44.61 0.2 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.088 -0.577 . . . . 0.0 112.83 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.825 HD12 ' HB1' ' A' ' 36' ' ' ALA . 13.8 mt -85.22 140.9 30.52 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.788 0.328 . . . . 0.0 110.366 179.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.9 mtt180 -141.14 119.68 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.584 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.68 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -41.22 126.64 2.73 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.637 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.17 -26.37 5.56 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.148 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.97 114.17 3.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-O 120.661 0.267 . . . . 0.0 110.571 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -73.37 128.57 35.85 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.529 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.894 ' HA ' HG22 ' A' ' 78' ' ' ILE . 20.6 mt -80.93 120.17 32.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.007 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 mp -101.52 -46.7 4.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.053 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.605 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -127.26 139.39 52.94 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.257 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.458 HG21 HG13 ' A' ' 63' ' ' VAL . 8.8 t -132.46 111.61 17.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.003 179.358 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 77.33 29.98 0.54 Allowed 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.419 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 82.54 -2.53 1.38 Allowed 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.412 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.646 HD11 ' CD1' ' A' ' 66' ' ' LEU . 20.4 pt -114.21 132.19 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 111.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.6 OUTLIER -63.23 156.15 26.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.714 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.447 HG21 HG23 ' A' ' 50' ' ' VAL . 2.6 m -149.36 55.32 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.614 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -58.62 -43.25 89.6 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.723 0.297 . . . . 0.0 110.854 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.492 ' HE3' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -141.73 38.55 1.66 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.308 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.437 ' CB ' HG12 ' A' ' 55' ' ' VAL . . . -72.75 -178.15 2.59 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.592 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.593 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -93.35 137.89 32.22 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.398 0.618 . . . . 0.0 111.08 -179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.794 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.6 t-80 -52.67 -43.92 65.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.942 -1.026 . . . . 0.0 111.913 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 58.1 mt-10 -65.63 -39.3 91.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.008 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -67.25 -39.37 86.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.709 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.67 HG21 ' SG ' ' A' ' 25' ' ' CYS . 46.4 t -67.44 -42.34 87.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.745 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 60' ' ' HIS . 42.7 t -65.67 -39.1 83.92 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.184 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.8 mtpp -57.74 -38.95 76.24 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.646 ' CD1' HD11 ' A' ' 53' ' ' ILE . 13.3 mt -68.3 -42.54 79.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.684 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.63 HG23 HD22 ' A' ' 74' ' ' LEU . 6.8 mt -67.47 -36.9 77.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.884 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -81.66 10.62 50.28 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.342 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 ttpt -114.16 -5.82 13.04 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.623 0.369 . . . . 0.0 111.2 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.433 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 14.0 p -47.8 -48.78 30.28 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 122.488 0.315 . . . . 0.0 111.752 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.9 t 65.65 33.34 8.5 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.069 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.16 -33.3 1.72 Allowed Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.275 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 8' ' ' VAL . 8.0 p -172.68 138.0 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-O 121.0 0.428 . . . . 0.0 111.784 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.63 HD22 HG23 ' A' ' 67' ' ' ILE . 9.1 tp -114.45 147.28 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.222 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -108.97 99.23 8.59 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.419 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.577 ' CG ' HD23 ' A' ' 74' ' ' LEU . 0.0 OUTLIER -105.43 135.04 47.55 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.959 -179.618 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.605 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 21.9 t -108.75 99.44 8.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.762 179.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.894 HG22 ' HA ' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -111.07 164.92 6.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.358 -179.747 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.636 ' HB2' HG22 ' A' ' 3' ' ' VAL . . . -128.38 130.9 48.39 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.241 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -82.79 121.69 27.23 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -87.23 -46.68 4.93 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.911 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.1 t -104.77 118.43 52.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.83 0.348 . . . . 0.0 111.116 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.333 -179.887 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.49 1.321 0 CA-C-O 120.721 0.217 . . . . 0.0 111.995 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.79 -50.98 4.03 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.253 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 29.9 t -71.22 123.09 24.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.865 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 -131.89 160.77 34.75 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.497 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.2 p -101.59 131.34 47.84 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.178 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.609 HG13 ' CG1' ' A' ' 39' ' ' VAL . 14.2 t -116.37 131.55 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.808 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -100.99 111.77 24.05 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.728 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.5 ' O ' HG23 ' A' ' 73' ' ' VAL . 16.2 t -97.67 114.41 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.349 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.77 92.42 9.2 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.782 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.463 ' HG3' ' CE1' ' A' ' 15' ' ' TYR . 9.7 ttt180 -51.6 127.43 20.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.738 -0.664 . . . . 0.0 111.188 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.81 20.91 25.77 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.684 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.45 0.38 3.44 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 117.118 0.459 . . . . 0.0 111.907 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.01 24.0 1.67 Allowed 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 120.83 0.348 . . . . 0.0 111.105 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.69 -162.11 23.76 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.705 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.463 ' CE1' ' HG3' ' A' ' 10' ' ' ARG . 64.6 m-85 -131.7 -43.98 0.99 Allowed 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.36 -13.48 7.87 Favored Glycine 0 CA--C 1.522 0.507 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.18 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -108.52 174.28 5.94 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 117.039 0.419 . . . . 0.0 111.386 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.0 m -130.0 142.86 50.58 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.684 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.665 HD21 HD12 ' A' ' 47' ' ' ILE . 0.8 OUTLIER -124.19 124.48 42.55 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.302 -179.63 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.2 m -150.29 159.17 44.65 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.4 -29.52 2.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 121.055 -0.593 . . . . 0.0 113.157 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.403 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 64.11 21.27 12.52 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.94 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.834 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . 179.58 -63.8 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.282 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.834 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 91.0 Cg_endo -79.25 85.53 1.84 Allowed 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 122.52 2.147 . . . . 0.0 111.561 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.643 ' SG ' HG21 ' A' ' 63' ' ' VAL . 61.2 m -52.88 110.6 0.54 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.578 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -144.62 147.52 19.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.536 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.464 HD12 ' CG1' ' A' ' 47' ' ' ILE . 7.1 mp -74.4 90.8 2.18 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.3 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -43.78 61.95 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.614 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -171.17 158.09 5.36 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.984 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 14.7 t -135.77 153.34 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.92 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 16.3 ptp -104.52 105.12 15.11 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.271 0.558 . . . . 0.0 110.745 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.5 mtt180 -46.68 123.09 4.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.096 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.28 16.29 10.55 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 121.132 -0.556 . . . . 0.0 112.961 -179.356 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.8 164.87 17.74 Favored Pre-proline 0 C--O 1.234 0.247 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.19 -27.83 31.41 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 122.767 2.312 . . . . 0.0 112.606 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.32 -49.92 51.33 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.99 -35.23 79.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.239 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 m-30 -56.18 -32.95 64.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.714 -179.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.609 ' CG1' HG13 ' A' ' 6' ' ' VAL . 14.7 t -89.33 -35.05 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.62 0.247 . . . . 0.0 110.964 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.87 43.21 0.17 Allowed Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.152 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.512 HD21 HG21 ' A' ' 6' ' ' VAL . 63.5 mt -108.23 121.08 44.15 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.506 0.193 . . . . 0.0 110.53 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.92 -152.66 0.5 Allowed 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.988 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.22 130.06 44.95 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.812 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 113.68 -27.43 9.29 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.918 -0.658 . . . . 0.0 113.188 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -58.03 120.47 8.62 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.927 0.363 . . . . 0.0 111.077 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.7 125.59 30.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.741 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.665 HD12 HD21 ' A' ' 19' ' ' LEU . 23.8 mt -85.86 126.36 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.711 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.9 mp -108.22 -71.49 0.76 Allowed 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.495 ' HB3' ' CG2' ' A' ' 77' ' ' VAL . . . -97.07 126.89 42.53 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.756 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.599 HG21 HG13 ' A' ' 63' ' ' VAL . 11.0 t -119.64 103.38 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.302 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.423 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.5 t-20 76.46 31.75 0.59 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.705 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.423 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 85.01 -4.19 0.92 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.783 179.68 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 66' ' ' LEU . 1.1 pp -110.58 131.96 60.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-O 120.94 0.4 . . . . 0.0 111.656 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -71.58 145.28 49.14 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.604 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.507 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.2 m -146.11 61.14 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.376 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.1 -46.94 68.9 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.058 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 3.5 mtpp -140.13 37.68 1.93 Allowed 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.977 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.507 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -74.79 -174.96 2.32 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.446 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 3.8 m -91.2 145.67 24.48 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.641 0.734 . . . . 0.0 111.103 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.753 ' O ' HG23 ' A' ' 64' ' ' VAL . 2.5 t60 -61.68 -44.52 96.8 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.547 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -58.84 -43.2 90.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.882 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -64.24 -44.08 92.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.492 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.643 HG21 ' SG ' ' A' ' 25' ' ' CYS . 67.5 t -64.64 -40.79 90.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.059 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.753 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.3 t -65.69 -38.84 83.25 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 178.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.37 -40.88 79.07 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.901 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.743 HD11 HD11 ' A' ' 53' ' ' ILE . 7.3 mt -67.27 -42.07 84.44 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.643 179.432 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.975 HG23 HD22 ' A' ' 74' ' ' LEU . 9.8 mt -68.03 -39.33 81.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -80.04 11.17 37.02 Favored Glycine 0 CA--C 1.524 0.595 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.585 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.21 -8.12 13.55 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.441 0.296 . . . . 0.0 111.24 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.459 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 24.9 p -48.49 -49.91 33.87 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.825 0.345 . . . . 0.0 111.798 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.1 t 66.33 33.42 7.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.002 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.83 -37.41 0.95 Allowed Glycine 0 C--N 1.334 0.464 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.008 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 8' ' ' VAL . 8.1 p -171.12 137.39 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.998 0.427 . . . . 0.0 111.922 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.975 HD22 HG23 ' A' ' 67' ' ' ILE . 1.2 pp -112.38 155.41 24.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.363 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 68.7 m80 -110.92 98.34 7.49 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.268 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.475 ' HG2' HG23 ' A' ' 47' ' ' ILE . 3.0 ttm -105.07 122.74 46.52 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.052 -179.366 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.495 ' CG2' ' HB3' ' A' ' 49' ' ' ALA . 21.3 t -101.06 100.44 10.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.566 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.469 HG22 ' HA ' ' A' ' 47' ' ' ILE . 6.5 pt -102.53 171.76 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.427 -179.69 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -143.13 148.04 35.94 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.416 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -97.86 135.12 40.06 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -147.4 108.57 0.44 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.218 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 33.4 t -72.18 93.24 0.52 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.307 0 CA-C-O 120.838 0.351 . . . . 0.0 110.585 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.979 0 CA-C-O 118.299 -1.279 . . . . 0.0 112.255 -179.575 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo . . . . . 0 N--CA 1.49 1.304 0 CA-C-O 120.592 0.164 . . . . 0.0 111.801 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -96.76 -68.12 0.82 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.683 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.422 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.7 p -85.06 118.6 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.641 179.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.471 ' HG3' HD11 ' A' ' 78' ' ' ILE . 14.8 ptm180 -137.35 162.59 33.16 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.219 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.28 141.43 37.63 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.175 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.624 HG11 HD22 ' A' ' 41' ' ' LEU . 21.7 t -126.9 139.28 52.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.295 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.792 ' O ' HG21 ' A' ' 39' ' ' VAL . 13.0 mt-10 -107.86 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.512 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.41 HG12 ' HD2' ' A' ' 15' ' ' TYR . 6.7 t -99.08 112.87 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-O 120.862 0.363 . . . . 0.0 111.187 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.79 88.82 7.42 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.343 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.491 ' HB3' ' O ' ' A' ' 71' ' ' SER . 2.1 ttt-85 -48.19 124.75 8.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.181 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.49 -87.81 0.14 Allowed Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.701 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.17 -55.85 0.45 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.615 0.245 . . . . 0.0 111.316 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.79 30.57 6.98 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.98 151.14 5.44 Favored Glycine 0 C--N 1.333 0.378 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.39 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.448 ' CE2' ' HG3' ' A' ' 10' ' ' ARG . 39.1 m-85 -77.43 -33.42 54.89 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-O 120.568 0.223 . . . . 0.0 111.086 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.84 61.77 0.83 Allowed Glycine 0 C--N 1.335 0.498 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.567 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.403 ' CD1' ' HB2' ' A' ' 15' ' ' TYR . 6.1 p90 -168.93 175.93 5.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 111.063 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -119.04 116.71 26.98 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.392 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.4 HD23 ' N ' ' A' ' 20' ' ' SER . 0.6 OUTLIER -105.97 132.41 52.09 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.801 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.4 ' N ' HD23 ' A' ' 19' ' ' LEU . 36.8 p -147.45 -176.68 5.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.819 179.333 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 109.4 82.27 1.35 Allowed Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 121.033 -0.604 . . . . 0.0 112.05 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -45.37 -53.44 8.6 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.843 0.354 . . . . 0.0 110.594 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.956 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -98.68 -62.93 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.94 178.395 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.956 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 97.3 Cg_endo -88.11 91.85 0.45 Allowed 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.872 2.381 . . . . 0.0 112.128 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.3 p -54.73 119.78 5.83 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.659 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.508 HG23 ' HA ' ' A' ' 46' ' ' GLN . 12.5 p -141.4 151.48 19.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.83 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -81.6 91.31 6.37 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.17 -43.87 52.51 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.493 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.44 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.3 t -167.23 158.58 12.06 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.367 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.632 HG21 ' HB3' ' A' ' 41' ' ' LEU . 12.4 t -119.1 154.76 21.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.341 179.462 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 41.8 mtp -98.41 101.38 12.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 121.036 0.446 . . . . 0.0 110.33 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -50.82 124.48 11.2 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.859 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 22.87 10.97 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.488 -179.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.37 165.08 26.39 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.621 ' O ' HG23 ' A' ' 39' ' ' VAL . 9.4 Cg_endo -52.59 -28.06 35.3 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.726 2.284 . . . . 0.0 112.869 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.655 ' O ' HD23 ' A' ' 41' ' ' LEU . . . -65.36 -49.84 67.83 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.782 0.325 . . . . 0.0 110.829 179.464 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.36 -31.25 68.43 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.397 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.427 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.4 m-30 -61.36 -23.95 66.13 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.419 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.792 HG21 ' O ' ' A' ' 7' ' ' GLU . 23.5 t -89.08 -33.73 6.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 CA-C-O 120.758 0.313 . . . . 0.0 111.167 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.45 42.51 0.31 Allowed Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.874 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.655 HD23 ' O ' ' A' ' 36' ' ' ALA . 1.7 mm? -75.18 178.49 5.71 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.644 0.259 . . . . 0.0 110.62 179.557 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -171.04 130.18 0.77 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.219 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.44 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -65.18 111.72 3.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.479 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 129.91 -23.96 4.62 Favored Glycine 0 CA--C 1.523 0.582 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.839 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.45 115.65 3.13 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.651 0.263 . . . . 0.0 110.518 179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLN . . . . . 0.508 ' HA ' HG23 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -74.64 120.3 19.99 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.832 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.639 ' HA ' HG22 ' A' ' 78' ' ' ILE . 24.2 mt -78.05 124.15 35.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.537 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.716 HD11 ' HB2' ' A' ' 79' ' ' ALA . 3.2 mt -105.67 -46.46 4.15 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.776 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.5 140.43 51.45 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.996 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.461 HG23 ' CG2' ' A' ' 55' ' ' VAL . 13.9 t -134.44 110.06 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.402 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.9 t-20 76.65 33.56 0.49 Allowed 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -178.441 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 77.32 -1.86 2.68 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 112.688 -179.869 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.587 HD11 HD13 ' A' ' 66' ' ' LEU . 5.0 pt -113.04 122.77 67.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 121.063 0.459 . . . . 0.0 111.315 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.541 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 6.9 t30 -63.4 128.16 34.57 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.339 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.575 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 13.1 m -136.33 54.18 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.22 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.409 ' HD3' HD22 ' A' ' 48' ' ' LEU . 2.4 mmmt -65.9 -30.0 70.52 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.25 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.4 mmtt -132.37 29.76 4.24 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.61 0.243 . . . . 0.0 111.129 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.575 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -81.75 -179.51 7.41 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.857 0.36 . . . . 0.0 111.405 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.627 ' O ' HG23 ' A' ' 63' ' ' VAL . 3.9 m -86.18 145.26 27.07 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.58 0.705 . . . . 0.0 111.011 179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.721 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.5 t-80 -59.1 -44.87 91.99 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.485 -1.234 . . . . 0.0 111.473 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.02 -38.72 89.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.546 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -42.55 92.43 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.627 HG23 ' O ' ' A' ' 59' ' ' SER . 65.2 t -65.53 -41.74 91.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.001 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 60' ' ' HIS . 46.6 t -65.82 -38.92 83.31 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 178.569 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -43.09 85.72 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.234 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.587 HD13 HD11 ' A' ' 53' ' ' ILE . 56.0 mt -64.53 -41.03 96.62 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.764 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.763 HG23 ' HG ' ' A' ' 74' ' ' LEU . 44.1 mt -66.35 -43.43 91.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.499 179.383 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.64 -21.94 63.41 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.72 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.81 -34.93 72.25 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.527 0.203 . . . . 0.0 111.531 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.527 ' HB3' HD22 ' A' ' 74' ' ' LEU . 0.1 OUTLIER -97.95 99.59 10.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.487 0.66 . . . . 0.0 110.254 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.491 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 30.3 t -88.99 -33.77 17.08 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.758 -1.11 . . . . 0.0 111.221 -179.665 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -65.12 -43.03 96.21 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.174 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -178.91 138.93 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 120.751 0.31 . . . . 0.0 111.44 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.763 ' HG ' HG23 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -94.19 146.5 23.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.318 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 -131.44 102.82 6.1 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.864 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.09 154.66 44.42 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.808 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.6 t -109.43 112.74 41.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.704 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.639 HG22 ' HA ' ' A' ' 47' ' ' ILE . 1.6 pp -107.24 172.18 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.387 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.716 ' HB2' HD11 ' A' ' 48' ' ' LEU . . . -145.94 129.17 16.7 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.258 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.08 169.86 10.82 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.031 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -157.07 -97.6 0.13 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.911 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m -67.09 109.37 1.33 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.283 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.46 -1.189 . . . . 0.0 112.343 -179.952 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo . . . . . 0 N--CA 1.49 1.308 0 CA-C-O 120.852 0.272 . . . . 0.0 111.92 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -165.23 -51.84 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.832 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 p -97.6 138.3 22.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.247 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.5 ptt-85 -153.34 166.42 32.68 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.24 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.6 m -118.16 140.96 49.01 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.801 HG21 ' CD1' ' A' ' 41' ' ' LEU . 25.2 t -115.3 138.39 45.78 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.329 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -110.69 105.78 14.78 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.987 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.488 ' O ' HG23 ' A' ' 73' ' ' VAL . 10.5 t -100.39 133.26 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.288 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.68 98.73 9.25 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.942 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.526 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.4 OUTLIER -53.35 126.07 19.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.978 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.82 15.14 44.29 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.706 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.8 mmt85 74.01 0.24 3.55 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.985 0.392 . . . . 0.0 111.753 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -146.28 25.57 1.23 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-O 120.77 0.319 . . . . 0.0 111.147 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 136.47 175.44 13.81 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.692 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.623 ' CE2' HG22 ' A' ' 67' ' ' ILE . 35.5 m-85 -114.26 -69.57 0.85 Allowed 'General case' 0 C--O 1.232 0.141 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.81 -22.25 1.8 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.988 -0.625 . . . . 0.0 113.226 -179.621 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.53 ' HB2' HD21 ' A' ' 27' ' ' LEU . 51.4 p90 -95.81 137.76 34.43 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.905 0.353 . . . . 0.0 110.777 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -98.08 133.25 42.8 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.201 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.674 HD21 HD12 ' A' ' 47' ' ' ILE . 3.0 mt -117.29 133.26 56.19 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.462 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.5 m -149.88 166.63 28.96 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.128 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.47 -34.22 4.89 Favored Glycine 0 C--N 1.336 0.568 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.897 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.523 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 79.91 -49.85 0.37 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.359 0.663 . . . . 0.0 111.552 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.889 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -97.79 -64.93 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.483 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.889 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 99.0 Cg_endo -79.74 94.86 1.03 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.402 2.068 . . . . 0.0 112.478 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 85.6 m -59.65 111.61 1.49 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.184 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -146.93 143.21 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.273 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.726 HD22 HG22 ' A' ' 30' ' ' VAL . 0.1 OUTLIER -79.2 91.46 4.97 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.671 179.655 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.1 m -54.96 -37.64 66.75 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.347 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.549 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.2 t -167.15 155.61 9.8 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.921 0.391 . . . . 0.0 111.273 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.726 HG22 HD22 ' A' ' 27' ' ' LEU . 2.4 t -112.5 155.17 13.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.558 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mmt -103.31 101.92 11.86 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 121.003 0.43 . . . . 0.0 110.636 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.4 mtt85 -51.73 124.4 12.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.764 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.68 3.61 37.14 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.717 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.413 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.6 OUTLIER -108.13 167.06 9.82 Favored Pre-proline 0 C--O 1.233 0.211 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.512 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.546 ' O ' HG23 ' A' ' 39' ' ' VAL . 9.8 Cg_endo -51.57 -29.51 32.54 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.924 2.416 . . . . 0.0 112.712 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.603 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -63.7 -49.36 73.44 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.024 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.13 -34.27 77.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -60.94 -26.79 67.76 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.492 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 35' ' ' PRO . 35.3 t -89.56 -30.41 5.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-O 120.661 0.267 . . . . 0.0 111.144 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.06 47.11 0.67 Allowed Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.801 ' CD1' HG21 ' A' ' 6' ' ' VAL . 2.8 tp -80.22 156.45 26.88 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.965 0.412 . . . . 0.0 110.782 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.8 mmm180 -146.28 117.79 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.549 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -53.41 152.15 5.0 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.739 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.71 -28.95 13.66 Favored Glycine 0 CA--C 1.521 0.427 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.344 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.451 ' OD2' HD13 ' A' ' 78' ' ' ILE . 19.0 p-10 -59.68 121.9 12.8 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 122.876 0.47 . . . . 0.0 111.438 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -78.37 130.56 36.28 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.079 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.674 HD12 HD21 ' A' ' 19' ' ' LEU . 17.3 mt -84.7 127.81 39.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.002 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.445 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.3 mm? -106.42 -43.27 4.8 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.428 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.556 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -129.95 137.2 50.21 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.504 -0.317 . . . . 0.0 111.41 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.585 HG11 HD11 ' A' ' 67' ' ' ILE . 3.9 t -136.91 113.03 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.338 179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 76.64 31.66 0.57 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 79.15 -5.01 2.02 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.581 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.827 HD11 HD13 ' A' ' 66' ' ' LEU . 1.2 pp -112.2 124.97 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-O 121.104 0.478 . . . . 0.0 111.343 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.556 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -66.19 131.41 46.1 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.307 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.604 HG11 HG22 ' A' ' 63' ' ' VAL . 17.5 m -129.05 53.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.309 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -55.41 -55.4 32.12 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.281 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.3 mttm -127.19 32.62 5.03 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.911 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.49 -176.84 3.88 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.669 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -85.69 133.88 34.0 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.511 0.672 . . . . 0.0 110.81 179.699 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.523 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 5.0 t60 -56.9 -44.31 82.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.811 -1.086 . . . . 0.0 111.882 -179.528 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.47 ' HA ' HG22 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -66.48 -33.84 76.6 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.912 179.706 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.56 -42.18 68.14 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.068 178.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.669 HG23 ' O ' ' A' ' 59' ' ' SER . 56.9 t -63.86 -44.02 97.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.083 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.47 HG22 ' HA ' ' A' ' 61' ' ' GLU . 28.6 m -66.14 -39.3 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -57.93 -42.44 84.86 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.956 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.827 HD13 HD11 ' A' ' 53' ' ' ILE . 5.9 mt -62.31 -43.87 97.83 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.623 HG22 ' CE2' ' A' ' 15' ' ' TYR . 53.3 mt -66.59 -41.62 88.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.677 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.38 -1.17 74.72 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.848 -0.692 . . . . 0.0 113.256 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -83.03 -34.76 26.19 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.027 0.413 . . . . 0.0 111.492 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.75 -57.3 9.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.809 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.8 34.76 5.36 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.974 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.8 -45.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.366 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.6 p -169.05 138.48 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-O 120.841 0.353 . . . . 0.0 111.726 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.464 HD11 HG12 ' A' ' 50' ' ' VAL . 10.7 tp -114.33 141.87 47.05 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.26 179.595 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -125.27 98.41 5.63 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.977 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 15.1 ptt? -116.67 154.84 29.86 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.391 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.0 t -111.98 109.21 27.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.878 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.451 HD13 ' OD2' ' A' ' 45' ' ' ASP . 1.1 pt -102.06 163.67 3.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.509 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.26 116.0 18.47 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.9 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -71.49 117.42 13.02 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.33 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -106.13 -30.6 4.41 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.924 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 17.8 t -92.47 134.29 31.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 120.823 0.344 . . . . 0.0 110.868 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.163 0 CA-C-O 118.685 -1.064 . . . . 0.0 113.104 -179.928 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo . . . . . 0 N--CA 1.489 1.227 0 CA-C-O 120.536 0.14 . . . . 0.0 112.162 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -176.99 -42.54 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.466 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 21.4 t -72.64 120.44 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.936 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -150.22 174.08 13.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.377 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -118.76 137.41 53.39 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.765 HG13 HG11 ' A' ' 39' ' ' VAL . 42.3 t -114.59 139.33 41.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.114 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -115.04 110.1 19.07 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.861 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 73' ' ' VAL . 5.9 t -95.9 130.31 44.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.027 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.5 93.13 8.39 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.964 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 -39.38 122.7 1.34 Allowed 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.555 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.31 -90.65 0.07 OUTLIER Glycine 0 C--N 1.333 0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.907 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 ptt85 -134.98 -47.37 0.73 Allowed 'General case' 0 C--O 1.233 0.196 0 N-CA-C 111.578 0.214 . . . . 0.0 111.578 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.49 40.43 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.528 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.28 -173.96 21.43 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.826 -0.702 . . . . 0.0 113.178 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -96.56 -71.93 0.66 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.653 0.263 . . . . 0.0 111.463 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.71 -39.34 0.61 Allowed Glycine 0 CA--C 1.519 0.323 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.785 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -71.62 179.93 2.85 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.691 0.282 . . . . 0.0 111.122 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 m -135.3 151.03 50.16 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.356 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 mt -124.97 131.06 53.48 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.942 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.7 p -148.06 157.77 43.69 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 120.713 0.292 . . . . 0.0 111.561 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 126.26 -25.73 5.39 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 121.213 -0.518 . . . . 0.0 113.027 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 61.81 14.24 6.07 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.736 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.801 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -166.87 -65.79 0.01 OUTLIER Pre-proline 0 N--CA 1.463 0.224 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.801 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.8 Cg_endo -74.39 83.68 1.66 Allowed 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.381 2.054 . . . . 0.0 111.361 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.5 m -52.23 108.45 0.29 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.3 p -143.22 141.37 26.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.54 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 1.003 HD12 HD11 ' A' ' 47' ' ' ILE . 2.1 mp -78.98 91.95 4.89 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.408 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.24 -42.98 42.33 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.408 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.59 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.9 t -171.07 157.1 5.06 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.964 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -120.42 155.56 23.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.655 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.0 mtp -97.83 102.29 14.01 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.224 0.535 . . . . 0.0 110.572 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.34 121.6 5.17 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.967 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.21 -18.32 23.54 Favored Glycine 0 CA--C 1.522 0.499 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.291 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.79 166.74 34.16 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.654 0.227 . . . . 0.0 110.521 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -53.14 -26.74 34.32 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.101 2.534 . . . . 0.0 113.166 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -65.5 -42.27 92.3 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.53 -26.65 63.67 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.375 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -55.31 -25.59 35.37 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 111.668 0.247 . . . . 0.0 111.668 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.765 HG11 HG13 ' A' ' 6' ' ' VAL . 21.4 t -89.46 -32.51 5.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 120.612 0.244 . . . . 0.0 111.122 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.77 41.65 1.68 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.454 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.5 mt -74.79 -178.28 3.62 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.628 0.251 . . . . 0.0 110.346 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 -163.85 122.79 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.402 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.59 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -47.26 125.25 7.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.97 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.53 -25.66 5.89 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.595 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.627 ' OD2' HG21 ' A' ' 78' ' ' ILE . 11.3 p-10 -56.91 122.62 12.69 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 121.018 0.437 . . . . 0.0 110.946 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.6 mp0 -76.98 117.78 18.91 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.062 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 1.003 HD11 HD12 ' A' ' 27' ' ' LEU . 14.0 mt -81.76 121.49 35.18 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.899 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mp -108.44 -40.59 5.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.086 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.558 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -120.8 133.08 55.33 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.99 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.4 t -135.3 111.29 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.22 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.28 32.62 0.58 Allowed 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.294 0.568 . . . . 0.0 109.717 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 76.82 -3.35 2.53 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.089 -0.96 . . . . 0.0 112.784 179.869 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.78 HD11 ' CD1' ' A' ' 66' ' ' LEU . 1.1 pt -116.12 125.92 73.4 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-O 120.834 0.349 . . . . 0.0 111.16 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.481 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 18.4 p-10 -64.95 135.91 56.21 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.473 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.0 m -134.2 59.0 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.902 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 46.4 mttt -48.48 -71.44 0.07 Allowed 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.921 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 35.6 mttp -119.81 39.87 3.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.664 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -73.86 -174.87 1.94 Allowed 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.933 -179.353 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.529 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.99 136.24 33.12 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 121.489 0.661 . . . . 0.0 110.678 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.742 ' O ' HG23 ' A' ' 64' ' ' VAL . 5.1 t60 -53.99 -44.48 70.87 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.279 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -61.17 -41.81 97.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.788 0.327 . . . . 0.0 110.737 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -66.3 -41.45 89.71 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 59' ' ' SER . 61.5 t -65.93 -39.13 83.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.606 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.5 t -65.75 -39.02 83.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 178.381 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -57.42 -41.26 80.05 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.887 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.78 ' CD1' HD11 ' A' ' 53' ' ' ILE . 14.2 mt -64.14 -43.62 94.66 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.46 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.782 HG23 HD22 ' A' ' 74' ' ' LEU . 52.0 mt -66.84 -37.47 79.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.623 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -79.31 8.56 45.94 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.444 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.54 1.91 15.16 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 122.448 0.299 . . . . 0.0 110.781 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.439 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 16.0 p -50.98 -44.73 60.78 Favored 'General case' 0 C--O 1.233 0.212 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.487 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.9 m 67.21 30.82 7.01 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.065 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.9 -30.93 2.78 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.152 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.439 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.1 p -163.84 138.0 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.047 0.451 . . . . 0.0 112.193 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.782 HD22 HG23 ' A' ' 67' ' ' ILE . 41.4 tp -114.35 150.41 34.59 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.164 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.4 m80 -120.01 105.82 11.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.344 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.506 ' SD ' HD23 ' A' ' 74' ' ' LEU . 0.9 OUTLIER -115.45 137.18 52.32 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.168 -179.381 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.558 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 20.6 t -107.34 105.75 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.767 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.638 HG22 ' HA ' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -106.82 170.64 2.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.461 -179.821 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -130.41 154.78 47.36 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.571 -179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -105.7 151.12 24.83 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.794 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.33 162.32 20.21 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.2 108.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.937 0.398 . . . . 0.0 111.0 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.44 -1.2 . . . . 0.0 112.273 -179.46 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo . . . . . 0 N--CA 1.493 1.467 0 CA-C-O 120.42 0.092 . . . . 0.0 112.317 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 25.7 ptt85 38.18 39.42 0.26 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.765 0.426 . . . . 0.0 112.068 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.5 p -111.61 132.18 60.92 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.181 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -130.81 145.09 51.88 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.244 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -110.44 132.66 53.99 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.664 179.484 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.672 HG13 HG11 ' A' ' 39' ' ' VAL . 37.1 t -118.33 141.1 39.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.554 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -128.66 100.8 5.87 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.794 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.632 ' O ' HG23 ' A' ' 73' ' ' VAL . 19.5 t -95.56 144.62 9.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-O 120.969 0.414 . . . . 0.0 111.533 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -115.14 106.44 14.09 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.625 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.424 ' HD3' ' HA ' ' A' ' 71' ' ' SER . 17.7 ttt180 -50.62 120.09 4.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.12 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.97 -61.92 5.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.392 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -150.7 -76.29 0.14 Allowed 'General case' 0 C--O 1.231 0.127 0 CA-C-O 120.613 0.244 . . . . 0.0 110.564 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.39 26.46 9.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.508 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.6 173.95 46.52 Favored Glycine 0 C--N 1.336 0.57 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.897 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -111.13 -77.24 0.59 Allowed 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 120.706 0.289 . . . . 0.0 110.922 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.53 45.32 0.04 OUTLIER Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.968 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -159.03 176.77 11.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.442 0.163 . . . . 0.0 110.713 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -140.9 150.38 43.11 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.628 0.252 . . . . 0.0 111.268 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.628 HD21 HD12 ' A' ' 47' ' ' ILE . 2.8 mt -120.98 131.48 54.33 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.568 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.7 m -147.08 163.0 37.67 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.258 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.61 -30.65 5.07 Favored Glycine 0 C--N 1.336 0.554 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.983 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.487 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 80.97 -44.73 0.22 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.443 0.697 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.799 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -111.04 -68.26 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.512 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.799 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 64.0 Cg_endo -73.73 95.72 0.89 Allowed 'Trans proline' 0 C--N 1.356 0.952 0 C-N-CA 122.26 1.974 . . . . 0.0 112.446 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.455 ' SG ' HG21 ' A' ' 63' ' ' VAL . 84.7 m -61.73 118.5 7.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.218 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.31 145.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.396 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.583 HD21 HD23 ' A' ' 41' ' ' LEU . 0.6 OUTLIER -75.86 90.99 2.95 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-O 120.846 0.355 . . . . 0.0 110.507 179.758 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.6 m -54.67 -36.67 64.86 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.417 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.474 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.2 t -164.52 157.94 17.66 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.031 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.419 HG21 ' O ' ' A' ' 41' ' ' LEU . 4.1 t -122.54 154.61 27.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.903 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -97.45 101.28 12.78 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.279 0.561 . . . . 0.0 110.216 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -51.87 121.59 6.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.122 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.86 27.97 8.07 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.193 -0.527 . . . . 0.0 112.525 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.2 m -129.36 164.63 38.23 Favored Pre-proline 0 C--N 1.332 -0.194 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.68 -25.12 25.27 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 122.865 2.376 . . . . 0.0 112.902 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.19 -49.98 65.45 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.815 0.341 . . . . 0.0 110.704 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.03 -25.98 65.64 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.168 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.1 m-30 -57.03 -30.18 64.0 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.599 0.238 . . . . 0.0 111.388 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.672 HG11 HG13 ' A' ' 6' ' ' VAL . 20.8 t -89.28 -25.92 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.253 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.84 5.4 6.94 Favored Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.348 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.617 HD11 HG11 ' A' ' 6' ' ' VAL . 7.3 mp -64.67 111.45 2.76 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 117.315 0.557 . . . . 0.0 109.675 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.482 ' O ' ' HB3' ' A' ' 43' ' ' ALA . 18.0 mmm180 -122.97 25.97 8.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.51 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 42' ' ' ARG . . . 72.92 159.27 0.22 Allowed 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.947 0.404 . . . . 0.0 111.636 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.15 -39.66 3.05 Favored Glycine 0 C--N 1.334 0.46 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.678 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.535 ' OD2' HD13 ' A' ' 27' ' ' LEU . 2.9 p-10 -52.3 119.91 4.94 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.917 0.389 . . . . 0.0 110.843 179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLN . . . . . 0.483 ' O ' HD12 ' A' ' 48' ' ' LEU . 11.0 mt-30 -75.22 126.22 30.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.031 -179.442 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.628 HD12 HD21 ' A' ' 19' ' ' LEU . 19.3 mt -83.09 120.29 34.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.819 179.696 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.483 HD12 ' O ' ' A' ' 46' ' ' GLN . 5.4 mp -105.2 -32.87 8.45 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.624 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.552 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -137.09 137.45 39.3 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 111.018 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.438 HG23 ' CG2' ' A' ' 55' ' ' VAL . 6.3 t -132.25 108.15 13.39 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.424 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 4.8 t-20 77.39 33.59 0.4 Allowed 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.417 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.52 -1.08 3.1 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.517 -179.621 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.655 HD11 HD13 ' A' ' 66' ' ' LEU . 9.0 pt -113.14 119.63 61.1 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 111.176 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 10.9 m120 -62.08 120.63 11.22 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.149 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.457 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 11.9 m -135.14 33.71 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.747 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -61.4 -28.43 69.25 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -123.55 26.83 7.65 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 120.544 0.211 . . . . 0.0 111.3 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.457 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -92.27 -178.96 5.1 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.765 0.317 . . . . 0.0 111.505 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.654 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.3 OUTLIER -80.23 135.36 36.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.362 0.601 . . . . 0.0 110.736 179.688 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.487 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 4.0 t60 -54.79 -44.24 73.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.927 -1.033 . . . . 0.0 111.978 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.469 ' HA ' HG22 ' A' ' 64' ' ' VAL . 20.9 mt-10 -65.64 -35.87 82.06 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.779 0.323 . . . . 0.0 110.567 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.29 -39.38 71.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.167 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 59' ' ' SER . 60.8 t -67.43 -42.31 87.09 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.162 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.469 HG22 ' HA ' ' A' ' 61' ' ' GLU . 31.4 m -65.93 -38.6 82.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.9 tttp -57.48 -40.31 78.3 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.697 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.655 HD13 HD11 ' A' ' 53' ' ' ILE . 21.2 mt -67.63 -42.42 82.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.736 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.508 HG23 HD13 ' A' ' 74' ' ' LEU . 9.5 mt -69.33 -38.38 77.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.996 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -60.1 -24.65 61.1 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.318 179.18 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -80.27 4.43 17.73 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.902 0.334 . . . . 0.0 111.902 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.607 ' HB2' HD12 ' A' ' 74' ' ' LEU . 0.1 OUTLIER -106.18 104.01 13.62 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.356 0.598 . . . . 0.0 110.109 179.708 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.424 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.1 OUTLIER -116.2 33.43 5.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.987 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.93 -53.91 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.088 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 8' ' ' VAL . 4.0 p -172.03 130.96 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-O 120.99 0.424 . . . . 0.0 111.8 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.607 HD12 ' HB2' ' A' ' 70' ' ' CYS . 0.5 OUTLIER -114.5 151.62 32.99 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.546 -179.878 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.522 ' N ' HD23 ' A' ' 74' ' ' LEU . 19.7 m170 -116.39 107.09 14.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.211 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.412 ' HG3' HD22 ' A' ' 74' ' ' LEU . 1.6 mpt? -108.74 145.76 34.61 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.03 -179.323 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.552 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 19.5 t -117.1 98.88 7.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.522 HG22 ' HA ' ' A' ' 47' ' ' ILE . 24.8 pt -101.62 172.1 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.479 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.57 146.84 52.22 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.12 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -61.28 120.96 11.42 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.118 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 175.55 120.87 0.62 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.247 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.1 p -159.25 136.49 2.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.815 0.34 . . . . 0.0 111.204 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.303 -1.276 . . . . 0.0 112.75 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo . . . . . 0 N--CA 1.491 1.343 0 CA-C-O 120.653 0.189 . . . . 0.0 112.348 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 4.6 mtt-85 -178.9 95.11 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.811 0.339 . . . . 0.0 110.68 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 3' ' ' VAL . 9.2 p -85.83 105.47 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.07 0.462 . . . . 0.0 111.26 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.73 ' HG2' HD11 ' A' ' 78' ' ' ILE . 6.9 tpt180 -114.18 139.27 49.5 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.844 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.81 131.06 57.05 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.182 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.825 HG11 HD13 ' A' ' 41' ' ' LEU . 25.6 t -120.91 131.49 72.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.693 0.282 . . . . 0.0 110.826 179.485 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.644 ' O ' HG21 ' A' ' 39' ' ' VAL . 25.6 mt-10 -116.7 115.25 25.29 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.009 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.448 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.2 t -108.57 138.58 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.787 0.327 . . . . 0.0 111.435 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.3 93.89 8.87 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.397 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.436 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 4.0 ttt-85 -51.81 126.41 17.9 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.445 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.92 -112.67 0.03 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.687 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -111.27 -39.33 4.75 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.468 0.175 . . . . 0.0 111.329 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -138.75 35.13 2.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.337 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 159.96 -170.45 36.1 Favored Glycine 0 C--N 1.338 0.65 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.731 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.436 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 71.5 m-85 -118.63 -69.42 0.85 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.865 0.364 . . . . 0.0 111.161 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.16 52.49 0.04 OUTLIER Glycine 0 C--N 1.332 0.315 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.317 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.525 ' HB2' HD21 ' A' ' 27' ' ' LEU . 51.0 p90 -162.99 155.47 18.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.549 0.214 . . . . 0.0 110.952 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.14 129.13 43.52 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.932 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -116.57 124.37 49.68 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.993 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 39.2 m -148.07 115.58 6.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.177 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -168.1 83.28 0.1 OUTLIER Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.49 -179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.25 -43.07 21.68 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.972 0.415 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.96 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -121.25 -66.69 0.02 OUTLIER Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.455 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.96 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 92.3 Cg_endo -85.23 94.88 0.64 Allowed 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 122.475 2.117 . . . . 0.0 112.214 179.269 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 2.6 m -51.87 117.66 2.89 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.822 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -141.51 149.41 20.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.378 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.612 HD11 HD21 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -80.46 91.49 5.74 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.741 179.661 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.08 -45.38 61.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.517 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.503 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.5 t -164.4 159.06 19.21 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.59 HG22 HD22 ' A' ' 27' ' ' LEU . 5.2 t -116.9 155.03 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.714 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -99.5 100.76 11.83 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.153 0.501 . . . . 0.0 110.278 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.3 mtm-85 -52.07 125.94 17.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.943 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.91 23.64 11.46 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.682 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.86 168.92 14.29 Favored Pre-proline 0 CA--C 1.531 0.218 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.669 ' O ' HG23 ' A' ' 39' ' ' VAL . 78.4 Cg_exo -50.66 -29.93 27.11 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.885 2.39 . . . . 0.0 113.051 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.796 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -65.09 -49.82 68.51 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 111.014 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -69.43 -32.79 71.98 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.243 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 16.7 m-30 -62.77 -23.78 67.38 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.455 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.669 HG23 ' O ' ' A' ' 35' ' ' PRO . 38.8 t -89.32 -29.6 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.58 0.229 . . . . 0.0 111.246 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.89 39.96 0.86 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.717 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.825 HD13 HG11 ' A' ' 6' ' ' VAL . 4.1 tp -73.28 178.62 4.38 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.806 0.336 . . . . 0.0 110.765 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -173.92 131.17 0.41 Allowed 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.944 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.503 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -62.67 120.81 11.92 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.911 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 128.23 -27.57 4.48 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.804 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -58.3 123.92 17.72 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 120.927 0.394 . . . . 0.0 111.062 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -78.21 124.7 28.37 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.716 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.3 mt -95.66 122.21 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.802 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.76 HD12 ' HD2' ' A' ' 56' ' ' LYS . 0.3 OUTLIER -108.19 -38.32 5.79 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.016 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.523 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -119.01 138.14 53.04 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.569 ' HB ' HG21 ' A' ' 55' ' ' VAL . 19.3 t -141.71 115.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.773 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.417 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.7 t-20 76.89 32.78 0.49 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -178.302 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.417 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.2 -0.71 3.23 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.454 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.71 HD11 HD13 ' A' ' 66' ' ' LEU . 12.1 pt -120.47 133.42 67.23 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 111.434 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.523 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 22.9 t-20 -63.07 121.73 14.32 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.966 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.569 HG21 ' HB ' ' A' ' 50' ' ' VAL . 5.0 m -140.41 55.35 0.21 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.553 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.76 ' HD2' HD12 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.03 14.52 31.74 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.546 179.572 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -150.89 27.95 0.7 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 122.279 0.232 . . . . 0.0 111.12 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -113.99 -167.45 1.21 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-O 120.706 0.289 . . . . 0.0 111.59 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.591 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.4 OUTLIER -88.74 139.15 30.75 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 121.361 0.6 . . . . 0.0 110.533 179.672 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.727 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.3 t60 -53.69 -44.78 70.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.871 -1.058 . . . . 0.0 112.052 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -60.62 -42.32 96.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.742 0.306 . . . . 0.0 110.731 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -64.79 -44.06 91.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.265 179.033 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 59' ' ' SER . 52.4 t -63.36 -42.81 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.128 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.727 HG23 ' O ' ' A' ' 60' ' ' HIS . 50.3 t -66.17 -38.91 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -57.77 -41.1 81.3 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.89 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.71 HD13 HD11 ' A' ' 53' ' ' ILE . 17.7 mt -64.05 -43.45 95.49 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.566 HG23 HD22 ' A' ' 74' ' ' LEU . 68.6 mt -62.42 -44.27 99.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.679 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -69.51 -22.37 76.5 Favored Glycine 0 CA--C 1.522 0.49 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.004 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.9 tptt -57.0 -34.68 68.38 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.577 0.227 . . . . 0.0 111.421 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -69.01 -57.8 4.96 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-O 120.912 0.387 . . . . 0.0 110.676 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.416 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.5 OUTLIER 65.05 36.09 7.61 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.108 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.28 -45.56 0.02 OUTLIER Glycine 0 C--N 1.332 0.313 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.196 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.2 p -165.46 138.78 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.829 0.347 . . . . 0.0 111.287 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.566 HD22 HG23 ' A' ' 67' ' ' ILE . 28.3 tp -112.29 134.65 53.71 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.286 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 55.6 m170 -119.53 98.49 6.16 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.2 179.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.97 145.15 40.12 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.327 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 22.9 t -96.67 114.0 32.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.545 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.73 HD11 ' HG2' ' A' ' 4' ' ' ARG . 1.7 pt -103.37 146.23 11.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.311 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -112.94 144.57 42.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.267 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -91.91 119.05 31.32 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.449 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -83.89 -122.27 0.91 Allowed Glycine 0 C--N 1.333 0.412 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.636 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 21.3 t -83.28 81.54 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-O 120.981 0.42 . . . . 0.0 110.372 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.465 -1.186 . . . . 0.0 112.322 -179.878 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 120.575 0.156 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -119.37 161.14 20.99 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.953 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.498 ' O ' HG13 ' A' ' 3' ' ' VAL . 11.9 p -114.44 112.31 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 120.887 0.375 . . . . 0.0 111.327 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.5 ttt85 -118.48 136.27 53.9 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.203 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.09 129.54 36.37 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.754 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.405 HG11 ' CD2' ' A' ' 41' ' ' LEU . 25.0 t -126.35 135.51 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.333 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -133.35 109.11 9.13 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.515 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.2 t -102.46 144.48 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.204 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -110.23 102.96 11.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.853 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.91 120.3 5.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.211 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.52 -122.03 0.58 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.647 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -114.41 -40.7 3.58 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.514 0.197 . . . . 0.0 111.151 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -105.94 29.42 6.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 120.721 0.296 . . . . 0.0 111.52 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.96 -176.92 16.77 Favored Glycine 0 C--N 1.337 0.606 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.826 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CE2' HG22 ' A' ' 67' ' ' ILE . 61.8 m-85 -79.3 -71.46 0.44 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.896 0.379 . . . . 0.0 110.718 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.23 48.99 0.04 OUTLIER Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.836 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.743 ' HB2' HD23 ' A' ' 27' ' ' LEU . 50.5 p90 -161.01 171.59 18.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.673 0.273 . . . . 0.0 110.946 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -126.31 133.17 51.47 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.899 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.531 HD21 ' CD1' ' A' ' 47' ' ' ILE . 3.4 mt -115.27 124.59 51.72 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.204 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.4 m -136.7 16.31 3.11 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.301 -0.409 . . . . 0.0 112.101 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.44 85.19 1.57 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.071 -0.585 . . . . 0.0 112.445 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.34 -66.66 0.35 Allowed 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.691 0.281 . . . . 0.0 111.011 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.883 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -91.76 -59.06 0.23 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.103 178.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.883 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 83.9 Cg_endo -88.59 94.32 0.38 Allowed 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 122.89 2.393 . . . . 0.0 111.607 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.57 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.2 m -50.98 124.24 10.91 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.679 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 45' ' ' ASP . 7.3 p -154.07 141.89 13.11 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.743 HD23 ' HB2' ' A' ' 17' ' ' PHE . 1.6 mp -79.71 89.53 5.18 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.771 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -56.22 -35.24 67.11 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.473 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.3 t -153.16 152.05 30.82 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.3 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.2 t -123.13 154.76 28.86 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.724 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 32.3 mtt -98.64 100.29 11.5 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.268 0.556 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.37 123.29 13.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.847 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 108.85 -19.71 30.15 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.785 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.0 166.59 25.64 Favored Pre-proline 0 CA--C 1.531 0.231 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -55.45 -24.93 46.14 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.709 2.273 . . . . 0.0 112.621 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.769 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -63.57 -49.11 74.7 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.993 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.08 -28.95 65.84 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.286 179.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.7 m-30 -56.64 -33.08 65.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.687 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -89.25 -31.06 5.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.024 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.2 51.71 1.44 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.176 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.769 HD12 ' HB1' ' A' ' 36' ' ' ALA . 5.3 mt -59.32 -25.81 64.47 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 20.5 mtt85 66.7 119.49 0.03 OUTLIER 'General case' 0 C--N 1.34 0.187 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.39 89.19 0.21 Allowed 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.496 179.249 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.0 -12.7 5.04 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 121.208 -0.52 . . . . 0.0 112.905 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.542 ' HB3' HD12 ' A' ' 78' ' ' ILE . 1.3 t70 -58.22 127.49 32.38 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.711 0.291 . . . . 0.0 110.573 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.59 126.65 30.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.739 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.812 ' HA ' HG22 ' A' ' 78' ' ' ILE . 15.1 mt -90.63 131.06 38.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.599 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -119.06 -43.65 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.358 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.07 137.25 47.27 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.008 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.6 t -144.28 110.98 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.297 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.413 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.3 t-20 76.99 35.74 0.35 Allowed 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -178.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.2 OUTLIER 71.55 -0.27 3.21 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.252 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 12.3 pt -120.97 125.5 74.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-O 120.81 0.338 . . . . 0.0 111.121 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.524 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -68.59 172.09 6.7 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.954 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.476 HG11 HG22 ' A' ' 63' ' ' VAL . 3.7 m -138.57 -51.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.039 -0.528 . . . . 0.0 112.121 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt 72.15 -59.41 0.56 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 123.119 0.567 . . . . 0.0 110.828 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.8 mtpt -148.23 40.26 0.94 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.75 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -72.74 -173.79 1.28 Allowed 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.859 0.362 . . . . 0.0 111.4 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.569 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -90.14 135.8 33.44 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.416 0.627 . . . . 0.0 111.174 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.539 ' O ' HG22 ' A' ' 64' ' ' VAL . 2.4 t-160 -53.13 -44.33 67.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.486 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.465 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.3 pm0 -66.21 -34.74 78.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.169 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.62 -39.43 70.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.725 0.297 . . . . 0.0 110.343 179.251 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.57 HG21 ' SG ' ' A' ' 25' ' ' CYS . 48.0 t -67.3 -43.87 87.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.941 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 60' ' ' HIS . 15.9 m -66.32 -38.96 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.6 mmtt -58.11 -39.73 79.42 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.059 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 25.3 mt -68.09 -41.19 82.21 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.772 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.557 HG23 HD22 ' A' ' 74' ' ' LEU . 17.7 mt -69.39 -38.49 77.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.035 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -87.77 14.33 58.72 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.102 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.57 -29.22 12.46 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.847 0.324 . . . . 0.0 111.299 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.426 ' HB2' HD12 ' A' ' 74' ' ' LEU . 0.5 OUTLIER -69.71 -61.86 1.61 Allowed 'General case' 0 C--O 1.233 0.217 0 CA-C-O 120.827 0.346 . . . . 0.0 110.645 -179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 70.63 33.88 2.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.088 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.52 -49.4 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.126 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -174.73 132.56 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 111.669 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.557 HD22 HG23 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.91 152.98 31.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.672 179.676 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.9 m170 -117.52 105.38 12.02 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.948 179.211 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.24 156.2 25.81 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.431 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.456 ' CG1' HG23 ' A' ' 3' ' ' VAL . 26.4 t -125.53 100.52 7.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.072 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.812 HG22 ' HA ' ' A' ' 47' ' ' ILE . 18.4 pt -101.36 158.67 4.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.388 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -114.86 116.64 28.89 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.72 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.44 120.83 18.6 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -168.89 43.26 0.22 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.397 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.61 104.33 15.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-O 120.667 0.27 . . . . 0.0 110.735 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.191 0 CA-C-O 118.675 -1.069 . . . . 0.0 112.937 -179.912 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo . . . . . 0 N--CA 1.492 1.395 0 CA-C-O 120.384 0.077 . . . . 0.0 112.072 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 70.78 131.47 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.837 0.455 . . . . 0.0 111.358 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.466 HG22 ' CG1' ' A' ' 77' ' ' VAL . 11.5 p -65.78 121.05 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.3 ptt180 -137.1 170.77 15.54 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.49 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.7 m -93.81 139.01 31.37 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.459 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.818 HG13 HG11 ' A' ' 39' ' ' VAL . 36.9 t -117.44 146.92 21.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.09 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -111.3 102.55 10.94 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.789 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 73' ' ' VAL . 13.4 t -88.54 119.88 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.174 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.119 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.91 89.63 8.07 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.472 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.405 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 7.9 ttm-85 -53.47 122.12 9.07 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.731 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.29 -68.98 1.42 Allowed Glycine 0 C--N 1.335 0.483 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.548 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -165.32 -51.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 120.725 0.298 . . . . 0.0 110.807 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -122.53 25.04 9.0 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.596 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 150.94 171.53 19.14 Favored Glycine 0 C--N 1.336 0.58 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.795 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.405 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 5.4 m-85 -108.04 -62.85 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.667 0.27 . . . . 0.0 110.646 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.26 -33.5 0.93 Allowed Glycine 0 CA--C 1.523 0.541 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.879 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -71.48 178.59 3.39 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.021 0.439 . . . . 0.0 111.445 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 m -139.84 142.6 36.6 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.205 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.62 HD21 HD12 ' A' ' 47' ' ' ILE . 0.7 OUTLIER -117.82 123.98 47.25 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.883 179.924 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.7 m -140.5 168.04 20.75 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.292 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 117.28 -35.2 4.24 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.877 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.44 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.35 -46.57 0.22 Allowed 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.457 0.703 . . . . 0.0 111.559 -179.829 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -101.64 -65.31 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.405 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.88 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 97.0 Cg_endo -79.77 96.04 1.04 Allowed 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.41 2.074 . . . . 0.0 112.384 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.419 ' SG ' HG11 ' A' ' 63' ' ' VAL . 69.8 m -61.44 114.26 3.12 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.135 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -149.0 143.72 18.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.253 -179.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.674 HD12 HD11 ' A' ' 47' ' ' ILE . 3.7 mp -73.13 89.75 1.51 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.655 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.8 m -52.49 -39.52 61.33 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.418 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -163.53 158.78 21.22 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.581 HG22 HD23 ' A' ' 27' ' ' LEU . 5.3 t -132.96 155.18 40.92 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.47 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 9.1 mtt -109.24 106.04 15.72 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.878 0.37 . . . . 0.0 110.477 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 32' ' ' ARG . 2.5 mtm105 -43.51 111.34 0.27 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.048 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 126.16 -16.1 6.81 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.754 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.502 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 10.0 p -80.58 162.98 58.7 Favored Pre-proline 0 CA--C 1.532 0.282 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.502 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 14.1 Cg_endo -55.84 -24.85 49.26 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 122.718 2.278 . . . . 0.0 112.751 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.546 ' HA ' HD12 ' A' ' 41' ' ' LEU . . . -68.75 -48.04 64.75 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.403 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.77 -30.97 72.0 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.321 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -56.03 -34.56 65.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.818 HG11 HG13 ' A' ' 6' ' ' VAL . 20.3 t -89.63 -29.35 5.07 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.271 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.88 -10.51 4.85 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.851 -0.69 . . . . 0.0 113.357 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.72 ' CD2' HD13 ' A' ' 78' ' ' ILE . 46.9 mt -54.0 116.15 2.41 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 117.016 0.408 . . . . 0.0 110.857 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.92 -153.32 0.56 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.747 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 104.02 15.97 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.424 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.94 -25.74 2.38 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.792 -0.718 . . . . 0.0 113.383 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.99 117.78 6.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.995 0.398 . . . . 0.0 111.101 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.04 132.27 35.14 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.799 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.674 HD11 HD12 ' A' ' 27' ' ' LEU . 17.1 mt -91.36 133.35 33.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.556 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.533 HD11 ' CB ' ' A' ' 79' ' ' ALA . 3.1 mp -117.51 -47.14 2.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.881 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.536 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -116.08 136.89 52.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.657 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.524 HG21 HG13 ' A' ' 63' ' ' VAL . 21.8 t -132.95 109.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.402 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 7.9 t30 76.83 33.62 0.46 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.642 -178.33 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 77.51 -2.66 2.53 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.651 -179.868 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.662 HD11 ' CD1' ' A' ' 66' ' ' LEU . 13.6 pt -111.84 121.48 64.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 120.871 0.367 . . . . 0.0 111.161 179.587 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.536 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -63.59 124.01 20.29 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.063 -179.683 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.689 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.6 m -134.55 53.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.299 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 9.0 mtmt -63.45 -37.12 86.08 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.568 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -127.16 27.55 5.89 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.574 -0.284 . . . . 0.0 111.34 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.689 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -81.31 -174.02 4.68 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.694 0.283 . . . . 0.0 111.281 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.661 ' O ' HG23 ' A' ' 63' ' ' VAL . 52.0 m -84.25 139.81 32.1 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.495 0.664 . . . . 0.0 110.825 179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.719 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.1 t60 -60.8 -44.62 96.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.697 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -63.04 -42.05 99.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.437 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.79 -45.11 94.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.556 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 59' ' ' SER . 58.5 t -63.83 -41.96 94.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.8 t -65.76 -39.04 83.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 178.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.67 -39.96 78.28 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.897 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.662 ' CD1' HD11 ' A' ' 53' ' ' ILE . 13.8 mt -66.41 -43.15 86.57 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.705 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.431 HG12 HD22 ' A' ' 74' ' ' LEU . 25.0 mt -65.25 -37.2 79.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.759 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -83.63 12.55 51.69 Favored Glycine 0 CA--C 1.525 0.673 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.549 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -112.44 -14.73 13.22 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 122.43 0.292 . . . . 0.0 111.459 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.471 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 27.2 p -45.99 -49.18 16.3 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 122.651 0.38 . . . . 0.0 111.96 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.16 33.87 9.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.974 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 151.74 -36.73 0.84 Allowed Glycine 0 C--N 1.334 0.44 0 C-N-CA 120.805 -0.712 . . . . 0.0 113.132 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.4 p -173.59 137.25 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.906 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.444 HD21 HG13 ' A' ' 50' ' ' VAL . 11.3 tp -112.63 142.34 45.33 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.947 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.3 m170 -107.31 98.05 7.73 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.124 179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.5 ptm -119.66 146.88 45.17 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.481 -179.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.466 ' CG1' HG22 ' A' ' 3' ' ' VAL . 24.6 t -102.12 112.9 36.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.963 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.72 HD13 ' CD2' ' A' ' 41' ' ' LEU . 19.5 pt -101.05 170.27 1.59 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.304 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.533 ' CB ' HD11 ' A' ' 48' ' ' LEU . . . -140.09 118.46 12.12 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.178 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.35 118.98 12.91 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.784 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -88.62 -174.37 47.12 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.783 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 m -64.37 -33.62 63.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.868 -0.962 . . . . 0.0 113.207 179.805 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo . . . . . 0 N--CA 1.491 1.374 0 CA-C-O 120.934 0.306 . . . . 0.0 112.141 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 7.0 ttt85 -92.71 151.18 20.21 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.8 t -91.94 128.72 43.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.972 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -121.99 140.81 52.02 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.132 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 m -97.64 127.68 43.78 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.849 HG13 HG11 ' A' ' 39' ' ' VAL . 38.9 t -120.08 141.8 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.137 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.9 122.6 36.5 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.158 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.534 ' O ' HG23 ' A' ' 73' ' ' VAL . 9.3 t -105.53 149.48 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.131 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -107.42 101.95 11.26 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.143 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -57.5 120.15 7.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.32 -110.11 0.34 Allowed Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.306 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 11.2 mtt85 -106.48 -70.94 0.77 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.65 0.262 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.52 44.52 1.24 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.172 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.55 -153.64 25.26 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.881 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.641 ' OH ' HG22 ' A' ' 67' ' ' ILE . 16.7 m-85 -131.69 -54.41 1.0 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.772 0.32 . . . . 0.0 111.184 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.27 -22.05 1.73 Allowed Glycine 0 CA--C 1.524 0.603 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.908 -179.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.84 163.01 12.79 Favored 'General case' 0 CA--C 1.53 0.203 0 CA-C-O 120.89 0.376 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.26 122.17 46.75 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD21 HD12 ' A' ' 47' ' ' ILE . 0.4 OUTLIER -105.18 125.26 50.78 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.229 -179.844 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.78 110.86 3.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.222 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -165.41 79.21 0.12 Allowed Glycine 0 N--CA 1.445 -0.74 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.893 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.89 -45.32 7.5 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.928 0.394 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.963 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -114.74 -66.42 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.402 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.963 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 95.0 Cg_endo -87.42 94.35 0.46 Allowed 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 122.606 2.204 . . . . 0.0 112.266 179.285 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 83.0 m -52.97 115.65 1.96 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.411 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -146.02 145.54 20.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.803 0.335 . . . . 0.0 111.796 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -73.75 90.1 1.84 Allowed 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.365 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -47.29 -51.61 18.61 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.868 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.6 t -154.45 159.36 41.01 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.475 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.5 t -125.21 154.47 33.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.597 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.2 mtp -107.6 104.72 14.32 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.211 0.529 . . . . 0.0 110.264 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -53.09 126.37 20.48 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.884 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.26 24.68 12.14 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.446 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.67 170.81 10.37 Favored Pre-proline 0 CA--C 1.532 0.252 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -47.27 -30.7 11.39 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 123.001 2.468 . . . . 0.0 113.619 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -71.3 -48.4 50.92 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 120.815 0.341 . . . . 0.0 111.029 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -69.59 -30.28 68.01 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.525 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.8 m-30 -60.13 -23.69 64.08 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 111.62 0.23 . . . . 0.0 111.62 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.849 HG11 HG13 ' A' ' 6' ' ' VAL . 22.9 t -89.19 -31.31 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.689 0.28 . . . . 0.0 110.897 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.8 36.3 3.26 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.522 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 6.4 mt -69.42 -177.99 1.29 Allowed 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.834 0.35 . . . . 0.0 110.738 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.84 131.94 7.19 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.266 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.43 98.92 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.378 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 148.51 -25.46 1.36 Allowed Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.703 -178.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.558 ' CG ' HD13 ' A' ' 78' ' ' ILE . 12.7 m-20 -56.11 118.46 4.7 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.833 0.316 . . . . 0.0 110.718 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -77.12 123.01 25.79 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.821 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.792 ' HA ' HG22 ' A' ' 78' ' ' ILE . 31.0 mt -77.91 121.64 31.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.685 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.977 HD11 ' HB2' ' A' ' 79' ' ' ALA . 2.4 mt -100.4 -46.83 5.11 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.408 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -133.4 138.79 46.43 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.224 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.6 t -128.91 110.48 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.458 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.8 t30 76.88 31.04 0.55 Allowed 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -178.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.62 -2.35 1.62 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.836 179.864 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.754 HD11 HD13 ' A' ' 66' ' ' LEU . 1.2 pp -110.49 128.18 66.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.057 0.456 . . . . 0.0 111.381 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.4 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -65.27 142.96 58.1 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.609 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.2 m -145.23 62.47 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.453 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -71.16 -37.94 72.19 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.485 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -139.13 32.9 2.13 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.803 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.89 -179.97 5.79 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.558 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.604 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.5 OUTLIER -93.16 135.61 34.19 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.421 0.629 . . . . 0.0 110.728 179.868 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 7.7 t60 -53.91 -43.88 70.09 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.974 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.471 ' HA ' HG22 ' A' ' 64' ' ' VAL . 1.5 mt-10 -62.05 -36.82 82.79 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.945 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.6 -40.66 69.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 59' ' ' SER . 46.3 t -65.59 -43.19 94.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.153 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.532 ' HA ' HD12 ' A' ' 67' ' ' ILE . 30.7 m -65.46 -38.41 82.41 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -57.98 -41.25 82.55 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.053 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.754 HD13 HD11 ' A' ' 53' ' ' ILE . 4.4 mt -68.17 -40.55 82.27 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.694 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.641 HG22 ' OH ' ' A' ' 15' ' ' TYR . 11.2 mt -69.21 -42.22 81.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.592 179.575 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.44 -4.26 84.11 Favored Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.923 -0.656 . . . . 0.0 113.41 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 7.1 tttt -79.34 -36.49 39.36 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 117.006 0.403 . . . . 0.0 111.647 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.32 -60.85 2.39 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.703 0.287 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 71.69 33.2 1.83 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.62 -49.92 0.01 OUTLIER Glycine 0 C--N 1.332 0.357 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.196 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.6 p -175.27 132.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 121.061 0.458 . . . . 0.0 111.691 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.464 HD22 HG12 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.83 154.66 28.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.756 179.776 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -109.68 98.45 7.79 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.055 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.49 ' HG2' HG23 ' A' ' 47' ' ' ILE . 13.8 ttm -97.54 128.28 44.16 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.35 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.31 95.64 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.388 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.792 HG22 ' HA ' ' A' ' 47' ' ' ILE . 2.5 pp -100.35 170.82 1.45 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.486 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.977 ' HB2' HD11 ' A' ' 48' ' ' LEU . . . -123.79 143.47 50.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.251 179.55 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -98.83 167.25 10.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.032 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -144.98 72.25 0.35 Allowed Glycine 0 C--N 1.332 0.317 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.376 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 m -62.75 109.89 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.789 0.328 . . . . 0.0 111.417 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.704 -1.053 . . . . 0.0 112.766 -179.66 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.486 1.084 0 CA-C-O 120.419 0.091 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 69.89 -66.56 0.26 Allowed 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 122.759 0.424 . . . . 0.0 111.409 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 p 42.81 100.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.745 0.818 . . . . 0.0 112.634 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.497 HH21 HG22 ' A' ' 6' ' ' VAL . 4.8 ptm180 -115.39 166.87 11.4 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.26 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -109.22 141.8 40.95 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.951 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.642 HG23 HD11 ' A' ' 78' ' ' ILE . 41.9 t -129.48 131.3 67.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.188 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -115.69 105.77 13.12 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.711 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.695 HG11 ' HB3' ' A' ' 15' ' ' TYR . 3.4 t -86.49 154.11 3.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.894 0.378 . . . . 0.0 111.035 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -112.92 104.99 12.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.935 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -48.36 110.59 0.35 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.714 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.95 -110.7 0.08 OUTLIER Glycine 0 C--N 1.333 0.378 0 C-N-CA 121.101 -0.571 . . . . 0.0 112.675 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.85 -39.89 2.91 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.83 36.68 4.35 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.815 0.34 . . . . 0.0 111.468 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.99 -129.21 5.53 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.534 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.695 ' HB3' HG11 ' A' ' 8' ' ' VAL . 98.8 m-85 -131.88 -70.96 0.56 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.663 0.268 . . . . 0.0 111.087 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 152.58 40.62 0.03 OUTLIER Glycine 0 CA--C 1.518 0.252 0 C-N-CA 121.053 -0.594 . . . . 0.0 113.179 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -158.58 -177.76 6.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.561 0.22 . . . . 0.0 110.691 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -134.7 158.02 45.19 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-O 120.775 0.322 . . . . 0.0 111.182 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -138.96 132.07 29.68 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.0 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 p -145.93 165.09 29.98 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 111.344 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 22' ' ' GLN . . . 122.47 -22.98 7.27 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 121.186 -0.53 . . . . 0.0 113.142 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.651 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 70.04 2.52 3.96 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -179.758 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.652 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -168.6 -61.75 0.01 OUTLIER Pre-proline 0 C--O 1.233 0.199 0 C-N-CA 122.162 0.185 . . . . 0.0 110.635 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.652 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 58.4 Cg_endo -69.86 81.4 0.84 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.306 2.004 . . . . 0.0 110.955 178.817 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.617 ' SG ' HG11 ' A' ' 63' ' ' VAL . 62.0 m -50.39 109.29 0.29 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.071 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.4 141.55 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.717 HD21 HD13 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -75.16 90.68 2.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.389 179.575 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 p -58.99 -38.16 78.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.189 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.1 t -168.17 154.91 7.66 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-O 120.823 0.344 . . . . 0.0 111.438 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.638 HG22 HD23 ' A' ' 27' ' ' LEU . 3.4 t -122.05 154.03 26.49 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.531 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.1 mtm -101.02 100.66 11.29 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.986 0.422 . . . . 0.0 110.52 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.0 mtt180 -51.42 125.75 15.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.749 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.52 26.61 10.67 Favored Glycine 0 CA--C 1.52 0.358 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.339 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.409 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 58.0 m -131.0 162.82 53.26 Favored Pre-proline 0 CA--C 1.529 0.163 0 N-CA-C 110.434 -0.21 . . . . 0.0 110.434 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.512 ' O ' HG23 ' A' ' 39' ' ' VAL . 83.2 Cg_exo -46.75 -31.85 11.25 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.17 2.58 . . . . 0.0 113.296 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.694 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -67.01 -50.0 63.54 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-O 120.814 0.34 . . . . 0.0 110.968 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -70.66 -30.75 67.45 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.13 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 22.6 m-30 -59.58 -23.61 63.07 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.704 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.575 ' CG1' HG13 ' A' ' 6' ' ' VAL . 20.1 t -89.31 -32.3 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 120.652 0.263 . . . . 0.0 111.207 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.84 58.63 0.34 Allowed Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.76 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.717 HD13 HD21 ' A' ' 27' ' ' LEU . 17.7 mt -97.25 176.4 5.92 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.791 0.329 . . . . 0.0 110.571 179.631 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.45 133.39 0.81 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.909 0.385 . . . . 0.0 111.082 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.03 125.72 24.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.909 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.13 -30.59 4.29 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.389 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -62.53 121.27 12.88 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.825 0.345 . . . . 0.0 110.734 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.4 tp60 -77.9 118.09 19.88 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.928 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.552 HD11 HD12 ' A' ' 27' ' ' LEU . 19.9 mt -79.45 122.85 35.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.817 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mp -106.8 -41.45 5.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.605 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.497 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -113.82 152.22 30.97 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.864 0.364 . . . . 0.0 111.302 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.81 HG21 HG13 ' A' ' 63' ' ' VAL . 2.7 m -149.42 102.63 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.363 179.463 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 75.65 39.62 0.33 Allowed 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 74.79 -1.23 3.14 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.733 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.653 HD11 HD13 ' A' ' 66' ' ' LEU . 23.8 pt -117.27 132.1 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 111.775 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.497 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 5.0 p-10 -66.92 154.67 40.44 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 121.273 0.559 . . . . 0.0 112.123 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.47 HG11 HG22 ' A' ' 63' ' ' VAL . 9.1 m -149.58 62.9 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.295 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -55.73 -77.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.661 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -115.72 37.33 3.65 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 120.769 0.318 . . . . 0.0 110.969 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' ALA . . . -75.28 -172.6 1.78 Allowed 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.45 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -89.29 135.43 33.58 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 121.385 0.612 . . . . 0.0 110.715 179.759 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.759 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.9 t60 -57.35 -44.56 84.43 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.654 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -63.27 -40.19 96.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.649 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.51 -45.34 87.68 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.451 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.81 HG13 HG21 ' A' ' 50' ' ' VAL . 48.7 t -63.49 -42.71 97.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.185 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 60' ' ' HIS . 50.7 t -65.64 -39.45 85.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.23 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -40.05 83.51 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.046 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.653 HD13 HD11 ' A' ' 53' ' ' ILE . 6.4 mt -66.92 -40.16 87.56 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.918 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.682 HD12 ' HA ' ' A' ' 64' ' ' VAL . 7.3 mt -69.12 -41.92 81.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.482 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -73.77 -25.74 71.16 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.633 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 tppt? -53.98 -35.02 61.39 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 t -69.86 -54.15 14.79 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.75 0.309 . . . . 0.0 110.84 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.1 m 63.62 35.7 11.43 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.963 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.99 -43.87 0.02 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.381 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 8' ' ' VAL . 6.5 p -162.01 134.47 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-O 120.959 0.409 . . . . 0.0 111.535 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.596 HD23 ' CE1' ' A' ' 15' ' ' TYR . 3.8 pp -114.41 154.42 28.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -131.61 116.06 16.9 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.68 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.446 ' CE ' HD13 ' A' ' 74' ' ' LEU . 4.0 mtt -131.92 139.44 48.73 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.88 0.371 . . . . 0.0 111.437 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 29.3 t -103.9 112.85 39.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.977 178.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.642 HD11 HG23 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.53 155.32 8.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.68 -179.193 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -116.85 139.01 51.1 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.285 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -105.38 119.85 40.11 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.661 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -122.73 66.14 0.5 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.449 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.512 HG22 ' O ' ' A' ' 82' ' ' VAL . 8.3 p -114.18 21.08 6.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 120.89 0.376 . . . . 0.0 111.45 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.388 -1.229 . . . . 0.0 112.62 179.783 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.49 1.273 0 CA-C-O 120.624 0.177 . . . . 0.0 111.935 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.47 161.11 14.51 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.096 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.7 p -111.23 115.57 50.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttt180 -115.81 142.74 46.35 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.01 -179.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 m -113.55 129.21 56.6 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.069 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.874 HG11 HD13 ' A' ' 41' ' ' LEU . 20.7 t -116.95 131.66 68.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.817 179.736 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -100.78 100.95 11.69 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.946 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.505 ' O ' HG23 ' A' ' 73' ' ' VAL . 13.5 t -86.09 108.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.056 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -94.82 91.82 6.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.8 ttt85 -36.55 119.12 0.6 Allowed 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.407 0.442 . . . . 0.0 111.118 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.01 -118.27 0.16 Allowed Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.746 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -113.7 -38.5 4.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.501 0.191 . . . . 0.0 111.338 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.34 28.11 8.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 124.07 -160.57 18.63 Favored Glycine 0 C--N 1.338 0.677 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.827 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 60.5 m-85 -89.82 -54.24 4.14 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.581 0.229 . . . . 0.0 111.039 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.91 65.05 0.59 Allowed Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.382 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.787 ' HB2' HD21 ' A' ' 27' ' ' LEU . 20.5 p90 -168.03 172.62 8.68 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.643 0.259 . . . . 0.0 111.41 179.645 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -122.5 159.73 27.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.28 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -149.26 130.07 14.21 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.038 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.93 158.71 38.4 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.782 0.325 . . . . 0.0 111.534 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 131.13 -27.15 3.86 Favored Glycine 0 CA--C 1.526 0.727 0 C-N-CA 121.204 -0.522 . . . . 0.0 113.114 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.529 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 62.01 13.83 5.97 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -179.825 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.832 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -170.74 -65.62 0.0 OUTLIER Pre-proline 0 N--CA 1.464 0.228 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.832 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.7 Cg_endo -75.84 83.6 1.92 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.359 2.039 . . . . 0.0 111.428 178.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 92.6 m -51.06 111.51 0.57 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.513 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.01 142.26 24.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.411 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.787 HD21 ' HB2' ' A' ' 17' ' ' PHE . 0.1 OUTLIER -83.69 92.53 7.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.483 179.682 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 t -58.28 -38.62 77.33 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.281 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.487 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.9 t -166.09 158.93 14.9 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.893 0.378 . . . . 0.0 111.135 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.599 HG22 HD22 ' A' ' 27' ' ' LEU . 17.2 t -115.15 154.46 16.52 Favored 'Isoleucine or valine' 0 C--O 1.232 0.182 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.638 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.7 mmm -89.72 99.29 12.32 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-O 121.342 0.592 . . . . 0.0 110.327 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.28 126.24 20.43 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.966 -1.015 . . . . 0.0 111.175 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.99 27.54 12.27 Favored Glycine 0 CA--C 1.52 0.402 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.606 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.26 168.81 15.7 Favored Pre-proline 0 C--O 1.234 0.256 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.518 ' O ' HG23 ' A' ' 39' ' ' VAL . 84.1 Cg_exo -48.58 -34.16 25.83 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 123.036 2.491 . . . . 0.0 113.018 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.595 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -60.16 -48.34 82.12 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.136 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -65.54 -33.2 75.36 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.501 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 14.6 m-30 -64.31 -24.8 67.78 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.411 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 35' ' ' PRO . 21.9 t -89.27 -27.94 5.23 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.782 0.325 . . . . 0.0 110.844 179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.39 32.19 2.61 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.541 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.874 HD13 HG11 ' A' ' 6' ' ' VAL . 6.0 tp -65.17 129.4 39.58 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 120.692 0.282 . . . . 0.0 110.446 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 71.3 mtt-85 -129.5 115.87 18.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.361 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.487 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -57.38 156.83 7.26 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.668 -179.405 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.15 -13.15 63.52 Favored Glycine 0 CA--C 1.522 0.479 0 CA-C-N 115.124 -0.944 . . . . 0.0 112.211 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.83 138.34 35.12 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 110.642 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -83.47 126.42 32.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.457 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.499 HG23 ' HG2' ' A' ' 76' ' ' MET . 12.9 mt -85.4 131.87 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.521 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.525 HD11 ' CB ' ' A' ' 79' ' ' ALA . 5.0 mp -107.71 -39.7 5.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.356 -179.815 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.487 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -131.27 141.26 49.95 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.1 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.424 HG11 HD11 ' A' ' 67' ' ' ILE . 13.5 t -133.54 110.5 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.874 179.231 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.413 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.6 t30 77.07 32.34 0.48 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.82 -1.2 2.39 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.535 179.981 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.784 HD11 HD13 ' A' ' 66' ' ' LEU . 13.0 pt -115.29 126.02 72.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.98 0.419 . . . . 0.0 111.794 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -66.87 136.87 56.06 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.511 -179.626 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.455 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.4 m -147.86 63.88 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.681 -179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -69.93 -31.69 69.58 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.136 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.0 mtpt -137.63 35.87 2.44 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.455 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -86.64 174.24 9.0 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 120.876 0.369 . . . . 0.0 111.534 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.661 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -81.27 134.75 35.64 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.399 0.619 . . . . 0.0 110.288 179.509 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.73 ' O ' HG23 ' A' ' 64' ' ' VAL . 3.7 t60 -54.73 -44.46 73.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.857 -1.065 . . . . 0.0 112.14 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -61.7 -43.36 99.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.951 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.83 -41.32 91.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.507 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 59' ' ' SER . 55.9 t -65.15 -42.51 94.46 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.001 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 60' ' ' HIS . 60.7 t -65.88 -39.29 84.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.708 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.68 -39.88 78.12 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.073 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.784 HD13 HD11 ' A' ' 53' ' ' ILE . 5.7 mt -67.71 -42.01 82.64 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.76 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.592 HG23 HD13 ' A' ' 74' ' ' LEU . 42.2 mt -66.06 -39.93 85.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.723 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.6 6.22 78.37 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.093 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.31 -32.69 16.41 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.857 0.328 . . . . 0.0 111.439 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.96 -61.21 2.3 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.784 0.326 . . . . 0.0 110.799 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.92 35.11 2.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.83 -47.14 0.01 OUTLIER Glycine 0 C--N 1.33 0.201 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.291 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -165.33 137.79 0.91 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.984 0.421 . . . . 0.0 111.331 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.592 HD13 HG23 ' A' ' 67' ' ' ILE . 11.1 tp -114.03 142.09 46.62 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.375 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.58 95.74 5.51 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.252 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.499 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.8 ttm -98.03 122.33 41.04 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.118 -179.356 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 21.0 t -102.23 96.64 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.464 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.492 HG22 ' HA ' ' A' ' 47' ' ' ILE . 2.7 pt -100.27 170.3 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.552 -179.55 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.525 ' CB ' HD11 ' A' ' 48' ' ' LEU . . . -130.83 137.2 49.29 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.234 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -61.55 112.0 2.04 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.147 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -164.12 52.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.504 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.5 m -66.61 103.55 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.237 0 CA-C-O 120.807 0.337 . . . . 0.0 111.4 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.471 -1.183 . . . . 0.0 112.563 -179.927 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.488 1.172 0 CA-C-O 120.638 0.182 . . . . 0.0 111.828 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? 68.43 122.75 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.26 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.507 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.7 p 31.58 100.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.086 0.954 . . . . 0.0 112.843 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 63.3 ttt180 -126.59 134.24 50.85 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.002 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.3 m -96.2 130.65 43.21 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.503 HG13 HG11 ' A' ' 39' ' ' VAL . 25.0 t -123.13 140.16 47.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.372 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.514 ' O ' HG21 ' A' ' 39' ' ' VAL . 4.2 mt-10 -116.94 126.95 53.71 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.144 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 73' ' ' VAL . 20.9 t -125.59 137.75 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.639 179.581 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.18 97.54 8.33 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.995 0.426 . . . . 0.0 110.603 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.471 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 2.9 ttt-85 -47.14 121.54 3.83 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.353 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.4 -130.19 1.1 Allowed Glycine 0 C--N 1.334 0.448 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.512 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.1 mtt180 -111.93 -39.57 4.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.413 0.149 . . . . 0.0 111.258 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.38 26.85 9.71 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.68 0.252 . . . . 0.0 111.68 179.355 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.67 -179.89 16.03 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.924 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.471 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 91.3 m-85 -83.97 -34.01 24.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.585 0.231 . . . . 0.0 111.18 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.84 47.96 0.93 Allowed Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.284 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.416 ' HA ' ' HA ' ' A' ' 30' ' ' VAL . 20.6 p90 -168.67 153.87 6.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 111.063 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.5 m -98.88 128.2 45.0 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.92 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -106.18 126.92 52.81 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.181 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.0 m -147.84 130.45 15.91 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.517 178.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.67 73.36 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.276 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.1 tp60 -44.96 -43.48 9.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.799 0.333 . . . . 0.0 110.576 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.966 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -110.98 -64.56 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.021 178.317 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.966 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.0 Cg_endo -91.74 92.7 0.21 Allowed 'Trans proline' 0 C--N 1.358 1.042 0 C-N-CA 122.943 2.428 . . . . 0.0 111.912 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 7.7 p -53.36 118.75 4.07 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.936 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 45' ' ' ASP . 7.1 p -146.68 145.3 19.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.256 -179.285 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.568 HD12 HD11 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -74.96 90.39 2.43 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.845 0.355 . . . . 0.0 110.496 179.603 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -53.98 -35.74 62.14 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.625 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.1 t -165.26 161.75 19.41 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.723 0.297 . . . . 0.0 110.988 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.45 HG22 HD23 ' A' ' 27' ' ' LEU . 38.0 t -131.19 152.5 37.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.877 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.4 mmt -90.24 99.66 12.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-O 121.338 0.59 . . . . 0.0 110.342 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.97 121.81 8.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.935 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.08 26.01 8.08 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.561 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -128.95 171.75 8.21 Favored Pre-proline 0 CA--C 1.532 0.269 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.441 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 77.7 Cg_exo -48.91 -30.51 17.73 Favored 'Trans proline' 0 C--N 1.352 0.737 0 C-N-CA 122.847 2.365 . . . . 0.0 113.128 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.05 -50.23 50.41 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.142 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.97 -31.86 73.3 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.42 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.441 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 17.7 m-30 -60.12 -30.71 69.45 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.198 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.514 HG21 ' O ' ' A' ' 7' ' ' GLU . 22.3 t -89.72 -24.37 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.107 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.22 17.56 6.65 Favored Glycine 0 CA--C 1.523 0.57 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.153 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.56 HD21 HD13 ' A' ' 78' ' ' ILE . 3.4 mt -78.87 123.21 27.01 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 117.019 0.409 . . . . 0.0 110.303 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.1 mtp85 -130.48 -149.9 0.41 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -107.76 127.53 53.77 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.594 -0.275 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.7 -22.44 5.8 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 120.78 -0.724 . . . . 0.0 113.017 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.403 ' HB3' HD12 ' A' ' 78' ' ' ILE . 6.5 m-20 -73.29 121.66 20.74 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 116.924 0.362 . . . . 0.0 110.948 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -82.45 128.04 33.87 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.696 ' HA ' HG22 ' A' ' 78' ' ' ILE . 6.0 mt -85.32 125.29 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.445 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.7 mm? -103.05 -39.41 6.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.939 -179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.535 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.91 145.81 50.83 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.239 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.669 HG21 HG13 ' A' ' 63' ' ' VAL . 42.8 t -132.97 111.72 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.926 179.257 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.415 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 76.5 32.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.655 -178.458 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.53 -2.03 1.64 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.11 -0.95 . . . . 0.0 112.732 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.678 HD11 HD13 ' A' ' 66' ' ' LEU . 20.4 pt -113.73 125.58 71.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-O 120.838 0.352 . . . . 0.0 111.421 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.535 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.7 OUTLIER -60.3 125.51 23.96 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.95 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.497 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 3.7 m -146.95 40.65 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.415 ' HB3' ' HA ' ' A' ' 48' ' ' LEU . 0.0 OUTLIER -61.58 -29.93 70.35 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.794 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.0 mttp -119.85 29.56 7.49 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.322 179.645 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.497 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -88.27 -174.13 4.5 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 111.573 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.615 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -91.34 140.68 29.54 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.406 0.622 . . . . 0.0 110.742 179.675 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.766 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.5 t-80 -52.86 -44.56 66.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.721 -1.127 . . . . 0.0 111.764 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.61 -39.52 91.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.665 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.01 -42.46 94.42 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.584 179.252 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.669 HG13 HG21 ' A' ' 50' ' ' VAL . 44.4 t -64.82 -42.45 94.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.122 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.766 HG23 ' O ' ' A' ' 60' ' ' HIS . 41.7 t -65.85 -39.19 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.688 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.2 ttmt -57.68 -40.73 80.09 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.093 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.678 HD13 HD11 ' A' ' 53' ' ' ILE . 17.7 mt -66.88 -42.82 84.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.763 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.702 HG23 ' HG ' ' A' ' 74' ' ' LEU . 25.2 mt -66.79 -40.6 86.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.97 179.745 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -70.21 -17.1 73.72 Favored Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.015 -0.612 . . . . 0.0 113.131 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -66.79 -42.09 86.55 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -67.62 -57.88 5.65 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.793 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.7 p 62.49 28.02 16.56 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.463 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -152.59 -40.48 0.03 OUTLIER Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.67 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 8' ' ' VAL . 6.5 p -150.53 138.58 14.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.089 0.471 . . . . 0.0 111.333 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.702 ' HG ' HG23 ' A' ' 67' ' ' ILE . 0.5 OUTLIER -102.81 138.02 40.25 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.952 -179.866 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -130.66 95.06 3.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 3.0 mtt -117.32 140.92 48.95 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.529 -179.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.505 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 22.0 t -104.86 95.19 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.237 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.696 HG22 ' HA ' ' A' ' 47' ' ' ILE . 16.6 pt -99.17 159.97 3.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.22 -179.659 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.82 147.83 45.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.492 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.84 111.38 23.59 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.861 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -148.41 50.77 0.57 Allowed Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.379 179.661 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.2 p -131.26 145.14 35.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.63 0.252 . . . . 0.0 111.12 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.718 -1.046 . . . . 0.0 113.054 -179.863 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.408 ' HD2' ' O ' ' A' ' 80' ' ' GLU . 3.4 Cg_endo . . . . . 0 N--CA 1.488 1.199 0 CA-C-O 120.435 0.098 . . . . 0.0 111.877 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 57.56 52.13 8.78 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.077 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.3 p -60.51 122.98 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.078 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -139.12 166.61 24.06 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.321 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -105.07 132.92 50.7 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.26 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.576 HG23 HG12 ' A' ' 78' ' ' ILE . 29.0 t -106.58 131.19 57.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.819 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 74' ' ' LEU . 1.6 mt-10 -118.83 116.57 26.8 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.543 HG11 ' HB3' ' A' ' 15' ' ' TYR . 3.7 t -110.01 133.97 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 111.421 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.67 94.05 9.77 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.93 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.455 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -48.47 121.03 4.08 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.176 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.45 -85.62 0.12 Allowed Glycine 0 C--N 1.335 0.501 0 C-N-CA 121.042 -0.599 . . . . 0.0 112.383 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 -145.98 -53.77 0.26 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.633 0.254 . . . . 0.0 111.013 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.18 28.91 8.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.535 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.37 164.79 11.16 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.709 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.543 ' HB3' HG11 ' A' ' 8' ' ' VAL . 73.3 m-85 -88.93 -66.77 0.89 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.84 0.352 . . . . 0.0 110.64 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.22 55.82 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.73 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -166.54 149.12 6.73 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.753 0.311 . . . . 0.0 110.93 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 109.43 22.12 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.03 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 6.2 tt -108.44 140.41 41.79 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.826 -179.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.7 m -150.35 161.44 42.48 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.457 179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.78 81.35 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.313 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.5 mm100 -47.41 -40.48 17.91 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.606 0.241 . . . . 0.0 110.775 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.949 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -113.73 -63.41 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.279 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.332 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.949 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 90.9 Cg_endo -89.92 94.04 0.3 Allowed 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.812 2.341 . . . . 0.0 111.739 179.128 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.593 ' SG ' HG23 ' A' ' 55' ' ' VAL . 6.0 p -52.29 117.16 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.72 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.1 p -134.83 144.31 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.643 -179.295 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.58 92.74 9.22 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.084 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -57.16 -52.67 64.39 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.02 -179.308 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.546 ' HA ' ' HB1' ' A' ' 43' ' ' ALA . 0.6 OUTLIER -148.14 162.3 39.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.444 -179.594 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 10.9 t -121.19 153.73 24.82 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.129 179.304 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -94.56 99.96 12.02 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.24 0.543 . . . . 0.0 110.771 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 7.2 mtt180 -55.06 126.48 24.83 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.014 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 99.66 -16.29 58.88 Favored Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.888 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.614 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.4 m -89.64 166.38 21.22 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.841 0.32 . . . . 0.0 110.343 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.614 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 9.2 Cg_endo -51.25 -26.76 21.08 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.928 2.419 . . . . 0.0 113.441 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.19 76.76 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.849 0.357 . . . . 0.0 110.77 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.83 -26.57 63.35 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.207 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -59.43 -23.66 62.86 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.42 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.542 HG11 HG13 ' A' ' 6' ' ' VAL . 21.4 t -89.27 -30.15 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 116.662 -0.244 . . . . 0.0 111.06 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 104.71 45.4 1.41 Allowed Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.496 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.452 ' HG ' HG11 ' A' ' 6' ' ' VAL . 6.4 mt -72.48 -178.95 2.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-O 120.726 0.298 . . . . 0.0 110.569 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 44.9 mtp85 -142.01 112.74 7.28 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.291 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.546 ' HB1' ' HA ' ' A' ' 29' ' ' CYS . . . -64.85 103.56 0.73 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.527 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.63 -10.55 5.77 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.266 -179.414 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -81.02 165.49 21.65 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.02 156.33 17.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.534 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 4.2 mt -109.11 146.25 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.589 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 mp -118.92 -57.49 2.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.893 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.08 139.28 44.19 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.008 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.42 HG23 ' CG2' ' A' ' 55' ' ' VAL . 2.9 t -138.97 110.35 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.406 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.9 t-20 75.97 35.86 0.47 Allowed 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.406 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.08 -0.39 3.33 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.808 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.618 HD11 HD22 ' A' ' 66' ' ' LEU . 8.5 pt -119.68 133.66 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-O 120.92 0.39 . . . . 0.0 111.388 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -69.74 150.84 46.5 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.67 -179.515 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.607 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 2.4 m -150.11 56.85 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.2 mmtp -60.19 -40.42 89.98 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.455 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.0 mtmp? -130.01 31.96 4.6 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.658 0.266 . . . . 0.0 111.421 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.607 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -79.6 176.51 9.64 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 120.716 0.293 . . . . 0.0 111.144 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 2.9 m -95.8 147.19 23.9 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.581 0.705 . . . . 0.0 111.355 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -56.11 -41.85 75.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.325 -1.307 . . . . 0.0 111.445 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.474 ' HA ' HG12 ' A' ' 64' ' ' VAL . 11.4 pt-20 -64.21 -41.09 97.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.904 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -69.79 -42.07 74.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 110.366 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.619 HG23 ' O ' ' A' ' 59' ' ' SER . 55.5 t -67.71 -42.35 86.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.027 179.573 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.474 HG12 ' HA ' ' A' ' 61' ' ' GLU . 7.3 p -66.61 -39.1 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -57.94 -40.13 79.75 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.158 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.618 HD22 HD11 ' A' ' 53' ' ' ILE . 15.0 mt -66.28 -42.85 87.85 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.741 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.627 HG23 HD13 ' A' ' 74' ' ' LEU . 33.5 mt -66.62 -40.71 86.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.623 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -85.39 8.27 72.17 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.184 179.368 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.7 -32.63 15.36 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 116.828 0.314 . . . . 0.0 111.293 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.67 -55.04 19.61 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.963 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 m 64.5 36.17 8.89 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.859 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.87 -44.05 0.02 OUTLIER Glycine 0 C--N 1.332 0.338 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.414 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -163.39 139.13 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.129 0 CA-C-O 120.959 0.409 . . . . 0.0 111.384 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.627 HD13 HG23 ' A' ' 67' ' ' ILE . 62.8 tp -103.15 136.26 43.27 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.049 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -127.13 101.37 6.49 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.411 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.595 ' SD ' HD21 ' A' ' 74' ' ' LEU . 13.7 ptm -132.83 141.52 48.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.47 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.9 t -91.23 120.63 40.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.79 179.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.576 HG12 HG23 ' A' ' 6' ' ' VAL . 15.0 pt -99.33 170.17 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.35 148.88 30.04 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.284 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.408 ' O ' ' HD2' ' A' ' 1' ' ' PRO . 0.6 OUTLIER -98.21 163.84 12.56 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.322 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -154.61 31.98 0.69 Allowed Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.793 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 82' ' ' VAL . 8.4 t -136.53 34.12 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-O 121.056 0.455 . . . . 0.0 110.939 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.284 -1.286 . . . . 0.0 112.703 -179.842 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.489 1.22 0 CA-C-O 120.85 0.271 . . . . 0.0 111.882 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 48.7 mtp180 -111.93 155.63 23.38 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.097 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.3 p -90.66 128.3 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.296 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.8 ttt180 -123.04 126.87 47.93 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -97.8 120.84 38.9 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.754 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.771 HG11 ' HG ' ' A' ' 41' ' ' LEU . 20.9 t -114.2 131.58 65.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.512 ' O ' HG21 ' A' ' 39' ' ' VAL . 3.1 mt-10 -115.6 112.92 22.87 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.902 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 t -94.57 134.14 33.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 CA-C-O 120.877 0.37 . . . . 0.0 111.221 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -102.17 97.64 7.91 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.687 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.431 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -47.81 118.38 2.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.006 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.92 -107.54 0.08 OUTLIER Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.553 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.8 mtt180 -123.67 -46.75 1.99 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.633 0.254 . . . . 0.0 111.046 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.01 41.79 3.45 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.651 179.692 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 158.4 -179.64 33.93 Favored Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.14 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.431 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 8.7 m-85 -111.41 -40.74 4.3 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.595 0.236 . . . . 0.0 111.349 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.96 23.69 5.17 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.285 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -157.26 156.24 32.15 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.997 0.398 . . . . 0.0 110.933 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.0 m -111.01 135.61 51.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.861 0.362 . . . . 0.0 111.239 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.484 HD22 ' CE1' ' A' ' 60' ' ' HIS . 0.4 OUTLIER -119.18 129.09 54.81 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.043 179.898 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.6 m -151.7 176.05 11.77 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.125 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.55 -46.32 1.13 Allowed Glycine 0 C--N 1.335 0.497 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.38 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.437 ' O ' ' HB2' ' A' ' 23' ' ' ALA . 0.0 OUTLIER 55.13 39.43 31.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.877 0.471 . . . . 0.0 112.09 179.489 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.758 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . 174.53 -61.64 0.0 OUTLIER Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.636 179.476 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.758 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.1 Cg_endo -75.17 -27.43 9.75 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.598 2.199 . . . . 0.0 113.127 179.758 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.401 ' CB ' ' HB ' ' A' ' 47' ' ' ILE . 18.4 m 56.79 93.44 0.03 OUTLIER 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.509 0.671 . . . . 0.0 109.788 -179.002 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.834 HG13 ' HA ' ' A' ' 46' ' ' GLN . 0.8 OUTLIER -146.75 144.21 20.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.973 -178.95 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.32 122.33 16.87 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.487 179.703 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.4 m -82.42 -41.53 19.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.196 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.559 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 25.3 t -173.09 152.44 2.31 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.364 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.413 HG21 ' HB3' ' A' ' 41' ' ' LEU . 5.2 t -118.04 155.19 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.753 179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 27.4 mmm -98.41 100.95 12.26 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.204 0.526 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mtt-85 -50.85 124.58 11.44 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.069 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.02 24.51 11.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.553 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -123.76 165.98 20.98 Favored Pre-proline 0 C--O 1.232 0.148 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.432 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 10.4 Cg_endo -53.58 -26.99 39.3 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.781 2.32 . . . . 0.0 112.747 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.691 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -69.48 -49.18 57.18 Favored 'General case' 0 CA--C 1.528 0.121 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.002 179.667 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -67.05 -31.99 72.88 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.304 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.432 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 20.4 m-30 -59.47 -23.46 62.75 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.557 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.512 HG21 ' O ' ' A' ' 7' ' ' GLU . 21.9 t -89.38 -30.12 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.684 0.278 . . . . 0.0 111.253 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.79 68.13 0.54 Allowed Glycine 0 C--N 1.334 0.45 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.413 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.771 ' HG ' HG11 ' A' ' 6' ' ' VAL . 5.5 mt -102.31 162.35 12.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.795 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.9 mmt180 -148.55 119.66 7.73 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.559 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -57.08 111.8 1.16 Allowed 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.835 179.546 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.44 -12.88 7.02 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.874 -179.49 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.562 ' CB ' HD12 ' A' ' 78' ' ' ILE . 0.1 OUTLIER -66.94 112.1 4.14 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.825 0.312 . . . . 0.0 110.52 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLN . . . . . 0.834 ' HA ' HG13 ' A' ' 26' ' ' VAL . 1.1 tt0 -55.45 125.7 22.04 Favored 'General case' 0 CA--C 1.53 0.173 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.71 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.643 ' HA ' HG22 ' A' ' 78' ' ' ILE . 66.7 mt -82.25 123.96 38.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.574 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.0 mp -107.81 -41.2 5.06 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.54 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -136.46 144.4 44.38 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.73 0.3 . . . . 0.0 111.102 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.493 HG13 ' HG2' ' A' ' 76' ' ' MET . 8.3 t -140.97 116.2 6.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.434 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.96 30.75 0.55 Allowed 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.773 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.434 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 80.78 -1.92 1.84 Allowed 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.239 -0.892 . . . . 0.0 112.706 179.631 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.822 HD11 ' CD1' ' A' ' 66' ' ' LEU . 1.6 pt -117.4 134.56 60.59 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.936 0.398 . . . . 0.0 111.635 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.1 m120 -63.1 152.51 36.97 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.572 -179.584 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.58 HG11 HG22 ' A' ' 63' ' ' VAL . 2.8 m -152.02 47.75 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.435 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.9 mttt -56.21 -40.12 73.53 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.215 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -137.72 31.98 2.5 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.005 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.452 ' CB ' HG12 ' A' ' 55' ' ' VAL . . . -75.86 -177.7 3.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.878 0.371 . . . . 0.0 111.604 -179.723 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.654 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -92.93 135.78 33.85 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.361 0.6 . . . . 0.0 110.703 179.705 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.747 ' O ' HG23 ' A' ' 64' ' ' VAL . 5.5 t60 -55.9 -44.39 78.17 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.783 -1.098 . . . . 0.0 111.883 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -61.58 -39.41 91.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.439 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -67.52 -43.07 81.7 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.225 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 59' ' ' SER . 48.4 t -63.79 -40.96 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.932 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.747 HG23 ' O ' ' A' ' 60' ' ' HIS . 48.8 t -65.97 -38.83 82.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 178.674 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -57.76 -42.64 84.45 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.822 ' CD1' HD11 ' A' ' 53' ' ' ILE . 12.0 mt -63.63 -42.26 98.19 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.647 179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.63 HG23 HD22 ' A' ' 74' ' ' LEU . 35.8 mt -63.42 -44.18 98.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.635 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.3 -12.52 84.14 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.793 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 41.3 tptt -68.19 -37.41 80.91 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -70.7 -52.46 20.9 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.811 0.339 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m 63.8 35.73 10.96 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.742 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.22 -44.35 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.295 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -163.15 138.24 1.4 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-O 121.014 0.435 . . . . 0.0 111.335 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.63 HD22 HG23 ' A' ' 67' ' ' ILE . 24.2 tp -114.24 146.79 39.95 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.376 -179.799 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 33.3 m-70 -119.6 103.22 9.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.177 179.164 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.493 ' HG2' HG13 ' A' ' 50' ' ' VAL . 59.0 mtp -109.14 142.09 40.41 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.671 -179.272 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.3 t -115.06 97.05 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.926 178.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.643 HG22 ' HA ' ' A' ' 47' ' ' ILE . 10.3 pt -105.78 170.74 2.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.64 -179.084 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -136.94 145.73 44.59 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.941 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -86.43 112.89 21.92 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.774 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -106.45 46.31 1.19 Allowed Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.456 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -119.41 131.85 70.87 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-O 120.734 0.302 . . . . 0.0 110.858 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.694 -1.059 . . . . 0.0 112.976 -179.804 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.493 1.499 0 CA-C-O 120.419 0.091 . . . . 0.0 112.221 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.61 -46.93 3.72 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.533 -179.74 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.2 p 44.33 101.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.955 0.902 . . . . 0.0 112.636 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.26 146.66 47.08 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.727 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.1 m -102.21 154.73 18.75 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.213 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.699 HG11 ' HG ' ' A' ' 41' ' ' LEU . 20.3 t -140.29 136.2 36.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.355 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.428 ' O ' HG21 ' A' ' 39' ' ' VAL . 25.6 mt-10 -104.7 111.15 23.76 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.725 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.605 ' O ' HG23 ' A' ' 73' ' ' VAL . 6.7 t -104.43 119.94 54.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-O 120.865 0.364 . . . . 0.0 111.475 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -90.32 92.28 8.85 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.066 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -49.5 125.07 10.51 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.646 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.69 -112.44 0.07 OUTLIER Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.818 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -115.39 -39.33 3.6 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.435 0.16 . . . . 0.0 111.328 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.9 30.61 6.38 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.388 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.59 -173.09 16.6 Favored Glycine 0 C--N 1.337 0.616 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.808 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.524 ' HD1' HG12 ' A' ' 8' ' ' VAL . 79.2 m-85 -79.34 -61.91 1.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.941 0.401 . . . . 0.0 111.013 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.43 59.22 0.26 Allowed Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.452 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.507 ' CD1' HD21 ' A' ' 27' ' ' LEU . 19.7 p90 -153.13 151.01 29.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 0.0 110.955 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -98.3 111.42 23.76 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.442 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.465 HD23 ' N ' ' A' ' 20' ' ' SER . 0.8 OUTLIER -99.95 133.49 44.25 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.465 ' N ' HD23 ' A' ' 19' ' ' LEU . 1.5 p -149.58 -174.26 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.762 179.697 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 107.28 85.43 1.77 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.3 -60.09 2.08 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.942 0.401 . . . . 0.0 110.799 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.892 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.41 -60.61 0.19 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.221 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.892 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.2 Cg_endo -87.69 95.35 0.44 Allowed 'Trans proline' 0 C--N 1.356 0.938 0 C-N-CA 122.692 2.261 . . . . 0.0 112.209 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 71.6 m -55.27 118.64 4.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.477 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.4 p -143.53 152.94 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.854 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.551 HD11 ' CE ' ' A' ' 76' ' ' MET . 1.0 OUTLIER -89.41 92.95 9.34 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.473 179.377 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -51.46 -39.93 58.43 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.504 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.67 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.6 t -169.07 161.43 10.46 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.961 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.432 HG13 ' HB3' ' A' ' 17' ' ' PHE . 18.5 t -124.8 154.35 32.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.431 179.556 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -85.58 98.0 10.4 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.227 0.537 . . . . 0.0 110.399 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.85 122.61 6.76 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.853 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.31 21.23 11.86 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.703 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.42 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -115.31 166.68 11.43 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.712 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.443 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 9.7 Cg_endo -51.75 -29.55 34.25 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.962 2.441 . . . . 0.0 112.77 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.8 -46.19 46.89 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.992 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -64.01 -32.3 73.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.069 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.443 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.1 m-30 -60.04 -28.07 67.45 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.39 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.439 HG11 HG13 ' A' ' 6' ' ' VAL . 18.3 t -89.48 -26.21 5.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-O 120.469 0.176 . . . . 0.0 111.241 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.63 1.13 7.13 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.639 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.699 ' HG ' HG11 ' A' ' 6' ' ' VAL . 12.0 mt -67.93 116.96 9.18 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 117.378 0.589 . . . . 0.0 110.449 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.01 -150.36 0.43 Allowed 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.006 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.67 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -105.29 146.29 29.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.636 0.255 . . . . 0.0 111.299 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.82 -16.97 33.22 Favored Glycine 0 CA--C 1.523 0.56 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.152 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.434 ' CG ' HD12 ' A' ' 78' ' ' ILE . 1.3 m-20 -84.57 128.31 34.53 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 117.122 0.461 . . . . 0.0 110.822 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -82.38 134.01 35.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.486 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.42 ' CG2' HG22 ' A' ' 50' ' ' VAL . 22.7 mt -85.82 122.57 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.798 179.776 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -106.57 -47.55 3.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -124.08 136.25 54.11 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.993 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.42 HG22 ' CG2' ' A' ' 47' ' ' ILE . 3.0 t -135.51 105.71 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.096 179.553 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 75.92 37.8 0.37 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.394 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 72.32 -0.56 3.23 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.834 -179.628 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.665 ' CD1' HD22 ' A' ' 66' ' ' LEU . 8.0 pt -113.96 119.39 61.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 120.955 0.407 . . . . 0.0 111.01 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.493 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.0 m120 -68.53 130.32 42.53 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.081 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 63' ' ' VAL . 24.3 m -124.03 52.3 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.095 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.0 mttm -55.45 -45.65 76.83 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.543 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -136.48 32.42 2.8 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.095 179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.37 177.85 7.62 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 120.805 0.336 . . . . 0.0 111.275 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.676 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.7 OUTLIER -80.73 133.67 35.71 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 121.418 0.628 . . . . 0.0 110.665 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.704 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.4 t-160 -54.49 -44.78 72.95 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.772 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -65.13 -41.91 94.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.693 179.547 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -64.34 -42.47 96.25 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.712 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 59' ' ' SER . 54.9 t -63.5 -43.34 98.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.124 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.704 HG23 ' O ' ' A' ' 60' ' ' HIS . 47.1 t -66.03 -39.73 85.34 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.162 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.79 -40.46 84.11 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.01 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.665 HD22 ' CD1' ' A' ' 53' ' ' ILE . 7.1 mt -65.53 -40.86 93.4 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.195 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 26.2 mt -69.55 -40.48 79.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.866 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -59.83 -27.82 64.87 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.278 179.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.69 -19.79 62.02 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.51 0.324 . . . . 0.0 111.668 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -98.54 100.89 12.18 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.408 0.623 . . . . 0.0 110.219 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.2 m -99.64 -29.16 12.83 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.975 -1.011 . . . . 0.0 111.663 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.05 -50.93 7.25 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.139 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.5 p -177.12 134.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.841 0.353 . . . . 0.0 111.487 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.408 ' HB2' ' OH ' ' A' ' 15' ' ' TYR . 1.2 tp -114.32 141.29 47.79 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.073 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -114.01 104.67 12.37 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.163 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.551 ' CE ' HD11 ' A' ' 27' ' ' LEU . 0.8 OUTLIER -107.19 148.5 28.8 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.211 -179.543 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.33 105.43 18.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.721 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.434 HD12 ' CG ' ' A' ' 45' ' ' ASP . 7.8 pt -100.98 173.58 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.208 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -155.86 124.73 6.05 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.666 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.32 120.84 41.16 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.639 179.206 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 128.27 -114.98 1.94 Allowed Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.187 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.6 t 57.2 90.39 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-O 121.034 0.445 . . . . 0.0 111.819 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.369 -1.239 . . . . 0.0 112.481 179.722 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo . . . . . 0 N--CA 1.49 1.272 0 N-CA-C 112.415 0.121 . . . . 0.0 112.415 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -61.72 89.21 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.925 0.393 . . . . 0.0 111.2 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.4 t -138.27 138.67 42.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.12 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -139.2 169.24 18.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.402 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -116.66 144.57 44.25 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.99 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.778 HG11 ' CD1' ' A' ' 41' ' ' LEU . 20.6 t -113.39 140.44 33.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.31 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.702 ' O ' HG21 ' A' ' 39' ' ' VAL . 30.8 mt-10 -112.68 108.05 16.94 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.973 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.7 t -102.66 126.23 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 111.277 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.39 92.24 8.03 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.979 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.468 ' HG3' ' CZ ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -52.92 122.53 9.44 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.972 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.83 -65.93 3.08 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 121.162 -0.542 . . . . 0.0 112.665 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -163.54 -48.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.568 0.223 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -131.93 26.36 4.62 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.455 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 179.71 164.69 32.49 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.607 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.674 ' CE2' HG22 ' A' ' 67' ' ' ILE . 40.1 m-85 -107.91 -73.72 0.68 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.65 0.262 . . . . 0.0 111.373 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.39 50.83 0.04 OUTLIER Glycine 0 C--N 1.33 0.242 0 C-N-CA 121.142 -0.552 . . . . 0.0 112.425 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.4 ' HB2' ' CD2' ' A' ' 27' ' ' LEU . 37.6 p90 -167.14 -177.08 3.57 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.428 0.156 . . . . 0.0 110.754 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -133.68 145.1 49.62 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 120.822 0.344 . . . . 0.0 111.353 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.4 mt -128.72 123.48 33.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.945 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.5 m -135.83 14.81 3.36 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.26 -0.427 . . . . 0.0 112.101 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -84.86 85.2 1.57 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.035 -0.603 . . . . 0.0 112.131 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.02 -63.24 0.9 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.837 0.351 . . . . 0.0 111.074 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.24 -61.04 0.18 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.146 178.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.88 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.5 Cg_endo -86.75 93.26 0.53 Allowed 'Trans proline' 0 C--N 1.353 0.793 0 C-N-CA 122.825 2.35 . . . . 0.0 111.764 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.503 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.5 m -54.46 121.14 7.71 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.884 0.373 . . . . 0.0 110.806 -179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.4 p -145.79 146.74 19.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.85 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.589 HD22 HD23 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -81.55 92.24 6.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.707 179.843 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.83 -34.82 63.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.317 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.732 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 1.3 t -169.72 160.47 8.77 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 111.242 179.612 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.416 HG21 ' HB3' ' A' ' 41' ' ' LEU . 4.7 t -116.52 154.1 18.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.745 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 12.1 mmm -99.22 99.24 10.18 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.101 0.477 . . . . 0.0 110.818 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -50.2 126.85 15.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.118 -0.946 . . . . 0.0 111.276 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.05 24.2 13.37 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.028 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.458 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -127.52 169.58 12.05 Favored Pre-proline 0 C--N 1.33 -0.253 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.265 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.552 ' O ' HG23 ' A' ' 39' ' ' VAL . 19.3 Cg_endo -58.13 -17.7 33.19 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.673 2.248 . . . . 0.0 113.043 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.951 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -70.59 -50.91 32.18 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -72.07 -29.83 64.52 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.229 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.433 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.7 m-30 -59.18 -27.5 65.75 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.616 -0.266 . . . . 0.0 110.973 179.594 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.702 HG21 ' O ' ' A' ' 7' ' ' GLU . 22.4 t -89.64 -50.31 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.762 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 146.65 46.77 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.068 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.951 HD22 ' HB1' ' A' ' 36' ' ' ALA . 1.0 OUTLIER -89.31 134.25 34.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.665 0.269 . . . . 0.0 110.412 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.4 mmt180 -144.91 120.38 10.34 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.732 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -45.97 125.74 6.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.449 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.33 -26.95 5.4 Favored Glycine 0 CA--C 1.517 0.189 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.322 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.4 ' CG ' HD12 ' A' ' 78' ' ' ILE . 0.7 OUTLIER -67.1 121.1 14.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 120.593 0.235 . . . . 0.0 110.682 179.731 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.43 127.69 32.96 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.77 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.478 HG21 HG22 ' A' ' 50' ' ' VAL . 18.9 mt -82.65 119.31 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.569 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -97.11 -42.22 7.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.84 140.85 51.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.007 179.691 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.504 HG23 ' CG2' ' A' ' 55' ' ' VAL . 21.5 t -133.14 112.52 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.13 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.411 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.4 t30 76.34 31.06 0.64 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.672 -178.597 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.77 -3.76 1.57 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 115.174 -0.921 . . . . 0.0 112.713 179.64 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.501 HD12 HG13 ' A' ' 55' ' ' VAL . 1.1 pp -114.45 128.93 71.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.016 0.436 . . . . 0.0 111.397 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.561 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.1 m120 -64.27 132.69 51.0 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.439 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.58 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 7.8 m -136.36 58.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.452 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -62.51 -40.2 95.98 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.422 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -132.92 31.11 3.94 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.208 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.58 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -78.04 179.92 6.5 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.771 0.32 . . . . 0.0 111.548 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.734 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.14 135.47 33.42 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.305 0.574 . . . . 0.0 110.951 179.881 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.76 ' O ' HG23 ' A' ' 64' ' ' VAL . 7.4 t60 -54.46 -44.63 72.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.815 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -62.63 -43.35 99.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.504 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.22 -41.38 97.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.543 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 59' ' ' SER . 47.0 t -64.94 -43.52 96.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.988 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.76 HG23 ' O ' ' A' ' 60' ' ' HIS . 45.0 t -65.76 -39.34 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -57.97 -40.98 81.94 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.01 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.625 HD12 ' HA ' ' A' ' 63' ' ' VAL . 4.5 mt -66.22 -42.43 88.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.668 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.799 HG23 HD13 ' A' ' 74' ' ' LEU . 18.5 mt -65.52 -42.92 94.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.51 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.98 -15.04 81.66 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.945 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -65.13 -39.79 93.56 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -62.72 -55.25 28.42 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.4 ' HA ' ' NH1' ' A' ' 10' ' ' ARG . 0.3 OUTLIER 65.94 35.03 6.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.903 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.29 -44.24 0.02 OUTLIER Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.554 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -160.72 138.86 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.784 0.326 . . . . 0.0 111.642 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.799 HD13 HG23 ' A' ' 67' ' ' ILE . 33.0 tp -105.8 143.18 34.31 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -128.56 96.8 4.5 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.191 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -121.66 154.59 36.62 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.43 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.1 t -111.63 110.87 33.77 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.746 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.428 HG12 HG23 ' A' ' 6' ' ' VAL . 7.6 pt -105.51 145.38 13.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.322 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -111.23 134.35 52.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.291 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -103.08 133.83 47.54 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 69.65 85.24 0.14 Allowed Glycine 0 C--N 1.333 0.404 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.459 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 21.7 t -67.54 116.2 6.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-O 120.711 0.291 . . . . 0.0 110.923 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.338 -1.257 . . . . 0.0 112.192 -179.842 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo . . . . . 0 N--CA 1.488 1.155 0 N-CA-C 111.565 -0.206 . . . . 0.0 111.565 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.91 148.52 0.09 Allowed 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 120.812 0.339 . . . . 0.0 111.062 -179.665 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.1 t -112.05 142.56 24.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -135.96 162.25 33.38 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.448 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.38 125.32 53.04 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.785 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.516 HG13 ' HB ' ' A' ' 39' ' ' VAL . 20.8 t -111.33 134.07 54.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.105 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.584 ' O ' HG21 ' A' ' 39' ' ' VAL . 16.9 mt-10 -105.71 112.87 26.11 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.404 ' O ' HG23 ' A' ' 73' ' ' VAL . 4.9 t -87.77 116.85 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-O 120.84 0.352 . . . . 0.0 111.28 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.813 ' HB3' ' HB3' ' A' ' 35' ' ' PRO . . . -81.54 89.72 6.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.861 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.404 ' HG3' ' CE2' ' A' ' 15' ' ' TYR . 5.3 ttp180 -56.14 120.97 8.38 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.116 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.97 -88.1 0.29 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.738 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -121.33 -73.5 0.65 Allowed 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.64 0.257 . . . . 0.0 110.76 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -121.11 31.96 6.15 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.111 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -178.26 -169.61 39.31 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.582 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.56 ' OH ' HG22 ' A' ' 67' ' ' ILE . 24.4 m-85 -133.17 -64.42 0.73 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.655 0.264 . . . . 0.0 111.27 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.03 47.24 0.08 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.814 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -156.73 172.31 18.83 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 120.708 0.289 . . . . 0.0 110.813 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -117.56 110.72 18.29 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.954 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.5 126.15 49.46 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.119 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 73.5 m -152.06 107.56 3.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.55 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.95 79.63 0.15 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.704 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.85 -45.88 30.57 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.03 0.443 . . . . 0.0 110.018 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.944 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -115.57 -67.35 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.24 178.523 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.944 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 90.3 Cg_endo -85.1 95.55 0.65 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 122.605 2.204 . . . . 0.0 112.155 179.158 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.635 ' SG ' HG21 ' A' ' 63' ' ' VAL . 80.8 m -53.27 118.91 4.16 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.679 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 p -146.79 149.63 15.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.393 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.463 HD22 HD22 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -87.48 93.61 9.46 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.319 179.401 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -46.91 -43.98 19.38 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.485 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.509 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 1.7 t -172.37 158.53 4.38 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.173 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.5 t -126.04 154.95 35.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.616 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mtp -100.33 101.59 12.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 121.153 0.501 . . . . 0.0 110.66 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.1 mtm-85 -49.96 123.95 9.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.39 16.7 10.75 Favored Glycine 0 CA--C 1.523 0.583 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.75 -179.176 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -120.98 166.68 15.03 Favored Pre-proline 0 CA--C 1.531 0.221 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.486 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.813 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 71.0 Cg_exo -49.27 -31.39 22.25 Favored 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.989 2.46 . . . . 0.0 113.346 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.61 -49.06 51.63 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.587 -0.278 . . . . 0.0 111.139 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.36 -32.47 73.88 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.486 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.9 m-30 -58.06 -29.25 65.24 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.457 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.584 HG21 ' O ' ' A' ' 7' ' ' GLU . 18.7 t -89.53 -32.73 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.696 0.284 . . . . 0.0 110.948 179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.45 51.39 0.16 Allowed Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.123 -0.56 . . . . 0.0 112.66 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.682 ' CD2' HD13 ' A' ' 78' ' ' ILE . 2.8 mt -116.55 129.3 56.1 Favored 'General case' 0 C--O 1.231 0.098 0 CA-C-O 120.574 0.226 . . . . 0.0 110.817 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -137.6 -152.9 0.46 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -99.58 148.14 24.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.799 179.6 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.3 -21.33 46.08 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.975 -0.631 . . . . 0.0 113.214 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.65 ' CG ' HD12 ' A' ' 78' ' ' ILE . 0.9 OUTLIER -69.9 116.86 10.77 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.883 0.341 . . . . 0.0 110.827 -179.853 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.53 132.09 37.06 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.425 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 27.2 mt -84.34 120.42 35.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.74 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.0 -40.37 5.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.402 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.512 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -128.88 135.99 49.83 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.626 0.25 . . . . 0.0 111.097 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.448 ' O ' HG13 ' A' ' 53' ' ' ILE . 4.8 t -135.73 110.09 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.186 179.53 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 75.99 33.71 0.58 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 77.6 -5.13 2.18 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 115.15 -0.932 . . . . 0.0 112.706 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.796 HD11 ' CD1' ' A' ' 66' ' ' LEU . 2.2 pp -116.71 130.82 70.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 111.403 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -67.11 141.62 57.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.691 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.604 HG13 HD12 ' A' ' 53' ' ' ILE . 4.2 m -142.68 51.16 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.413 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.2 mtpp -58.16 -35.27 71.31 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.657 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -137.2 34.62 2.55 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.694 0.283 . . . . 0.0 111.03 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.537 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -78.13 -172.9 2.96 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.843 0.354 . . . . 0.0 111.556 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.616 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.4 OUTLIER -94.55 141.0 29.11 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.275 0.56 . . . . 0.0 110.791 179.738 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.697 ' O ' HG22 ' A' ' 64' ' ' VAL . 1.1 t-160 -52.86 -43.29 65.98 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.443 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.429 ' HA ' ' CG2' ' A' ' 64' ' ' VAL . 2.7 mt-10 -66.53 -35.06 79.32 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.457 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.59 -38.39 70.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.798 0.332 . . . . 0.0 110.286 179.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.635 HG21 ' SG ' ' A' ' 25' ' ' CYS . 46.6 t -66.47 -44.89 90.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.042 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.697 HG22 ' O ' ' A' ' 60' ' ' HIS . 2.9 m -66.42 -39.19 83.45 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.39 -39.18 82.57 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.972 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.796 ' CD1' HD11 ' A' ' 53' ' ' ILE . 14.3 mt -66.03 -41.99 90.19 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.864 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.924 ' HA ' HD13 ' A' ' 74' ' ' LEU . 31.5 mt -68.11 -41.41 84.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.762 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.74 8.73 19.64 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.954 178.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 2.0 tttp -111.61 -4.0 14.9 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 116.943 0.371 . . . . 0.0 111.071 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.469 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 26.4 p -50.62 -47.56 58.23 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 122.536 0.334 . . . . 0.0 111.71 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.74 31.71 4.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.004 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 150.02 -37.51 0.94 Allowed Glycine 0 C--N 1.335 0.499 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.062 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.469 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.8 p -172.05 138.07 0.35 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.234 0 CA-C-O 120.894 0.378 . . . . 0.0 112.012 -179.657 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.924 HD13 ' HA ' ' A' ' 67' ' ' ILE . 3.8 tp -111.04 139.77 46.12 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.111 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -100.95 101.52 12.33 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.29 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 35.5 ttm -103.44 125.1 49.84 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.512 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 40.5 t -97.86 103.61 14.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.511 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.682 HD13 ' CD2' ' A' ' 41' ' ' LEU . 14.7 pt -106.72 168.31 3.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.468 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.91 155.2 39.58 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.703 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.34 135.37 42.95 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -141.61 -87.98 0.12 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.449 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.0 t -86.3 -35.49 9.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.496 0.188 . . . . 0.0 110.975 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.27 -1.294 . . . . 0.0 112.624 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo . . . . . 0 N--CA 1.486 1.07 0 CA-C-O 120.147 -0.022 . . . . 0.0 112.087 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.39 178.83 0.13 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 120.869 0.366 . . . . 0.0 111.501 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 20.4 t -131.44 148.93 32.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.98 167.5 21.99 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.657 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 m -102.94 135.19 45.07 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.919 HG11 HD12 ' A' ' 41' ' ' LEU . 25.1 t -115.69 131.84 66.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.109 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -113.05 120.51 41.59 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.105 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.7 t -104.92 134.18 47.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.179 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -103.55 98.79 8.62 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.039 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -48.84 124.11 8.04 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.268 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.41 118.43 0.45 Allowed Glycine 0 CA--C 1.52 0.353 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER 78.51 90.0 0.06 Allowed 'General case' 0 C--O 1.235 0.34 0 CA-C-O 121.393 0.616 . . . . 0.0 110.396 -179.22 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 71.15 34.26 1.85 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.548 -1.206 . . . . 0.0 111.569 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 -113.1 3.6 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.837 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.45 ' HB3' HG11 ' A' ' 8' ' ' VAL . 79.3 m-85 -110.64 -66.32 1.08 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.414 0.149 . . . . 0.0 111.171 -179.546 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.17 61.14 0.2 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.894 -0.67 . . . . 0.0 113.351 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -166.41 167.79 15.46 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 120.556 0.217 . . . . 0.0 111.183 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -120.34 150.84 40.11 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.007 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -137.62 124.32 21.08 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.363 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 m -140.15 15.74 2.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.092 -0.503 . . . . 0.0 112.021 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.65 84.36 1.59 Allowed Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.417 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -44.2 -61.98 1.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.795 0.331 . . . . 0.0 110.783 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.904 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.29 -62.81 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.881 178.574 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.904 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 92.0 Cg_endo -85.84 96.45 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.925 0 C-N-CA 122.76 2.307 . . . . 0.0 111.915 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.524 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.0 m -55.8 124.95 19.25 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.567 -179.642 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.16 143.8 17.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.395 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.771 HD22 HD22 ' A' ' 41' ' ' LEU . 0.4 OUTLIER -80.81 90.62 5.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.462 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 5.8 p -53.8 -38.44 64.52 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.473 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 8.1 t -161.75 153.41 18.89 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.836 0.351 . . . . 0.0 111.447 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.3 t -116.23 155.38 17.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.554 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.3 mtp -97.79 100.35 11.72 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.236 0.541 . . . . 0.0 110.791 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.4 mtm-85 -53.74 124.23 14.61 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.892 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.13 -24.04 21.88 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.534 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.414 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.4 OUTLIER -82.5 166.61 35.36 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 110.533 179.722 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 11.0 Cg_endo -53.95 -23.53 28.35 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 123.19 2.593 . . . . 0.0 113.186 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.59 76.91 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.887 0.375 . . . . 0.0 110.731 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -68.24 -27.1 66.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.194 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -55.97 -24.31 37.6 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 112.141 0.422 . . . . 0.0 112.141 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.748 HG11 HG13 ' A' ' 6' ' ' VAL . 34.8 t -89.09 -29.21 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 111.034 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.86 43.95 2.17 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.518 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.919 HD12 HG11 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -74.25 176.42 6.67 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 120.913 0.387 . . . . 0.0 110.762 179.857 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.519 ' H ' HD23 ' A' ' 41' ' ' LEU . 4.1 mtp85 -139.0 116.95 11.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.44 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.53 101.03 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.801 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.35 -21.26 3.47 Favored Glycine 0 CA--C 1.524 0.606 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.407 -179.062 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -58.24 123.31 15.62 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 120.633 0.254 . . . . 0.0 110.8 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -66.68 127.87 34.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.089 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.72 HD11 HD12 ' A' ' 27' ' ' LEU . 21.2 mt -85.27 125.89 40.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.573 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.492 ' N ' HD12 ' A' ' 48' ' ' LEU . 6.9 mp -98.76 -70.27 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.575 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.504 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -99.99 143.94 29.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.739 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.445 HG23 ' CG2' ' A' ' 55' ' ' VAL . 18.6 t -135.84 113.94 15.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.428 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 76.38 33.05 0.55 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -177.837 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.74 -1.78 2.37 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 115.189 -0.914 . . . . 0.0 113.074 179.72 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.794 HD11 ' CD1' ' A' ' 66' ' ' LEU . 5.4 pt -115.65 133.0 63.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-O 120.817 0.342 . . . . 0.0 111.827 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.504 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 42.8 t30 -66.83 130.22 42.45 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.143 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.472 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 15.3 m -137.28 59.57 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.965 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.9 mmtm -51.91 -72.46 0.05 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.999 -179.532 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.2 mttt -111.72 39.55 2.34 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.255 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.472 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -73.86 -175.93 2.29 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.515 -179.462 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.632 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.44 134.67 33.78 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.443 0.639 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -53.04 -44.76 67.64 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.689 -1.142 . . . . 0.0 111.419 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.472 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.7 pm0 -66.36 -34.7 78.56 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.184 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.6 -39.31 70.6 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.728 0.299 . . . . 0.0 110.443 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 59' ' ' SER . 41.4 t -67.02 -43.36 89.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.497 ' HA ' HD12 ' A' ' 67' ' ' ILE . 29.8 m -65.93 -38.71 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.699 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 1.9 mtmp? -57.87 -39.38 77.67 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.881 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.794 ' CD1' HD11 ' A' ' 53' ' ' ILE . 7.5 mt -67.41 -43.28 81.65 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.761 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.83 HG23 ' HG ' ' A' ' 74' ' ' LEU . 13.8 mt -65.66 -38.03 81.36 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.981 179.564 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -86.61 3.77 86.76 Favored Glycine 0 CA--C 1.524 0.645 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.015 179.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.6 tptm -86.91 -34.88 19.23 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.824 0.312 . . . . 0.0 111.25 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -71.66 -57.86 4.01 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.809 0.338 . . . . 0.0 110.86 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.1 m 64.65 36.02 8.61 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.072 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.13 -44.13 0.02 OUTLIER Glycine 0 C--N 1.331 0.296 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.434 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.1 p -162.12 137.08 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 CA-C-O 120.985 0.421 . . . . 0.0 111.385 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.83 ' HG ' HG23 ' A' ' 67' ' ' ILE . 1.9 mm? -112.6 134.37 54.17 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.523 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -117.09 96.36 5.41 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.999 179.446 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 16.5 ptt? -122.01 156.31 33.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.791 -179.155 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.7 t -111.42 109.73 29.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.735 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 pt -106.1 139.39 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.304 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -105.86 125.15 50.65 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.154 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -87.31 122.55 31.23 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.696 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.55 145.7 4.85 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.428 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m -67.82 95.1 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 120.976 0.417 . . . . 0.0 111.169 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.435 -1.203 . . . . 0.0 112.179 -179.624 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_endo . . . . . 0 N--CA 1.492 1.398 0 CA-C-O 120.943 0.31 . . . . 0.0 112.183 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 15.4 ttm-85 -105.6 -43.72 4.86 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.832 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -118.56 156.84 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.566 ' HD3' HD11 ' A' ' 78' ' ' ILE . 4.0 ttt85 -114.05 141.21 47.74 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 120.883 0.373 . . . . 0.0 111.1 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.0 m -110.9 137.16 48.88 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.664 179.518 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.756 HG11 HD22 ' A' ' 41' ' ' LEU . 16.7 t -111.8 136.01 49.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.756 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -134.59 100.84 4.76 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.535 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.645 ' O ' HG23 ' A' ' 73' ' ' VAL . 11.2 t -106.47 150.51 9.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.276 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -99.4 98.54 9.45 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.988 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 50.9 ttp85 -50.71 120.67 4.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.696 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.73 -107.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.705 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -118.28 -39.94 2.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.419 0.152 . . . . 0.0 111.249 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -111.3 32.19 5.53 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.668 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.11 -137.96 14.57 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.828 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.41 ' O ' ' HD2' ' A' ' 35' ' ' PRO . 80.2 m-85 -116.17 -83.33 0.63 Allowed 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.633 0.254 . . . . 0.0 111.19 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.61 55.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.265 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.525 ' HZ ' HG21 ' A' ' 67' ' ' ILE . 14.3 p90 -143.31 166.83 23.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.631 0.253 . . . . 0.0 110.756 179.743 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.1 m -113.92 142.03 46.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.943 0.401 . . . . 0.0 111.479 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 mt -133.89 122.87 23.78 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.943 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.8 m -146.92 169.37 19.29 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.31 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.91 -37.51 2.88 Favored Glycine 0 C--N 1.336 0.532 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.509 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.404 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.55 -48.92 0.24 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.286 0.635 . . . . 0.0 111.493 -179.817 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.896 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -100.97 -65.09 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.438 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.896 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 91.5 Cg_endo -80.55 96.21 1.0 Allowed 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.292 1.994 . . . . 0.0 112.318 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.0 m -61.37 115.66 4.04 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.334 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.84 142.46 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.154 -179.302 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.648 HD12 HD11 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -75.87 90.98 2.96 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.468 179.743 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 69.4 p -53.2 -36.59 61.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.308 -179.715 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.443 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.0 t -167.22 158.63 12.13 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.237 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.592 HG21 ' HA ' ' A' ' 42' ' ' ARG . 11.8 t -119.08 154.97 21.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.858 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 30.8 mtt -98.28 101.85 13.42 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 121.21 0.529 . . . . 0.0 110.623 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 26.8 mtt-85 -51.84 123.69 10.82 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.22 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.07 -22.3 31.72 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 120.938 -0.649 . . . . 0.0 113.071 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.448 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.6 m -83.47 168.01 25.04 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.711 0.255 . . . . 0.0 110.658 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.448 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 73.6 Cg_exo -50.43 -25.51 14.23 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 123.033 2.489 . . . . 0.0 113.448 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.26 -47.8 82.74 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 120.868 0.366 . . . . 0.0 111.024 179.628 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.96 -26.73 65.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.31 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.4 m-30 -54.98 -28.71 53.79 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 111.674 0.249 . . . . 0.0 111.674 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.763 ' HB ' HD23 ' A' ' 41' ' ' LEU . 22.6 t -89.43 -34.4 6.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 CA-C-O 120.83 0.347 . . . . 0.0 111.037 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.6 -11.81 15.88 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.747 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.763 HD23 ' HB ' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -64.58 127.59 32.16 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 179.918 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.592 ' HA ' HG21 ' A' ' 30' ' ' VAL . 1.7 mmm180 -115.51 -146.52 0.4 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.249 -179.687 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.443 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -95.11 159.19 15.13 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.926 0.393 . . . . 0.0 110.908 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.24 -33.52 6.1 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.577 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -61.39 118.56 7.11 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.79 0.328 . . . . 0.0 110.989 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.02 131.44 35.31 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.679 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.648 HD11 HD12 ' A' ' 27' ' ' LEU . 8.3 mm -87.38 124.55 40.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.5 179.68 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.439 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.5 mm? -105.49 -46.51 4.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.352 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.561 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -120.49 139.2 53.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.195 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 53' ' ' ILE . 9.0 t -140.79 109.27 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.487 179.407 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.405 ' HB2' ' HB3' ' A' ' 66' ' ' LEU . 0.1 OUTLIER 76.54 34.21 0.48 Allowed 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.878 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 76.02 -3.4 2.57 Favored 'General case' 0 CA--C 1.537 0.481 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.773 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.882 HD11 HD11 ' A' ' 66' ' ' LEU . 1.1 pt -114.27 120.5 64.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-O 121.047 0.451 . . . . 0.0 111.312 179.501 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.559 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -64.71 131.84 47.98 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.054 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.503 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 5.8 m -131.11 55.97 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.355 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.9 mtmt -59.88 -40.5 88.94 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.188 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.0 mttp -136.35 30.84 2.92 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.061 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.503 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -75.93 -169.22 1.05 Allowed 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.272 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -92.01 135.0 34.3 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.47 0.652 . . . . 0.0 110.616 179.713 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.742 ' O ' HG23 ' A' ' 64' ' ' VAL . 4.9 t60 -54.44 -44.6 72.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.818 -1.083 . . . . 0.0 111.957 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -63.41 -38.11 89.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.811 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.4 -42.9 82.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.541 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 59' ' ' SER . 42.9 t -65.29 -42.18 93.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.754 179.644 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 60' ' ' HIS . 47.5 t -65.8 -39.08 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.6 mttt -57.64 -39.41 76.92 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.45 -0.796 . . . . 0.0 110.89 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.882 HD11 HD11 ' A' ' 53' ' ' ILE . 11.3 mt -66.57 -43.7 84.26 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.773 179.444 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.757 HG23 HD22 ' A' ' 74' ' ' LEU . 54.0 mt -63.16 -37.96 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.642 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.47 11.98 57.02 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.316 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.5 ttpm? -110.32 -16.23 13.77 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 122.406 0.282 . . . . 0.0 111.264 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' CYS . . . . . 0.403 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 23.3 p -44.2 -50.85 8.61 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 122.576 0.351 . . . . 0.0 111.6 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.5 p 63.26 32.22 14.97 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.454 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.17 -36.73 0.6 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.993 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -172.46 136.58 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-O 120.995 0.426 . . . . 0.0 111.917 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.757 HD22 HG23 ' A' ' 67' ' ' ILE . 9.8 tp -114.45 145.0 42.41 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.827 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -119.37 107.11 12.96 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.16 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 1.1 ptp -122.71 135.04 54.46 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.012 0.434 . . . . 0.0 111.239 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.561 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 41.3 t -94.37 115.1 32.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.642 179.741 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.566 HD11 ' HD3' ' A' ' 4' ' ' ARG . 3.7 pt -107.06 167.05 3.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.551 -179.66 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.82 128.22 26.36 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -74.25 109.82 8.05 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.471 179.788 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 134.72 125.14 2.52 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.287 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m -65.09 120.25 11.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-O 120.814 0.34 . . . . 0.0 111.495 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.219 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.62 -179.91 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.636 HG22 ' HB2' ' A' ' 79' ' ' ALA . 25.2 t . . . . . 0 C--O 1.234 0.255 0 CA-C-O 120.687 0.279 . . . . 0.0 111.152 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -134.93 174.5 10.53 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.349 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 m -118.9 149.75 41.05 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.312 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.658 HG23 HD11 ' A' ' 78' ' ' ILE . 54.6 t -129.65 134.17 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.079 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -105.41 103.68 13.25 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 73' ' ' VAL . 14.6 t -95.64 129.47 45.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.807 0.337 . . . . 0.0 111.229 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -91.43 90.94 7.89 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.284 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -55.3 123.49 13.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.734 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.05 -103.17 0.1 OUTLIER Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.241 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.14 -46.4 1.94 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.536 0.208 . . . . 0.0 111.164 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -103.76 31.69 4.31 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.692 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.69 -126.77 8.3 Favored Glycine 0 C--N 1.336 0.556 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.745 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -132.88 -64.97 0.73 Allowed 'General case' 0 C--O 1.231 0.103 0 CA-C-O 120.733 0.302 . . . . 0.0 111.076 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.0 -34.53 1.31 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.925 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.578 ' CD1' HD21 ' A' ' 27' ' ' LEU . 41.6 p90 -65.18 179.47 0.72 Allowed 'General case' 0 CA--C 1.532 0.256 0 CA-C-O 121.064 0.459 . . . . 0.0 111.569 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.8 144.06 49.43 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.264 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.79 128.01 45.92 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.197 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 46.3 m -150.47 106.78 3.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.674 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -163.18 76.11 0.17 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.446 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -45.68 -44.71 13.63 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.736 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.976 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -114.33 -64.47 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.263 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.197 178.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.976 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 84.4 Cg_endo -89.42 91.51 0.36 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.791 2.327 . . . . 0.0 112.008 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.67 ' SG ' HG21 ' A' ' 63' ' ' VAL . 72.6 m -50.32 121.48 5.68 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.731 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.0 p -147.14 146.06 18.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.871 0.367 . . . . 0.0 111.724 -179.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.627 HD13 HD22 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -80.31 92.41 5.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.476 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.9 m -46.54 -46.29 19.22 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.867 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.68 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.0 t -171.3 158.41 5.36 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 111.431 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' A' ' 41' ' ' LEU . 50.6 t -122.13 153.23 26.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.619 179.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.6 mmt -103.3 100.81 10.72 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.076 0.465 . . . . 0.0 110.574 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 5.7 ptt180 -45.49 120.12 2.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.971 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 120.19 -17.81 9.73 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.542 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.413 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -85.59 166.77 28.33 Favored Pre-proline 0 CA--C 1.533 0.312 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.352 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 15.0 Cg_endo -57.13 -22.55 48.42 Favored 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 122.667 2.245 . . . . 0.0 112.748 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.825 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -68.83 -48.73 62.78 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.72 0.295 . . . . 0.0 110.913 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.36 -27.12 65.98 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.302 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-30 -57.54 -26.34 61.23 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.59 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.617 HG11 HG13 ' A' ' 6' ' ' VAL . 15.7 t -89.39 -39.39 12.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 120.794 0.33 . . . . 0.0 111.013 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 129.08 44.61 0.2 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.088 -0.577 . . . . 0.0 112.83 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.825 HD12 ' HB1' ' A' ' 36' ' ' ALA . 13.8 mt -85.22 140.9 30.52 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.788 0.328 . . . . 0.0 110.366 179.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.9 mtt180 -141.14 119.68 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.584 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.68 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -41.22 126.64 2.73 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.637 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.17 -26.37 5.56 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.148 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.97 114.17 3.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-O 120.661 0.267 . . . . 0.0 110.571 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -73.37 128.57 35.85 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.529 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.894 ' HA ' HG22 ' A' ' 78' ' ' ILE . 20.6 mt -80.93 120.17 32.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.007 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 mp -101.52 -46.7 4.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.053 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.605 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -127.26 139.39 52.94 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.257 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.458 HG21 HG13 ' A' ' 63' ' ' VAL . 8.8 t -132.46 111.61 17.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.003 179.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 77.33 29.98 0.54 Allowed 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.419 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 82.54 -2.53 1.38 Allowed 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.412 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.646 HD11 ' CD1' ' A' ' 66' ' ' LEU . 20.4 pt -114.21 132.19 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 111.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.6 OUTLIER -63.23 156.15 26.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.714 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.447 HG21 HG23 ' A' ' 50' ' ' VAL . 2.6 m -149.36 55.32 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.614 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -58.62 -43.25 89.6 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.723 0.297 . . . . 0.0 110.854 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.492 ' HE3' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -141.73 38.55 1.66 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.308 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.437 ' CB ' HG12 ' A' ' 55' ' ' VAL . . . -72.75 -178.15 2.59 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.592 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.593 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -93.35 137.89 32.22 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.398 0.618 . . . . 0.0 111.08 -179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.794 ' O ' HG23 ' A' ' 64' ' ' VAL . 2.0 t-160 -52.67 -43.92 65.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.942 -1.026 . . . . 0.0 111.913 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 58.1 mt-10 -65.63 -39.3 91.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.008 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -67.25 -39.37 86.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.709 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.67 HG21 ' SG ' ' A' ' 25' ' ' CYS . 46.4 t -67.44 -42.34 87.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.745 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 60' ' ' HIS . 42.7 t -65.67 -39.1 83.92 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.184 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.8 mtpp -57.74 -38.95 76.24 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.646 ' CD1' HD11 ' A' ' 53' ' ' ILE . 13.3 mt -68.3 -42.54 79.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.684 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.63 HG23 HD22 ' A' ' 74' ' ' LEU . 6.8 mt -67.47 -36.9 77.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.884 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -81.66 10.62 50.28 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.342 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 ttpt -114.16 -5.82 13.04 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.623 0.369 . . . . 0.0 111.2 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.433 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 14.0 p -47.8 -48.78 30.28 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 122.488 0.315 . . . . 0.0 111.752 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.9 t 65.65 33.34 8.5 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.069 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.16 -33.3 1.72 Allowed Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.275 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 8' ' ' VAL . 8.0 p -172.68 138.0 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-O 121.0 0.428 . . . . 0.0 111.784 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.63 HD22 HG23 ' A' ' 67' ' ' ILE . 9.1 tp -114.45 147.28 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.222 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -108.97 99.23 8.59 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.419 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.577 ' CG ' HD23 ' A' ' 74' ' ' LEU . 0.0 OUTLIER -105.43 135.04 47.55 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.959 -179.618 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.605 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 21.9 t -108.75 99.44 8.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.762 179.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.894 HG22 ' HA ' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -111.07 164.92 6.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.358 -179.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.636 ' HB2' HG22 ' A' ' 3' ' ' VAL . . . -128.38 130.9 48.39 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.241 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.234 0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.989 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 29.9 t . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.71 0.291 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 -131.89 160.77 34.75 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.497 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.2 p -101.59 131.34 47.84 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.178 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.609 HG13 ' CG1' ' A' ' 39' ' ' VAL . 14.2 t -116.37 131.55 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.808 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -100.99 111.77 24.05 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.728 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.5 ' O ' HG23 ' A' ' 73' ' ' VAL . 16.2 t -97.67 114.41 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.349 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.77 92.42 9.2 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.782 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.463 ' HG3' ' CE1' ' A' ' 15' ' ' TYR . 9.7 ttt180 -51.6 127.43 20.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.738 -0.664 . . . . 0.0 111.188 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.81 20.91 25.77 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.684 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.45 0.38 3.44 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 117.118 0.459 . . . . 0.0 111.907 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.01 24.0 1.67 Allowed 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 120.83 0.348 . . . . 0.0 111.105 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.69 -162.11 23.76 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.705 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.463 ' CE1' ' HG3' ' A' ' 10' ' ' ARG . 64.6 m-85 -131.7 -43.98 0.99 Allowed 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.36 -13.48 7.87 Favored Glycine 0 CA--C 1.522 0.507 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.18 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -108.52 174.28 5.94 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 117.039 0.419 . . . . 0.0 111.386 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.0 m -130.0 142.86 50.58 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.684 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.665 HD21 HD12 ' A' ' 47' ' ' ILE . 0.8 OUTLIER -124.19 124.48 42.55 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.302 -179.63 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.2 m -150.29 159.17 44.65 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.4 -29.52 2.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 121.055 -0.593 . . . . 0.0 113.157 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.403 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 64.11 21.27 12.52 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.94 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.834 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . 179.58 -63.8 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.282 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.834 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 91.0 Cg_endo -79.25 85.53 1.84 Allowed 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 122.52 2.147 . . . . 0.0 111.561 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.643 ' SG ' HG21 ' A' ' 63' ' ' VAL . 61.2 m -52.88 110.6 0.54 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.578 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -144.62 147.52 19.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.536 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.464 HD12 ' CG1' ' A' ' 47' ' ' ILE . 7.1 mp -74.4 90.8 2.18 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.3 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -43.78 61.95 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.614 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -171.17 158.09 5.36 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.984 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 14.7 t -135.77 153.34 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.92 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 16.3 ptp -104.52 105.12 15.11 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.271 0.558 . . . . 0.0 110.745 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.5 mtt180 -46.68 123.09 4.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.096 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.28 16.29 10.55 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 121.132 -0.556 . . . . 0.0 112.961 -179.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.8 164.87 17.74 Favored Pre-proline 0 C--O 1.234 0.247 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.19 -27.83 31.41 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 122.767 2.312 . . . . 0.0 112.606 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.32 -49.92 51.33 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.99 -35.23 79.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.239 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 m-30 -56.18 -32.95 64.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.714 -179.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.609 ' CG1' HG13 ' A' ' 6' ' ' VAL . 14.7 t -89.33 -35.05 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.62 0.247 . . . . 0.0 110.964 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.87 43.21 0.17 Allowed Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.152 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.512 HD21 HG21 ' A' ' 6' ' ' VAL . 63.5 mt -108.23 121.08 44.15 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.506 0.193 . . . . 0.0 110.53 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.92 -152.66 0.5 Allowed 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.988 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.22 130.06 44.95 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.812 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 113.68 -27.43 9.29 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.918 -0.658 . . . . 0.0 113.188 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -58.03 120.47 8.62 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.927 0.363 . . . . 0.0 111.077 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.7 125.59 30.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.741 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.665 HD12 HD21 ' A' ' 19' ' ' LEU . 23.8 mt -85.86 126.36 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.711 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.9 mp -108.22 -71.49 0.76 Allowed 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.495 ' HB3' ' CG2' ' A' ' 77' ' ' VAL . . . -97.07 126.89 42.53 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.756 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.599 HG21 HG13 ' A' ' 63' ' ' VAL . 11.0 t -119.64 103.38 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.302 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.423 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.5 t-20 76.46 31.75 0.59 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.705 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.423 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 85.01 -4.19 0.92 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.783 179.68 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 66' ' ' LEU . 1.1 pp -110.58 131.96 60.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-O 120.94 0.4 . . . . 0.0 111.656 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -71.58 145.28 49.14 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.604 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.507 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.2 m -146.11 61.14 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.376 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.1 -46.94 68.9 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.058 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 3.5 mtpp -140.13 37.68 1.93 Allowed 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.977 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.507 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -74.79 -174.96 2.32 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.446 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 3.8 m -91.2 145.67 24.48 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.641 0.734 . . . . 0.0 111.103 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.753 ' O ' HG23 ' A' ' 64' ' ' VAL . 2.5 t60 -61.68 -44.52 96.8 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.547 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -58.84 -43.2 90.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.882 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -64.24 -44.08 92.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.492 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.643 HG21 ' SG ' ' A' ' 25' ' ' CYS . 67.5 t -64.64 -40.79 90.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.059 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.753 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.3 t -65.69 -38.84 83.25 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 178.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.37 -40.88 79.07 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.901 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.743 HD11 HD11 ' A' ' 53' ' ' ILE . 7.3 mt -67.27 -42.07 84.44 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.643 179.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.975 HG23 HD22 ' A' ' 74' ' ' LEU . 9.8 mt -68.03 -39.33 81.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -80.04 11.17 37.02 Favored Glycine 0 CA--C 1.524 0.595 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.585 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.21 -8.12 13.55 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.441 0.296 . . . . 0.0 111.24 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.459 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 24.9 p -48.49 -49.91 33.87 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.825 0.345 . . . . 0.0 111.798 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.1 t 66.33 33.42 7.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.002 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.83 -37.41 0.95 Allowed Glycine 0 C--N 1.334 0.464 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.008 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 8' ' ' VAL . 8.1 p -171.12 137.39 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.998 0.427 . . . . 0.0 111.922 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.975 HD22 HG23 ' A' ' 67' ' ' ILE . 1.2 pp -112.38 155.41 24.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.363 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 68.7 m80 -110.92 98.34 7.49 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.268 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.475 ' HG2' HG23 ' A' ' 47' ' ' ILE . 3.0 ttm -105.07 122.74 46.52 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.052 -179.366 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.495 ' CG2' ' HB3' ' A' ' 49' ' ' ALA . 21.3 t -101.06 100.44 10.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.566 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.469 HG22 ' HA ' ' A' ' 47' ' ' ILE . 6.5 pt -102.53 171.76 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.427 -179.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -143.13 148.04 35.94 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.416 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 . . . . . 0 C--O 1.232 0.161 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.668 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.422 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.7 p . . . . . 0 CA--C 1.53 0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.641 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.471 ' HG3' HD11 ' A' ' 78' ' ' ILE . 14.8 ptm180 -137.35 162.59 33.16 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.219 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.28 141.43 37.63 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.175 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.624 HG11 HD22 ' A' ' 41' ' ' LEU . 21.7 t -126.9 139.28 52.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.295 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.792 ' O ' HG21 ' A' ' 39' ' ' VAL . 13.0 mt-10 -107.86 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.512 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.41 HG12 ' HD2' ' A' ' 15' ' ' TYR . 6.7 t -99.08 112.87 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-O 120.862 0.363 . . . . 0.0 111.187 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.79 88.82 7.42 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.343 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.491 ' HB3' ' O ' ' A' ' 71' ' ' SER . 2.1 ttt-85 -48.19 124.75 8.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.181 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.49 -87.81 0.14 Allowed Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.701 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.17 -55.85 0.45 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.615 0.245 . . . . 0.0 111.316 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.79 30.57 6.98 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.98 151.14 5.44 Favored Glycine 0 C--N 1.333 0.378 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.39 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.448 ' CE2' ' HG3' ' A' ' 10' ' ' ARG . 39.1 m-85 -77.43 -33.42 54.89 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-O 120.568 0.223 . . . . 0.0 111.086 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.84 61.77 0.83 Allowed Glycine 0 C--N 1.335 0.498 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.567 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.403 ' CD1' ' HB2' ' A' ' 15' ' ' TYR . 6.1 p90 -168.93 175.93 5.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 111.063 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -119.04 116.71 26.98 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.392 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.4 HD23 ' N ' ' A' ' 20' ' ' SER . 0.6 OUTLIER -105.97 132.41 52.09 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.801 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.474 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 36.8 p -147.45 -176.68 5.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.819 179.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 109.4 82.27 1.35 Allowed Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 121.033 -0.604 . . . . 0.0 112.05 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.1 tp60 -45.37 -53.44 8.6 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.843 0.354 . . . . 0.0 110.594 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.956 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -98.68 -62.93 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.94 178.395 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.956 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 97.3 Cg_endo -88.11 91.85 0.45 Allowed 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.872 2.381 . . . . 0.0 112.128 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.3 p -54.73 119.78 5.83 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.659 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.508 HG23 ' HA ' ' A' ' 46' ' ' GLN . 12.5 p -141.4 151.48 19.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.83 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -81.6 91.31 6.37 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.17 -43.87 52.51 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.493 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.44 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.3 t -167.23 158.58 12.06 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.367 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.632 HG21 ' HB3' ' A' ' 41' ' ' LEU . 12.4 t -119.1 154.76 21.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.341 179.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 41.8 mtp -98.41 101.38 12.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 121.036 0.446 . . . . 0.0 110.33 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -50.82 124.48 11.2 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.859 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 22.87 10.97 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.488 -179.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.37 165.08 26.39 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.621 ' O ' HG23 ' A' ' 39' ' ' VAL . 9.4 Cg_endo -52.59 -28.06 35.3 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.726 2.284 . . . . 0.0 112.869 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.655 ' O ' HD23 ' A' ' 41' ' ' LEU . . . -65.36 -49.84 67.83 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.782 0.325 . . . . 0.0 110.829 179.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.36 -31.25 68.43 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.397 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.427 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.4 m-30 -61.36 -23.95 66.13 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.419 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.792 HG21 ' O ' ' A' ' 7' ' ' GLU . 23.5 t -89.08 -33.73 6.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 CA-C-O 120.758 0.313 . . . . 0.0 111.167 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.45 42.51 0.31 Allowed Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.874 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.655 HD23 ' O ' ' A' ' 36' ' ' ALA . 1.7 mm? -75.18 178.49 5.71 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.644 0.259 . . . . 0.0 110.62 179.557 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -171.04 130.18 0.77 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.219 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.44 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -65.18 111.72 3.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.479 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 129.91 -23.96 4.62 Favored Glycine 0 CA--C 1.523 0.582 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.839 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.45 115.65 3.13 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.651 0.263 . . . . 0.0 110.518 179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . 0.508 ' HA ' HG23 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -74.64 120.3 19.99 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.832 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.639 ' HA ' HG22 ' A' ' 78' ' ' ILE . 24.2 mt -78.05 124.15 35.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.537 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.716 HD11 ' HB2' ' A' ' 79' ' ' ALA . 3.2 mt -105.67 -46.46 4.15 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.776 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.5 140.43 51.45 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.996 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.461 HG23 ' CG2' ' A' ' 55' ' ' VAL . 13.9 t -134.44 110.06 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.402 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.9 t-20 76.65 33.56 0.49 Allowed 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -178.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 77.32 -1.86 2.68 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 112.688 -179.869 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.587 HD11 HD13 ' A' ' 66' ' ' LEU . 5.0 pt -113.04 122.77 67.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 121.063 0.459 . . . . 0.0 111.315 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.541 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 6.9 t30 -63.4 128.16 34.57 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.339 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.575 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 13.1 m -136.33 54.18 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.22 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.409 ' HD3' HD22 ' A' ' 48' ' ' LEU . 2.4 mmmt -65.9 -30.0 70.52 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.25 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.4 mmtt -132.37 29.76 4.24 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.61 0.243 . . . . 0.0 111.129 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.575 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -81.75 -179.51 7.41 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.857 0.36 . . . . 0.0 111.405 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.627 ' O ' HG23 ' A' ' 63' ' ' VAL . 3.9 m -86.18 145.26 27.07 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.58 0.705 . . . . 0.0 111.011 179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.721 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.7 t-160 -59.1 -44.87 91.99 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.485 -1.234 . . . . 0.0 111.473 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.02 -38.72 89.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.546 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -42.55 92.43 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.627 HG23 ' O ' ' A' ' 59' ' ' SER . 65.2 t -65.53 -41.74 91.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.001 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 60' ' ' HIS . 46.6 t -65.82 -38.92 83.31 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 178.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -43.09 85.72 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.234 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.587 HD13 HD11 ' A' ' 53' ' ' ILE . 56.0 mt -64.53 -41.03 96.62 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.764 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.763 HG23 ' HG ' ' A' ' 74' ' ' LEU . 44.1 mt -66.35 -43.43 91.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.499 179.383 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.64 -21.94 63.41 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.72 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.81 -34.93 72.25 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.527 0.203 . . . . 0.0 111.531 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.527 ' HB3' HD22 ' A' ' 74' ' ' LEU . 0.1 OUTLIER -97.95 99.59 10.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.487 0.66 . . . . 0.0 110.254 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.491 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 30.3 t -88.99 -33.77 17.08 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.758 -1.11 . . . . 0.0 111.221 -179.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -65.12 -43.03 96.21 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.174 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.488 HG13 ' CE1' ' A' ' 75' ' ' HIS . 7.3 p -178.91 138.93 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 120.751 0.31 . . . . 0.0 111.44 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.763 ' HG ' HG23 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -94.19 146.5 23.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.318 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.488 ' CE1' HG13 ' A' ' 73' ' ' VAL . 40.7 m80 -131.44 102.82 6.1 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.864 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.09 154.66 44.42 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.808 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.6 t -109.43 112.74 41.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.704 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.639 HG22 ' HA ' ' A' ' 47' ' ' ILE . 1.6 pp -107.24 172.18 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.387 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.716 ' HB2' HD11 ' A' ' 48' ' ' LEU . . . -145.94 129.17 16.7 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.258 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.234 0.28 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.031 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.235 0.342 0 CA-C-O 120.701 0.286 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.5 ptt-85 -153.34 166.42 32.68 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.24 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.6 m -118.16 140.96 49.01 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.801 HG21 ' CD1' ' A' ' 41' ' ' LEU . 25.2 t -115.3 138.39 45.78 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.329 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -110.69 105.78 14.78 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.987 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.488 ' O ' HG23 ' A' ' 73' ' ' VAL . 10.5 t -100.39 133.26 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.288 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.68 98.73 9.25 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.942 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.526 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.4 OUTLIER -53.35 126.07 19.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.978 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.82 15.14 44.29 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.706 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.8 mmt85 74.01 0.24 3.55 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.985 0.392 . . . . 0.0 111.753 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -146.28 25.57 1.23 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-O 120.77 0.319 . . . . 0.0 111.147 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 136.47 175.44 13.81 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.692 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.623 ' CE2' HG22 ' A' ' 67' ' ' ILE . 35.5 m-85 -114.26 -69.57 0.85 Allowed 'General case' 0 C--O 1.232 0.141 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.81 -22.25 1.8 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.988 -0.625 . . . . 0.0 113.226 -179.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.53 ' HB2' HD21 ' A' ' 27' ' ' LEU . 51.4 p90 -95.81 137.76 34.43 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.905 0.353 . . . . 0.0 110.777 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -98.08 133.25 42.8 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.201 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.674 HD21 HD12 ' A' ' 47' ' ' ILE . 3.0 mt -117.29 133.26 56.19 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.462 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.5 m -149.88 166.63 28.96 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.128 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.47 -34.22 4.89 Favored Glycine 0 C--N 1.336 0.568 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.897 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.523 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 79.91 -49.85 0.37 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.359 0.663 . . . . 0.0 111.552 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.889 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -97.79 -64.93 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.483 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.889 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 99.0 Cg_endo -79.74 94.86 1.03 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.402 2.068 . . . . 0.0 112.478 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 85.6 m -59.65 111.61 1.49 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.184 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -146.93 143.21 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.273 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.726 HD22 HG22 ' A' ' 30' ' ' VAL . 0.1 OUTLIER -79.2 91.46 4.97 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.671 179.655 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.1 m -54.96 -37.64 66.75 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.347 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.549 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.2 t -167.15 155.61 9.8 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.921 0.391 . . . . 0.0 111.273 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.726 HG22 HD22 ' A' ' 27' ' ' LEU . 2.4 t -112.5 155.17 13.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.558 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mmt -103.31 101.92 11.86 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 121.003 0.43 . . . . 0.0 110.636 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.4 mtt85 -51.73 124.4 12.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.764 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.68 3.61 37.14 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.717 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.413 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.6 OUTLIER -108.13 167.06 9.82 Favored Pre-proline 0 C--O 1.233 0.211 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.512 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.546 ' O ' HG23 ' A' ' 39' ' ' VAL . 9.8 Cg_endo -51.57 -29.51 32.54 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.924 2.416 . . . . 0.0 112.712 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.603 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -63.7 -49.36 73.44 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.024 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.13 -34.27 77.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -60.94 -26.79 67.76 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.492 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 35' ' ' PRO . 35.3 t -89.56 -30.41 5.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-O 120.661 0.267 . . . . 0.0 111.144 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.06 47.11 0.67 Allowed Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.801 ' CD1' HG21 ' A' ' 6' ' ' VAL . 2.8 tp -80.22 156.45 26.88 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.965 0.412 . . . . 0.0 110.782 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.8 mmm180 -146.28 117.79 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.549 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -53.41 152.15 5.0 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.739 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.71 -28.95 13.66 Favored Glycine 0 CA--C 1.521 0.427 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.344 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.451 ' OD2' HD13 ' A' ' 78' ' ' ILE . 19.0 p-10 -59.68 121.9 12.8 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 122.876 0.47 . . . . 0.0 111.438 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -78.37 130.56 36.28 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.079 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.674 HD12 HD21 ' A' ' 19' ' ' LEU . 17.3 mt -84.7 127.81 39.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.002 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.445 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.3 mm? -106.42 -43.27 4.8 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.428 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.556 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -129.95 137.2 50.21 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.504 -0.317 . . . . 0.0 111.41 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.585 HG11 HD11 ' A' ' 67' ' ' ILE . 3.9 t -136.91 113.03 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.338 179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 76.64 31.66 0.57 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 79.15 -5.01 2.02 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.581 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.827 HD11 HD13 ' A' ' 66' ' ' LEU . 1.2 pp -112.2 124.97 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-O 121.104 0.478 . . . . 0.0 111.343 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.556 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -66.19 131.41 46.1 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.307 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.604 HG11 HG22 ' A' ' 63' ' ' VAL . 17.5 m -129.05 53.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.309 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -55.41 -55.4 32.12 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.281 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.3 mttm -127.19 32.62 5.03 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.911 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.49 -176.84 3.88 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.669 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -85.69 133.88 34.0 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.511 0.672 . . . . 0.0 110.81 179.699 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.523 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 5.0 t60 -56.9 -44.31 82.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.811 -1.086 . . . . 0.0 111.882 -179.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.47 ' HA ' HG22 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -66.48 -33.84 76.6 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.912 179.706 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.56 -42.18 68.14 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.068 178.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.669 HG23 ' O ' ' A' ' 59' ' ' SER . 56.9 t -63.86 -44.02 97.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.083 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.47 HG22 ' HA ' ' A' ' 61' ' ' GLU . 28.6 m -66.14 -39.3 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -57.93 -42.44 84.86 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.956 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.827 HD13 HD11 ' A' ' 53' ' ' ILE . 5.9 mt -62.31 -43.87 97.83 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.623 HG22 ' CE2' ' A' ' 15' ' ' TYR . 53.3 mt -66.59 -41.62 88.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.677 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.38 -1.17 74.72 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.848 -0.692 . . . . 0.0 113.256 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -83.03 -34.76 26.19 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.027 0.413 . . . . 0.0 111.492 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.75 -57.3 9.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.809 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.8 34.76 5.36 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.974 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.8 -45.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.366 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.6 p -169.05 138.48 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-O 120.841 0.353 . . . . 0.0 111.726 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.464 HD11 HG12 ' A' ' 50' ' ' VAL . 10.7 tp -114.33 141.87 47.05 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.26 179.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -125.27 98.41 5.63 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.977 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 15.1 ptt? -116.67 154.84 29.86 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.391 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.0 t -111.98 109.21 27.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.878 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.451 HD13 ' OD2' ' A' ' 45' ' ' ASP . 1.1 pt -102.06 163.67 3.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.509 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.26 116.0 18.47 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.9 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 . . . . . 0 CA--C 1.53 0.174 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.33 -179.555 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.463 0.183 0 CA-C-O 120.719 0.295 . . . . 0.0 110.936 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -150.22 174.08 13.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.377 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -118.76 137.41 53.39 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.765 HG13 HG11 ' A' ' 39' ' ' VAL . 42.3 t -114.59 139.33 41.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.114 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -115.04 110.1 19.07 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.861 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 73' ' ' VAL . 5.9 t -95.9 130.31 44.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.027 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.5 93.13 8.39 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.964 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 -39.38 122.7 1.34 Allowed 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.555 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.31 -90.65 0.07 OUTLIER Glycine 0 C--N 1.333 0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.907 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 ptt85 -134.98 -47.37 0.73 Allowed 'General case' 0 C--O 1.233 0.196 0 N-CA-C 111.578 0.214 . . . . 0.0 111.578 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.49 40.43 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.528 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.28 -173.96 21.43 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.826 -0.702 . . . . 0.0 113.178 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -96.56 -71.93 0.66 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.653 0.263 . . . . 0.0 111.463 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.71 -39.34 0.61 Allowed Glycine 0 CA--C 1.519 0.323 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.785 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -71.62 179.93 2.85 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.691 0.282 . . . . 0.0 111.122 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 m -135.3 151.03 50.16 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.356 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 mt -124.97 131.06 53.48 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.942 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.7 p -148.06 157.77 43.69 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 120.713 0.292 . . . . 0.0 111.561 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 126.26 -25.73 5.39 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 121.213 -0.518 . . . . 0.0 113.027 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 61.81 14.24 6.07 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.736 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.801 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -166.87 -65.79 0.01 OUTLIER Pre-proline 0 N--CA 1.463 0.224 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.801 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.8 Cg_endo -74.39 83.68 1.66 Allowed 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.381 2.054 . . . . 0.0 111.361 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.5 m -52.23 108.45 0.29 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.3 p -143.22 141.37 26.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.54 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 1.003 HD12 HD11 ' A' ' 47' ' ' ILE . 2.1 mp -78.98 91.95 4.89 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.408 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.24 -42.98 42.33 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.408 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.59 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.9 t -171.07 157.1 5.06 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.964 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -120.42 155.56 23.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.655 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.0 mtp -97.83 102.29 14.01 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.224 0.535 . . . . 0.0 110.572 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.34 121.6 5.17 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.967 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.21 -18.32 23.54 Favored Glycine 0 CA--C 1.522 0.499 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.291 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.79 166.74 34.16 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.654 0.227 . . . . 0.0 110.521 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -53.14 -26.74 34.32 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.101 2.534 . . . . 0.0 113.166 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -65.5 -42.27 92.3 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.53 -26.65 63.67 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.375 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -55.31 -25.59 35.37 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 111.668 0.247 . . . . 0.0 111.668 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.765 HG11 HG13 ' A' ' 6' ' ' VAL . 21.4 t -89.46 -32.51 5.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 120.612 0.244 . . . . 0.0 111.122 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.77 41.65 1.68 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.454 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.5 mt -74.79 -178.28 3.62 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.628 0.251 . . . . 0.0 110.346 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 -163.85 122.79 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.402 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.59 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -47.26 125.25 7.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.97 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.53 -25.66 5.89 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.595 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.627 ' OD2' HG21 ' A' ' 78' ' ' ILE . 11.3 p-10 -56.91 122.62 12.69 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 121.018 0.437 . . . . 0.0 110.946 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.6 mp0 -76.98 117.78 18.91 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.062 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 1.003 HD11 HD12 ' A' ' 27' ' ' LEU . 14.0 mt -81.76 121.49 35.18 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.899 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mp -108.44 -40.59 5.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.086 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.558 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -120.8 133.08 55.33 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.99 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.4 t -135.3 111.29 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.22 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.28 32.62 0.58 Allowed 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.294 0.568 . . . . 0.0 109.717 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 76.82 -3.35 2.53 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.089 -0.96 . . . . 0.0 112.784 179.869 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.78 HD11 ' CD1' ' A' ' 66' ' ' LEU . 1.1 pt -116.12 125.92 73.4 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-O 120.834 0.349 . . . . 0.0 111.16 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.481 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 18.4 p-10 -64.95 135.91 56.21 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.473 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.0 m -134.2 59.0 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.902 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 46.4 mttt -48.48 -71.44 0.07 Allowed 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.921 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 35.6 mttp -119.81 39.87 3.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.664 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -73.86 -174.87 1.94 Allowed 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.933 -179.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.529 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.99 136.24 33.12 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 121.489 0.661 . . . . 0.0 110.678 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.742 ' O ' HG23 ' A' ' 64' ' ' VAL . 5.1 t60 -53.99 -44.48 70.87 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.279 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -61.17 -41.81 97.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.788 0.327 . . . . 0.0 110.737 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -66.3 -41.45 89.71 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 59' ' ' SER . 61.5 t -65.93 -39.13 83.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.606 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.5 t -65.75 -39.02 83.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 178.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -57.42 -41.26 80.05 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.887 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.78 ' CD1' HD11 ' A' ' 53' ' ' ILE . 14.2 mt -64.14 -43.62 94.66 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.46 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.782 HG23 HD22 ' A' ' 74' ' ' LEU . 52.0 mt -66.84 -37.47 79.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.623 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -79.31 8.56 45.94 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.444 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.54 1.91 15.16 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 122.448 0.299 . . . . 0.0 110.781 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.439 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 16.0 p -50.98 -44.73 60.78 Favored 'General case' 0 C--O 1.233 0.212 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.487 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.9 m 67.21 30.82 7.01 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.065 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.9 -30.93 2.78 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.152 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.439 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.1 p -163.84 138.0 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.047 0.451 . . . . 0.0 112.193 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.782 HD22 HG23 ' A' ' 67' ' ' ILE . 41.4 tp -114.35 150.41 34.59 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.164 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.4 m80 -120.01 105.82 11.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.344 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.506 ' SD ' HD23 ' A' ' 74' ' ' LEU . 0.9 OUTLIER -115.45 137.18 52.32 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.168 -179.381 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.558 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 20.6 t -107.34 105.75 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.767 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.638 HG22 ' HA ' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -106.82 170.64 2.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.461 -179.821 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -130.41 154.78 47.36 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.571 -179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.234 0.239 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.794 179.724 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.5 p . . . . . 0 C--O 1.233 0.232 0 CA-C-O 120.78 0.324 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -130.81 145.09 51.88 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.244 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -110.44 132.66 53.99 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.664 179.484 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.672 HG13 HG11 ' A' ' 39' ' ' VAL . 37.1 t -118.33 141.1 39.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.554 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -128.66 100.8 5.87 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.794 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.632 ' O ' HG23 ' A' ' 73' ' ' VAL . 19.5 t -95.56 144.62 9.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-O 120.969 0.414 . . . . 0.0 111.533 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -115.14 106.44 14.09 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.625 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.424 ' HD3' ' HA ' ' A' ' 71' ' ' SER . 17.7 ttt180 -50.62 120.09 4.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.12 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.97 -61.92 5.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.392 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -150.7 -76.29 0.14 Allowed 'General case' 0 C--O 1.231 0.127 0 CA-C-O 120.613 0.244 . . . . 0.0 110.564 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.39 26.46 9.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.508 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.6 173.95 46.52 Favored Glycine 0 C--N 1.336 0.57 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.897 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -111.13 -77.24 0.59 Allowed 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 120.706 0.289 . . . . 0.0 110.922 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.53 45.32 0.04 OUTLIER Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.968 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -159.03 176.77 11.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.442 0.163 . . . . 0.0 110.713 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -140.9 150.38 43.11 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.628 0.252 . . . . 0.0 111.268 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.628 HD21 HD12 ' A' ' 47' ' ' ILE . 2.8 mt -120.98 131.48 54.33 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.568 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.7 m -147.08 163.0 37.67 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.258 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.61 -30.65 5.07 Favored Glycine 0 C--N 1.336 0.554 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.983 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.487 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 80.97 -44.73 0.22 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.443 0.697 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.799 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -111.04 -68.26 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.512 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.799 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 64.0 Cg_endo -73.73 95.72 0.89 Allowed 'Trans proline' 0 C--N 1.356 0.952 0 C-N-CA 122.26 1.974 . . . . 0.0 112.446 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.455 ' SG ' HG21 ' A' ' 63' ' ' VAL . 84.7 m -61.73 118.5 7.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.218 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.31 145.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.583 HD21 HD23 ' A' ' 41' ' ' LEU . 0.6 OUTLIER -75.86 90.99 2.95 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-O 120.846 0.355 . . . . 0.0 110.507 179.758 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.6 m -54.67 -36.67 64.86 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.417 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.474 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.2 t -164.52 157.94 17.66 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.031 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.419 HG21 ' O ' ' A' ' 41' ' ' LEU . 4.1 t -122.54 154.61 27.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.903 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -97.45 101.28 12.78 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.279 0.561 . . . . 0.0 110.216 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -51.87 121.59 6.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.122 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.86 27.97 8.07 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.193 -0.527 . . . . 0.0 112.525 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.2 m -129.36 164.63 38.23 Favored Pre-proline 0 C--N 1.332 -0.194 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.68 -25.12 25.27 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 122.865 2.376 . . . . 0.0 112.902 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.19 -49.98 65.45 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.815 0.341 . . . . 0.0 110.704 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.03 -25.98 65.64 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.168 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.1 m-30 -57.03 -30.18 64.0 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.599 0.238 . . . . 0.0 111.388 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.672 HG11 HG13 ' A' ' 6' ' ' VAL . 20.8 t -89.28 -25.92 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.253 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.84 5.4 6.94 Favored Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.348 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.617 HD11 HG11 ' A' ' 6' ' ' VAL . 7.3 mp -64.67 111.45 2.76 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 117.315 0.557 . . . . 0.0 109.675 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.482 ' O ' ' HB3' ' A' ' 43' ' ' ALA . 18.0 mmm180 -122.97 25.97 8.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.51 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 42' ' ' ARG . . . 72.92 159.27 0.22 Allowed 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.947 0.404 . . . . 0.0 111.636 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.15 -39.66 3.05 Favored Glycine 0 C--N 1.334 0.46 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.678 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.535 ' OD2' HD13 ' A' ' 27' ' ' LEU . 2.9 p-10 -52.3 119.91 4.94 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.917 0.389 . . . . 0.0 110.843 179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . 0.483 ' O ' HD12 ' A' ' 48' ' ' LEU . 11.0 mt-30 -75.22 126.22 30.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.031 -179.442 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.628 HD12 HD21 ' A' ' 19' ' ' LEU . 19.3 mt -83.09 120.29 34.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.819 179.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.483 HD12 ' O ' ' A' ' 46' ' ' GLN . 5.4 mp -105.2 -32.87 8.45 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.624 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.552 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -137.09 137.45 39.3 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 111.018 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.438 HG23 ' CG2' ' A' ' 55' ' ' VAL . 6.3 t -132.25 108.15 13.39 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.424 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 4.8 t-20 77.39 33.59 0.4 Allowed 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.52 -1.08 3.1 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.517 -179.621 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.655 HD11 HD13 ' A' ' 66' ' ' LEU . 9.0 pt -113.14 119.63 61.1 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 111.176 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 10.9 m120 -62.08 120.63 11.22 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.149 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.457 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 11.9 m -135.14 33.71 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.747 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -61.4 -28.43 69.25 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -123.55 26.83 7.65 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 120.544 0.211 . . . . 0.0 111.3 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.457 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -92.27 -178.96 5.1 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.765 0.317 . . . . 0.0 111.505 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.654 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.3 OUTLIER -80.23 135.36 36.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.362 0.601 . . . . 0.0 110.736 179.688 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.487 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 4.0 t60 -54.79 -44.24 73.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.927 -1.033 . . . . 0.0 111.978 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.469 ' HA ' HG22 ' A' ' 64' ' ' VAL . 20.9 mt-10 -65.64 -35.87 82.06 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.779 0.323 . . . . 0.0 110.567 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.29 -39.38 71.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.167 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 59' ' ' SER . 60.8 t -67.43 -42.31 87.09 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.162 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.469 HG22 ' HA ' ' A' ' 61' ' ' GLU . 31.4 m -65.93 -38.6 82.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.9 tttp -57.48 -40.31 78.3 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.697 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.655 HD13 HD11 ' A' ' 53' ' ' ILE . 21.2 mt -67.63 -42.42 82.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.736 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.508 HG23 HD13 ' A' ' 74' ' ' LEU . 9.5 mt -69.33 -38.38 77.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.996 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -60.1 -24.65 61.1 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.318 179.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -80.27 4.43 17.73 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.902 0.334 . . . . 0.0 111.902 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.607 ' HB2' HD12 ' A' ' 74' ' ' LEU . 0.1 OUTLIER -106.18 104.01 13.62 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.356 0.598 . . . . 0.0 110.109 179.708 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.424 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.1 OUTLIER -116.2 33.43 5.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.987 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.93 -53.91 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.088 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 8' ' ' VAL . 4.0 p -172.03 130.96 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-O 120.99 0.424 . . . . 0.0 111.8 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.607 HD12 ' HB2' ' A' ' 70' ' ' CYS . 0.5 OUTLIER -114.5 151.62 32.99 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.546 -179.878 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.522 ' N ' HD23 ' A' ' 74' ' ' LEU . 19.7 m170 -116.39 107.09 14.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.211 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.412 ' HG3' HD22 ' A' ' 74' ' ' LEU . 1.6 mpt? -108.74 145.76 34.61 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.03 -179.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.552 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 19.5 t -117.1 98.88 7.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.522 HG22 ' HA ' ' A' ' 47' ' ' ILE . 24.8 pt -101.62 172.1 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.479 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.57 146.84 52.22 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.12 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 . . . . . 0 C--O 1.232 0.16 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.118 179.912 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 3' ' ' VAL . 9.2 p . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.07 0.462 . . . . 0.0 111.26 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.73 ' HG2' HD11 ' A' ' 78' ' ' ILE . 6.9 tpt180 -114.18 139.27 49.5 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.844 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.81 131.06 57.05 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.182 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.825 HG11 HD13 ' A' ' 41' ' ' LEU . 25.6 t -120.91 131.49 72.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.693 0.282 . . . . 0.0 110.826 179.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.644 ' O ' HG21 ' A' ' 39' ' ' VAL . 25.6 mt-10 -116.7 115.25 25.29 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.009 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.448 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.2 t -108.57 138.58 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.787 0.327 . . . . 0.0 111.435 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.3 93.89 8.87 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.397 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.436 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 4.0 ttt-85 -51.81 126.41 17.9 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.445 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.92 -112.67 0.03 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.687 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -111.27 -39.33 4.75 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.468 0.175 . . . . 0.0 111.329 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -138.75 35.13 2.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.337 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 159.96 -170.45 36.1 Favored Glycine 0 C--N 1.338 0.65 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.731 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.436 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 71.5 m-85 -118.63 -69.42 0.85 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.865 0.364 . . . . 0.0 111.161 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.16 52.49 0.04 OUTLIER Glycine 0 C--N 1.332 0.315 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.317 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.525 ' HB2' HD21 ' A' ' 27' ' ' LEU . 51.0 p90 -162.99 155.47 18.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.549 0.214 . . . . 0.0 110.952 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.14 129.13 43.52 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.932 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -116.57 124.37 49.68 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.993 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 39.2 m -148.07 115.58 6.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.177 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -168.1 83.28 0.1 OUTLIER Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.49 -179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.25 -43.07 21.68 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.972 0.415 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.96 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -121.25 -66.69 0.02 OUTLIER Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.455 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.96 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 92.3 Cg_endo -85.23 94.88 0.64 Allowed 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 122.475 2.117 . . . . 0.0 112.214 179.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 2.6 m -51.87 117.66 2.89 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.822 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -141.51 149.41 20.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.378 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.612 HD11 HD21 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -80.46 91.49 5.74 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.741 179.661 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.08 -45.38 61.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.517 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.503 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.5 t -164.4 159.06 19.21 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.59 HG22 HD22 ' A' ' 27' ' ' LEU . 5.2 t -116.9 155.03 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.714 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -99.5 100.76 11.83 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.153 0.501 . . . . 0.0 110.278 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.3 mtm-85 -52.07 125.94 17.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.943 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.91 23.64 11.46 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.682 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.86 168.92 14.29 Favored Pre-proline 0 CA--C 1.531 0.218 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.669 ' O ' HG23 ' A' ' 39' ' ' VAL . 78.4 Cg_exo -50.66 -29.93 27.11 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.885 2.39 . . . . 0.0 113.051 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.796 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -65.09 -49.82 68.51 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 111.014 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -69.43 -32.79 71.98 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.243 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 16.7 m-30 -62.77 -23.78 67.38 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.455 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.669 HG23 ' O ' ' A' ' 35' ' ' PRO . 38.8 t -89.32 -29.6 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.58 0.229 . . . . 0.0 111.246 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.89 39.96 0.86 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.717 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.825 HD13 HG11 ' A' ' 6' ' ' VAL . 4.1 tp -73.28 178.62 4.38 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.806 0.336 . . . . 0.0 110.765 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -173.92 131.17 0.41 Allowed 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.944 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.503 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -62.67 120.81 11.92 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.911 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 128.23 -27.57 4.48 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.804 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -58.3 123.92 17.72 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 120.927 0.394 . . . . 0.0 111.062 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -78.21 124.7 28.37 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.716 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.3 mt -95.66 122.21 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.802 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.76 HD12 ' HD2' ' A' ' 56' ' ' LYS . 0.3 OUTLIER -108.19 -38.32 5.79 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.016 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.523 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -119.01 138.14 53.04 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.569 ' HB ' HG21 ' A' ' 55' ' ' VAL . 19.3 t -141.71 115.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.773 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.417 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.7 t-20 76.89 32.78 0.49 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -178.302 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.417 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.2 -0.71 3.23 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.454 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.71 HD11 HD13 ' A' ' 66' ' ' LEU . 12.1 pt -120.47 133.42 67.23 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 111.434 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.523 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 22.9 t-20 -63.07 121.73 14.32 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.966 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.569 HG21 ' HB ' ' A' ' 50' ' ' VAL . 5.0 m -140.41 55.35 0.21 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.553 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.76 ' HD2' HD12 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.03 14.52 31.74 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.546 179.572 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -150.89 27.95 0.7 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 122.279 0.232 . . . . 0.0 111.12 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -113.99 -167.45 1.21 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-O 120.706 0.289 . . . . 0.0 111.59 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.591 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.4 OUTLIER -88.74 139.15 30.75 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 121.361 0.6 . . . . 0.0 110.533 179.672 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.727 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.3 t60 -53.69 -44.78 70.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.871 -1.058 . . . . 0.0 112.052 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -60.62 -42.32 96.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.742 0.306 . . . . 0.0 110.731 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -64.79 -44.06 91.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.265 179.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 59' ' ' SER . 52.4 t -63.36 -42.81 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.128 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.727 HG23 ' O ' ' A' ' 60' ' ' HIS . 50.3 t -66.17 -38.91 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -57.77 -41.1 81.3 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.89 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.71 HD13 HD11 ' A' ' 53' ' ' ILE . 17.7 mt -64.05 -43.45 95.49 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.566 HG23 HD22 ' A' ' 74' ' ' LEU . 68.6 mt -62.42 -44.27 99.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.679 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -69.51 -22.37 76.5 Favored Glycine 0 CA--C 1.522 0.49 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.004 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.9 tptt -57.0 -34.68 68.38 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.577 0.227 . . . . 0.0 111.421 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -69.01 -57.8 4.96 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-O 120.912 0.387 . . . . 0.0 110.676 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.416 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.5 OUTLIER 65.05 36.09 7.61 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.108 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.28 -45.56 0.02 OUTLIER Glycine 0 C--N 1.332 0.313 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.196 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.2 p -165.46 138.78 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.829 0.347 . . . . 0.0 111.287 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.566 HD22 HG23 ' A' ' 67' ' ' ILE . 28.3 tp -112.29 134.65 53.71 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.286 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 55.6 m170 -119.53 98.49 6.16 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.2 179.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.97 145.15 40.12 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.327 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 22.9 t -96.67 114.0 32.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.545 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.73 HD11 ' HG2' ' A' ' 4' ' ' ARG . 1.7 pt -103.37 146.23 11.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.311 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -112.94 144.57 42.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.267 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.233 0.205 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.449 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.498 ' O ' HG13 ' A' ' 3' ' ' VAL . 11.9 p . . . . . 0 CA--C 1.533 0.319 0 CA-C-O 120.887 0.375 . . . . 0.0 111.327 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.5 ttt85 -118.48 136.27 53.9 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.203 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.09 129.54 36.37 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.754 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.405 HG11 ' CD2' ' A' ' 41' ' ' LEU . 25.0 t -126.35 135.51 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.333 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -133.35 109.11 9.13 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.515 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.2 t -102.46 144.48 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.204 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -110.23 102.96 11.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.853 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.91 120.3 5.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.211 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.52 -122.03 0.58 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.647 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -114.41 -40.7 3.58 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.514 0.197 . . . . 0.0 111.151 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -105.94 29.42 6.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 120.721 0.296 . . . . 0.0 111.52 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.96 -176.92 16.77 Favored Glycine 0 C--N 1.337 0.606 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.826 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CE2' HG22 ' A' ' 67' ' ' ILE . 61.8 m-85 -79.3 -71.46 0.44 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.896 0.379 . . . . 0.0 110.718 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.23 48.99 0.04 OUTLIER Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.836 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.743 ' HB2' HD23 ' A' ' 27' ' ' LEU . 50.5 p90 -161.01 171.59 18.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.673 0.273 . . . . 0.0 110.946 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -126.31 133.17 51.47 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.899 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.531 HD21 ' CD1' ' A' ' 47' ' ' ILE . 3.4 mt -115.27 124.59 51.72 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.204 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.4 m -136.7 16.31 3.11 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.301 -0.409 . . . . 0.0 112.101 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.44 85.19 1.57 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.071 -0.585 . . . . 0.0 112.445 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.34 -66.66 0.35 Allowed 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.691 0.281 . . . . 0.0 111.011 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.883 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -91.76 -59.06 0.23 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.103 178.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.883 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 83.9 Cg_endo -88.59 94.32 0.38 Allowed 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 122.89 2.393 . . . . 0.0 111.607 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.57 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.2 m -50.98 124.24 10.91 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.679 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 45' ' ' ASP . 7.3 p -154.07 141.89 13.11 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.743 HD23 ' HB2' ' A' ' 17' ' ' PHE . 1.6 mp -79.71 89.53 5.18 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.771 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -56.22 -35.24 67.11 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.473 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.3 t -153.16 152.05 30.82 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.3 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.2 t -123.13 154.76 28.86 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.724 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 32.3 mtt -98.64 100.29 11.5 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.268 0.556 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.37 123.29 13.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.847 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 108.85 -19.71 30.15 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.785 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.0 166.59 25.64 Favored Pre-proline 0 CA--C 1.531 0.231 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -55.45 -24.93 46.14 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.709 2.273 . . . . 0.0 112.621 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.769 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -63.57 -49.11 74.7 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.993 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.08 -28.95 65.84 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.286 179.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.7 m-30 -56.64 -33.08 65.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.687 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -89.25 -31.06 5.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.024 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.2 51.71 1.44 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.176 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.769 HD12 ' HB1' ' A' ' 36' ' ' ALA . 5.3 mt -59.32 -25.81 64.47 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 20.5 mtt85 66.7 119.49 0.03 OUTLIER 'General case' 0 C--N 1.34 0.187 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.39 89.19 0.21 Allowed 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.496 179.249 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.0 -12.7 5.04 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 121.208 -0.52 . . . . 0.0 112.905 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.542 ' HB3' HD12 ' A' ' 78' ' ' ILE . 1.3 t70 -58.22 127.49 32.38 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.711 0.291 . . . . 0.0 110.573 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.59 126.65 30.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.739 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.812 ' HA ' HG22 ' A' ' 78' ' ' ILE . 15.1 mt -90.63 131.06 38.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.599 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -119.06 -43.65 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.358 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.07 137.25 47.27 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.008 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.6 t -144.28 110.98 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.297 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.413 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.3 t-20 76.99 35.74 0.35 Allowed 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -178.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.2 OUTLIER 71.55 -0.27 3.21 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.252 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 12.3 pt -120.97 125.5 74.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-O 120.81 0.338 . . . . 0.0 111.121 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.524 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -68.59 172.09 6.7 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.954 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.476 HG11 HG22 ' A' ' 63' ' ' VAL . 3.7 m -138.57 -51.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.039 -0.528 . . . . 0.0 112.121 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt 72.15 -59.41 0.56 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 123.119 0.567 . . . . 0.0 110.828 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.8 mtpt -148.23 40.26 0.94 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.75 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -72.74 -173.79 1.28 Allowed 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.859 0.362 . . . . 0.0 111.4 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.569 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -90.14 135.8 33.44 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.416 0.627 . . . . 0.0 111.174 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.539 ' O ' HG22 ' A' ' 64' ' ' VAL . 2.4 t-160 -53.13 -44.33 67.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.486 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.465 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.3 pm0 -66.21 -34.74 78.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.169 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.62 -39.43 70.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.725 0.297 . . . . 0.0 110.343 179.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.57 HG21 ' SG ' ' A' ' 25' ' ' CYS . 48.0 t -67.3 -43.87 87.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.941 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 60' ' ' HIS . 15.9 m -66.32 -38.96 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.6 mmtt -58.11 -39.73 79.42 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.059 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 25.3 mt -68.09 -41.19 82.21 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.772 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.557 HG23 HD22 ' A' ' 74' ' ' LEU . 17.7 mt -69.39 -38.49 77.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.035 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -87.77 14.33 58.72 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.102 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.57 -29.22 12.46 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.847 0.324 . . . . 0.0 111.299 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.426 ' HB2' HD12 ' A' ' 74' ' ' LEU . 0.5 OUTLIER -69.71 -61.86 1.61 Allowed 'General case' 0 C--O 1.233 0.217 0 CA-C-O 120.827 0.346 . . . . 0.0 110.645 -179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 70.63 33.88 2.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.088 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.52 -49.4 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.126 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -174.73 132.56 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 111.669 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.557 HD22 HG23 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.91 152.98 31.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.672 179.676 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.9 m170 -117.52 105.38 12.02 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.948 179.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.24 156.2 25.81 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.431 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.456 ' CG1' HG23 ' A' ' 3' ' ' VAL . 26.4 t -125.53 100.52 7.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.072 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.812 HG22 ' HA ' ' A' ' 47' ' ' ILE . 18.4 pt -101.36 158.67 4.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.388 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -114.86 116.64 28.89 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.72 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.18 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.466 HG22 ' CG1' ' A' ' 77' ' ' VAL . 11.5 p . . . . . 0 C--O 1.234 0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.935 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.3 ptt180 -137.1 170.77 15.54 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.49 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.7 m -93.81 139.01 31.37 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.459 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.818 HG13 HG11 ' A' ' 39' ' ' VAL . 36.9 t -117.44 146.92 21.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.09 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -111.3 102.55 10.94 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.789 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 73' ' ' VAL . 13.4 t -88.54 119.88 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.174 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.119 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.91 89.63 8.07 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.472 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.405 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 7.9 ttm-85 -53.47 122.12 9.07 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.731 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.29 -68.98 1.42 Allowed Glycine 0 C--N 1.335 0.483 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.548 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -165.32 -51.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 120.725 0.298 . . . . 0.0 110.807 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -122.53 25.04 9.0 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.596 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 150.94 171.53 19.14 Favored Glycine 0 C--N 1.336 0.58 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.795 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.405 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 5.4 m-85 -108.04 -62.85 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.667 0.27 . . . . 0.0 110.646 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.26 -33.5 0.93 Allowed Glycine 0 CA--C 1.523 0.541 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.879 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -71.48 178.59 3.39 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.021 0.439 . . . . 0.0 111.445 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 m -139.84 142.6 36.6 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.205 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.62 HD21 HD12 ' A' ' 47' ' ' ILE . 0.7 OUTLIER -117.82 123.98 47.25 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.883 179.924 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.7 m -140.5 168.04 20.75 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.292 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 117.28 -35.2 4.24 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.877 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.44 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.35 -46.57 0.22 Allowed 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.457 0.703 . . . . 0.0 111.559 -179.829 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -101.64 -65.31 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.405 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.88 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 97.0 Cg_endo -79.77 96.04 1.04 Allowed 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.41 2.074 . . . . 0.0 112.384 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.419 ' SG ' HG11 ' A' ' 63' ' ' VAL . 69.8 m -61.44 114.26 3.12 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.135 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -149.0 143.72 18.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.253 -179.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.674 HD12 HD11 ' A' ' 47' ' ' ILE . 3.7 mp -73.13 89.75 1.51 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.655 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.8 m -52.49 -39.52 61.33 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.418 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -163.53 158.78 21.22 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.581 HG22 HD23 ' A' ' 27' ' ' LEU . 5.3 t -132.96 155.18 40.92 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.47 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 9.1 mtt -109.24 106.04 15.72 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.878 0.37 . . . . 0.0 110.477 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 32' ' ' ARG . 2.5 mtm105 -43.51 111.34 0.27 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.048 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 126.16 -16.1 6.81 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.754 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.502 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 10.0 p -80.58 162.98 58.7 Favored Pre-proline 0 CA--C 1.532 0.282 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.502 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 14.1 Cg_endo -55.84 -24.85 49.26 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 122.718 2.278 . . . . 0.0 112.751 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.546 ' HA ' HD12 ' A' ' 41' ' ' LEU . . . -68.75 -48.04 64.75 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.403 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.77 -30.97 72.0 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.321 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -56.03 -34.56 65.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.818 HG11 HG13 ' A' ' 6' ' ' VAL . 20.3 t -89.63 -29.35 5.07 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.271 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.88 -10.51 4.85 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.851 -0.69 . . . . 0.0 113.357 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.72 ' CD2' HD13 ' A' ' 78' ' ' ILE . 46.9 mt -54.0 116.15 2.41 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 117.016 0.408 . . . . 0.0 110.857 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.92 -153.32 0.56 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.747 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 104.02 15.97 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.424 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.94 -25.74 2.38 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.792 -0.718 . . . . 0.0 113.383 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.99 117.78 6.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.995 0.398 . . . . 0.0 111.101 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.04 132.27 35.14 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.799 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.674 HD11 HD12 ' A' ' 27' ' ' LEU . 17.1 mt -91.36 133.35 33.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.556 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.533 HD11 ' CB ' ' A' ' 79' ' ' ALA . 3.1 mp -117.51 -47.14 2.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.881 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.536 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -116.08 136.89 52.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.657 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.524 HG21 HG13 ' A' ' 63' ' ' VAL . 21.8 t -132.95 109.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.402 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 7.9 t30 76.83 33.62 0.46 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.642 -178.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 77.51 -2.66 2.53 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.651 -179.868 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.662 HD11 ' CD1' ' A' ' 66' ' ' LEU . 13.6 pt -111.84 121.48 64.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 120.871 0.367 . . . . 0.0 111.161 179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.536 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -63.59 124.01 20.29 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.063 -179.683 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.689 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.6 m -134.55 53.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.299 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 9.0 mtmt -63.45 -37.12 86.08 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.568 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -127.16 27.55 5.89 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.574 -0.284 . . . . 0.0 111.34 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.689 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -81.31 -174.02 4.68 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.694 0.283 . . . . 0.0 111.281 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.661 ' O ' HG23 ' A' ' 63' ' ' VAL . 52.0 m -84.25 139.81 32.1 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.495 0.664 . . . . 0.0 110.825 179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.719 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.1 t60 -60.8 -44.62 96.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.697 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -63.04 -42.05 99.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.437 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.79 -45.11 94.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.556 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 59' ' ' SER . 58.5 t -63.83 -41.96 94.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.8 t -65.76 -39.04 83.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 178.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.67 -39.96 78.28 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.897 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.662 ' CD1' HD11 ' A' ' 53' ' ' ILE . 13.8 mt -66.41 -43.15 86.57 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.705 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.431 HG12 HD22 ' A' ' 74' ' ' LEU . 25.0 mt -65.25 -37.2 79.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.759 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -83.63 12.55 51.69 Favored Glycine 0 CA--C 1.525 0.673 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.549 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -112.44 -14.73 13.22 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 122.43 0.292 . . . . 0.0 111.459 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.471 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 27.2 p -45.99 -49.18 16.3 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 122.651 0.38 . . . . 0.0 111.96 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.16 33.87 9.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.974 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 151.74 -36.73 0.84 Allowed Glycine 0 C--N 1.334 0.44 0 C-N-CA 120.805 -0.712 . . . . 0.0 113.132 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.4 p -173.59 137.25 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.906 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.444 HD21 HG13 ' A' ' 50' ' ' VAL . 11.3 tp -112.63 142.34 45.33 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.947 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.3 m170 -107.31 98.05 7.73 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.124 179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.5 ptm -119.66 146.88 45.17 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.481 -179.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.466 ' CG1' HG22 ' A' ' 3' ' ' VAL . 24.6 t -102.12 112.9 36.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.963 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.72 HD13 ' CD2' ' A' ' 41' ' ' LEU . 19.5 pt -101.05 170.27 1.59 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.304 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.533 ' CB ' HD11 ' A' ' 48' ' ' LEU . . . -140.09 118.46 12.12 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.178 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.233 0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.784 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.8 t . . . . . 0 C--O 1.234 0.267 0 CA-C-O 120.616 0.246 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -121.99 140.81 52.02 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.132 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 m -97.64 127.68 43.78 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.849 HG13 HG11 ' A' ' 39' ' ' VAL . 38.9 t -120.08 141.8 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.137 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.9 122.6 36.5 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.158 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.534 ' O ' HG23 ' A' ' 73' ' ' VAL . 9.3 t -105.53 149.48 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.131 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -107.42 101.95 11.26 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.143 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -57.5 120.15 7.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.32 -110.11 0.34 Allowed Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.306 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 11.2 mtt85 -106.48 -70.94 0.77 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.65 0.262 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.52 44.52 1.24 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.172 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.55 -153.64 25.26 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.881 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.641 ' OH ' HG22 ' A' ' 67' ' ' ILE . 16.7 m-85 -131.69 -54.41 1.0 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.772 0.32 . . . . 0.0 111.184 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.27 -22.05 1.73 Allowed Glycine 0 CA--C 1.524 0.603 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.908 -179.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.84 163.01 12.79 Favored 'General case' 0 CA--C 1.53 0.203 0 CA-C-O 120.89 0.376 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.26 122.17 46.75 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD21 HD12 ' A' ' 47' ' ' ILE . 0.4 OUTLIER -105.18 125.26 50.78 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.229 -179.844 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.78 110.86 3.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.222 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -165.41 79.21 0.12 Allowed Glycine 0 N--CA 1.445 -0.74 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.893 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.89 -45.32 7.5 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.928 0.394 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.963 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -114.74 -66.42 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.402 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.963 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 95.0 Cg_endo -87.42 94.35 0.46 Allowed 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 122.606 2.204 . . . . 0.0 112.266 179.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 83.0 m -52.97 115.65 1.96 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.411 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -146.02 145.54 20.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.803 0.335 . . . . 0.0 111.796 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -73.75 90.1 1.84 Allowed 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.365 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -47.29 -51.61 18.61 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.868 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.6 t -154.45 159.36 41.01 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.475 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.5 t -125.21 154.47 33.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.597 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.2 mtp -107.6 104.72 14.32 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.211 0.529 . . . . 0.0 110.264 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -53.09 126.37 20.48 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.884 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.26 24.68 12.14 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.446 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.67 170.81 10.37 Favored Pre-proline 0 CA--C 1.532 0.252 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -47.27 -30.7 11.39 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 123.001 2.468 . . . . 0.0 113.619 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -71.3 -48.4 50.92 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 120.815 0.341 . . . . 0.0 111.029 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -69.59 -30.28 68.01 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.525 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.8 m-30 -60.13 -23.69 64.08 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 111.62 0.23 . . . . 0.0 111.62 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.849 HG11 HG13 ' A' ' 6' ' ' VAL . 22.9 t -89.19 -31.31 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.689 0.28 . . . . 0.0 110.897 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.8 36.3 3.26 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.522 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 6.4 mt -69.42 -177.99 1.29 Allowed 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.834 0.35 . . . . 0.0 110.738 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.84 131.94 7.19 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.266 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.43 98.92 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.378 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 148.51 -25.46 1.36 Allowed Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.703 -178.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.558 ' CG ' HD13 ' A' ' 78' ' ' ILE . 12.7 m-20 -56.11 118.46 4.7 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.833 0.316 . . . . 0.0 110.718 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -77.12 123.01 25.79 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.821 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.792 ' HA ' HG22 ' A' ' 78' ' ' ILE . 31.0 mt -77.91 121.64 31.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.685 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.977 HD11 ' HB2' ' A' ' 79' ' ' ALA . 2.4 mt -100.4 -46.83 5.11 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.408 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -133.4 138.79 46.43 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.224 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.6 t -128.91 110.48 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.458 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.6 t-20 76.88 31.04 0.55 Allowed 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -178.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.62 -2.35 1.62 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.836 179.864 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.754 HD11 HD13 ' A' ' 66' ' ' LEU . 1.2 pp -110.49 128.18 66.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.057 0.456 . . . . 0.0 111.381 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.4 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -65.27 142.96 58.1 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.609 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.2 m -145.23 62.47 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.453 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -71.16 -37.94 72.19 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.485 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -139.13 32.9 2.13 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.803 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.89 -179.97 5.79 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.558 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.604 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.5 OUTLIER -93.16 135.61 34.19 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.421 0.629 . . . . 0.0 110.728 179.868 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 7.7 t60 -53.91 -43.88 70.09 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.974 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.471 ' HA ' HG22 ' A' ' 64' ' ' VAL . 1.5 mt-10 -62.05 -36.82 82.79 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.945 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.6 -40.66 69.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 59' ' ' SER . 46.3 t -65.59 -43.19 94.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.153 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.532 ' HA ' HD12 ' A' ' 67' ' ' ILE . 30.7 m -65.46 -38.41 82.41 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -57.98 -41.25 82.55 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.053 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.754 HD13 HD11 ' A' ' 53' ' ' ILE . 4.4 mt -68.17 -40.55 82.27 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.694 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.641 HG22 ' OH ' ' A' ' 15' ' ' TYR . 11.2 mt -69.21 -42.22 81.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.592 179.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.44 -4.26 84.11 Favored Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.923 -0.656 . . . . 0.0 113.41 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 7.1 tttt -79.34 -36.49 39.36 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 117.006 0.403 . . . . 0.0 111.647 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.32 -60.85 2.39 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.703 0.287 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 71.69 33.2 1.83 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.62 -49.92 0.01 OUTLIER Glycine 0 C--N 1.332 0.357 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.196 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.6 p -175.27 132.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 121.061 0.458 . . . . 0.0 111.691 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.464 HD22 HG12 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.83 154.66 28.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.756 179.776 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -109.68 98.45 7.79 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.055 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.49 ' HG2' HG23 ' A' ' 47' ' ' ILE . 13.8 ttm -97.54 128.28 44.16 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.35 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.31 95.64 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.388 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.792 HG22 ' HA ' ' A' ' 47' ' ' ILE . 2.5 pp -100.35 170.82 1.45 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.486 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.977 ' HB2' HD11 ' A' ' 48' ' ' LEU . . . -123.79 143.47 50.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.251 179.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 . . . . . 0 C--O 1.233 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.032 179.888 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 N--CA 1.471 0.616 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.497 HH21 HG22 ' A' ' 6' ' ' VAL . 4.8 ptm180 -115.39 166.87 11.4 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.26 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -109.22 141.8 40.95 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.951 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.642 HG23 HD11 ' A' ' 78' ' ' ILE . 41.9 t -129.48 131.3 67.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.188 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -115.69 105.77 13.12 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.711 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.695 HG11 ' HB3' ' A' ' 15' ' ' TYR . 3.4 t -86.49 154.11 3.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.894 0.378 . . . . 0.0 111.035 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -112.92 104.99 12.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.935 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -48.36 110.59 0.35 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.714 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.95 -110.7 0.08 OUTLIER Glycine 0 C--N 1.333 0.378 0 C-N-CA 121.101 -0.571 . . . . 0.0 112.675 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.85 -39.89 2.91 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.83 36.68 4.35 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.815 0.34 . . . . 0.0 111.468 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.99 -129.21 5.53 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.534 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.695 ' HB3' HG11 ' A' ' 8' ' ' VAL . 98.8 m-85 -131.88 -70.96 0.56 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.663 0.268 . . . . 0.0 111.087 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 152.58 40.62 0.03 OUTLIER Glycine 0 CA--C 1.518 0.252 0 C-N-CA 121.053 -0.594 . . . . 0.0 113.179 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -158.58 -177.76 6.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.561 0.22 . . . . 0.0 110.691 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -134.7 158.02 45.19 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-O 120.775 0.322 . . . . 0.0 111.182 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -138.96 132.07 29.68 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.0 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 p -145.93 165.09 29.98 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 111.344 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 22' ' ' GLN . . . 122.47 -22.98 7.27 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 121.186 -0.53 . . . . 0.0 113.142 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.651 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 70.04 2.52 3.96 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -179.758 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.652 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -168.6 -61.75 0.01 OUTLIER Pre-proline 0 C--O 1.233 0.199 0 C-N-CA 122.162 0.185 . . . . 0.0 110.635 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.652 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 58.4 Cg_endo -69.86 81.4 0.84 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.306 2.004 . . . . 0.0 110.955 178.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.617 ' SG ' HG11 ' A' ' 63' ' ' VAL . 62.0 m -50.39 109.29 0.29 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.071 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.4 141.55 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.717 HD21 HD13 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -75.16 90.68 2.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.389 179.575 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 p -58.99 -38.16 78.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.189 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.1 t -168.17 154.91 7.66 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-O 120.823 0.344 . . . . 0.0 111.438 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.638 HG22 HD23 ' A' ' 27' ' ' LEU . 3.4 t -122.05 154.03 26.49 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.531 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.1 mtm -101.02 100.66 11.29 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.986 0.422 . . . . 0.0 110.52 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.0 mtt180 -51.42 125.75 15.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.749 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.52 26.61 10.67 Favored Glycine 0 CA--C 1.52 0.358 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.339 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.409 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 58.0 m -131.0 162.82 53.26 Favored Pre-proline 0 CA--C 1.529 0.163 0 N-CA-C 110.434 -0.21 . . . . 0.0 110.434 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.512 ' O ' HG23 ' A' ' 39' ' ' VAL . 83.2 Cg_exo -46.75 -31.85 11.25 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.17 2.58 . . . . 0.0 113.296 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.694 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -67.01 -50.0 63.54 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-O 120.814 0.34 . . . . 0.0 110.968 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -70.66 -30.75 67.45 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.13 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 22.6 m-30 -59.58 -23.61 63.07 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.704 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.575 ' CG1' HG13 ' A' ' 6' ' ' VAL . 20.1 t -89.31 -32.3 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 120.652 0.263 . . . . 0.0 111.207 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.84 58.63 0.34 Allowed Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.76 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.717 HD13 HD21 ' A' ' 27' ' ' LEU . 17.7 mt -97.25 176.4 5.92 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.791 0.329 . . . . 0.0 110.571 179.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.45 133.39 0.81 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.909 0.385 . . . . 0.0 111.082 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.03 125.72 24.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.909 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.13 -30.59 4.29 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.389 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -62.53 121.27 12.88 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.825 0.345 . . . . 0.0 110.734 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.4 tp60 -77.9 118.09 19.88 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.928 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.552 HD11 HD12 ' A' ' 27' ' ' LEU . 19.9 mt -79.45 122.85 35.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.817 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mp -106.8 -41.45 5.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.605 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.497 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -113.82 152.22 30.97 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.864 0.364 . . . . 0.0 111.302 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.81 HG21 HG13 ' A' ' 63' ' ' VAL . 2.7 m -149.42 102.63 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.363 179.463 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 75.65 39.62 0.33 Allowed 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 74.79 -1.23 3.14 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.733 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.653 HD11 HD13 ' A' ' 66' ' ' LEU . 23.8 pt -117.27 132.1 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 111.775 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.497 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 5.0 p-10 -66.92 154.67 40.44 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 121.273 0.559 . . . . 0.0 112.123 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.47 HG11 HG22 ' A' ' 63' ' ' VAL . 9.1 m -149.58 62.9 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.295 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -55.73 -77.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.661 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -115.72 37.33 3.65 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 120.769 0.318 . . . . 0.0 110.969 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' ALA . . . -75.28 -172.6 1.78 Allowed 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.45 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -89.29 135.43 33.58 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 121.385 0.612 . . . . 0.0 110.715 179.759 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.759 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.9 t60 -57.35 -44.56 84.43 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.654 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -63.27 -40.19 96.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.649 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.51 -45.34 87.68 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.451 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.81 HG13 HG21 ' A' ' 50' ' ' VAL . 48.7 t -63.49 -42.71 97.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.185 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 60' ' ' HIS . 50.7 t -65.64 -39.45 85.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.23 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -40.05 83.51 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.046 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.653 HD13 HD11 ' A' ' 53' ' ' ILE . 6.4 mt -66.92 -40.16 87.56 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.918 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.682 HD12 ' HA ' ' A' ' 64' ' ' VAL . 7.3 mt -69.12 -41.92 81.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.482 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -73.77 -25.74 71.16 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.633 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 tppt? -53.98 -35.02 61.39 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 t -69.86 -54.15 14.79 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.75 0.309 . . . . 0.0 110.84 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.1 m 63.62 35.7 11.43 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.963 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.99 -43.87 0.02 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.381 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 8' ' ' VAL . 6.5 p -162.01 134.47 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-O 120.959 0.409 . . . . 0.0 111.535 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.596 HD23 ' CE1' ' A' ' 15' ' ' TYR . 3.8 pp -114.41 154.42 28.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -131.61 116.06 16.9 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.68 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.446 ' CE ' HD13 ' A' ' 74' ' ' LEU . 4.0 mtt -131.92 139.44 48.73 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.88 0.371 . . . . 0.0 111.437 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 29.3 t -103.9 112.85 39.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.977 178.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.642 HD11 HG23 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.53 155.32 8.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.68 -179.193 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -116.85 139.01 51.1 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.285 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 CA--C 1.53 0.199 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.661 179.801 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.7 p . . . . . 0 CA--C 1.532 0.274 0 CA-C-O 120.845 0.355 . . . . 0.0 111.065 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttt180 -115.81 142.74 46.35 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.01 -179.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 m -113.55 129.21 56.6 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.069 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.874 HG11 HD13 ' A' ' 41' ' ' LEU . 20.7 t -116.95 131.66 68.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.817 179.736 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -100.78 100.95 11.69 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.946 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.505 ' O ' HG23 ' A' ' 73' ' ' VAL . 13.5 t -86.09 108.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.056 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -94.82 91.82 6.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.8 ttt85 -36.55 119.12 0.6 Allowed 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.407 0.442 . . . . 0.0 111.118 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.01 -118.27 0.16 Allowed Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.746 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -113.7 -38.5 4.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.501 0.191 . . . . 0.0 111.338 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.34 28.11 8.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 124.07 -160.57 18.63 Favored Glycine 0 C--N 1.338 0.677 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.827 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 60.5 m-85 -89.82 -54.24 4.14 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.581 0.229 . . . . 0.0 111.039 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.91 65.05 0.59 Allowed Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.382 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.787 ' HB2' HD21 ' A' ' 27' ' ' LEU . 20.5 p90 -168.03 172.62 8.68 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.643 0.259 . . . . 0.0 111.41 179.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -122.5 159.73 27.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.28 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -149.26 130.07 14.21 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.038 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.93 158.71 38.4 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.782 0.325 . . . . 0.0 111.534 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 131.13 -27.15 3.86 Favored Glycine 0 CA--C 1.526 0.727 0 C-N-CA 121.204 -0.522 . . . . 0.0 113.114 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.529 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 62.01 13.83 5.97 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -179.825 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.832 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -170.74 -65.62 0.0 OUTLIER Pre-proline 0 N--CA 1.464 0.228 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.832 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.7 Cg_endo -75.84 83.6 1.92 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.359 2.039 . . . . 0.0 111.428 178.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 92.6 m -51.06 111.51 0.57 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.513 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.01 142.26 24.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.411 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.787 HD21 ' HB2' ' A' ' 17' ' ' PHE . 0.1 OUTLIER -83.69 92.53 7.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.483 179.682 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 t -58.28 -38.62 77.33 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.281 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.487 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.9 t -166.09 158.93 14.9 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.893 0.378 . . . . 0.0 111.135 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.599 HG22 HD22 ' A' ' 27' ' ' LEU . 17.2 t -115.15 154.46 16.52 Favored 'Isoleucine or valine' 0 C--O 1.232 0.182 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.638 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.7 mmm -89.72 99.29 12.32 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-O 121.342 0.592 . . . . 0.0 110.327 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.28 126.24 20.43 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.966 -1.015 . . . . 0.0 111.175 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.99 27.54 12.27 Favored Glycine 0 CA--C 1.52 0.402 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.606 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.26 168.81 15.7 Favored Pre-proline 0 C--O 1.234 0.256 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.518 ' O ' HG23 ' A' ' 39' ' ' VAL . 84.1 Cg_exo -48.58 -34.16 25.83 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 123.036 2.491 . . . . 0.0 113.018 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.595 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -60.16 -48.34 82.12 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.136 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -65.54 -33.2 75.36 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.501 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 14.6 m-30 -64.31 -24.8 67.78 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.411 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 35' ' ' PRO . 21.9 t -89.27 -27.94 5.23 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.782 0.325 . . . . 0.0 110.844 179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.39 32.19 2.61 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.541 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.874 HD13 HG11 ' A' ' 6' ' ' VAL . 6.0 tp -65.17 129.4 39.58 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 120.692 0.282 . . . . 0.0 110.446 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 71.3 mtt-85 -129.5 115.87 18.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.361 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.487 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -57.38 156.83 7.26 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.668 -179.405 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.15 -13.15 63.52 Favored Glycine 0 CA--C 1.522 0.479 0 CA-C-N 115.124 -0.944 . . . . 0.0 112.211 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.83 138.34 35.12 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 110.642 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -83.47 126.42 32.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.457 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.499 HG23 ' HG2' ' A' ' 76' ' ' MET . 12.9 mt -85.4 131.87 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.521 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.525 HD11 ' CB ' ' A' ' 79' ' ' ALA . 5.0 mp -107.71 -39.7 5.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.356 -179.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.487 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -131.27 141.26 49.95 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.1 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.424 HG11 HD11 ' A' ' 67' ' ' ILE . 13.5 t -133.54 110.5 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.874 179.231 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.413 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.6 t30 77.07 32.34 0.48 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.82 -1.2 2.39 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.535 179.981 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.784 HD11 HD13 ' A' ' 66' ' ' LEU . 13.0 pt -115.29 126.02 72.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.98 0.419 . . . . 0.0 111.794 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -66.87 136.87 56.06 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.511 -179.626 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.455 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.4 m -147.86 63.88 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.681 -179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -69.93 -31.69 69.58 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.136 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.0 mtpt -137.63 35.87 2.44 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.455 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -86.64 174.24 9.0 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 120.876 0.369 . . . . 0.0 111.534 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.661 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -81.27 134.75 35.64 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.399 0.619 . . . . 0.0 110.288 179.509 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.73 ' O ' HG23 ' A' ' 64' ' ' VAL . 3.7 t60 -54.73 -44.46 73.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.857 -1.065 . . . . 0.0 112.14 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -61.7 -43.36 99.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.951 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.83 -41.32 91.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.507 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 59' ' ' SER . 55.9 t -65.15 -42.51 94.46 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.001 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 60' ' ' HIS . 60.7 t -65.88 -39.29 84.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.68 -39.88 78.12 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.073 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.784 HD13 HD11 ' A' ' 53' ' ' ILE . 5.7 mt -67.71 -42.01 82.64 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.76 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.592 HG23 HD13 ' A' ' 74' ' ' LEU . 42.2 mt -66.06 -39.93 85.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.723 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.6 6.22 78.37 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.093 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.31 -32.69 16.41 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.857 0.328 . . . . 0.0 111.439 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.96 -61.21 2.3 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.784 0.326 . . . . 0.0 110.799 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.92 35.11 2.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.83 -47.14 0.01 OUTLIER Glycine 0 C--N 1.33 0.201 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.291 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -165.33 137.79 0.91 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.984 0.421 . . . . 0.0 111.331 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.592 HD13 HG23 ' A' ' 67' ' ' ILE . 11.1 tp -114.03 142.09 46.62 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.375 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.58 95.74 5.51 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.252 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.499 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.8 ttm -98.03 122.33 41.04 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.118 -179.356 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 21.0 t -102.23 96.64 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.464 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.492 HG22 ' HA ' ' A' ' 47' ' ' ILE . 2.7 pt -100.27 170.3 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.552 -179.55 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.525 ' CB ' HD11 ' A' ' 48' ' ' LEU . . . -130.83 137.2 49.29 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.234 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 . . . . . 0 C--O 1.234 0.267 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.147 179.902 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.507 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.7 p . . . . . 0 N--CA 1.473 0.686 0 N-CA-C 112.843 0.683 . . . . 0.0 112.843 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 63.3 ttt180 -126.59 134.24 50.85 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.002 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.3 m -96.2 130.65 43.21 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.503 HG13 HG11 ' A' ' 39' ' ' VAL . 25.0 t -123.13 140.16 47.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.372 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.514 ' O ' HG21 ' A' ' 39' ' ' VAL . 4.2 mt-10 -116.94 126.95 53.71 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.144 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 73' ' ' VAL . 20.9 t -125.59 137.75 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.639 179.581 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.18 97.54 8.33 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.995 0.426 . . . . 0.0 110.603 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.471 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 2.9 ttt-85 -47.14 121.54 3.83 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.353 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.4 -130.19 1.1 Allowed Glycine 0 C--N 1.334 0.448 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.512 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.1 mtt180 -111.93 -39.57 4.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.413 0.149 . . . . 0.0 111.258 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.38 26.85 9.71 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.68 0.252 . . . . 0.0 111.68 179.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.67 -179.89 16.03 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.924 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.471 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 91.3 m-85 -83.97 -34.01 24.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.585 0.231 . . . . 0.0 111.18 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.84 47.96 0.93 Allowed Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.284 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.416 ' HA ' ' HA ' ' A' ' 30' ' ' VAL . 20.6 p90 -168.67 153.87 6.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 111.063 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.5 m -98.88 128.2 45.0 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.92 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -106.18 126.92 52.81 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.181 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.0 m -147.84 130.45 15.91 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.517 178.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.67 73.36 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.276 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.1 tp60 -44.96 -43.48 9.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.799 0.333 . . . . 0.0 110.576 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.966 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -110.98 -64.56 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.021 178.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.966 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.0 Cg_endo -91.74 92.7 0.21 Allowed 'Trans proline' 0 C--N 1.358 1.042 0 C-N-CA 122.943 2.428 . . . . 0.0 111.912 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 7.7 p -53.36 118.75 4.07 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.936 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 45' ' ' ASP . 7.1 p -146.68 145.3 19.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.256 -179.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.568 HD12 HD11 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -74.96 90.39 2.43 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.845 0.355 . . . . 0.0 110.496 179.603 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -53.98 -35.74 62.14 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.625 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.1 t -165.26 161.75 19.41 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.723 0.297 . . . . 0.0 110.988 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.45 HG22 HD23 ' A' ' 27' ' ' LEU . 38.0 t -131.19 152.5 37.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.877 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.4 mmt -90.24 99.66 12.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-O 121.338 0.59 . . . . 0.0 110.342 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.97 121.81 8.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.935 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.08 26.01 8.08 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.561 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -128.95 171.75 8.21 Favored Pre-proline 0 CA--C 1.532 0.269 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.441 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 77.7 Cg_exo -48.91 -30.51 17.73 Favored 'Trans proline' 0 C--N 1.352 0.737 0 C-N-CA 122.847 2.365 . . . . 0.0 113.128 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.05 -50.23 50.41 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.142 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.97 -31.86 73.3 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.42 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.441 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 17.7 m-30 -60.12 -30.71 69.45 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.198 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.514 HG21 ' O ' ' A' ' 7' ' ' GLU . 22.3 t -89.72 -24.37 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.107 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.22 17.56 6.65 Favored Glycine 0 CA--C 1.523 0.57 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.153 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.56 HD21 HD13 ' A' ' 78' ' ' ILE . 3.4 mt -78.87 123.21 27.01 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 117.019 0.409 . . . . 0.0 110.303 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.1 mtp85 -130.48 -149.9 0.41 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -107.76 127.53 53.77 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.594 -0.275 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.7 -22.44 5.8 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 120.78 -0.724 . . . . 0.0 113.017 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.403 ' HB3' HD12 ' A' ' 78' ' ' ILE . 6.5 m-20 -73.29 121.66 20.74 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 116.924 0.362 . . . . 0.0 110.948 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -82.45 128.04 33.87 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.696 ' HA ' HG22 ' A' ' 78' ' ' ILE . 6.0 mt -85.32 125.29 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.445 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.7 mm? -103.05 -39.41 6.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.939 -179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.535 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.91 145.81 50.83 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.239 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.669 HG21 HG13 ' A' ' 63' ' ' VAL . 42.8 t -132.97 111.72 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.926 179.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.415 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 76.5 32.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.655 -178.458 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.53 -2.03 1.64 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.11 -0.95 . . . . 0.0 112.732 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.678 HD11 HD13 ' A' ' 66' ' ' LEU . 20.4 pt -113.73 125.58 71.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-O 120.838 0.352 . . . . 0.0 111.421 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.535 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.7 OUTLIER -60.3 125.51 23.96 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.95 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.497 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 3.7 m -146.95 40.65 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.415 ' HB3' ' HA ' ' A' ' 48' ' ' LEU . 0.0 OUTLIER -61.58 -29.93 70.35 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.794 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.0 mttp -119.85 29.56 7.49 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.322 179.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.497 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -88.27 -174.13 4.5 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 111.573 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.615 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -91.34 140.68 29.54 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.406 0.622 . . . . 0.0 110.742 179.675 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.766 ' O ' HG23 ' A' ' 64' ' ' VAL . 2.0 t-160 -52.86 -44.56 66.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.721 -1.127 . . . . 0.0 111.764 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.61 -39.52 91.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.665 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.01 -42.46 94.42 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.584 179.252 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.669 HG13 HG21 ' A' ' 50' ' ' VAL . 44.4 t -64.82 -42.45 94.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.122 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.766 HG23 ' O ' ' A' ' 60' ' ' HIS . 41.7 t -65.85 -39.19 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.2 ttmt -57.68 -40.73 80.09 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.093 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.678 HD13 HD11 ' A' ' 53' ' ' ILE . 17.7 mt -66.88 -42.82 84.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.763 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.702 HG23 ' HG ' ' A' ' 74' ' ' LEU . 25.2 mt -66.79 -40.6 86.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.97 179.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -70.21 -17.1 73.72 Favored Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.015 -0.612 . . . . 0.0 113.131 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -66.79 -42.09 86.55 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -67.62 -57.88 5.65 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.793 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.7 p 62.49 28.02 16.56 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.463 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -152.59 -40.48 0.03 OUTLIER Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.67 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 8' ' ' VAL . 6.5 p -150.53 138.58 14.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.089 0.471 . . . . 0.0 111.333 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.702 ' HG ' HG23 ' A' ' 67' ' ' ILE . 0.5 OUTLIER -102.81 138.02 40.25 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.952 -179.866 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -130.66 95.06 3.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 3.0 mtt -117.32 140.92 48.95 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.529 -179.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.505 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 22.0 t -104.86 95.19 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.237 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.696 HG22 ' HA ' ' A' ' 47' ' ' ILE . 16.6 pt -99.17 159.97 3.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.22 -179.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.82 147.83 45.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.492 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.233 0.207 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.861 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.464 0.226 0 CA-C-O 120.925 0.393 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -139.12 166.61 24.06 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.321 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -105.07 132.92 50.7 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.26 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.576 HG23 HG12 ' A' ' 78' ' ' ILE . 29.0 t -106.58 131.19 57.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.819 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 74' ' ' LEU . 1.6 mt-10 -118.83 116.57 26.8 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.543 HG11 ' HB3' ' A' ' 15' ' ' TYR . 3.7 t -110.01 133.97 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 111.421 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.67 94.05 9.77 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.93 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.455 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -48.47 121.03 4.08 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.176 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.45 -85.62 0.12 Allowed Glycine 0 C--N 1.335 0.501 0 C-N-CA 121.042 -0.599 . . . . 0.0 112.383 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 -145.98 -53.77 0.26 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.633 0.254 . . . . 0.0 111.013 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.18 28.91 8.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.535 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.37 164.79 11.16 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.709 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.543 ' HB3' HG11 ' A' ' 8' ' ' VAL . 73.3 m-85 -88.93 -66.77 0.89 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.84 0.352 . . . . 0.0 110.64 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.22 55.82 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.73 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -166.54 149.12 6.73 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.753 0.311 . . . . 0.0 110.93 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 109.43 22.12 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.03 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 6.2 tt -108.44 140.41 41.79 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.826 -179.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.437 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 22.7 m -150.35 161.44 42.48 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.457 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.78 81.35 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.313 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.5 mm100 -47.41 -40.48 17.91 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.606 0.241 . . . . 0.0 110.775 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.949 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -113.73 -63.41 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.279 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.332 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.949 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 90.9 Cg_endo -89.92 94.04 0.3 Allowed 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.812 2.341 . . . . 0.0 111.739 179.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.593 ' SG ' HG23 ' A' ' 55' ' ' VAL . 6.0 p -52.29 117.16 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.72 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.1 p -134.83 144.31 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.643 -179.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.58 92.74 9.22 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.084 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -57.16 -52.67 64.39 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.02 -179.308 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.546 ' HA ' ' HB1' ' A' ' 43' ' ' ALA . 0.6 OUTLIER -148.14 162.3 39.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.444 -179.594 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 10.9 t -121.19 153.73 24.82 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.129 179.304 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -94.56 99.96 12.02 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.24 0.543 . . . . 0.0 110.771 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 7.2 mtt180 -55.06 126.48 24.83 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.014 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 99.66 -16.29 58.88 Favored Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.888 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.614 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.4 m -89.64 166.38 21.22 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.841 0.32 . . . . 0.0 110.343 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.614 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 9.2 Cg_endo -51.25 -26.76 21.08 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.928 2.419 . . . . 0.0 113.441 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.19 76.76 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.849 0.357 . . . . 0.0 110.77 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.83 -26.57 63.35 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.207 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -59.43 -23.66 62.86 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.42 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.542 HG11 HG13 ' A' ' 6' ' ' VAL . 21.4 t -89.27 -30.15 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 116.662 -0.244 . . . . 0.0 111.06 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 104.71 45.4 1.41 Allowed Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.496 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.452 ' HG ' HG11 ' A' ' 6' ' ' VAL . 6.4 mt -72.48 -178.95 2.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-O 120.726 0.298 . . . . 0.0 110.569 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 44.9 mtp85 -142.01 112.74 7.28 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.291 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.546 ' HB1' ' HA ' ' A' ' 29' ' ' CYS . . . -64.85 103.56 0.73 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.527 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.63 -10.55 5.77 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.266 -179.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -81.02 165.49 21.65 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.02 156.33 17.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.534 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 4.2 mt -109.11 146.25 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.589 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 mp -118.92 -57.49 2.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.893 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.08 139.28 44.19 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.008 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.42 HG23 ' CG2' ' A' ' 55' ' ' VAL . 2.9 t -138.97 110.35 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.406 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.9 t-20 75.97 35.86 0.47 Allowed 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.406 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.08 -0.39 3.33 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.808 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.618 HD11 HD22 ' A' ' 66' ' ' LEU . 8.5 pt -119.68 133.66 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-O 120.92 0.39 . . . . 0.0 111.388 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -69.74 150.84 46.5 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.67 -179.515 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.607 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 2.4 m -150.11 56.85 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.2 mmtp -60.19 -40.42 89.98 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.455 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.0 mtmp? -130.01 31.96 4.6 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.658 0.266 . . . . 0.0 111.421 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.607 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -79.6 176.51 9.64 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 120.716 0.293 . . . . 0.0 111.144 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 2.9 m -95.8 147.19 23.9 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.581 0.705 . . . . 0.0 111.355 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.437 ' CE1' ' HA ' ' A' ' 20' ' ' SER . 2.7 t-160 -56.11 -41.85 75.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.325 -1.307 . . . . 0.0 111.445 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.474 ' HA ' HG12 ' A' ' 64' ' ' VAL . 11.4 pt-20 -64.21 -41.09 97.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.904 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -69.79 -42.07 74.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 110.366 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.619 HG23 ' O ' ' A' ' 59' ' ' SER . 55.5 t -67.71 -42.35 86.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.027 179.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.474 HG12 ' HA ' ' A' ' 61' ' ' GLU . 7.3 p -66.61 -39.1 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -57.94 -40.13 79.75 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.158 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.618 HD22 HD11 ' A' ' 53' ' ' ILE . 15.0 mt -66.28 -42.85 87.85 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.741 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.627 HG23 HD13 ' A' ' 74' ' ' LEU . 33.5 mt -66.62 -40.71 86.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.623 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -85.39 8.27 72.17 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.184 179.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.7 -32.63 15.36 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 116.828 0.314 . . . . 0.0 111.293 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.67 -55.04 19.61 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.963 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 m 64.5 36.17 8.89 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.859 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.87 -44.05 0.02 OUTLIER Glycine 0 C--N 1.332 0.338 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.414 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -163.39 139.13 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.129 0 CA-C-O 120.959 0.409 . . . . 0.0 111.384 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.627 HD13 HG23 ' A' ' 67' ' ' ILE . 62.8 tp -103.15 136.26 43.27 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.049 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -127.13 101.37 6.49 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.411 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.595 ' SD ' HD21 ' A' ' 74' ' ' LEU . 13.7 ptm -132.83 141.52 48.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.47 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.9 t -91.23 120.63 40.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.79 179.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.576 HG12 HG23 ' A' ' 6' ' ' VAL . 15.0 pt -99.33 170.17 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.35 148.88 30.04 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.284 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.233 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.322 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.463 0.22 0 CA-C-O 120.862 0.363 . . . . 0.0 111.296 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.8 ttt180 -123.04 126.87 47.93 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -97.8 120.84 38.9 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.754 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.771 HG11 ' HG ' ' A' ' 41' ' ' LEU . 20.9 t -114.2 131.58 65.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.512 ' O ' HG21 ' A' ' 39' ' ' VAL . 3.1 mt-10 -115.6 112.92 22.87 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.902 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 t -94.57 134.14 33.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 CA-C-O 120.877 0.37 . . . . 0.0 111.221 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -102.17 97.64 7.91 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.687 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.431 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -47.81 118.38 2.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.006 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.92 -107.54 0.08 OUTLIER Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.553 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.8 mtt180 -123.67 -46.75 1.99 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.633 0.254 . . . . 0.0 111.046 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.01 41.79 3.45 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.651 179.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 158.4 -179.64 33.93 Favored Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.14 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.431 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 8.7 m-85 -111.41 -40.74 4.3 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.595 0.236 . . . . 0.0 111.349 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.96 23.69 5.17 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.285 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -157.26 156.24 32.15 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.997 0.398 . . . . 0.0 110.933 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.0 m -111.01 135.61 51.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.861 0.362 . . . . 0.0 111.239 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.484 HD22 ' CE1' ' A' ' 60' ' ' HIS . 0.4 OUTLIER -119.18 129.09 54.81 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.043 179.898 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.6 m -151.7 176.05 11.77 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.125 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.55 -46.32 1.13 Allowed Glycine 0 C--N 1.335 0.497 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.38 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.437 ' O ' ' HB2' ' A' ' 23' ' ' ALA . 0.0 OUTLIER 55.13 39.43 31.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.877 0.471 . . . . 0.0 112.09 179.489 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.758 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . 174.53 -61.64 0.0 OUTLIER Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.636 179.476 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.758 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.1 Cg_endo -75.17 -27.43 9.75 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.598 2.199 . . . . 0.0 113.127 179.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.401 ' CB ' ' HB ' ' A' ' 47' ' ' ILE . 18.4 m 56.79 93.44 0.03 OUTLIER 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.509 0.671 . . . . 0.0 109.788 -179.002 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.834 HG13 ' HA ' ' A' ' 46' ' ' GLN . 0.8 OUTLIER -146.75 144.21 20.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.973 -178.95 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.32 122.33 16.87 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.487 179.703 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.4 m -82.42 -41.53 19.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.196 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.559 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 25.3 t -173.09 152.44 2.31 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.364 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.413 HG21 ' HB3' ' A' ' 41' ' ' LEU . 5.2 t -118.04 155.19 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.753 179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 27.4 mmm -98.41 100.95 12.26 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.204 0.526 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mtt-85 -50.85 124.58 11.44 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.069 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.02 24.51 11.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.553 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -123.76 165.98 20.98 Favored Pre-proline 0 C--O 1.232 0.148 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.432 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 10.4 Cg_endo -53.58 -26.99 39.3 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.781 2.32 . . . . 0.0 112.747 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.691 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -69.48 -49.18 57.18 Favored 'General case' 0 CA--C 1.528 0.121 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.002 179.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -67.05 -31.99 72.88 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.304 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.432 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 20.4 m-30 -59.47 -23.46 62.75 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.557 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.512 HG21 ' O ' ' A' ' 7' ' ' GLU . 21.9 t -89.38 -30.12 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.684 0.278 . . . . 0.0 111.253 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.79 68.13 0.54 Allowed Glycine 0 C--N 1.334 0.45 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.413 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.771 ' HG ' HG11 ' A' ' 6' ' ' VAL . 5.5 mt -102.31 162.35 12.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.795 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.9 mmt180 -148.55 119.66 7.73 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.559 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -57.08 111.8 1.16 Allowed 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.835 179.546 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.44 -12.88 7.02 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.874 -179.49 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.562 ' CB ' HD12 ' A' ' 78' ' ' ILE . 0.1 OUTLIER -66.94 112.1 4.14 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.825 0.312 . . . . 0.0 110.52 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . 0.834 ' HA ' HG13 ' A' ' 26' ' ' VAL . 1.1 tt0 -55.45 125.7 22.04 Favored 'General case' 0 CA--C 1.53 0.173 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.71 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.643 ' HA ' HG22 ' A' ' 78' ' ' ILE . 66.7 mt -82.25 123.96 38.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.574 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.0 mp -107.81 -41.2 5.06 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.54 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -136.46 144.4 44.38 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.73 0.3 . . . . 0.0 111.102 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.493 HG13 ' HG2' ' A' ' 76' ' ' MET . 8.3 t -140.97 116.2 6.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.434 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.96 30.75 0.55 Allowed 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.434 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 80.78 -1.92 1.84 Allowed 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.239 -0.892 . . . . 0.0 112.706 179.631 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.822 HD11 ' CD1' ' A' ' 66' ' ' LEU . 1.6 pt -117.4 134.56 60.59 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.936 0.398 . . . . 0.0 111.635 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.1 m120 -63.1 152.51 36.97 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.572 -179.584 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.58 HG11 HG22 ' A' ' 63' ' ' VAL . 2.8 m -152.02 47.75 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.435 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.9 mttt -56.21 -40.12 73.53 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.215 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -137.72 31.98 2.5 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.005 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.452 ' CB ' HG12 ' A' ' 55' ' ' VAL . . . -75.86 -177.7 3.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.878 0.371 . . . . 0.0 111.604 -179.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.654 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -92.93 135.78 33.85 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.361 0.6 . . . . 0.0 110.703 179.705 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.747 ' O ' HG23 ' A' ' 64' ' ' VAL . 5.5 t60 -55.9 -44.39 78.17 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.783 -1.098 . . . . 0.0 111.883 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -61.58 -39.41 91.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.439 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -67.52 -43.07 81.7 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.225 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 59' ' ' SER . 48.4 t -63.79 -40.96 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.932 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.747 HG23 ' O ' ' A' ' 60' ' ' HIS . 48.8 t -65.97 -38.83 82.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 178.674 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -57.76 -42.64 84.45 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.822 ' CD1' HD11 ' A' ' 53' ' ' ILE . 12.0 mt -63.63 -42.26 98.19 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.647 179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.63 HG23 HD22 ' A' ' 74' ' ' LEU . 35.8 mt -63.42 -44.18 98.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.635 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.3 -12.52 84.14 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.793 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 41.3 tptt -68.19 -37.41 80.91 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -70.7 -52.46 20.9 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.811 0.339 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m 63.8 35.73 10.96 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.742 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.22 -44.35 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.295 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -163.15 138.24 1.4 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-O 121.014 0.435 . . . . 0.0 111.335 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.63 HD22 HG23 ' A' ' 67' ' ' ILE . 24.2 tp -114.24 146.79 39.95 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.376 -179.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.474 ' CD2' ' HG2' ' A' ' 7' ' ' GLU . 48.1 m80 -119.6 103.22 9.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.177 179.164 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.493 ' HG2' HG13 ' A' ' 50' ' ' VAL . 59.0 mtp -109.14 142.09 40.41 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.671 -179.272 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.3 t -115.06 97.05 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.926 178.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.643 HG22 ' HA ' ' A' ' 47' ' ' ILE . 10.3 pt -105.78 170.74 2.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.64 -179.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -136.94 145.73 44.59 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.941 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 . . . . . 0 C--O 1.234 0.284 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.774 179.846 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.476 0.846 0 CA-C-O 121.386 0.612 . . . . 0.0 112.636 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.26 146.66 47.08 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.727 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.1 m -102.21 154.73 18.75 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.213 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.699 HG11 ' HG ' ' A' ' 41' ' ' LEU . 20.3 t -140.29 136.2 36.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.355 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.428 ' O ' HG21 ' A' ' 39' ' ' VAL . 25.6 mt-10 -104.7 111.15 23.76 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.725 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.605 ' O ' HG23 ' A' ' 73' ' ' VAL . 6.7 t -104.43 119.94 54.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-O 120.865 0.364 . . . . 0.0 111.475 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -90.32 92.28 8.85 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.066 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -49.5 125.07 10.51 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.646 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.69 -112.44 0.07 OUTLIER Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.818 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -115.39 -39.33 3.6 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.435 0.16 . . . . 0.0 111.328 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.9 30.61 6.38 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.388 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.59 -173.09 16.6 Favored Glycine 0 C--N 1.337 0.616 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.808 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.524 ' HD1' HG12 ' A' ' 8' ' ' VAL . 79.2 m-85 -79.34 -61.91 1.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.941 0.401 . . . . 0.0 111.013 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.43 59.22 0.26 Allowed Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.452 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.507 ' CD1' HD21 ' A' ' 27' ' ' LEU . 19.7 p90 -153.13 151.01 29.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 0.0 110.955 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -98.3 111.42 23.76 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.442 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.465 HD23 ' N ' ' A' ' 20' ' ' SER . 0.8 OUTLIER -99.95 133.49 44.25 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.465 ' N ' HD23 ' A' ' 19' ' ' LEU . 1.5 p -149.58 -174.26 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.762 179.697 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 107.28 85.43 1.77 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.3 -60.09 2.08 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.942 0.401 . . . . 0.0 110.799 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.892 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.41 -60.61 0.19 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.221 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.892 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.2 Cg_endo -87.69 95.35 0.44 Allowed 'Trans proline' 0 C--N 1.356 0.938 0 C-N-CA 122.692 2.261 . . . . 0.0 112.209 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 71.6 m -55.27 118.64 4.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.477 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.4 p -143.53 152.94 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.854 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.551 HD11 ' CE ' ' A' ' 76' ' ' MET . 1.0 OUTLIER -89.41 92.95 9.34 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.473 179.377 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -51.46 -39.93 58.43 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.504 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.67 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.6 t -169.07 161.43 10.46 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.961 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.432 HG13 ' HB3' ' A' ' 17' ' ' PHE . 18.5 t -124.8 154.35 32.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.431 179.556 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -85.58 98.0 10.4 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.227 0.537 . . . . 0.0 110.399 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.85 122.61 6.76 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.853 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.31 21.23 11.86 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.703 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.42 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -115.31 166.68 11.43 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.712 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.443 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 9.7 Cg_endo -51.75 -29.55 34.25 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.962 2.441 . . . . 0.0 112.77 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.8 -46.19 46.89 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.992 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -64.01 -32.3 73.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.069 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.443 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.1 m-30 -60.04 -28.07 67.45 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.39 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.439 HG11 HG13 ' A' ' 6' ' ' VAL . 18.3 t -89.48 -26.21 5.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-O 120.469 0.176 . . . . 0.0 111.241 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.63 1.13 7.13 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.639 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.699 ' HG ' HG11 ' A' ' 6' ' ' VAL . 12.0 mt -67.93 116.96 9.18 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 117.378 0.589 . . . . 0.0 110.449 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.01 -150.36 0.43 Allowed 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.006 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.67 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -105.29 146.29 29.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.636 0.255 . . . . 0.0 111.299 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.82 -16.97 33.22 Favored Glycine 0 CA--C 1.523 0.56 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.152 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.434 ' CG ' HD12 ' A' ' 78' ' ' ILE . 1.3 m-20 -84.57 128.31 34.53 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 117.122 0.461 . . . . 0.0 110.822 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -82.38 134.01 35.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.486 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.42 ' CG2' HG22 ' A' ' 50' ' ' VAL . 22.7 mt -85.82 122.57 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.798 179.776 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -106.57 -47.55 3.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -124.08 136.25 54.11 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.993 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.42 HG22 ' CG2' ' A' ' 47' ' ' ILE . 3.0 t -135.51 105.71 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.096 179.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 75.92 37.8 0.37 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 72.32 -0.56 3.23 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.834 -179.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.665 ' CD1' HD22 ' A' ' 66' ' ' LEU . 8.0 pt -113.96 119.39 61.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 120.955 0.407 . . . . 0.0 111.01 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.493 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.0 m120 -68.53 130.32 42.53 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.081 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 63' ' ' VAL . 24.3 m -124.03 52.3 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.095 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.0 mttm -55.45 -45.65 76.83 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.543 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -136.48 32.42 2.8 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.095 179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.37 177.85 7.62 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 120.805 0.336 . . . . 0.0 111.275 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.676 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.7 OUTLIER -80.73 133.67 35.71 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 121.418 0.628 . . . . 0.0 110.665 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.704 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.4 t-160 -54.49 -44.78 72.95 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.772 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -65.13 -41.91 94.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.693 179.547 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -64.34 -42.47 96.25 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.712 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 59' ' ' SER . 54.9 t -63.5 -43.34 98.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.124 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.704 HG23 ' O ' ' A' ' 60' ' ' HIS . 47.1 t -66.03 -39.73 85.34 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.162 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.79 -40.46 84.11 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.01 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.665 HD22 ' CD1' ' A' ' 53' ' ' ILE . 7.1 mt -65.53 -40.86 93.4 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.195 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 26.2 mt -69.55 -40.48 79.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.866 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -59.83 -27.82 64.87 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.278 179.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.69 -19.79 62.02 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.51 0.324 . . . . 0.0 111.668 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -98.54 100.89 12.18 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.408 0.623 . . . . 0.0 110.219 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.2 m -99.64 -29.16 12.83 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.975 -1.011 . . . . 0.0 111.663 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.05 -50.93 7.25 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.139 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.5 p -177.12 134.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.841 0.353 . . . . 0.0 111.487 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.408 ' HB2' ' OH ' ' A' ' 15' ' ' TYR . 1.2 tp -114.32 141.29 47.79 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.073 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -114.01 104.67 12.37 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.163 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.551 ' CE ' HD11 ' A' ' 27' ' ' LEU . 0.8 OUTLIER -107.19 148.5 28.8 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.211 -179.543 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.33 105.43 18.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.721 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.434 HD12 ' CG ' ' A' ' 45' ' ' ASP . 7.8 pt -100.98 173.58 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.208 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -155.86 124.73 6.05 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.666 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.375 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.639 179.206 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 120.702 0.287 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -139.2 169.24 18.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.402 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -116.66 144.57 44.25 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.99 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.778 HG11 ' CD1' ' A' ' 41' ' ' LEU . 20.6 t -113.39 140.44 33.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.31 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.702 ' O ' HG21 ' A' ' 39' ' ' VAL . 30.8 mt-10 -112.68 108.05 16.94 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.973 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.7 t -102.66 126.23 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 111.277 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.39 92.24 8.03 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.979 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.468 ' HG3' ' CZ ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -52.92 122.53 9.44 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.972 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.83 -65.93 3.08 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 121.162 -0.542 . . . . 0.0 112.665 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -163.54 -48.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.568 0.223 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -131.93 26.36 4.62 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.455 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 179.71 164.69 32.49 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.607 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.674 ' CE2' HG22 ' A' ' 67' ' ' ILE . 40.1 m-85 -107.91 -73.72 0.68 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.65 0.262 . . . . 0.0 111.373 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.39 50.83 0.04 OUTLIER Glycine 0 C--N 1.33 0.242 0 C-N-CA 121.142 -0.552 . . . . 0.0 112.425 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.4 ' HB2' ' CD2' ' A' ' 27' ' ' LEU . 37.6 p90 -167.14 -177.08 3.57 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.428 0.156 . . . . 0.0 110.754 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -133.68 145.1 49.62 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 120.822 0.344 . . . . 0.0 111.353 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.4 mt -128.72 123.48 33.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.945 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.5 m -135.83 14.81 3.36 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.26 -0.427 . . . . 0.0 112.101 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -84.86 85.2 1.57 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.035 -0.603 . . . . 0.0 112.131 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.02 -63.24 0.9 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.837 0.351 . . . . 0.0 111.074 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.24 -61.04 0.18 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.146 178.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.88 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.5 Cg_endo -86.75 93.26 0.53 Allowed 'Trans proline' 0 C--N 1.353 0.793 0 C-N-CA 122.825 2.35 . . . . 0.0 111.764 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.503 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.5 m -54.46 121.14 7.71 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.884 0.373 . . . . 0.0 110.806 -179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.4 p -145.79 146.74 19.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.85 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.589 HD22 HD23 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -81.55 92.24 6.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.707 179.843 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.83 -34.82 63.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.317 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.732 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 1.3 t -169.72 160.47 8.77 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 111.242 179.612 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.416 HG21 ' HB3' ' A' ' 41' ' ' LEU . 4.7 t -116.52 154.1 18.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.745 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 12.1 mmm -99.22 99.24 10.18 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.101 0.477 . . . . 0.0 110.818 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -50.2 126.85 15.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.118 -0.946 . . . . 0.0 111.276 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.05 24.2 13.37 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.028 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.458 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -127.52 169.58 12.05 Favored Pre-proline 0 C--N 1.33 -0.253 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.265 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.552 ' O ' HG23 ' A' ' 39' ' ' VAL . 19.3 Cg_endo -58.13 -17.7 33.19 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.673 2.248 . . . . 0.0 113.043 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.951 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -70.59 -50.91 32.18 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -72.07 -29.83 64.52 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.229 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.433 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.7 m-30 -59.18 -27.5 65.75 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.616 -0.266 . . . . 0.0 110.973 179.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.702 HG21 ' O ' ' A' ' 7' ' ' GLU . 22.4 t -89.64 -50.31 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.762 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 146.65 46.77 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.068 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.951 HD22 ' HB1' ' A' ' 36' ' ' ALA . 1.0 OUTLIER -89.31 134.25 34.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.665 0.269 . . . . 0.0 110.412 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.4 mmt180 -144.91 120.38 10.34 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.732 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -45.97 125.74 6.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.449 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.33 -26.95 5.4 Favored Glycine 0 CA--C 1.517 0.189 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.322 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.4 ' CG ' HD12 ' A' ' 78' ' ' ILE . 0.7 OUTLIER -67.1 121.1 14.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 120.593 0.235 . . . . 0.0 110.682 179.731 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.43 127.69 32.96 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.77 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.478 HG21 HG22 ' A' ' 50' ' ' VAL . 18.9 mt -82.65 119.31 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.569 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -97.11 -42.22 7.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.84 140.85 51.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.007 179.691 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.504 HG23 ' CG2' ' A' ' 55' ' ' VAL . 21.5 t -133.14 112.52 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.13 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.411 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.4 t30 76.34 31.06 0.64 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.672 -178.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.77 -3.76 1.57 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 115.174 -0.921 . . . . 0.0 112.713 179.64 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.501 HD12 HG13 ' A' ' 55' ' ' VAL . 1.1 pp -114.45 128.93 71.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.016 0.436 . . . . 0.0 111.397 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.561 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.1 m120 -64.27 132.69 51.0 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.439 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.58 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 7.8 m -136.36 58.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.452 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -62.51 -40.2 95.98 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.422 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -132.92 31.11 3.94 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.208 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.58 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -78.04 179.92 6.5 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.771 0.32 . . . . 0.0 111.548 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.734 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.14 135.47 33.42 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.305 0.574 . . . . 0.0 110.951 179.881 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.76 ' O ' HG23 ' A' ' 64' ' ' VAL . 7.4 t60 -54.46 -44.63 72.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.815 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -62.63 -43.35 99.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.504 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.22 -41.38 97.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.543 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 59' ' ' SER . 47.0 t -64.94 -43.52 96.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.988 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.76 HG23 ' O ' ' A' ' 60' ' ' HIS . 45.0 t -65.76 -39.34 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -57.97 -40.98 81.94 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.01 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.625 HD12 ' HA ' ' A' ' 63' ' ' VAL . 4.5 mt -66.22 -42.43 88.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.668 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.799 HG23 HD13 ' A' ' 74' ' ' LEU . 18.5 mt -65.52 -42.92 94.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.51 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.98 -15.04 81.66 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.945 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -65.13 -39.79 93.56 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -62.72 -55.25 28.42 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.4 ' HA ' ' NH1' ' A' ' 10' ' ' ARG . 0.3 OUTLIER 65.94 35.03 6.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.903 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.29 -44.24 0.02 OUTLIER Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.554 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -160.72 138.86 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.784 0.326 . . . . 0.0 111.642 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.799 HD13 HG23 ' A' ' 67' ' ' ILE . 33.0 tp -105.8 143.18 34.31 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -128.56 96.8 4.5 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.191 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -121.66 154.59 36.62 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.43 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.1 t -111.63 110.87 33.77 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.746 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.428 HG12 HG23 ' A' ' 6' ' ' VAL . 7.6 pt -105.51 145.38 13.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.322 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -111.23 134.35 52.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.291 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 . . . . . 0 C--O 1.233 0.207 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.852 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.465 0.28 0 CA-C-O 120.725 0.298 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -135.96 162.25 33.38 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.448 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.38 125.32 53.04 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.785 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.516 HG13 ' HB ' ' A' ' 39' ' ' VAL . 20.8 t -111.33 134.07 54.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.105 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.584 ' O ' HG21 ' A' ' 39' ' ' VAL . 16.9 mt-10 -105.71 112.87 26.11 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.404 ' O ' HG23 ' A' ' 73' ' ' VAL . 4.9 t -87.77 116.85 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-O 120.84 0.352 . . . . 0.0 111.28 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.813 ' HB3' ' HB3' ' A' ' 35' ' ' PRO . . . -81.54 89.72 6.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.861 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.404 ' HG3' ' CE2' ' A' ' 15' ' ' TYR . 5.3 ttp180 -56.14 120.97 8.38 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.116 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.97 -88.1 0.29 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.738 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -121.33 -73.5 0.65 Allowed 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.64 0.257 . . . . 0.0 110.76 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -121.11 31.96 6.15 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.111 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -178.26 -169.61 39.31 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.582 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.56 ' OH ' HG22 ' A' ' 67' ' ' ILE . 24.4 m-85 -133.17 -64.42 0.73 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.655 0.264 . . . . 0.0 111.27 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.03 47.24 0.08 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.814 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -156.73 172.31 18.83 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 120.708 0.289 . . . . 0.0 110.813 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -117.56 110.72 18.29 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.954 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.5 126.15 49.46 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.119 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 73.5 m -152.06 107.56 3.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.55 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.95 79.63 0.15 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.704 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.85 -45.88 30.57 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.03 0.443 . . . . 0.0 110.018 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.944 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -115.57 -67.35 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.24 178.523 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.944 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 90.3 Cg_endo -85.1 95.55 0.65 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 122.605 2.204 . . . . 0.0 112.155 179.158 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.635 ' SG ' HG21 ' A' ' 63' ' ' VAL . 80.8 m -53.27 118.91 4.16 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.679 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 p -146.79 149.63 15.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.393 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.463 HD22 HD22 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -87.48 93.61 9.46 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.319 179.401 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -46.91 -43.98 19.38 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.485 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.509 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 1.7 t -172.37 158.53 4.38 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.173 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.5 t -126.04 154.95 35.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.616 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mtp -100.33 101.59 12.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 121.153 0.501 . . . . 0.0 110.66 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.1 mtm-85 -49.96 123.95 9.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.39 16.7 10.75 Favored Glycine 0 CA--C 1.523 0.583 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.75 -179.176 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -120.98 166.68 15.03 Favored Pre-proline 0 CA--C 1.531 0.221 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.486 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.813 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 71.0 Cg_exo -49.27 -31.39 22.25 Favored 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.989 2.46 . . . . 0.0 113.346 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.61 -49.06 51.63 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.587 -0.278 . . . . 0.0 111.139 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.36 -32.47 73.88 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.486 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.9 m-30 -58.06 -29.25 65.24 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.457 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.584 HG21 ' O ' ' A' ' 7' ' ' GLU . 18.7 t -89.53 -32.73 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.696 0.284 . . . . 0.0 110.948 179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.45 51.39 0.16 Allowed Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.123 -0.56 . . . . 0.0 112.66 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.682 ' CD2' HD13 ' A' ' 78' ' ' ILE . 2.8 mt -116.55 129.3 56.1 Favored 'General case' 0 C--O 1.231 0.098 0 CA-C-O 120.574 0.226 . . . . 0.0 110.817 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -137.6 -152.9 0.46 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -99.58 148.14 24.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.799 179.6 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.3 -21.33 46.08 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.975 -0.631 . . . . 0.0 113.214 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.65 ' CG ' HD12 ' A' ' 78' ' ' ILE . 0.9 OUTLIER -69.9 116.86 10.77 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.883 0.341 . . . . 0.0 110.827 -179.853 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.53 132.09 37.06 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.425 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 27.2 mt -84.34 120.42 35.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.74 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.0 -40.37 5.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.402 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.512 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -128.88 135.99 49.83 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.626 0.25 . . . . 0.0 111.097 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.448 ' O ' HG13 ' A' ' 53' ' ' ILE . 4.8 t -135.73 110.09 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.186 179.53 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 75.99 33.71 0.58 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 77.6 -5.13 2.18 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 115.15 -0.932 . . . . 0.0 112.706 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.796 HD11 ' CD1' ' A' ' 66' ' ' LEU . 2.2 pp -116.71 130.82 70.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 111.403 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -67.11 141.62 57.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.691 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.604 HG13 HD12 ' A' ' 53' ' ' ILE . 4.2 m -142.68 51.16 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.413 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.2 mtpp -58.16 -35.27 71.31 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.657 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -137.2 34.62 2.55 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.694 0.283 . . . . 0.0 111.03 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.537 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -78.13 -172.9 2.96 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.843 0.354 . . . . 0.0 111.556 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.616 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.4 OUTLIER -94.55 141.0 29.11 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.275 0.56 . . . . 0.0 110.791 179.738 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.697 ' O ' HG22 ' A' ' 64' ' ' VAL . 1.1 t-160 -52.86 -43.29 65.98 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.443 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.429 ' HA ' ' CG2' ' A' ' 64' ' ' VAL . 2.7 mt-10 -66.53 -35.06 79.32 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.457 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.59 -38.39 70.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.798 0.332 . . . . 0.0 110.286 179.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.635 HG21 ' SG ' ' A' ' 25' ' ' CYS . 46.6 t -66.47 -44.89 90.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.042 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.697 HG22 ' O ' ' A' ' 60' ' ' HIS . 2.9 m -66.42 -39.19 83.45 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.39 -39.18 82.57 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.972 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.796 ' CD1' HD11 ' A' ' 53' ' ' ILE . 14.3 mt -66.03 -41.99 90.19 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.864 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.924 ' HA ' HD13 ' A' ' 74' ' ' LEU . 31.5 mt -68.11 -41.41 84.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.762 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.74 8.73 19.64 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.954 178.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 2.0 tttp -111.61 -4.0 14.9 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 116.943 0.371 . . . . 0.0 111.071 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.469 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 26.4 p -50.62 -47.56 58.23 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 122.536 0.334 . . . . 0.0 111.71 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.74 31.71 4.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.004 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 150.02 -37.51 0.94 Allowed Glycine 0 C--N 1.335 0.499 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.062 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.469 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.8 p -172.05 138.07 0.35 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.234 0 CA-C-O 120.894 0.378 . . . . 0.0 112.012 -179.657 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.924 HD13 ' HA ' ' A' ' 67' ' ' ILE . 3.8 tp -111.04 139.77 46.12 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.111 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -100.95 101.52 12.33 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.29 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 35.5 ttm -103.44 125.1 49.84 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.512 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 40.5 t -97.86 103.61 14.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.511 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.682 HD13 ' CD2' ' A' ' 41' ' ' LEU . 14.7 pt -106.72 168.31 3.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.468 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.91 155.2 39.58 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.703 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.235 0.298 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.234 0.279 0 CA-C-O 120.64 0.257 . . . . 0.0 111.369 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.98 167.5 21.99 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.657 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 m -102.94 135.19 45.07 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.919 HG11 HD12 ' A' ' 41' ' ' LEU . 25.1 t -115.69 131.84 66.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.109 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -113.05 120.51 41.59 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.105 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.7 t -104.92 134.18 47.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.179 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -103.55 98.79 8.62 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.039 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -48.84 124.11 8.04 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.268 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.41 118.43 0.45 Allowed Glycine 0 CA--C 1.52 0.353 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER 78.51 90.0 0.06 Allowed 'General case' 0 C--O 1.235 0.34 0 CA-C-O 121.393 0.616 . . . . 0.0 110.396 -179.22 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 71.15 34.26 1.85 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.548 -1.206 . . . . 0.0 111.569 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 -113.1 3.6 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.837 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.45 ' HB3' HG11 ' A' ' 8' ' ' VAL . 79.3 m-85 -110.64 -66.32 1.08 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.414 0.149 . . . . 0.0 111.171 -179.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.17 61.14 0.2 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.894 -0.67 . . . . 0.0 113.351 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -166.41 167.79 15.46 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 120.556 0.217 . . . . 0.0 111.183 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -120.34 150.84 40.11 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.007 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -137.62 124.32 21.08 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.363 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 m -140.15 15.74 2.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.092 -0.503 . . . . 0.0 112.021 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.65 84.36 1.59 Allowed Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.417 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -44.2 -61.98 1.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.795 0.331 . . . . 0.0 110.783 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.904 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.29 -62.81 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.881 178.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.904 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 92.0 Cg_endo -85.84 96.45 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.925 0 C-N-CA 122.76 2.307 . . . . 0.0 111.915 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.524 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.0 m -55.8 124.95 19.25 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.567 -179.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.16 143.8 17.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.395 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.771 HD22 HD22 ' A' ' 41' ' ' LEU . 0.4 OUTLIER -80.81 90.62 5.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.462 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 5.8 p -53.8 -38.44 64.52 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.473 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 8.1 t -161.75 153.41 18.89 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.836 0.351 . . . . 0.0 111.447 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.3 t -116.23 155.38 17.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.554 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.3 mtp -97.79 100.35 11.72 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.236 0.541 . . . . 0.0 110.791 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.4 mtm-85 -53.74 124.23 14.61 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.892 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.13 -24.04 21.88 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.534 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.414 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.4 OUTLIER -82.5 166.61 35.36 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 110.533 179.722 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 11.0 Cg_endo -53.95 -23.53 28.35 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 123.19 2.593 . . . . 0.0 113.186 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.59 76.91 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.887 0.375 . . . . 0.0 110.731 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -68.24 -27.1 66.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.194 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -55.97 -24.31 37.6 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 112.141 0.422 . . . . 0.0 112.141 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.748 HG11 HG13 ' A' ' 6' ' ' VAL . 34.8 t -89.09 -29.21 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 111.034 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.86 43.95 2.17 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.518 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.919 HD12 HG11 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -74.25 176.42 6.67 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 120.913 0.387 . . . . 0.0 110.762 179.857 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.519 ' H ' HD23 ' A' ' 41' ' ' LEU . 4.1 mtp85 -139.0 116.95 11.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.44 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.53 101.03 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.801 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.35 -21.26 3.47 Favored Glycine 0 CA--C 1.524 0.606 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.407 -179.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -58.24 123.31 15.62 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 120.633 0.254 . . . . 0.0 110.8 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -66.68 127.87 34.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.089 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.72 HD11 HD12 ' A' ' 27' ' ' LEU . 21.2 mt -85.27 125.89 40.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.573 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.492 ' N ' HD12 ' A' ' 48' ' ' LEU . 6.9 mp -98.76 -70.27 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.575 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.504 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -99.99 143.94 29.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.739 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.445 HG23 ' CG2' ' A' ' 55' ' ' VAL . 18.6 t -135.84 113.94 15.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.428 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.1 t-20 76.38 33.05 0.55 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -177.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.74 -1.78 2.37 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 115.189 -0.914 . . . . 0.0 113.074 179.72 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.794 HD11 ' CD1' ' A' ' 66' ' ' LEU . 5.4 pt -115.65 133.0 63.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-O 120.817 0.342 . . . . 0.0 111.827 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.504 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 42.8 t30 -66.83 130.22 42.45 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.143 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.472 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 15.3 m -137.28 59.57 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.965 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.9 mmtm -51.91 -72.46 0.05 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.999 -179.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.2 mttt -111.72 39.55 2.34 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.255 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.472 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -73.86 -175.93 2.29 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.515 -179.462 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.632 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.44 134.67 33.78 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.443 0.639 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -53.04 -44.76 67.64 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.689 -1.142 . . . . 0.0 111.419 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.472 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.7 pm0 -66.36 -34.7 78.56 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.184 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.6 -39.31 70.6 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.728 0.299 . . . . 0.0 110.443 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 59' ' ' SER . 41.4 t -67.02 -43.36 89.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.497 ' HA ' HD12 ' A' ' 67' ' ' ILE . 29.8 m -65.93 -38.71 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 1.9 mtmp? -57.87 -39.38 77.67 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.881 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.794 ' CD1' HD11 ' A' ' 53' ' ' ILE . 7.5 mt -67.41 -43.28 81.65 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.761 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.83 HG23 ' HG ' ' A' ' 74' ' ' LEU . 13.8 mt -65.66 -38.03 81.36 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.981 179.564 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -86.61 3.77 86.76 Favored Glycine 0 CA--C 1.524 0.645 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.015 179.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.6 tptm -86.91 -34.88 19.23 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.824 0.312 . . . . 0.0 111.25 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -71.66 -57.86 4.01 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.809 0.338 . . . . 0.0 110.86 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.1 m 64.65 36.02 8.61 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.072 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.13 -44.13 0.02 OUTLIER Glycine 0 C--N 1.331 0.296 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.434 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.1 p -162.12 137.08 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 CA-C-O 120.985 0.421 . . . . 0.0 111.385 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.83 ' HG ' HG23 ' A' ' 67' ' ' ILE . 1.9 mm? -112.6 134.37 54.17 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.523 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -117.09 96.36 5.41 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.999 179.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 16.5 ptt? -122.01 156.31 33.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.791 -179.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.7 t -111.42 109.73 29.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.735 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 pt -106.1 139.39 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.304 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -105.86 125.15 50.65 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.154 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 . . . . . 0 C--O 1.232 0.139 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.696 179.715 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 CA--C 1.534 0.345 0 CA-C-O 120.495 0.188 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.566 ' HD3' HD11 ' A' ' 78' ' ' ILE . 4.0 ttt85 -114.05 141.21 47.74 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 120.883 0.373 . . . . 0.0 111.1 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.0 m -110.9 137.16 48.88 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.664 179.518 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.756 HG11 HD22 ' A' ' 41' ' ' LEU . 16.7 t -111.8 136.01 49.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.756 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -134.59 100.84 4.76 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.535 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.645 ' O ' HG23 ' A' ' 73' ' ' VAL . 11.2 t -106.47 150.51 9.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.276 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -99.4 98.54 9.45 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.988 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 50.9 ttp85 -50.71 120.67 4.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.696 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.73 -107.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.705 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -118.28 -39.94 2.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.419 0.152 . . . . 0.0 111.249 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -111.3 32.19 5.53 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.668 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.11 -137.96 14.57 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.828 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.41 ' O ' ' HD2' ' A' ' 35' ' ' PRO . 80.2 m-85 -116.17 -83.33 0.63 Allowed 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.633 0.254 . . . . 0.0 111.19 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.61 55.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.265 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.525 ' HZ ' HG21 ' A' ' 67' ' ' ILE . 14.3 p90 -143.31 166.83 23.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.631 0.253 . . . . 0.0 110.756 179.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.1 m -113.92 142.03 46.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.943 0.401 . . . . 0.0 111.479 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 mt -133.89 122.87 23.78 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.943 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.8 m -146.92 169.37 19.29 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.31 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.91 -37.51 2.88 Favored Glycine 0 C--N 1.336 0.532 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.509 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.404 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.55 -48.92 0.24 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.286 0.635 . . . . 0.0 111.493 -179.817 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.896 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -100.97 -65.09 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.438 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.896 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 91.5 Cg_endo -80.55 96.21 1.0 Allowed 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.292 1.994 . . . . 0.0 112.318 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.0 m -61.37 115.66 4.04 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.334 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.84 142.46 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.154 -179.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.648 HD12 HD11 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -75.87 90.98 2.96 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.468 179.743 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 69.4 p -53.2 -36.59 61.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.308 -179.715 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.443 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.0 t -167.22 158.63 12.13 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.237 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.592 HG21 ' HA ' ' A' ' 42' ' ' ARG . 11.8 t -119.08 154.97 21.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.858 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 30.8 mtt -98.28 101.85 13.42 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 121.21 0.529 . . . . 0.0 110.623 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 26.8 mtt-85 -51.84 123.69 10.82 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.22 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.07 -22.3 31.72 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 120.938 -0.649 . . . . 0.0 113.071 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.448 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.6 m -83.47 168.01 25.04 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.711 0.255 . . . . 0.0 110.658 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.448 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 73.6 Cg_exo -50.43 -25.51 14.23 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 123.033 2.489 . . . . 0.0 113.448 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.26 -47.8 82.74 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 120.868 0.366 . . . . 0.0 111.024 179.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.96 -26.73 65.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.31 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.4 m-30 -54.98 -28.71 53.79 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 111.674 0.249 . . . . 0.0 111.674 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.763 ' HB ' HD23 ' A' ' 41' ' ' LEU . 22.6 t -89.43 -34.4 6.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 CA-C-O 120.83 0.347 . . . . 0.0 111.037 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.6 -11.81 15.88 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.747 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.763 HD23 ' HB ' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -64.58 127.59 32.16 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 179.918 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.592 ' HA ' HG21 ' A' ' 30' ' ' VAL . 1.7 mmm180 -115.51 -146.52 0.4 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.249 -179.687 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.443 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -95.11 159.19 15.13 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.926 0.393 . . . . 0.0 110.908 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.24 -33.52 6.1 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.577 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -61.39 118.56 7.11 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.79 0.328 . . . . 0.0 110.989 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.02 131.44 35.31 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.679 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.648 HD11 HD12 ' A' ' 27' ' ' LEU . 8.3 mm -87.38 124.55 40.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.5 179.68 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.439 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.5 mm? -105.49 -46.51 4.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.352 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.561 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -120.49 139.2 53.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.195 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 53' ' ' ILE . 9.0 t -140.79 109.27 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.487 179.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.405 ' HB2' ' HB3' ' A' ' 66' ' ' LEU . 0.1 OUTLIER 76.54 34.21 0.48 Allowed 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.878 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 76.02 -3.4 2.57 Favored 'General case' 0 CA--C 1.537 0.481 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.773 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.882 HD11 HD11 ' A' ' 66' ' ' LEU . 1.1 pt -114.27 120.5 64.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-O 121.047 0.451 . . . . 0.0 111.312 179.501 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.559 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -64.71 131.84 47.98 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.054 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.503 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 5.8 m -131.11 55.97 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.355 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.9 mtmt -59.88 -40.5 88.94 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.188 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.0 mttp -136.35 30.84 2.92 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.061 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.503 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -75.93 -169.22 1.05 Allowed 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.272 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -92.01 135.0 34.3 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.47 0.652 . . . . 0.0 110.616 179.713 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.742 ' O ' HG23 ' A' ' 64' ' ' VAL . 4.9 t60 -54.44 -44.6 72.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.818 -1.083 . . . . 0.0 111.957 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -63.41 -38.11 89.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.811 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.4 -42.9 82.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.541 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 59' ' ' SER . 42.9 t -65.29 -42.18 93.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.754 179.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 60' ' ' HIS . 47.5 t -65.8 -39.08 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.6 mttt -57.64 -39.41 76.92 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.45 -0.796 . . . . 0.0 110.89 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.882 HD11 HD11 ' A' ' 53' ' ' ILE . 11.3 mt -66.57 -43.7 84.26 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.773 179.444 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.757 HG23 HD22 ' A' ' 74' ' ' LEU . 54.0 mt -63.16 -37.96 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.642 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.47 11.98 57.02 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.316 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.5 ttpm? -110.32 -16.23 13.77 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 122.406 0.282 . . . . 0.0 111.264 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . 0.403 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 23.3 p -44.2 -50.85 8.61 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 122.576 0.351 . . . . 0.0 111.6 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.5 p 63.26 32.22 14.97 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.454 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.17 -36.73 0.6 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.993 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -172.46 136.58 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-O 120.995 0.426 . . . . 0.0 111.917 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.757 HD22 HG23 ' A' ' 67' ' ' ILE . 9.8 tp -114.45 145.0 42.41 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.827 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -119.37 107.11 12.96 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.16 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 1.1 ptp -122.71 135.04 54.46 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.012 0.434 . . . . 0.0 111.239 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.561 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 41.3 t -94.37 115.1 32.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.642 179.741 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.566 HD11 ' HD3' ' A' ' 4' ' ' ARG . 3.7 pt -107.06 167.05 3.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.551 -179.66 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.82 128.22 26.36 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.331 -0.207 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.471 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.488 1.169 0 CA-C-O 120.933 0.305 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.44 -173.16 4.47 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.848 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.636 HG22 ' HB2' ' A' ' 79' ' ' ALA . 25.2 t -99.31 136.29 31.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.152 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -134.93 174.5 10.53 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.349 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 m -118.9 149.75 41.05 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.312 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.658 HG23 HD11 ' A' ' 78' ' ' ILE . 54.6 t -129.65 134.17 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.079 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -105.41 103.68 13.25 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 73' ' ' VAL . 14.6 t -95.64 129.47 45.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.807 0.337 . . . . 0.0 111.229 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -91.43 90.94 7.89 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.284 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -55.3 123.49 13.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.734 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.05 -103.17 0.1 OUTLIER Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.241 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.14 -46.4 1.94 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.536 0.208 . . . . 0.0 111.164 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -103.76 31.69 4.31 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.692 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.69 -126.77 8.3 Favored Glycine 0 C--N 1.336 0.556 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.745 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -132.88 -64.97 0.73 Allowed 'General case' 0 C--O 1.231 0.103 0 CA-C-O 120.733 0.302 . . . . 0.0 111.076 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.0 -34.53 1.31 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.925 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.578 ' CD1' HD21 ' A' ' 27' ' ' LEU . 41.6 p90 -65.18 179.47 0.72 Allowed 'General case' 0 CA--C 1.532 0.256 0 CA-C-O 121.064 0.459 . . . . 0.0 111.569 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.8 144.06 49.43 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.264 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.79 128.01 45.92 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.197 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 46.3 m -150.47 106.78 3.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.674 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -163.18 76.11 0.17 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.446 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -45.68 -44.71 13.63 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.736 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.976 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -114.33 -64.47 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.263 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.197 178.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.976 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 84.4 Cg_endo -89.42 91.51 0.36 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.791 2.327 . . . . 0.0 112.008 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.67 ' SG ' HG21 ' A' ' 63' ' ' VAL . 72.6 m -50.32 121.48 5.68 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.731 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.0 p -147.14 146.06 18.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.871 0.367 . . . . 0.0 111.724 -179.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.627 HD13 HD22 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -80.31 92.41 5.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.476 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.9 m -46.54 -46.29 19.22 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.867 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.68 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.0 t -171.3 158.41 5.36 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 111.431 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' A' ' 41' ' ' LEU . 50.6 t -122.13 153.23 26.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.619 179.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.6 mmt -103.3 100.81 10.72 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.076 0.465 . . . . 0.0 110.574 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 5.7 ptt180 -45.49 120.12 2.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.971 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 120.19 -17.81 9.73 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.542 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.413 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -85.59 166.77 28.33 Favored Pre-proline 0 CA--C 1.533 0.312 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.352 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 15.0 Cg_endo -57.13 -22.55 48.42 Favored 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 122.667 2.245 . . . . 0.0 112.748 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.825 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -68.83 -48.73 62.78 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.72 0.295 . . . . 0.0 110.913 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.36 -27.12 65.98 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.302 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-30 -57.54 -26.34 61.23 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.59 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.617 HG11 HG13 ' A' ' 6' ' ' VAL . 15.7 t -89.39 -39.39 12.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 120.794 0.33 . . . . 0.0 111.013 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 129.08 44.61 0.2 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 121.088 -0.577 . . . . 0.0 112.83 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.825 HD12 ' HB1' ' A' ' 36' ' ' ALA . 13.8 mt -85.22 140.9 30.52 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.788 0.328 . . . . 0.0 110.366 179.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.9 mtt180 -141.14 119.68 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.584 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.68 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -41.22 126.64 2.73 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.637 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.17 -26.37 5.56 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.148 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.97 114.17 3.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-O 120.661 0.267 . . . . 0.0 110.571 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -73.37 128.57 35.85 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.529 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.894 ' HA ' HG22 ' A' ' 78' ' ' ILE . 20.6 mt -80.93 120.17 32.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.007 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 mp -101.52 -46.7 4.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.053 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.605 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -127.26 139.39 52.94 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.257 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.458 HG21 HG13 ' A' ' 63' ' ' VAL . 8.8 t -132.46 111.61 17.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.003 179.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.419 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 77.33 29.98 0.54 Allowed 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.419 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 82.54 -2.53 1.38 Allowed 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.412 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.646 HD11 ' CD1' ' A' ' 66' ' ' LEU . 20.4 pt -114.21 132.19 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 111.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.6 OUTLIER -63.23 156.15 26.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.714 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.447 HG21 HG23 ' A' ' 50' ' ' VAL . 2.6 m -149.36 55.32 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.614 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -58.62 -43.25 89.6 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.723 0.297 . . . . 0.0 110.854 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.492 ' HE3' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -141.73 38.55 1.66 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.308 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.437 ' CB ' HG12 ' A' ' 55' ' ' VAL . . . -72.75 -178.15 2.59 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.592 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.593 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -93.35 137.89 32.22 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.398 0.618 . . . . 0.0 111.08 -179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.794 ' O ' HG23 ' A' ' 64' ' ' VAL . 2.0 t-160 -52.67 -43.92 65.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.942 -1.026 . . . . 0.0 111.913 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 58.1 mt-10 -65.63 -39.3 91.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.008 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -67.25 -39.37 86.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.709 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.67 HG21 ' SG ' ' A' ' 25' ' ' CYS . 46.4 t -67.44 -42.34 87.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.745 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 60' ' ' HIS . 42.7 t -65.67 -39.1 83.92 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.184 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.8 mtpp -57.74 -38.95 76.24 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.646 ' CD1' HD11 ' A' ' 53' ' ' ILE . 13.3 mt -68.3 -42.54 79.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.684 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.63 HG23 HD22 ' A' ' 74' ' ' LEU . 6.8 mt -67.47 -36.9 77.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.884 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -81.66 10.62 50.28 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.342 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 ttpt -114.16 -5.82 13.04 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.623 0.369 . . . . 0.0 111.2 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.433 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 14.0 p -47.8 -48.78 30.28 Favored 'General case' 0 C--N 1.34 0.173 0 C-N-CA 122.488 0.315 . . . . 0.0 111.752 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.9 t 65.65 33.34 8.5 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.069 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.16 -33.3 1.72 Allowed Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.275 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 8' ' ' VAL . 8.0 p -172.68 138.0 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-O 121.0 0.428 . . . . 0.0 111.784 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.63 HD22 HG23 ' A' ' 67' ' ' ILE . 9.1 tp -114.45 147.28 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.222 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -108.97 99.23 8.59 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.419 179.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.577 ' CG ' HD23 ' A' ' 74' ' ' LEU . 0.0 OUTLIER -105.43 135.04 47.55 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.959 -179.618 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.605 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 21.9 t -108.75 99.44 8.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.762 179.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.894 HG22 ' HA ' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -111.07 164.92 6.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.358 -179.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.636 ' HB2' HG22 ' A' ' 3' ' ' VAL . . . -128.38 130.9 48.39 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.241 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -82.79 121.69 27.23 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -87.23 -46.68 4.93 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.911 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.1 t -104.77 118.43 52.09 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.83 0.348 . . . . 0.0 111.116 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.333 -179.887 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.49 1.321 0 CA-C-O 120.721 0.217 . . . . 0.0 111.995 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.79 -50.98 4.03 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.253 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 29.9 t -71.22 123.09 24.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.865 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 -131.89 160.77 34.75 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.497 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.2 p -101.59 131.34 47.84 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.178 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.609 HG13 ' CG1' ' A' ' 39' ' ' VAL . 14.2 t -116.37 131.55 68.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.808 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -100.99 111.77 24.05 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.728 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.5 ' O ' HG23 ' A' ' 73' ' ' VAL . 16.2 t -97.67 114.41 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.349 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.77 92.42 9.2 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.782 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.463 ' HG3' ' CE1' ' A' ' 15' ' ' TYR . 9.7 ttt180 -51.6 127.43 20.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.738 -0.664 . . . . 0.0 111.188 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.81 20.91 25.77 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.684 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.45 0.38 3.44 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 117.118 0.459 . . . . 0.0 111.907 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.01 24.0 1.67 Allowed 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 120.83 0.348 . . . . 0.0 111.105 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.69 -162.11 23.76 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.705 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.463 ' CE1' ' HG3' ' A' ' 10' ' ' ARG . 64.6 m-85 -131.7 -43.98 0.99 Allowed 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.36 -13.48 7.87 Favored Glycine 0 CA--C 1.522 0.507 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.18 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -108.52 174.28 5.94 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 117.039 0.419 . . . . 0.0 111.386 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.0 m -130.0 142.86 50.58 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.684 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.665 HD21 HD12 ' A' ' 47' ' ' ILE . 0.8 OUTLIER -124.19 124.48 42.55 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.302 -179.63 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.2 m -150.29 159.17 44.65 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 179.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.4 -29.52 2.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 121.055 -0.593 . . . . 0.0 113.157 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.403 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 64.11 21.27 12.52 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.94 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.834 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . 179.58 -63.8 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.282 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.834 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 91.0 Cg_endo -79.25 85.53 1.84 Allowed 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 122.52 2.147 . . . . 0.0 111.561 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.643 ' SG ' HG21 ' A' ' 63' ' ' VAL . 61.2 m -52.88 110.6 0.54 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.578 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -144.62 147.52 19.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.536 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.464 HD12 ' CG1' ' A' ' 47' ' ' ILE . 7.1 mp -74.4 90.8 2.18 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.3 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -43.78 61.95 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.614 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -171.17 158.09 5.36 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.984 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 14.7 t -135.77 153.34 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.92 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 16.3 ptp -104.52 105.12 15.11 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.271 0.558 . . . . 0.0 110.745 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.5 mtt180 -46.68 123.09 4.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.096 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.28 16.29 10.55 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 121.132 -0.556 . . . . 0.0 112.961 -179.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.8 164.87 17.74 Favored Pre-proline 0 C--O 1.234 0.247 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.19 -27.83 31.41 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 122.767 2.312 . . . . 0.0 112.606 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.32 -49.92 51.33 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.99 -35.23 79.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.239 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 m-30 -56.18 -32.95 64.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.714 -179.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.609 ' CG1' HG13 ' A' ' 6' ' ' VAL . 14.7 t -89.33 -35.05 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.62 0.247 . . . . 0.0 110.964 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.87 43.21 0.17 Allowed Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.152 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.512 HD21 HG21 ' A' ' 6' ' ' VAL . 63.5 mt -108.23 121.08 44.15 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.506 0.193 . . . . 0.0 110.53 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.92 -152.66 0.5 Allowed 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.988 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.22 130.06 44.95 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.812 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 113.68 -27.43 9.29 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.918 -0.658 . . . . 0.0 113.188 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -58.03 120.47 8.62 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.927 0.363 . . . . 0.0 111.077 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.7 125.59 30.23 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.741 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.665 HD12 HD21 ' A' ' 19' ' ' LEU . 23.8 mt -85.86 126.36 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.711 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.9 mp -108.22 -71.49 0.76 Allowed 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.495 ' HB3' ' CG2' ' A' ' 77' ' ' VAL . . . -97.07 126.89 42.53 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.756 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.599 HG21 HG13 ' A' ' 63' ' ' VAL . 11.0 t -119.64 103.38 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.302 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.423 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.5 t-20 76.46 31.75 0.59 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.705 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.423 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 85.01 -4.19 0.92 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.783 179.68 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 66' ' ' LEU . 1.1 pp -110.58 131.96 60.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 CA-C-O 120.94 0.4 . . . . 0.0 111.656 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -71.58 145.28 49.14 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.604 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.507 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.2 m -146.11 61.14 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.376 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.1 -46.94 68.9 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.058 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 3.5 mtpp -140.13 37.68 1.93 Allowed 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.977 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.507 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -74.79 -174.96 2.32 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.446 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 3.8 m -91.2 145.67 24.48 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.641 0.734 . . . . 0.0 111.103 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.753 ' O ' HG23 ' A' ' 64' ' ' VAL . 2.5 t60 -61.68 -44.52 96.8 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.547 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -58.84 -43.2 90.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.882 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -64.24 -44.08 92.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.492 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.643 HG21 ' SG ' ' A' ' 25' ' ' CYS . 67.5 t -64.64 -40.79 90.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.059 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.753 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.3 t -65.69 -38.84 83.25 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 178.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.37 -40.88 79.07 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.901 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.743 HD11 HD11 ' A' ' 53' ' ' ILE . 7.3 mt -67.27 -42.07 84.44 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.643 179.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.975 HG23 HD22 ' A' ' 74' ' ' LEU . 9.8 mt -68.03 -39.33 81.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -80.04 11.17 37.02 Favored Glycine 0 CA--C 1.524 0.595 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.585 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.21 -8.12 13.55 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.441 0.296 . . . . 0.0 111.24 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.459 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 24.9 p -48.49 -49.91 33.87 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.825 0.345 . . . . 0.0 111.798 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.1 t 66.33 33.42 7.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.002 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.83 -37.41 0.95 Allowed Glycine 0 C--N 1.334 0.464 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.008 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 8' ' ' VAL . 8.1 p -171.12 137.39 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.998 0.427 . . . . 0.0 111.922 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.975 HD22 HG23 ' A' ' 67' ' ' ILE . 1.2 pp -112.38 155.41 24.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.363 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 68.7 m80 -110.92 98.34 7.49 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.268 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.475 ' HG2' HG23 ' A' ' 47' ' ' ILE . 3.0 ttm -105.07 122.74 46.52 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.052 -179.366 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.495 ' CG2' ' HB3' ' A' ' 49' ' ' ALA . 21.3 t -101.06 100.44 10.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.566 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.469 HG22 ' HA ' ' A' ' 47' ' ' ILE . 6.5 pt -102.53 171.76 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.427 -179.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -143.13 148.04 35.94 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.416 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -97.86 135.12 40.06 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -147.4 108.57 0.44 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.218 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 33.4 t -72.18 93.24 0.52 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.307 0 CA-C-O 120.838 0.351 . . . . 0.0 110.585 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.979 0 CA-C-O 118.299 -1.279 . . . . 0.0 112.255 -179.575 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo . . . . . 0 N--CA 1.49 1.304 0 CA-C-O 120.592 0.164 . . . . 0.0 111.801 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -96.76 -68.12 0.82 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.683 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.422 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.7 p -85.06 118.6 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.641 179.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.471 ' HG3' HD11 ' A' ' 78' ' ' ILE . 14.8 ptm180 -137.35 162.59 33.16 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.219 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.28 141.43 37.63 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.175 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.624 HG11 HD22 ' A' ' 41' ' ' LEU . 21.7 t -126.9 139.28 52.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.295 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.792 ' O ' HG21 ' A' ' 39' ' ' VAL . 13.0 mt-10 -107.86 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.512 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.41 HG12 ' HD2' ' A' ' 15' ' ' TYR . 6.7 t -99.08 112.87 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-O 120.862 0.363 . . . . 0.0 111.187 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.79 88.82 7.42 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.343 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.491 ' HB3' ' O ' ' A' ' 71' ' ' SER . 2.1 ttt-85 -48.19 124.75 8.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.181 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.49 -87.81 0.14 Allowed Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.701 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.17 -55.85 0.45 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.615 0.245 . . . . 0.0 111.316 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.79 30.57 6.98 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.98 151.14 5.44 Favored Glycine 0 C--N 1.333 0.378 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.39 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.448 ' CE2' ' HG3' ' A' ' 10' ' ' ARG . 39.1 m-85 -77.43 -33.42 54.89 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-O 120.568 0.223 . . . . 0.0 111.086 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.84 61.77 0.83 Allowed Glycine 0 C--N 1.335 0.498 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.567 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.403 ' CD1' ' HB2' ' A' ' 15' ' ' TYR . 6.1 p90 -168.93 175.93 5.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 111.063 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -119.04 116.71 26.98 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.392 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.4 HD23 ' N ' ' A' ' 20' ' ' SER . 0.6 OUTLIER -105.97 132.41 52.09 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.801 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.474 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 36.8 p -147.45 -176.68 5.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.819 179.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 109.4 82.27 1.35 Allowed Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 121.033 -0.604 . . . . 0.0 112.05 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.1 tp60 -45.37 -53.44 8.6 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 120.843 0.354 . . . . 0.0 110.594 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.956 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -98.68 -62.93 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.94 178.395 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.956 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 97.3 Cg_endo -88.11 91.85 0.45 Allowed 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.872 2.381 . . . . 0.0 112.128 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.3 p -54.73 119.78 5.83 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.659 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.508 HG23 ' HA ' ' A' ' 46' ' ' GLN . 12.5 p -141.4 151.48 19.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.83 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -81.6 91.31 6.37 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.17 -43.87 52.51 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.493 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.44 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.3 t -167.23 158.58 12.06 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.367 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.632 HG21 ' HB3' ' A' ' 41' ' ' LEU . 12.4 t -119.1 154.76 21.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.341 179.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 41.8 mtp -98.41 101.38 12.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 121.036 0.446 . . . . 0.0 110.33 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -50.82 124.48 11.2 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.859 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.31 22.87 10.97 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.488 -179.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.37 165.08 26.39 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.621 ' O ' HG23 ' A' ' 39' ' ' VAL . 9.4 Cg_endo -52.59 -28.06 35.3 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.726 2.284 . . . . 0.0 112.869 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.655 ' O ' HD23 ' A' ' 41' ' ' LEU . . . -65.36 -49.84 67.83 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.782 0.325 . . . . 0.0 110.829 179.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -70.36 -31.25 68.43 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.397 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.427 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.4 m-30 -61.36 -23.95 66.13 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.419 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.792 HG21 ' O ' ' A' ' 7' ' ' GLU . 23.5 t -89.08 -33.73 6.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 CA-C-O 120.758 0.313 . . . . 0.0 111.167 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.45 42.51 0.31 Allowed Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.874 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.655 HD23 ' O ' ' A' ' 36' ' ' ALA . 1.7 mm? -75.18 178.49 5.71 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.644 0.259 . . . . 0.0 110.62 179.557 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -171.04 130.18 0.77 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.219 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.44 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -65.18 111.72 3.08 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.479 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 129.91 -23.96 4.62 Favored Glycine 0 CA--C 1.523 0.582 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.839 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.45 115.65 3.13 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 120.651 0.263 . . . . 0.0 110.518 179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . 0.508 ' HA ' HG23 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -74.64 120.3 19.99 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.832 -179.469 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.639 ' HA ' HG22 ' A' ' 78' ' ' ILE . 24.2 mt -78.05 124.15 35.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.537 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.716 HD11 ' HB2' ' A' ' 79' ' ' ALA . 3.2 mt -105.67 -46.46 4.15 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.776 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -120.5 140.43 51.45 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.996 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.461 HG23 ' CG2' ' A' ' 55' ' ' VAL . 13.9 t -134.44 110.06 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.402 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.9 t-20 76.65 33.56 0.49 Allowed 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -178.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 77.32 -1.86 2.68 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 112.688 -179.869 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.587 HD11 HD13 ' A' ' 66' ' ' LEU . 5.0 pt -113.04 122.77 67.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-O 121.063 0.459 . . . . 0.0 111.315 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.541 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 6.9 t30 -63.4 128.16 34.57 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.339 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.575 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 13.1 m -136.33 54.18 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.22 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.409 ' HD3' HD22 ' A' ' 48' ' ' LEU . 2.4 mmmt -65.9 -30.0 70.52 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.25 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.4 mmtt -132.37 29.76 4.24 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.61 0.243 . . . . 0.0 111.129 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.575 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -81.75 -179.51 7.41 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.857 0.36 . . . . 0.0 111.405 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.627 ' O ' HG23 ' A' ' 63' ' ' VAL . 3.9 m -86.18 145.26 27.07 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.58 0.705 . . . . 0.0 111.011 179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.721 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.7 t-160 -59.1 -44.87 91.99 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.485 -1.234 . . . . 0.0 111.473 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.02 -38.72 89.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.546 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -42.55 92.43 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.627 HG23 ' O ' ' A' ' 59' ' ' SER . 65.2 t -65.53 -41.74 91.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.001 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 60' ' ' HIS . 46.6 t -65.82 -38.92 83.31 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 178.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -43.09 85.72 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.234 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.587 HD13 HD11 ' A' ' 53' ' ' ILE . 56.0 mt -64.53 -41.03 96.62 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.764 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.763 HG23 ' HG ' ' A' ' 74' ' ' LEU . 44.1 mt -66.35 -43.43 91.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.499 179.383 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.64 -21.94 63.41 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.72 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.81 -34.93 72.25 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.527 0.203 . . . . 0.0 111.531 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.527 ' HB3' HD22 ' A' ' 74' ' ' LEU . 0.1 OUTLIER -97.95 99.59 10.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.487 0.66 . . . . 0.0 110.254 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.491 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 30.3 t -88.99 -33.77 17.08 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.758 -1.11 . . . . 0.0 111.221 -179.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -65.12 -43.03 96.21 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.174 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.488 HG13 ' CE1' ' A' ' 75' ' ' HIS . 7.3 p -178.91 138.93 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 120.751 0.31 . . . . 0.0 111.44 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.763 ' HG ' HG23 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -94.19 146.5 23.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.318 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.488 ' CE1' HG13 ' A' ' 73' ' ' VAL . 40.7 m80 -131.44 102.82 6.1 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.864 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.09 154.66 44.42 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.808 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.6 t -109.43 112.74 41.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.704 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.639 HG22 ' HA ' ' A' ' 47' ' ' ILE . 1.6 pp -107.24 172.18 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.387 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.716 ' HB2' HD11 ' A' ' 48' ' ' LEU . . . -145.94 129.17 16.7 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.258 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.08 169.86 10.82 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.031 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -157.07 -97.6 0.13 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.911 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m -67.09 109.37 1.33 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.283 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.46 -1.189 . . . . 0.0 112.343 -179.952 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo . . . . . 0 N--CA 1.49 1.308 0 CA-C-O 120.852 0.272 . . . . 0.0 111.92 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -165.23 -51.84 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.832 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 p -97.6 138.3 22.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.247 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.5 ptt-85 -153.34 166.42 32.68 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.24 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.6 m -118.16 140.96 49.01 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.801 HG21 ' CD1' ' A' ' 41' ' ' LEU . 25.2 t -115.3 138.39 45.78 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.329 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -110.69 105.78 14.78 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.987 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.488 ' O ' HG23 ' A' ' 73' ' ' VAL . 10.5 t -100.39 133.26 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.288 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.68 98.73 9.25 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.942 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.526 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.4 OUTLIER -53.35 126.07 19.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.978 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.82 15.14 44.29 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.706 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.8 mmt85 74.01 0.24 3.55 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.985 0.392 . . . . 0.0 111.753 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -146.28 25.57 1.23 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-O 120.77 0.319 . . . . 0.0 111.147 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 136.47 175.44 13.81 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.692 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.623 ' CE2' HG22 ' A' ' 67' ' ' ILE . 35.5 m-85 -114.26 -69.57 0.85 Allowed 'General case' 0 C--O 1.232 0.141 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.81 -22.25 1.8 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.988 -0.625 . . . . 0.0 113.226 -179.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.53 ' HB2' HD21 ' A' ' 27' ' ' LEU . 51.4 p90 -95.81 137.76 34.43 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.905 0.353 . . . . 0.0 110.777 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -98.08 133.25 42.8 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.201 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.674 HD21 HD12 ' A' ' 47' ' ' ILE . 3.0 mt -117.29 133.26 56.19 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.462 -179.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.5 m -149.88 166.63 28.96 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.128 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.47 -34.22 4.89 Favored Glycine 0 C--N 1.336 0.568 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.897 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.523 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 79.91 -49.85 0.37 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.359 0.663 . . . . 0.0 111.552 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.889 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -97.79 -64.93 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.483 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.889 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 99.0 Cg_endo -79.74 94.86 1.03 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.402 2.068 . . . . 0.0 112.478 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 85.6 m -59.65 111.61 1.49 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.184 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -146.93 143.21 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.273 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.726 HD22 HG22 ' A' ' 30' ' ' VAL . 0.1 OUTLIER -79.2 91.46 4.97 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.671 179.655 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.1 m -54.96 -37.64 66.75 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.347 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.549 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.2 t -167.15 155.61 9.8 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.921 0.391 . . . . 0.0 111.273 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.726 HG22 HD22 ' A' ' 27' ' ' LEU . 2.4 t -112.5 155.17 13.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.558 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mmt -103.31 101.92 11.86 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 121.003 0.43 . . . . 0.0 110.636 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.4 mtt85 -51.73 124.4 12.34 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.764 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.68 3.61 37.14 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.717 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.413 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.6 OUTLIER -108.13 167.06 9.82 Favored Pre-proline 0 C--O 1.233 0.211 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.512 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.546 ' O ' HG23 ' A' ' 39' ' ' VAL . 9.8 Cg_endo -51.57 -29.51 32.54 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.924 2.416 . . . . 0.0 112.712 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.603 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -63.7 -49.36 73.44 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.024 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.13 -34.27 77.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -60.94 -26.79 67.76 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.492 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 35' ' ' PRO . 35.3 t -89.56 -30.41 5.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-O 120.661 0.267 . . . . 0.0 111.144 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.06 47.11 0.67 Allowed Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.801 ' CD1' HG21 ' A' ' 6' ' ' VAL . 2.8 tp -80.22 156.45 26.88 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.965 0.412 . . . . 0.0 110.782 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.8 mmm180 -146.28 117.79 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.549 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -53.41 152.15 5.0 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.739 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.71 -28.95 13.66 Favored Glycine 0 CA--C 1.521 0.427 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.344 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.451 ' OD2' HD13 ' A' ' 78' ' ' ILE . 19.0 p-10 -59.68 121.9 12.8 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 122.876 0.47 . . . . 0.0 111.438 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -78.37 130.56 36.28 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.079 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.674 HD12 HD21 ' A' ' 19' ' ' LEU . 17.3 mt -84.7 127.81 39.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.002 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.445 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.3 mm? -106.42 -43.27 4.8 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.428 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.556 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -129.95 137.2 50.21 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.504 -0.317 . . . . 0.0 111.41 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.585 HG11 HD11 ' A' ' 67' ' ' ILE . 3.9 t -136.91 113.03 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.338 179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 76.64 31.66 0.57 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 79.15 -5.01 2.02 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.581 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.827 HD11 HD13 ' A' ' 66' ' ' LEU . 1.2 pp -112.2 124.97 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-O 121.104 0.478 . . . . 0.0 111.343 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.556 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -66.19 131.41 46.1 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.307 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.604 HG11 HG22 ' A' ' 63' ' ' VAL . 17.5 m -129.05 53.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.309 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -55.41 -55.4 32.12 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.281 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.3 mttm -127.19 32.62 5.03 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.911 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.49 -176.84 3.88 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.132 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.669 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -85.69 133.88 34.0 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.511 0.672 . . . . 0.0 110.81 179.699 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.523 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 5.0 t60 -56.9 -44.31 82.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.811 -1.086 . . . . 0.0 111.882 -179.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.47 ' HA ' HG22 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -66.48 -33.84 76.6 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.912 179.706 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.56 -42.18 68.14 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.068 178.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.669 HG23 ' O ' ' A' ' 59' ' ' SER . 56.9 t -63.86 -44.02 97.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.083 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.47 HG22 ' HA ' ' A' ' 61' ' ' GLU . 28.6 m -66.14 -39.3 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -57.93 -42.44 84.86 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.956 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.827 HD13 HD11 ' A' ' 53' ' ' ILE . 5.9 mt -62.31 -43.87 97.83 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.623 HG22 ' CE2' ' A' ' 15' ' ' TYR . 53.3 mt -66.59 -41.62 88.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.677 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.38 -1.17 74.72 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.848 -0.692 . . . . 0.0 113.256 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -83.03 -34.76 26.19 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.027 0.413 . . . . 0.0 111.492 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.75 -57.3 9.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.809 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.8 34.76 5.36 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.974 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.8 -45.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.366 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.6 p -169.05 138.48 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-O 120.841 0.353 . . . . 0.0 111.726 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.464 HD11 HG12 ' A' ' 50' ' ' VAL . 10.7 tp -114.33 141.87 47.05 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.26 179.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -125.27 98.41 5.63 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.977 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 15.1 ptt? -116.67 154.84 29.86 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.391 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.0 t -111.98 109.21 27.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.878 179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.451 HD13 ' OD2' ' A' ' 45' ' ' ASP . 1.1 pt -102.06 163.67 3.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.509 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.26 116.0 18.47 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.9 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -71.49 117.42 13.02 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.33 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -106.13 -30.6 4.41 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.924 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 17.8 t -92.47 134.29 31.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 120.823 0.344 . . . . 0.0 110.868 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.163 0 CA-C-O 118.685 -1.064 . . . . 0.0 113.104 -179.928 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo . . . . . 0 N--CA 1.489 1.227 0 CA-C-O 120.536 0.14 . . . . 0.0 112.162 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -176.99 -42.54 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.466 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 21.4 t -72.64 120.44 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.936 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -150.22 174.08 13.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.377 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -118.76 137.41 53.39 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.765 HG13 HG11 ' A' ' 39' ' ' VAL . 42.3 t -114.59 139.33 41.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.114 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -115.04 110.1 19.07 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.861 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 73' ' ' VAL . 5.9 t -95.9 130.31 44.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.027 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.5 93.13 8.39 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.964 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 -39.38 122.7 1.34 Allowed 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.555 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.31 -90.65 0.07 OUTLIER Glycine 0 C--N 1.333 0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 112.907 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 ptt85 -134.98 -47.37 0.73 Allowed 'General case' 0 C--O 1.233 0.196 0 N-CA-C 111.578 0.214 . . . . 0.0 111.578 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.49 40.43 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.528 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.28 -173.96 21.43 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.826 -0.702 . . . . 0.0 113.178 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -96.56 -71.93 0.66 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.653 0.263 . . . . 0.0 111.463 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.71 -39.34 0.61 Allowed Glycine 0 CA--C 1.519 0.323 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.785 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -71.62 179.93 2.85 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.691 0.282 . . . . 0.0 111.122 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 m -135.3 151.03 50.16 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.356 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 mt -124.97 131.06 53.48 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.942 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.7 p -148.06 157.77 43.69 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 120.713 0.292 . . . . 0.0 111.561 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 126.26 -25.73 5.39 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 121.213 -0.518 . . . . 0.0 113.027 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 61.81 14.24 6.07 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.736 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.801 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -166.87 -65.79 0.01 OUTLIER Pre-proline 0 N--CA 1.463 0.224 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.801 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.8 Cg_endo -74.39 83.68 1.66 Allowed 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.381 2.054 . . . . 0.0 111.361 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.5 m -52.23 108.45 0.29 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.3 p -143.22 141.37 26.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.54 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 1.003 HD12 HD11 ' A' ' 47' ' ' ILE . 2.1 mp -78.98 91.95 4.89 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.408 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.24 -42.98 42.33 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.408 -179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.59 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.9 t -171.07 157.1 5.06 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.964 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.0 t -120.42 155.56 23.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.655 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.0 mtp -97.83 102.29 14.01 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.224 0.535 . . . . 0.0 110.572 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.34 121.6 5.17 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.967 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.21 -18.32 23.54 Favored Glycine 0 CA--C 1.522 0.499 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.291 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.79 166.74 34.16 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.654 0.227 . . . . 0.0 110.521 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -53.14 -26.74 34.32 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.101 2.534 . . . . 0.0 113.166 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -65.5 -42.27 92.3 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.53 -26.65 63.67 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.375 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -55.31 -25.59 35.37 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 111.668 0.247 . . . . 0.0 111.668 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.765 HG11 HG13 ' A' ' 6' ' ' VAL . 21.4 t -89.46 -32.51 5.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 120.612 0.244 . . . . 0.0 111.122 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.77 41.65 1.68 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.454 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.5 mt -74.79 -178.28 3.62 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.628 0.251 . . . . 0.0 110.346 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 -163.85 122.79 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.402 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.59 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -47.26 125.25 7.68 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.97 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.53 -25.66 5.89 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.595 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.627 ' OD2' HG21 ' A' ' 78' ' ' ILE . 11.3 p-10 -56.91 122.62 12.69 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 121.018 0.437 . . . . 0.0 110.946 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.6 mp0 -76.98 117.78 18.91 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.062 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 1.003 HD11 HD12 ' A' ' 27' ' ' LEU . 14.0 mt -81.76 121.49 35.18 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.899 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mp -108.44 -40.59 5.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.086 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.558 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -120.8 133.08 55.33 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.99 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.4 t -135.3 111.29 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.22 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.401 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.28 32.62 0.58 Allowed 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.294 0.568 . . . . 0.0 109.717 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 76.82 -3.35 2.53 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.089 -0.96 . . . . 0.0 112.784 179.869 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.78 HD11 ' CD1' ' A' ' 66' ' ' LEU . 1.1 pt -116.12 125.92 73.4 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-O 120.834 0.349 . . . . 0.0 111.16 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.481 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 18.4 p-10 -64.95 135.91 56.21 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.473 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.0 m -134.2 59.0 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.902 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 46.4 mttt -48.48 -71.44 0.07 Allowed 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.921 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 35.6 mttp -119.81 39.87 3.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.664 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -73.86 -174.87 1.94 Allowed 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.933 -179.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.529 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.99 136.24 33.12 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 121.489 0.661 . . . . 0.0 110.678 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.742 ' O ' HG23 ' A' ' 64' ' ' VAL . 5.1 t60 -53.99 -44.48 70.87 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.279 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -61.17 -41.81 97.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.788 0.327 . . . . 0.0 110.737 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -66.3 -41.45 89.71 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.706 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 59' ' ' SER . 61.5 t -65.93 -39.13 83.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.606 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.5 t -65.75 -39.02 83.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 178.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -57.42 -41.26 80.05 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.887 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.78 ' CD1' HD11 ' A' ' 53' ' ' ILE . 14.2 mt -64.14 -43.62 94.66 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.46 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.782 HG23 HD22 ' A' ' 74' ' ' LEU . 52.0 mt -66.84 -37.47 79.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.623 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -79.31 8.56 45.94 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.444 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.54 1.91 15.16 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 122.448 0.299 . . . . 0.0 110.781 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.439 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 16.0 p -50.98 -44.73 60.78 Favored 'General case' 0 C--O 1.233 0.212 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.487 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.9 m 67.21 30.82 7.01 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.065 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.9 -30.93 2.78 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.152 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.439 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.1 p -163.84 138.0 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.047 0.451 . . . . 0.0 112.193 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.782 HD22 HG23 ' A' ' 67' ' ' ILE . 41.4 tp -114.35 150.41 34.59 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.164 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.4 m80 -120.01 105.82 11.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.344 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.506 ' SD ' HD23 ' A' ' 74' ' ' LEU . 0.9 OUTLIER -115.45 137.18 52.32 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.168 -179.381 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.558 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 20.6 t -107.34 105.75 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.767 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.638 HG22 ' HA ' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -106.82 170.64 2.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.461 -179.821 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -130.41 154.78 47.36 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.571 -179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -105.7 151.12 24.83 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.794 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.33 162.32 20.21 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.2 108.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.937 0.398 . . . . 0.0 111.0 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.44 -1.2 . . . . 0.0 112.273 -179.46 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo . . . . . 0 N--CA 1.493 1.467 0 CA-C-O 120.42 0.092 . . . . 0.0 112.317 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 25.7 ptt85 38.18 39.42 0.26 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.765 0.426 . . . . 0.0 112.068 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.5 p -111.61 132.18 60.92 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.181 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -130.81 145.09 51.88 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.244 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -110.44 132.66 53.99 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.664 179.484 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.672 HG13 HG11 ' A' ' 39' ' ' VAL . 37.1 t -118.33 141.1 39.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.554 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -128.66 100.8 5.87 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.794 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.632 ' O ' HG23 ' A' ' 73' ' ' VAL . 19.5 t -95.56 144.62 9.71 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-O 120.969 0.414 . . . . 0.0 111.533 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -115.14 106.44 14.09 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.625 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.424 ' HD3' ' HA ' ' A' ' 71' ' ' SER . 17.7 ttt180 -50.62 120.09 4.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.12 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.97 -61.92 5.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.392 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -150.7 -76.29 0.14 Allowed 'General case' 0 C--O 1.231 0.127 0 CA-C-O 120.613 0.244 . . . . 0.0 110.564 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.39 26.46 9.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.508 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.6 173.95 46.52 Favored Glycine 0 C--N 1.336 0.57 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.897 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -111.13 -77.24 0.59 Allowed 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 120.706 0.289 . . . . 0.0 110.922 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.53 45.32 0.04 OUTLIER Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.968 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -159.03 176.77 11.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.442 0.163 . . . . 0.0 110.713 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -140.9 150.38 43.11 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.628 0.252 . . . . 0.0 111.268 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.628 HD21 HD12 ' A' ' 47' ' ' ILE . 2.8 mt -120.98 131.48 54.33 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.568 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.7 m -147.08 163.0 37.67 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.258 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.61 -30.65 5.07 Favored Glycine 0 C--N 1.336 0.554 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.983 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.487 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 80.97 -44.73 0.22 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.443 0.697 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.799 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -111.04 -68.26 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.512 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.799 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 64.0 Cg_endo -73.73 95.72 0.89 Allowed 'Trans proline' 0 C--N 1.356 0.952 0 C-N-CA 122.26 1.974 . . . . 0.0 112.446 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.455 ' SG ' HG21 ' A' ' 63' ' ' VAL . 84.7 m -61.73 118.5 7.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.218 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.31 145.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.583 HD21 HD23 ' A' ' 41' ' ' LEU . 0.6 OUTLIER -75.86 90.99 2.95 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-O 120.846 0.355 . . . . 0.0 110.507 179.758 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.6 m -54.67 -36.67 64.86 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.417 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.474 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 4.2 t -164.52 157.94 17.66 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.031 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.419 HG21 ' O ' ' A' ' 41' ' ' LEU . 4.1 t -122.54 154.61 27.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.903 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -97.45 101.28 12.78 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.279 0.561 . . . . 0.0 110.216 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -51.87 121.59 6.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.122 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.86 27.97 8.07 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 121.193 -0.527 . . . . 0.0 112.525 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.2 m -129.36 164.63 38.23 Favored Pre-proline 0 C--N 1.332 -0.194 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.68 -25.12 25.27 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 122.865 2.376 . . . . 0.0 112.902 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.19 -49.98 65.45 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.815 0.341 . . . . 0.0 110.704 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.03 -25.98 65.64 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.168 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.1 m-30 -57.03 -30.18 64.0 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.599 0.238 . . . . 0.0 111.388 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.672 HG11 HG13 ' A' ' 6' ' ' VAL . 20.8 t -89.28 -25.92 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.253 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.84 5.4 6.94 Favored Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.348 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.617 HD11 HG11 ' A' ' 6' ' ' VAL . 7.3 mp -64.67 111.45 2.76 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 117.315 0.557 . . . . 0.0 109.675 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.482 ' O ' ' HB3' ' A' ' 43' ' ' ALA . 18.0 mmm180 -122.97 25.97 8.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.51 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 42' ' ' ARG . . . 72.92 159.27 0.22 Allowed 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.947 0.404 . . . . 0.0 111.636 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.15 -39.66 3.05 Favored Glycine 0 C--N 1.334 0.46 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.678 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.535 ' OD2' HD13 ' A' ' 27' ' ' LEU . 2.9 p-10 -52.3 119.91 4.94 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.917 0.389 . . . . 0.0 110.843 179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . 0.483 ' O ' HD12 ' A' ' 48' ' ' LEU . 11.0 mt-30 -75.22 126.22 30.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.031 -179.442 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.628 HD12 HD21 ' A' ' 19' ' ' LEU . 19.3 mt -83.09 120.29 34.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.819 179.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.483 HD12 ' O ' ' A' ' 46' ' ' GLN . 5.4 mp -105.2 -32.87 8.45 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.624 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.552 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -137.09 137.45 39.3 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 111.018 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.438 HG23 ' CG2' ' A' ' 55' ' ' VAL . 6.3 t -132.25 108.15 13.39 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.424 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 4.8 t-20 77.39 33.59 0.4 Allowed 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.52 -1.08 3.1 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.517 -179.621 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.655 HD11 HD13 ' A' ' 66' ' ' LEU . 9.0 pt -113.14 119.63 61.1 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 111.176 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 10.9 m120 -62.08 120.63 11.22 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.149 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.457 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 11.9 m -135.14 33.71 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.747 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -61.4 -28.43 69.25 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -123.55 26.83 7.65 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 120.544 0.211 . . . . 0.0 111.3 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.457 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -92.27 -178.96 5.1 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.765 0.317 . . . . 0.0 111.505 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.654 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.3 OUTLIER -80.23 135.36 36.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.362 0.601 . . . . 0.0 110.736 179.688 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.487 ' HB2' ' HA ' ' A' ' 22' ' ' GLN . 4.0 t60 -54.79 -44.24 73.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.927 -1.033 . . . . 0.0 111.978 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.469 ' HA ' HG22 ' A' ' 64' ' ' VAL . 20.9 mt-10 -65.64 -35.87 82.06 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.779 0.323 . . . . 0.0 110.567 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.29 -39.38 71.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.167 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 59' ' ' SER . 60.8 t -67.43 -42.31 87.09 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.162 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.469 HG22 ' HA ' ' A' ' 61' ' ' GLU . 31.4 m -65.93 -38.6 82.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.9 tttp -57.48 -40.31 78.3 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.697 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.655 HD13 HD11 ' A' ' 53' ' ' ILE . 21.2 mt -67.63 -42.42 82.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.736 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.508 HG23 HD13 ' A' ' 74' ' ' LEU . 9.5 mt -69.33 -38.38 77.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.996 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -60.1 -24.65 61.1 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.318 179.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -80.27 4.43 17.73 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.902 0.334 . . . . 0.0 111.902 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.607 ' HB2' HD12 ' A' ' 74' ' ' LEU . 0.1 OUTLIER -106.18 104.01 13.62 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.356 0.598 . . . . 0.0 110.109 179.708 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.424 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.1 OUTLIER -116.2 33.43 5.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.987 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.93 -53.91 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.088 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 8' ' ' VAL . 4.0 p -172.03 130.96 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.142 0 CA-C-O 120.99 0.424 . . . . 0.0 111.8 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.607 HD12 ' HB2' ' A' ' 70' ' ' CYS . 0.5 OUTLIER -114.5 151.62 32.99 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.546 -179.878 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.522 ' N ' HD23 ' A' ' 74' ' ' LEU . 19.7 m170 -116.39 107.09 14.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.211 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.412 ' HG3' HD22 ' A' ' 74' ' ' LEU . 1.6 mpt? -108.74 145.76 34.61 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.03 -179.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.552 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 19.5 t -117.1 98.88 7.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.522 HG22 ' HA ' ' A' ' 47' ' ' ILE . 24.8 pt -101.62 172.1 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.479 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.57 146.84 52.22 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.12 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -61.28 120.96 11.42 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.118 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 175.55 120.87 0.62 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.247 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.1 p -159.25 136.49 2.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-O 120.815 0.34 . . . . 0.0 111.204 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.303 -1.276 . . . . 0.0 112.75 -179.953 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo . . . . . 0 N--CA 1.491 1.343 0 CA-C-O 120.653 0.189 . . . . 0.0 112.348 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 4.6 mtt-85 -178.9 95.11 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.811 0.339 . . . . 0.0 110.68 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 3' ' ' VAL . 9.2 p -85.83 105.47 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-O 121.07 0.462 . . . . 0.0 111.26 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.73 ' HG2' HD11 ' A' ' 78' ' ' ILE . 6.9 tpt180 -114.18 139.27 49.5 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.844 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.81 131.06 57.05 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.182 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.825 HG11 HD13 ' A' ' 41' ' ' LEU . 25.6 t -120.91 131.49 72.81 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.693 0.282 . . . . 0.0 110.826 179.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.644 ' O ' HG21 ' A' ' 39' ' ' VAL . 25.6 mt-10 -116.7 115.25 25.29 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.009 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.448 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.2 t -108.57 138.58 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.787 0.327 . . . . 0.0 111.435 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.3 93.89 8.87 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.397 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.436 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 4.0 ttt-85 -51.81 126.41 17.9 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.445 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.92 -112.67 0.03 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.687 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -111.27 -39.33 4.75 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.468 0.175 . . . . 0.0 111.329 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -138.75 35.13 2.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.337 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 159.96 -170.45 36.1 Favored Glycine 0 C--N 1.338 0.65 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.731 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.436 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 71.5 m-85 -118.63 -69.42 0.85 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.865 0.364 . . . . 0.0 111.161 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 141.16 52.49 0.04 OUTLIER Glycine 0 C--N 1.332 0.315 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.317 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.525 ' HB2' HD21 ' A' ' 27' ' ' LEU . 51.0 p90 -162.99 155.47 18.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.549 0.214 . . . . 0.0 110.952 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.14 129.13 43.52 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.932 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -116.57 124.37 49.68 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.993 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 39.2 m -148.07 115.58 6.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.177 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -168.1 83.28 0.1 OUTLIER Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.49 -179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.25 -43.07 21.68 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.972 0.415 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.96 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -121.25 -66.69 0.02 OUTLIER Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.455 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.96 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 92.3 Cg_endo -85.23 94.88 0.64 Allowed 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 122.475 2.117 . . . . 0.0 112.214 179.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 2.6 m -51.87 117.66 2.89 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.822 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -141.51 149.41 20.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.378 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.612 HD11 HD21 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -80.46 91.49 5.74 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.741 179.661 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.08 -45.38 61.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.517 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.503 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.5 t -164.4 159.06 19.21 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.59 HG22 HD22 ' A' ' 27' ' ' LEU . 5.2 t -116.9 155.03 18.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.714 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.2 mmt -99.5 100.76 11.83 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.153 0.501 . . . . 0.0 110.278 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.3 mtm-85 -52.07 125.94 17.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.943 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.91 23.64 11.46 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.682 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.86 168.92 14.29 Favored Pre-proline 0 CA--C 1.531 0.218 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.669 ' O ' HG23 ' A' ' 39' ' ' VAL . 78.4 Cg_exo -50.66 -29.93 27.11 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.885 2.39 . . . . 0.0 113.051 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.796 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -65.09 -49.82 68.51 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 111.014 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -69.43 -32.79 71.98 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.243 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 16.7 m-30 -62.77 -23.78 67.38 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.455 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.669 HG23 ' O ' ' A' ' 35' ' ' PRO . 38.8 t -89.32 -29.6 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.58 0.229 . . . . 0.0 111.246 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.89 39.96 0.86 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.717 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.825 HD13 HG11 ' A' ' 6' ' ' VAL . 4.1 tp -73.28 178.62 4.38 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.806 0.336 . . . . 0.0 110.765 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -173.92 131.17 0.41 Allowed 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.944 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.503 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -62.67 120.81 11.92 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.911 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 128.23 -27.57 4.48 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.804 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -58.3 123.92 17.72 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 120.927 0.394 . . . . 0.0 111.062 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -78.21 124.7 28.37 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.716 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.3 mt -95.66 122.21 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.802 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.76 HD12 ' HD2' ' A' ' 56' ' ' LYS . 0.3 OUTLIER -108.19 -38.32 5.79 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.016 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.523 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -119.01 138.14 53.04 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.569 ' HB ' HG21 ' A' ' 55' ' ' VAL . 19.3 t -141.71 115.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.773 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.417 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.7 t-20 76.89 32.78 0.49 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -178.302 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.417 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.2 -0.71 3.23 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.454 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.71 HD11 HD13 ' A' ' 66' ' ' LEU . 12.1 pt -120.47 133.42 67.23 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 111.434 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.523 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 22.9 t-20 -63.07 121.73 14.32 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.966 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.569 HG21 ' HB ' ' A' ' 50' ' ' VAL . 5.0 m -140.41 55.35 0.21 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.553 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.76 ' HD2' HD12 ' A' ' 48' ' ' LEU . 0.1 OUTLIER -102.03 14.52 31.74 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.546 179.572 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -150.89 27.95 0.7 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 122.279 0.232 . . . . 0.0 111.12 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -113.99 -167.45 1.21 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-O 120.706 0.289 . . . . 0.0 111.59 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.591 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.4 OUTLIER -88.74 139.15 30.75 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-O 121.361 0.6 . . . . 0.0 110.533 179.672 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.727 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.3 t60 -53.69 -44.78 70.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.871 -1.058 . . . . 0.0 112.052 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -60.62 -42.32 96.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.742 0.306 . . . . 0.0 110.731 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -64.79 -44.06 91.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.265 179.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 59' ' ' SER . 52.4 t -63.36 -42.81 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.128 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.727 HG23 ' O ' ' A' ' 60' ' ' HIS . 50.3 t -66.17 -38.91 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -57.77 -41.1 81.3 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.89 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.71 HD13 HD11 ' A' ' 53' ' ' ILE . 17.7 mt -64.05 -43.45 95.49 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.533 179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.566 HG23 HD22 ' A' ' 74' ' ' LEU . 68.6 mt -62.42 -44.27 99.07 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.679 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -69.51 -22.37 76.5 Favored Glycine 0 CA--C 1.522 0.49 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.004 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.9 tptt -57.0 -34.68 68.38 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.577 0.227 . . . . 0.0 111.421 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -69.01 -57.8 4.96 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-O 120.912 0.387 . . . . 0.0 110.676 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.416 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 0.5 OUTLIER 65.05 36.09 7.61 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.108 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.28 -45.56 0.02 OUTLIER Glycine 0 C--N 1.332 0.313 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.196 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.2 p -165.46 138.78 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.829 0.347 . . . . 0.0 111.287 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.566 HD22 HG23 ' A' ' 67' ' ' ILE . 28.3 tp -112.29 134.65 53.71 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.286 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 55.6 m170 -119.53 98.49 6.16 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.2 179.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.97 145.15 40.12 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.327 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 22.9 t -96.67 114.0 32.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.545 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.73 HD11 ' HG2' ' A' ' 4' ' ' ARG . 1.7 pt -103.37 146.23 11.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.311 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -112.94 144.57 42.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.267 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -91.91 119.05 31.32 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.449 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -83.89 -122.27 0.91 Allowed Glycine 0 C--N 1.333 0.412 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.636 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 21.3 t -83.28 81.54 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-O 120.981 0.42 . . . . 0.0 110.372 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.465 -1.186 . . . . 0.0 112.322 -179.878 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 120.575 0.156 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -119.37 161.14 20.99 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.953 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.498 ' O ' HG13 ' A' ' 3' ' ' VAL . 11.9 p -114.44 112.31 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 CA-C-O 120.887 0.375 . . . . 0.0 111.327 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.5 ttt85 -118.48 136.27 53.9 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.203 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.09 129.54 36.37 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.754 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.405 HG11 ' CD2' ' A' ' 41' ' ' LEU . 25.0 t -126.35 135.51 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.333 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -133.35 109.11 9.13 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.515 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.2 t -102.46 144.48 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.204 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -110.23 102.96 11.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.853 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.91 120.3 5.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.211 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.52 -122.03 0.58 Allowed Glycine 0 C--N 1.333 0.396 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.647 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -114.41 -40.7 3.58 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.514 0.197 . . . . 0.0 111.151 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -105.94 29.42 6.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 120.721 0.296 . . . . 0.0 111.52 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.96 -176.92 16.77 Favored Glycine 0 C--N 1.337 0.606 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.826 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.487 ' CE2' HG22 ' A' ' 67' ' ' ILE . 61.8 m-85 -79.3 -71.46 0.44 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.896 0.379 . . . . 0.0 110.718 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.23 48.99 0.04 OUTLIER Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.836 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.743 ' HB2' HD23 ' A' ' 27' ' ' LEU . 50.5 p90 -161.01 171.59 18.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.673 0.273 . . . . 0.0 110.946 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 m -126.31 133.17 51.47 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.899 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.531 HD21 ' CD1' ' A' ' 47' ' ' ILE . 3.4 mt -115.27 124.59 51.72 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.204 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.4 m -136.7 16.31 3.11 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.301 -0.409 . . . . 0.0 112.101 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.44 85.19 1.57 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.071 -0.585 . . . . 0.0 112.445 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.34 -66.66 0.35 Allowed 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.691 0.281 . . . . 0.0 111.011 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.883 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -91.76 -59.06 0.23 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.103 178.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.883 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 83.9 Cg_endo -88.59 94.32 0.38 Allowed 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 122.89 2.393 . . . . 0.0 111.607 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.57 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.2 m -50.98 124.24 10.91 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.679 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 45' ' ' ASP . 7.3 p -154.07 141.89 13.11 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.743 HD23 ' HB2' ' A' ' 17' ' ' PHE . 1.6 mp -79.71 89.53 5.18 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.771 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -56.22 -35.24 67.11 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.473 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.3 t -153.16 152.05 30.82 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.3 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.2 t -123.13 154.76 28.86 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.724 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 32.3 mtt -98.64 100.29 11.5 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.268 0.556 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.37 123.29 13.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.847 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 108.85 -19.71 30.15 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.785 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.0 166.59 25.64 Favored Pre-proline 0 CA--C 1.531 0.231 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -55.45 -24.93 46.14 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.709 2.273 . . . . 0.0 112.621 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.769 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -63.57 -49.11 74.7 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.993 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.08 -28.95 65.84 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.286 179.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.7 m-30 -56.64 -33.08 65.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.687 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -89.25 -31.06 5.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.024 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.2 51.71 1.44 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.176 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.769 HD12 ' HB1' ' A' ' 36' ' ' ALA . 5.3 mt -59.32 -25.81 64.47 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 20.5 mtt85 66.7 119.49 0.03 OUTLIER 'General case' 0 C--N 1.34 0.187 0 CA-C-O 120.963 0.411 . . . . 0.0 111.684 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.39 89.19 0.21 Allowed 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.496 179.249 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.0 -12.7 5.04 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 121.208 -0.52 . . . . 0.0 112.905 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.542 ' HB3' HD12 ' A' ' 78' ' ' ILE . 1.3 t70 -58.22 127.49 32.38 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.711 0.291 . . . . 0.0 110.573 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.59 126.65 30.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.739 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.812 ' HA ' HG22 ' A' ' 78' ' ' ILE . 15.1 mt -90.63 131.06 38.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.599 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -119.06 -43.65 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.358 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.07 137.25 47.27 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.008 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.6 t -144.28 110.98 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.297 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.413 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.3 t-20 76.99 35.74 0.35 Allowed 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 -178.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.2 OUTLIER 71.55 -0.27 3.21 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.252 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 12.3 pt -120.97 125.5 74.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-O 120.81 0.338 . . . . 0.0 111.121 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.524 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.2 m120 -68.59 172.09 6.7 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.954 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.476 HG11 HG22 ' A' ' 63' ' ' VAL . 3.7 m -138.57 -51.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.039 -0.528 . . . . 0.0 112.121 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt 72.15 -59.41 0.56 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 123.119 0.567 . . . . 0.0 110.828 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.8 mtpt -148.23 40.26 0.94 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.75 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -72.74 -173.79 1.28 Allowed 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.859 0.362 . . . . 0.0 111.4 -179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.569 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -90.14 135.8 33.44 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.416 0.627 . . . . 0.0 111.174 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.539 ' O ' HG22 ' A' ' 64' ' ' VAL . 2.4 t-160 -53.13 -44.33 67.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.486 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.465 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.3 pm0 -66.21 -34.74 78.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.169 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.62 -39.43 70.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.725 0.297 . . . . 0.0 110.343 179.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.57 HG21 ' SG ' ' A' ' 25' ' ' CYS . 48.0 t -67.3 -43.87 87.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.941 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 60' ' ' HIS . 15.9 m -66.32 -38.96 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.6 mmtt -58.11 -39.73 79.42 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.059 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 25.3 mt -68.09 -41.19 82.21 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.772 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.557 HG23 HD22 ' A' ' 74' ' ' LEU . 17.7 mt -69.39 -38.49 77.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.035 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -87.77 14.33 58.72 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.764 -0.731 . . . . 0.0 113.102 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.57 -29.22 12.46 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.847 0.324 . . . . 0.0 111.299 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.426 ' HB2' HD12 ' A' ' 74' ' ' LEU . 0.5 OUTLIER -69.71 -61.86 1.61 Allowed 'General case' 0 C--O 1.233 0.217 0 CA-C-O 120.827 0.346 . . . . 0.0 110.645 -179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 70.63 33.88 2.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.088 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.52 -49.4 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.126 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -174.73 132.56 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 111.669 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.557 HD22 HG23 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.91 152.98 31.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.672 179.676 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.9 m170 -117.52 105.38 12.02 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.948 179.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.24 156.2 25.81 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.431 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.456 ' CG1' HG23 ' A' ' 3' ' ' VAL . 26.4 t -125.53 100.52 7.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.072 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.812 HG22 ' HA ' ' A' ' 47' ' ' ILE . 18.4 pt -101.36 158.67 4.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.388 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -114.86 116.64 28.89 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.72 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.44 120.83 18.6 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -168.89 43.26 0.22 Allowed Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.397 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.61 104.33 15.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-O 120.667 0.27 . . . . 0.0 110.735 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.191 0 CA-C-O 118.675 -1.069 . . . . 0.0 112.937 -179.912 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo . . . . . 0 N--CA 1.492 1.395 0 CA-C-O 120.384 0.077 . . . . 0.0 112.072 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 70.78 131.47 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.837 0.455 . . . . 0.0 111.358 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.466 HG22 ' CG1' ' A' ' 77' ' ' VAL . 11.5 p -65.78 121.05 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.3 ptt180 -137.1 170.77 15.54 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.49 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.7 m -93.81 139.01 31.37 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.459 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.818 HG13 HG11 ' A' ' 39' ' ' VAL . 36.9 t -117.44 146.92 21.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.09 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -111.3 102.55 10.94 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.789 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 73' ' ' VAL . 13.4 t -88.54 119.88 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.174 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.119 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.91 89.63 8.07 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.472 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.405 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 7.9 ttm-85 -53.47 122.12 9.07 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.731 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.29 -68.98 1.42 Allowed Glycine 0 C--N 1.335 0.483 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.548 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -165.32 -51.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 120.725 0.298 . . . . 0.0 110.807 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -122.53 25.04 9.0 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.596 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 150.94 171.53 19.14 Favored Glycine 0 C--N 1.336 0.58 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.795 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.405 ' CE2' ' HB2' ' A' ' 10' ' ' ARG . 5.4 m-85 -108.04 -62.85 1.39 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.667 0.27 . . . . 0.0 110.646 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.26 -33.5 0.93 Allowed Glycine 0 CA--C 1.523 0.541 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.879 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -71.48 178.59 3.39 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.021 0.439 . . . . 0.0 111.445 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 m -139.84 142.6 36.6 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.205 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.62 HD21 HD12 ' A' ' 47' ' ' ILE . 0.7 OUTLIER -117.82 123.98 47.25 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.883 179.924 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.7 m -140.5 168.04 20.75 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.292 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 117.28 -35.2 4.24 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.877 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.44 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.35 -46.57 0.22 Allowed 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.457 0.703 . . . . 0.0 111.559 -179.829 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -101.64 -65.31 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.405 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.88 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 97.0 Cg_endo -79.77 96.04 1.04 Allowed 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.41 2.074 . . . . 0.0 112.384 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.419 ' SG ' HG11 ' A' ' 63' ' ' VAL . 69.8 m -61.44 114.26 3.12 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.135 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -149.0 143.72 18.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.253 -179.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.674 HD12 HD11 ' A' ' 47' ' ' ILE . 3.7 mp -73.13 89.75 1.51 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.655 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.8 m -52.49 -39.52 61.33 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.418 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.4 t -163.53 158.78 21.22 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.581 HG22 HD23 ' A' ' 27' ' ' LEU . 5.3 t -132.96 155.18 40.92 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.47 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 9.1 mtt -109.24 106.04 15.72 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.878 0.37 . . . . 0.0 110.477 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 32' ' ' ARG . 2.5 mtm105 -43.51 111.34 0.27 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.048 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 126.16 -16.1 6.81 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.754 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.502 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 10.0 p -80.58 162.98 58.7 Favored Pre-proline 0 CA--C 1.532 0.282 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.502 ' HD2' ' HB2' ' A' ' 34' ' ' SER . 14.1 Cg_endo -55.84 -24.85 49.26 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 122.718 2.278 . . . . 0.0 112.751 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.546 ' HA ' HD12 ' A' ' 41' ' ' LEU . . . -68.75 -48.04 64.75 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.403 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.77 -30.97 72.0 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.321 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -56.03 -34.56 65.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.818 HG11 HG13 ' A' ' 6' ' ' VAL . 20.3 t -89.63 -29.35 5.07 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.271 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.88 -10.51 4.85 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 120.851 -0.69 . . . . 0.0 113.357 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.72 ' CD2' HD13 ' A' ' 78' ' ' ILE . 46.9 mt -54.0 116.15 2.41 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 117.016 0.408 . . . . 0.0 110.857 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.92 -153.32 0.56 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.747 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 104.02 15.97 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.424 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.94 -25.74 2.38 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.792 -0.718 . . . . 0.0 113.383 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.99 117.78 6.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.995 0.398 . . . . 0.0 111.101 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.04 132.27 35.14 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.799 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.674 HD11 HD12 ' A' ' 27' ' ' LEU . 17.1 mt -91.36 133.35 33.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.556 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.533 HD11 ' CB ' ' A' ' 79' ' ' ALA . 3.1 mp -117.51 -47.14 2.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.881 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.536 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -116.08 136.89 52.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.657 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.524 HG21 HG13 ' A' ' 63' ' ' VAL . 21.8 t -132.95 109.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.402 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 7.9 t30 76.83 33.62 0.46 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.642 -178.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 77.51 -2.66 2.53 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.651 -179.868 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.662 HD11 ' CD1' ' A' ' 66' ' ' LEU . 13.6 pt -111.84 121.48 64.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 120.871 0.367 . . . . 0.0 111.161 179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.536 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -63.59 124.01 20.29 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.063 -179.683 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.689 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.6 m -134.55 53.93 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.299 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 9.0 mtmt -63.45 -37.12 86.08 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.568 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -127.16 27.55 5.89 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.574 -0.284 . . . . 0.0 111.34 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.689 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -81.31 -174.02 4.68 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.694 0.283 . . . . 0.0 111.281 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.661 ' O ' HG23 ' A' ' 63' ' ' VAL . 52.0 m -84.25 139.81 32.1 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.495 0.664 . . . . 0.0 110.825 179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.719 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.1 t60 -60.8 -44.62 96.61 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.697 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -63.04 -42.05 99.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.437 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.79 -45.11 94.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.556 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 59' ' ' SER . 58.5 t -63.83 -41.96 94.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 60' ' ' HIS . 61.8 t -65.76 -39.04 83.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 178.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.67 -39.96 78.28 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.897 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.662 ' CD1' HD11 ' A' ' 53' ' ' ILE . 13.8 mt -66.41 -43.15 86.57 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.705 179.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.431 HG12 HD22 ' A' ' 74' ' ' LEU . 25.0 mt -65.25 -37.2 79.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.759 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -83.63 12.55 51.69 Favored Glycine 0 CA--C 1.525 0.673 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.549 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -112.44 -14.73 13.22 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 122.43 0.292 . . . . 0.0 111.459 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.471 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 27.2 p -45.99 -49.18 16.3 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 122.651 0.38 . . . . 0.0 111.96 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.16 33.87 9.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.974 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 151.74 -36.73 0.84 Allowed Glycine 0 C--N 1.334 0.44 0 C-N-CA 120.805 -0.712 . . . . 0.0 113.132 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.4 p -173.59 137.25 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-O 120.974 0.416 . . . . 0.0 111.906 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.444 HD21 HG13 ' A' ' 50' ' ' VAL . 11.3 tp -112.63 142.34 45.33 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.947 179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.3 m170 -107.31 98.05 7.73 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.124 179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 12.5 ptm -119.66 146.88 45.17 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.481 -179.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.466 ' CG1' HG22 ' A' ' 3' ' ' VAL . 24.6 t -102.12 112.9 36.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.963 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.72 HD13 ' CD2' ' A' ' 41' ' ' LEU . 19.5 pt -101.05 170.27 1.59 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-N 115.894 -0.593 . . . . 0.0 111.304 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.533 ' CB ' HD11 ' A' ' 48' ' ' LEU . . . -140.09 118.46 12.12 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.178 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -69.35 118.98 12.91 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.784 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -88.62 -174.37 47.12 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.783 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 m -64.37 -33.62 63.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.868 -0.962 . . . . 0.0 113.207 179.805 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo . . . . . 0 N--CA 1.491 1.374 0 CA-C-O 120.934 0.306 . . . . 0.0 112.141 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 7.0 ttt85 -92.71 151.18 20.21 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.8 t -91.94 128.72 43.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.972 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -121.99 140.81 52.02 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.132 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 m -97.64 127.68 43.78 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.849 HG13 HG11 ' A' ' 39' ' ' VAL . 38.9 t -120.08 141.8 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.137 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.9 122.6 36.5 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.158 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.534 ' O ' HG23 ' A' ' 73' ' ' VAL . 9.3 t -105.53 149.48 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.131 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -107.42 101.95 11.26 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.143 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -57.5 120.15 7.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.32 -110.11 0.34 Allowed Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.003 -0.618 . . . . 0.0 112.306 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 11.2 mtt85 -106.48 -70.94 0.77 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.65 0.262 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.52 44.52 1.24 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.172 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.55 -153.64 25.26 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.881 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.641 ' OH ' HG22 ' A' ' 67' ' ' ILE . 16.7 m-85 -131.69 -54.41 1.0 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.772 0.32 . . . . 0.0 111.184 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 146.27 -22.05 1.73 Allowed Glycine 0 CA--C 1.524 0.603 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.908 -179.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.84 163.01 12.79 Favored 'General case' 0 CA--C 1.53 0.203 0 CA-C-O 120.89 0.376 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.26 122.17 46.75 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD21 HD12 ' A' ' 47' ' ' ILE . 0.4 OUTLIER -105.18 125.26 50.78 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.229 -179.844 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.78 110.86 3.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.222 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -165.41 79.21 0.12 Allowed Glycine 0 N--CA 1.445 -0.74 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.893 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -43.89 -45.32 7.5 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.928 0.394 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.963 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -114.74 -66.42 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.402 178.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.963 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 95.0 Cg_endo -87.42 94.35 0.46 Allowed 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 122.606 2.204 . . . . 0.0 112.266 179.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 83.0 m -52.97 115.65 1.96 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.411 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -146.02 145.54 20.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.803 0.335 . . . . 0.0 111.796 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -73.75 90.1 1.84 Allowed 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.365 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -47.29 -51.61 18.61 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.868 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.6 t -154.45 159.36 41.01 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.475 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.5 t -125.21 154.47 33.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.597 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.2 mtp -107.6 104.72 14.32 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.211 0.529 . . . . 0.0 110.264 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -53.09 126.37 20.48 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.884 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.26 24.68 12.14 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.446 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.67 170.81 10.37 Favored Pre-proline 0 CA--C 1.532 0.252 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -47.27 -30.7 11.39 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 123.001 2.468 . . . . 0.0 113.619 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -71.3 -48.4 50.92 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 120.815 0.341 . . . . 0.0 111.029 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -69.59 -30.28 68.01 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.525 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 19.8 m-30 -60.13 -23.69 64.08 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 111.62 0.23 . . . . 0.0 111.62 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.849 HG11 HG13 ' A' ' 6' ' ' VAL . 22.9 t -89.19 -31.31 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.689 0.28 . . . . 0.0 110.897 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.8 36.3 3.26 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.522 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 6.4 mt -69.42 -177.99 1.29 Allowed 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.834 0.35 . . . . 0.0 110.738 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.84 131.94 7.19 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.266 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.43 98.92 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.378 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 148.51 -25.46 1.36 Allowed Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.703 -178.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.558 ' CG ' HD13 ' A' ' 78' ' ' ILE . 12.7 m-20 -56.11 118.46 4.7 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.833 0.316 . . . . 0.0 110.718 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 44.0 mt-30 -77.12 123.01 25.79 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.821 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.792 ' HA ' HG22 ' A' ' 78' ' ' ILE . 31.0 mt -77.91 121.64 31.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.144 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.685 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.977 HD11 ' HB2' ' A' ' 79' ' ' ALA . 2.4 mt -100.4 -46.83 5.11 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.408 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -133.4 138.79 46.43 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.224 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 53' ' ' ILE . 5.6 t -128.91 110.48 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.458 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.6 t-20 76.88 31.04 0.55 Allowed 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -178.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.62 -2.35 1.62 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.836 179.864 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.754 HD11 HD13 ' A' ' 66' ' ' LEU . 1.2 pp -110.49 128.18 66.97 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.057 0.456 . . . . 0.0 111.381 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.4 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -65.27 142.96 58.1 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.609 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.2 m -145.23 62.47 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.453 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -71.16 -37.94 72.19 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.485 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -139.13 32.9 2.13 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.803 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.89 -179.97 5.79 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.558 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.604 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.5 OUTLIER -93.16 135.61 34.19 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.421 0.629 . . . . 0.0 110.728 179.868 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 7.7 t60 -53.91 -43.88 70.09 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.974 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.471 ' HA ' HG22 ' A' ' 64' ' ' VAL . 1.5 mt-10 -62.05 -36.82 82.79 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.945 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.6 -40.66 69.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 59' ' ' SER . 46.3 t -65.59 -43.19 94.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.153 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.532 ' HA ' HD12 ' A' ' 67' ' ' ILE . 30.7 m -65.46 -38.41 82.41 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -57.98 -41.25 82.55 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.053 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.754 HD13 HD11 ' A' ' 53' ' ' ILE . 4.4 mt -68.17 -40.55 82.27 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.694 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.641 HG22 ' OH ' ' A' ' 15' ' ' TYR . 11.2 mt -69.21 -42.22 81.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.592 179.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.44 -4.26 84.11 Favored Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.923 -0.656 . . . . 0.0 113.41 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 7.1 tttt -79.34 -36.49 39.36 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 117.006 0.403 . . . . 0.0 111.647 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.32 -60.85 2.39 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.703 0.287 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 71.69 33.2 1.83 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.62 -49.92 0.01 OUTLIER Glycine 0 C--N 1.332 0.357 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.196 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.6 p -175.27 132.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-O 121.061 0.458 . . . . 0.0 111.691 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.464 HD22 HG12 ' A' ' 67' ' ' ILE . 0.2 OUTLIER -114.83 154.66 28.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.756 179.776 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -109.68 98.45 7.79 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.055 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.49 ' HG2' HG23 ' A' ' 47' ' ' ILE . 13.8 ttm -97.54 128.28 44.16 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.35 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.31 95.64 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.388 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.792 HG22 ' HA ' ' A' ' 47' ' ' ILE . 2.5 pp -100.35 170.82 1.45 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.486 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.977 ' HB2' HD11 ' A' ' 48' ' ' LEU . . . -123.79 143.47 50.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.251 179.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -98.83 167.25 10.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.032 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -144.98 72.25 0.35 Allowed Glycine 0 C--N 1.332 0.317 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.376 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 m -62.75 109.89 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.789 0.328 . . . . 0.0 111.417 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.704 -1.053 . . . . 0.0 112.766 -179.66 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.486 1.084 0 CA-C-O 120.419 0.091 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 69.89 -66.56 0.26 Allowed 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 122.759 0.424 . . . . 0.0 111.409 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 p 42.81 100.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.745 0.818 . . . . 0.0 112.634 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.497 HH21 HG22 ' A' ' 6' ' ' VAL . 4.8 ptm180 -115.39 166.87 11.4 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.26 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -109.22 141.8 40.95 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.951 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.642 HG23 HD11 ' A' ' 78' ' ' ILE . 41.9 t -129.48 131.3 67.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.188 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -115.69 105.77 13.12 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.711 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.695 HG11 ' HB3' ' A' ' 15' ' ' TYR . 3.4 t -86.49 154.11 3.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.894 0.378 . . . . 0.0 111.035 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -112.92 104.99 12.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.935 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -48.36 110.59 0.35 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.714 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.95 -110.7 0.08 OUTLIER Glycine 0 C--N 1.333 0.378 0 C-N-CA 121.101 -0.571 . . . . 0.0 112.675 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.85 -39.89 2.91 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -118.83 36.68 4.35 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.815 0.34 . . . . 0.0 111.468 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.99 -129.21 5.53 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.534 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.695 ' HB3' HG11 ' A' ' 8' ' ' VAL . 98.8 m-85 -131.88 -70.96 0.56 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.663 0.268 . . . . 0.0 111.087 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 152.58 40.62 0.03 OUTLIER Glycine 0 CA--C 1.518 0.252 0 C-N-CA 121.053 -0.594 . . . . 0.0 113.179 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -158.58 -177.76 6.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.561 0.22 . . . . 0.0 110.691 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -134.7 158.02 45.19 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-O 120.775 0.322 . . . . 0.0 111.182 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -138.96 132.07 29.68 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.0 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 p -145.93 165.09 29.98 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 111.344 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 22' ' ' GLN . . . 122.47 -22.98 7.27 Favored Glycine 0 CA--C 1.524 0.627 0 C-N-CA 121.186 -0.53 . . . . 0.0 113.142 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.651 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 70.04 2.52 3.96 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -179.758 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.652 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -168.6 -61.75 0.01 OUTLIER Pre-proline 0 C--O 1.233 0.199 0 C-N-CA 122.162 0.185 . . . . 0.0 110.635 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.652 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 58.4 Cg_endo -69.86 81.4 0.84 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.306 2.004 . . . . 0.0 110.955 178.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.617 ' SG ' HG11 ' A' ' 63' ' ' VAL . 62.0 m -50.39 109.29 0.29 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.071 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.4 141.55 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.717 HD21 HD13 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -75.16 90.68 2.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.389 179.575 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 p -58.99 -38.16 78.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.189 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.1 t -168.17 154.91 7.66 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-O 120.823 0.344 . . . . 0.0 111.438 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.638 HG22 HD23 ' A' ' 27' ' ' LEU . 3.4 t -122.05 154.03 26.49 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.531 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.1 mtm -101.02 100.66 11.29 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.986 0.422 . . . . 0.0 110.52 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.0 mtt180 -51.42 125.75 15.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.749 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.52 26.61 10.67 Favored Glycine 0 CA--C 1.52 0.358 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.339 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.409 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 58.0 m -131.0 162.82 53.26 Favored Pre-proline 0 CA--C 1.529 0.163 0 N-CA-C 110.434 -0.21 . . . . 0.0 110.434 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.512 ' O ' HG23 ' A' ' 39' ' ' VAL . 83.2 Cg_exo -46.75 -31.85 11.25 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.17 2.58 . . . . 0.0 113.296 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.694 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -67.01 -50.0 63.54 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-O 120.814 0.34 . . . . 0.0 110.968 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -70.66 -30.75 67.45 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.13 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 22.6 m-30 -59.58 -23.61 63.07 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.704 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.575 ' CG1' HG13 ' A' ' 6' ' ' VAL . 20.1 t -89.31 -32.3 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-O 120.652 0.263 . . . . 0.0 111.207 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.84 58.63 0.34 Allowed Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.76 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.717 HD13 HD21 ' A' ' 27' ' ' LEU . 17.7 mt -97.25 176.4 5.92 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.791 0.329 . . . . 0.0 110.571 179.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.45 133.39 0.81 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.909 0.385 . . . . 0.0 111.082 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.03 125.72 24.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.909 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.13 -30.59 4.29 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.389 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -62.53 121.27 12.88 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.825 0.345 . . . . 0.0 110.734 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 13.4 tp60 -77.9 118.09 19.88 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.928 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.552 HD11 HD12 ' A' ' 27' ' ' LEU . 19.9 mt -79.45 122.85 35.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.817 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mp -106.8 -41.45 5.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.605 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.497 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -113.82 152.22 30.97 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.864 0.364 . . . . 0.0 111.302 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.81 HG21 HG13 ' A' ' 63' ' ' VAL . 2.7 m -149.42 102.63 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.363 179.463 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 75.65 39.62 0.33 Allowed 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 74.79 -1.23 3.14 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.733 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.653 HD11 HD13 ' A' ' 66' ' ' LEU . 23.8 pt -117.27 132.1 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 111.775 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.497 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 5.0 p-10 -66.92 154.67 40.44 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 121.273 0.559 . . . . 0.0 112.123 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.47 HG11 HG22 ' A' ' 63' ' ' VAL . 9.1 m -149.58 62.9 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.295 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -55.73 -77.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.661 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.8 mtmt -115.72 37.33 3.65 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-O 120.769 0.318 . . . . 0.0 110.969 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' ALA . . . -75.28 -172.6 1.78 Allowed 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.45 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -89.29 135.43 33.58 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-O 121.385 0.612 . . . . 0.0 110.715 179.759 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.759 ' O ' HG23 ' A' ' 64' ' ' VAL . 6.9 t60 -57.35 -44.56 84.43 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.864 -1.062 . . . . 0.0 111.654 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -63.27 -40.19 96.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.649 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.51 -45.34 87.68 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.451 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.81 HG13 HG21 ' A' ' 50' ' ' VAL . 48.7 t -63.49 -42.71 97.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.185 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 60' ' ' HIS . 50.7 t -65.64 -39.45 85.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.23 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -40.05 83.51 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.046 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.653 HD13 HD11 ' A' ' 53' ' ' ILE . 6.4 mt -66.92 -40.16 87.56 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.918 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.682 HD12 ' HA ' ' A' ' 64' ' ' VAL . 7.3 mt -69.12 -41.92 81.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.482 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -73.77 -25.74 71.16 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.633 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 tppt? -53.98 -35.02 61.39 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 t -69.86 -54.15 14.79 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.75 0.309 . . . . 0.0 110.84 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.1 m 63.62 35.7 11.43 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.963 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.99 -43.87 0.02 OUTLIER Glycine 0 C--N 1.33 0.246 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.381 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 8' ' ' VAL . 6.5 p -162.01 134.47 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-O 120.959 0.409 . . . . 0.0 111.535 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.596 HD23 ' CE1' ' A' ' 15' ' ' TYR . 3.8 pp -114.41 154.42 28.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -131.61 116.06 16.9 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.68 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.446 ' CE ' HD13 ' A' ' 74' ' ' LEU . 4.0 mtt -131.92 139.44 48.73 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.88 0.371 . . . . 0.0 111.437 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 29.3 t -103.9 112.85 39.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.977 178.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.642 HD11 HG23 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.53 155.32 8.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.68 -179.193 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -116.85 139.01 51.1 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.285 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -105.38 119.85 40.11 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.661 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -122.73 66.14 0.5 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.449 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.512 ' O ' HG22 ' A' ' 82' ' ' VAL . 8.3 p -114.18 21.08 6.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 120.89 0.376 . . . . 0.0 111.45 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.388 -1.229 . . . . 0.0 112.62 179.783 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.49 1.273 0 CA-C-O 120.624 0.177 . . . . 0.0 111.935 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.47 161.11 14.51 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.096 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.7 p -111.23 115.57 50.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttt180 -115.81 142.74 46.35 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.01 -179.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 m -113.55 129.21 56.6 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.069 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.874 HG11 HD13 ' A' ' 41' ' ' LEU . 20.7 t -116.95 131.66 68.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.817 179.736 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -100.78 100.95 11.69 Favored 'General case' 0 CA--C 1.528 0.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.946 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.505 ' O ' HG23 ' A' ' 73' ' ' VAL . 13.5 t -86.09 108.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.056 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -94.82 91.82 6.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.8 ttt85 -36.55 119.12 0.6 Allowed 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.407 0.442 . . . . 0.0 111.118 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.01 -118.27 0.16 Allowed Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.746 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -113.7 -38.5 4.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.501 0.191 . . . . 0.0 111.338 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -110.34 28.11 8.96 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 124.07 -160.57 18.63 Favored Glycine 0 C--N 1.338 0.677 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.827 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 60.5 m-85 -89.82 -54.24 4.14 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.581 0.229 . . . . 0.0 111.039 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.91 65.05 0.59 Allowed Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.382 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.787 ' HB2' HD21 ' A' ' 27' ' ' LEU . 20.5 p90 -168.03 172.62 8.68 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.643 0.259 . . . . 0.0 111.41 179.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -122.5 159.73 27.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.28 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -149.26 130.07 14.21 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.038 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.93 158.71 38.4 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.782 0.325 . . . . 0.0 111.534 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 131.13 -27.15 3.86 Favored Glycine 0 CA--C 1.526 0.727 0 C-N-CA 121.204 -0.522 . . . . 0.0 113.114 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.529 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 62.01 13.83 5.97 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 -179.825 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.832 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -170.74 -65.62 0.0 OUTLIER Pre-proline 0 N--CA 1.464 0.228 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.832 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.7 Cg_endo -75.84 83.6 1.92 Allowed 'Trans proline' 0 C--N 1.355 0.883 0 C-N-CA 122.359 2.039 . . . . 0.0 111.428 178.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 92.6 m -51.06 111.51 0.57 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.513 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.01 142.26 24.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.411 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.787 HD21 ' HB2' ' A' ' 17' ' ' PHE . 0.1 OUTLIER -83.69 92.53 7.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.483 179.682 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 t -58.28 -38.62 77.33 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.281 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.487 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.9 t -166.09 158.93 14.9 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.893 0.378 . . . . 0.0 111.135 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.599 HG22 HD22 ' A' ' 27' ' ' LEU . 17.2 t -115.15 154.46 16.52 Favored 'Isoleucine or valine' 0 C--O 1.232 0.182 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.638 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 8.7 mmm -89.72 99.29 12.32 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-O 121.342 0.592 . . . . 0.0 110.327 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.28 126.24 20.43 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.966 -1.015 . . . . 0.0 111.175 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.99 27.54 12.27 Favored Glycine 0 CA--C 1.52 0.402 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.606 -179.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -131.26 168.81 15.7 Favored Pre-proline 0 C--O 1.234 0.256 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.518 ' O ' HG23 ' A' ' 39' ' ' VAL . 84.1 Cg_exo -48.58 -34.16 25.83 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 123.036 2.491 . . . . 0.0 113.018 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.595 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -60.16 -48.34 82.12 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.136 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -65.54 -33.2 75.36 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.501 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 14.6 m-30 -64.31 -24.8 67.78 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.411 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 35' ' ' PRO . 21.9 t -89.27 -27.94 5.23 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.782 0.325 . . . . 0.0 110.844 179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.39 32.19 2.61 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.541 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.874 HD13 HG11 ' A' ' 6' ' ' VAL . 6.0 tp -65.17 129.4 39.58 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 120.692 0.282 . . . . 0.0 110.446 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 71.3 mtt-85 -129.5 115.87 18.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.361 -179.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.487 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -57.38 156.83 7.26 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.668 -179.405 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.15 -13.15 63.52 Favored Glycine 0 CA--C 1.522 0.479 0 CA-C-N 115.124 -0.944 . . . . 0.0 112.211 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.83 138.34 35.12 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 110.642 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -83.47 126.42 32.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.457 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.499 HG23 ' HG2' ' A' ' 76' ' ' MET . 12.9 mt -85.4 131.87 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.521 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.525 HD11 ' CB ' ' A' ' 79' ' ' ALA . 5.0 mp -107.71 -39.7 5.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.356 -179.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.487 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -131.27 141.26 49.95 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.1 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.424 HG11 HD11 ' A' ' 67' ' ' ILE . 13.5 t -133.54 110.5 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.874 179.231 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.413 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 2.6 t30 77.07 32.34 0.48 Allowed 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.82 -1.2 2.39 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.535 179.981 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.784 HD11 HD13 ' A' ' 66' ' ' LEU . 13.0 pt -115.29 126.02 72.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.98 0.419 . . . . 0.0 111.794 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -66.87 136.87 56.06 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.511 -179.626 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.455 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 6.4 m -147.86 63.88 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.681 -179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -69.93 -31.69 69.58 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.136 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.0 mtpt -137.63 35.87 2.44 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.455 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -86.64 174.24 9.0 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 120.876 0.369 . . . . 0.0 111.534 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.661 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -81.27 134.75 35.64 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.399 0.619 . . . . 0.0 110.288 179.509 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.73 ' O ' HG23 ' A' ' 64' ' ' VAL . 3.7 t60 -54.73 -44.46 73.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.857 -1.065 . . . . 0.0 112.14 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -61.7 -43.36 99.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.951 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.83 -41.32 91.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.507 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 59' ' ' SER . 55.9 t -65.15 -42.51 94.46 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.001 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 60' ' ' HIS . 60.7 t -65.88 -39.29 84.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.68 -39.88 78.12 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.073 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.784 HD13 HD11 ' A' ' 53' ' ' ILE . 5.7 mt -67.71 -42.01 82.64 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.76 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.592 HG23 HD13 ' A' ' 74' ' ' LEU . 42.2 mt -66.06 -39.93 85.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.723 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.6 6.22 78.37 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.093 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.31 -32.69 16.41 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.857 0.328 . . . . 0.0 111.439 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -64.96 -61.21 2.3 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.784 0.326 . . . . 0.0 110.799 -179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.92 35.11 2.98 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -159.83 -47.14 0.01 OUTLIER Glycine 0 C--N 1.33 0.201 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.291 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -165.33 137.79 0.91 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.984 0.421 . . . . 0.0 111.331 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.592 HD13 HG23 ' A' ' 67' ' ' ILE . 11.1 tp -114.03 142.09 46.62 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.375 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.58 95.74 5.51 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.252 179.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.499 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.8 ttm -98.03 122.33 41.04 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.118 -179.356 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 21.0 t -102.23 96.64 4.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.464 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.492 HG22 ' HA ' ' A' ' 47' ' ' ILE . 2.7 pt -100.27 170.3 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.552 -179.55 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.525 ' CB ' HD11 ' A' ' 48' ' ' LEU . . . -130.83 137.2 49.29 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.234 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -61.55 112.0 2.04 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.147 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -164.12 52.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.504 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.5 m -66.61 103.55 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.237 0 CA-C-O 120.807 0.337 . . . . 0.0 111.4 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.471 -1.183 . . . . 0.0 112.563 -179.927 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.488 1.172 0 CA-C-O 120.638 0.182 . . . . 0.0 111.828 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? 68.43 122.75 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.26 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.507 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.7 p 31.58 100.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.086 0.954 . . . . 0.0 112.843 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 63.3 ttt180 -126.59 134.24 50.85 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.002 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.3 m -96.2 130.65 43.21 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.503 HG13 HG11 ' A' ' 39' ' ' VAL . 25.0 t -123.13 140.16 47.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.372 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.514 ' O ' HG21 ' A' ' 39' ' ' VAL . 4.2 mt-10 -116.94 126.95 53.71 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.144 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 73' ' ' VAL . 20.9 t -125.59 137.75 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.639 179.581 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -100.18 97.54 8.33 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.995 0.426 . . . . 0.0 110.603 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.471 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 2.9 ttt-85 -47.14 121.54 3.83 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.353 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.4 -130.19 1.1 Allowed Glycine 0 C--N 1.334 0.448 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.512 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.1 mtt180 -111.93 -39.57 4.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.413 0.149 . . . . 0.0 111.258 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.38 26.85 9.71 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.68 0.252 . . . . 0.0 111.68 179.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 122.67 -179.89 16.03 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.924 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.471 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 91.3 m-85 -83.97 -34.01 24.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.585 0.231 . . . . 0.0 111.18 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 107.84 47.96 0.93 Allowed Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.284 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.416 ' HA ' ' HA ' ' A' ' 30' ' ' VAL . 20.6 p90 -168.67 153.87 6.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 111.063 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.5 m -98.88 128.2 45.0 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.92 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -106.18 126.92 52.81 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.181 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.0 m -147.84 130.45 15.91 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.517 178.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.67 73.36 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.276 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.1 tp60 -44.96 -43.48 9.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.799 0.333 . . . . 0.0 110.576 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.966 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -110.98 -64.56 0.03 OUTLIER Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.021 178.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.966 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.0 Cg_endo -91.74 92.7 0.21 Allowed 'Trans proline' 0 C--N 1.358 1.042 0 C-N-CA 122.943 2.428 . . . . 0.0 111.912 179.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 7.7 p -53.36 118.75 4.07 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.936 -179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 45' ' ' ASP . 7.1 p -146.68 145.3 19.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.256 -179.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.568 HD12 HD11 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -74.96 90.39 2.43 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.845 0.355 . . . . 0.0 110.496 179.603 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -53.98 -35.74 62.14 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.625 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.1 t -165.26 161.75 19.41 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.723 0.297 . . . . 0.0 110.988 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.45 HG22 HD23 ' A' ' 27' ' ' LEU . 38.0 t -131.19 152.5 37.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.877 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.4 mmt -90.24 99.66 12.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-O 121.338 0.59 . . . . 0.0 110.342 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.97 121.81 8.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.935 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.08 26.01 8.08 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.561 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -128.95 171.75 8.21 Favored Pre-proline 0 CA--C 1.532 0.269 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.441 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 77.7 Cg_exo -48.91 -30.51 17.73 Favored 'Trans proline' 0 C--N 1.352 0.737 0 C-N-CA 122.847 2.365 . . . . 0.0 113.128 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -69.05 -50.23 50.41 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.142 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.97 -31.86 73.3 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.42 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.441 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 17.7 m-30 -60.12 -30.71 69.45 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.198 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.514 HG21 ' O ' ' A' ' 7' ' ' GLU . 22.3 t -89.72 -24.37 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.107 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 115.22 17.56 6.65 Favored Glycine 0 CA--C 1.523 0.57 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.153 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.56 HD21 HD13 ' A' ' 78' ' ' ILE . 3.4 mt -78.87 123.21 27.01 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 117.019 0.409 . . . . 0.0 110.303 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.1 mtp85 -130.48 -149.9 0.41 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -107.76 127.53 53.77 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.594 -0.275 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.7 -22.44 5.8 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 120.78 -0.724 . . . . 0.0 113.017 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.403 ' HB3' HD12 ' A' ' 78' ' ' ILE . 6.5 m-20 -73.29 121.66 20.74 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 116.924 0.362 . . . . 0.0 110.948 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -82.45 128.04 33.87 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.526 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.696 ' HA ' HG22 ' A' ' 78' ' ' ILE . 6.0 mt -85.32 125.29 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.445 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.7 mm? -103.05 -39.41 6.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.939 -179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.535 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.91 145.81 50.83 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.239 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.669 HG21 HG13 ' A' ' 63' ' ' VAL . 42.8 t -132.97 111.72 17.18 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.926 179.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.415 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 0.1 OUTLIER 76.5 32.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.655 -178.458 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.53 -2.03 1.64 Allowed 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.11 -0.95 . . . . 0.0 112.732 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.678 HD11 HD13 ' A' ' 66' ' ' LEU . 20.4 pt -113.73 125.58 71.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-O 120.838 0.352 . . . . 0.0 111.421 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.535 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.7 OUTLIER -60.3 125.51 23.96 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.95 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.497 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 3.7 m -146.95 40.65 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.415 ' HB3' ' HA ' ' A' ' 48' ' ' LEU . 0.0 OUTLIER -61.58 -29.93 70.35 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.794 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.0 mttp -119.85 29.56 7.49 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.322 179.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.497 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -88.27 -174.13 4.5 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 111.573 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.615 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -91.34 140.68 29.54 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.406 0.622 . . . . 0.0 110.742 179.675 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.766 ' O ' HG23 ' A' ' 64' ' ' VAL . 2.0 t-160 -52.86 -44.56 66.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.721 -1.127 . . . . 0.0 111.764 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.61 -39.52 91.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.665 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.01 -42.46 94.42 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.584 179.252 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.669 HG13 HG21 ' A' ' 50' ' ' VAL . 44.4 t -64.82 -42.45 94.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.122 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.766 HG23 ' O ' ' A' ' 60' ' ' HIS . 41.7 t -65.85 -39.19 84.01 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 178.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 3.2 ttmt -57.68 -40.73 80.09 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.093 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.678 HD13 HD11 ' A' ' 53' ' ' ILE . 17.7 mt -66.88 -42.82 84.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.763 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.702 HG23 ' HG ' ' A' ' 74' ' ' LEU . 25.2 mt -66.79 -40.6 86.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.97 179.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -70.21 -17.1 73.72 Favored Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.015 -0.612 . . . . 0.0 113.131 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -66.79 -42.09 86.55 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -67.62 -57.88 5.65 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.793 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.7 p 62.49 28.02 16.56 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.463 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -152.59 -40.48 0.03 OUTLIER Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.176 -0.535 . . . . 0.0 112.67 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 8' ' ' VAL . 6.5 p -150.53 138.58 14.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.089 0.471 . . . . 0.0 111.333 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.702 ' HG ' HG23 ' A' ' 67' ' ' ILE . 0.5 OUTLIER -102.81 138.02 40.25 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.952 -179.866 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -130.66 95.06 3.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 3.0 mtt -117.32 140.92 48.95 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.529 -179.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.505 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 22.0 t -104.86 95.19 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.237 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.696 HG22 ' HA ' ' A' ' 47' ' ' ILE . 16.6 pt -99.17 159.97 3.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.22 -179.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.82 147.83 45.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.492 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.84 111.38 23.59 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.861 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -148.41 50.77 0.57 Allowed Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.379 179.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.2 p -131.26 145.14 35.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.63 0.252 . . . . 0.0 111.12 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.718 -1.046 . . . . 0.0 113.054 -179.863 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.408 ' HD2' ' O ' ' A' ' 80' ' ' GLU . 3.4 Cg_endo . . . . . 0 N--CA 1.488 1.199 0 CA-C-O 120.435 0.098 . . . . 0.0 111.877 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 57.56 52.13 8.78 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.077 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.3 p -60.51 122.98 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.078 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -139.12 166.61 24.06 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.321 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -105.07 132.92 50.7 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.26 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.576 HG23 HG12 ' A' ' 78' ' ' ILE . 29.0 t -106.58 131.19 57.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.819 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 74' ' ' LEU . 1.6 mt-10 -118.83 116.57 26.8 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.543 HG11 ' HB3' ' A' ' 15' ' ' TYR . 3.7 t -110.01 133.97 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 111.421 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -88.67 94.05 9.77 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.93 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.455 ' HB2' ' CE2' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -48.47 121.03 4.08 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.176 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.45 -85.62 0.12 Allowed Glycine 0 C--N 1.335 0.501 0 C-N-CA 121.042 -0.599 . . . . 0.0 112.383 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 -145.98 -53.77 0.26 Allowed 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.633 0.254 . . . . 0.0 111.013 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.18 28.91 8.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.535 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.37 164.79 11.16 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.709 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.543 ' HB3' HG11 ' A' ' 8' ' ' VAL . 73.3 m-85 -88.93 -66.77 0.89 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.84 0.352 . . . . 0.0 110.64 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.22 55.82 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 121.027 -0.606 . . . . 0.0 112.73 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -166.54 149.12 6.73 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.753 0.311 . . . . 0.0 110.93 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.82 109.43 22.12 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.03 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 6.2 tt -108.44 140.41 41.79 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.826 -179.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.437 ' HA ' ' CE1' ' A' ' 60' ' ' HIS . 22.7 m -150.35 161.44 42.48 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.457 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.78 81.35 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.313 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.5 mm100 -47.41 -40.48 17.91 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.606 0.241 . . . . 0.0 110.775 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.949 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -113.73 -63.41 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.279 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.332 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.949 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 90.9 Cg_endo -89.92 94.04 0.3 Allowed 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.812 2.341 . . . . 0.0 111.739 179.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.593 ' SG ' HG23 ' A' ' 55' ' ' VAL . 6.0 p -52.29 117.16 2.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.72 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.1 p -134.83 144.31 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.643 -179.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.58 92.74 9.22 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.084 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -57.16 -52.67 64.39 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.02 -179.308 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.546 ' HA ' ' HB1' ' A' ' 43' ' ' ALA . 0.6 OUTLIER -148.14 162.3 39.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.444 -179.594 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 10.9 t -121.19 153.73 24.82 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.129 179.304 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -94.56 99.96 12.02 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.24 0.543 . . . . 0.0 110.771 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 7.2 mtt180 -55.06 126.48 24.83 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.014 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 99.66 -16.29 58.88 Favored Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.888 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.614 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.4 m -89.64 166.38 21.22 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.841 0.32 . . . . 0.0 110.343 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.614 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 9.2 Cg_endo -51.25 -26.76 21.08 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.928 2.419 . . . . 0.0 113.441 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.19 76.76 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.849 0.357 . . . . 0.0 110.77 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.83 -26.57 63.35 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.207 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.2 m-30 -59.43 -23.66 62.86 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.42 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.542 HG11 HG13 ' A' ' 6' ' ' VAL . 21.4 t -89.27 -30.15 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 116.662 -0.244 . . . . 0.0 111.06 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 104.71 45.4 1.41 Allowed Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.496 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.452 ' HG ' HG11 ' A' ' 6' ' ' VAL . 6.4 mt -72.48 -178.95 2.77 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-O 120.726 0.298 . . . . 0.0 110.569 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 44.9 mtp85 -142.01 112.74 7.28 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.291 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.546 ' HB1' ' HA ' ' A' ' 29' ' ' CYS . . . -64.85 103.56 0.73 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.527 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.63 -10.55 5.77 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.266 -179.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -81.02 165.49 21.65 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.834 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.02 156.33 17.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.534 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 4.2 mt -109.11 146.25 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.589 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 mp -118.92 -57.49 2.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.893 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -109.08 139.28 44.19 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.008 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.42 HG23 ' CG2' ' A' ' 55' ' ' VAL . 2.9 t -138.97 110.35 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.406 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.9 t-20 75.97 35.86 0.47 Allowed 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.406 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.1 OUTLIER 75.08 -0.39 3.33 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.808 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.618 HD11 HD22 ' A' ' 66' ' ' LEU . 8.5 pt -119.68 133.66 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-O 120.92 0.39 . . . . 0.0 111.388 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -69.74 150.84 46.5 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.67 -179.515 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.607 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 2.4 m -150.11 56.85 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.647 -179.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.2 mmtp -60.19 -40.42 89.98 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.455 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.0 mtmp? -130.01 31.96 4.6 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.658 0.266 . . . . 0.0 111.421 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.607 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -79.6 176.51 9.64 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 120.716 0.293 . . . . 0.0 111.144 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.619 ' O ' HG23 ' A' ' 63' ' ' VAL . 2.9 m -95.8 147.19 23.9 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.581 0.705 . . . . 0.0 111.355 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.437 ' CE1' ' HA ' ' A' ' 20' ' ' SER . 2.7 t-160 -56.11 -41.85 75.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.325 -1.307 . . . . 0.0 111.445 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.474 ' HA ' HG12 ' A' ' 64' ' ' VAL . 11.4 pt-20 -64.21 -41.09 97.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.904 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -69.79 -42.07 74.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.916 0.389 . . . . 0.0 110.366 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.619 HG23 ' O ' ' A' ' 59' ' ' SER . 55.5 t -67.71 -42.35 86.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.027 179.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.474 HG12 ' HA ' ' A' ' 61' ' ' GLU . 7.3 p -66.61 -39.1 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -57.94 -40.13 79.75 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.158 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.618 HD22 HD11 ' A' ' 53' ' ' ILE . 15.0 mt -66.28 -42.85 87.85 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.741 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.627 HG23 HD13 ' A' ' 74' ' ' LEU . 33.5 mt -66.62 -40.71 86.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.623 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -85.39 8.27 72.17 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.184 179.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -91.7 -32.63 15.36 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 116.828 0.314 . . . . 0.0 111.293 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.67 -55.04 19.61 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.963 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 m 64.5 36.17 8.89 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.859 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.87 -44.05 0.02 OUTLIER Glycine 0 C--N 1.332 0.338 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.414 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -163.39 139.13 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.129 0 CA-C-O 120.959 0.409 . . . . 0.0 111.384 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.627 HD13 HG23 ' A' ' 67' ' ' ILE . 62.8 tp -103.15 136.26 43.27 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.049 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 23.0 m170 -127.13 101.37 6.49 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.411 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.595 ' SD ' HD21 ' A' ' 74' ' ' LEU . 13.7 ptm -132.83 141.52 48.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.47 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.9 t -91.23 120.63 40.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.79 179.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.576 HG12 HG23 ' A' ' 6' ' ' VAL . 15.0 pt -99.33 170.17 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.35 148.88 30.04 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.284 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.408 ' O ' ' HD2' ' A' ' 1' ' ' PRO . 0.6 OUTLIER -98.21 163.84 12.56 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.322 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -154.61 31.98 0.69 Allowed Glycine 0 CA--C 1.52 0.378 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.793 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 82' ' ' VAL . 8.4 t -136.53 34.12 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-O 121.056 0.455 . . . . 0.0 110.939 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.284 -1.286 . . . . 0.0 112.703 -179.842 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.489 1.22 0 CA-C-O 120.85 0.271 . . . . 0.0 111.882 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 48.7 mtp180 -111.93 155.63 23.38 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.097 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.3 p -90.66 128.3 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.296 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.8 ttt180 -123.04 126.87 47.93 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -97.8 120.84 38.9 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.754 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.771 HG11 ' HG ' ' A' ' 41' ' ' LEU . 20.9 t -114.2 131.58 65.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.512 ' O ' HG21 ' A' ' 39' ' ' VAL . 3.1 mt-10 -115.6 112.92 22.87 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.902 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 t -94.57 134.14 33.09 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 CA-C-O 120.877 0.37 . . . . 0.0 111.221 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -102.17 97.64 7.91 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.687 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.431 ' HB2' ' CE1' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -47.81 118.38 2.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.006 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.92 -107.54 0.08 OUTLIER Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.553 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.8 mtt180 -123.67 -46.75 1.99 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.633 0.254 . . . . 0.0 111.046 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -127.01 41.79 3.45 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.651 179.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 158.4 -179.64 33.93 Favored Glycine 0 C--N 1.334 0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.14 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.431 ' CE1' ' HB2' ' A' ' 10' ' ' ARG . 8.7 m-85 -111.41 -40.74 4.3 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.595 0.236 . . . . 0.0 111.349 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.96 23.69 5.17 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.285 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -157.26 156.24 32.15 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.997 0.398 . . . . 0.0 110.933 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.0 m -111.01 135.61 51.26 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.861 0.362 . . . . 0.0 111.239 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.484 HD22 ' CE1' ' A' ' 60' ' ' HIS . 0.4 OUTLIER -119.18 129.09 54.81 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.043 179.898 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.6 m -151.7 176.05 11.77 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.125 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.55 -46.32 1.13 Allowed Glycine 0 C--N 1.335 0.497 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.38 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.437 ' O ' ' HB2' ' A' ' 23' ' ' ALA . 0.0 OUTLIER 55.13 39.43 31.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.877 0.471 . . . . 0.0 112.09 179.489 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.758 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . 174.53 -61.64 0.0 OUTLIER Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.636 179.476 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.758 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 73.1 Cg_endo -75.17 -27.43 9.75 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.598 2.199 . . . . 0.0 113.127 179.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.401 ' CB ' ' HB ' ' A' ' 47' ' ' ILE . 18.4 m 56.79 93.44 0.03 OUTLIER 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.509 0.671 . . . . 0.0 109.788 -179.002 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.834 HG13 ' HA ' ' A' ' 46' ' ' GLN . 0.8 OUTLIER -146.75 144.21 20.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.973 -178.95 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.32 122.33 16.87 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.487 179.703 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.4 m -82.42 -41.53 19.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.196 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.559 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 25.3 t -173.09 152.44 2.31 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.364 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.413 HG21 ' HB3' ' A' ' 41' ' ' LEU . 5.2 t -118.04 155.19 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.753 179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 27.4 mmm -98.41 100.95 12.26 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.204 0.526 . . . . 0.0 110.422 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mtt-85 -50.85 124.58 11.44 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.069 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 98.02 24.51 11.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.553 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -123.76 165.98 20.98 Favored Pre-proline 0 C--O 1.232 0.148 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.432 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 10.4 Cg_endo -53.58 -26.99 39.3 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.781 2.32 . . . . 0.0 112.747 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.691 ' HB1' HD12 ' A' ' 41' ' ' LEU . . . -69.48 -49.18 57.18 Favored 'General case' 0 CA--C 1.528 0.121 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.002 179.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -67.05 -31.99 72.88 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.304 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.432 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 20.4 m-30 -59.47 -23.46 62.75 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.557 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.512 HG21 ' O ' ' A' ' 7' ' ' GLU . 21.9 t -89.38 -30.12 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.684 0.278 . . . . 0.0 111.253 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.79 68.13 0.54 Allowed Glycine 0 C--N 1.334 0.45 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.413 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.771 ' HG ' HG11 ' A' ' 6' ' ' VAL . 5.5 mt -102.31 162.35 12.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.795 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.9 mmt180 -148.55 119.66 7.73 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.559 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -57.08 111.8 1.16 Allowed 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.835 179.546 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.44 -12.88 7.02 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.874 -179.49 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.562 ' CB ' HD12 ' A' ' 78' ' ' ILE . 0.1 OUTLIER -66.94 112.1 4.14 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.825 0.312 . . . . 0.0 110.52 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . 0.834 ' HA ' HG13 ' A' ' 26' ' ' VAL . 1.1 tt0 -55.45 125.7 22.04 Favored 'General case' 0 CA--C 1.53 0.173 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.71 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.643 ' HA ' HG22 ' A' ' 78' ' ' ILE . 66.7 mt -82.25 123.96 38.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.574 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 5.0 mp -107.81 -41.2 5.06 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.54 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -136.46 144.4 44.38 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.73 0.3 . . . . 0.0 111.102 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.493 HG13 ' HG2' ' A' ' 76' ' ' MET . 8.3 t -140.97 116.2 6.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.434 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 6.7 t-20 76.96 30.75 0.55 Allowed 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.434 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 80.78 -1.92 1.84 Allowed 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 115.239 -0.892 . . . . 0.0 112.706 179.631 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.822 HD11 ' CD1' ' A' ' 66' ' ' LEU . 1.6 pt -117.4 134.56 60.59 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.936 0.398 . . . . 0.0 111.635 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.1 m120 -63.1 152.51 36.97 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.572 -179.584 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.58 HG11 HG22 ' A' ' 63' ' ' VAL . 2.8 m -152.02 47.75 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.435 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.9 mttt -56.21 -40.12 73.53 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.215 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -137.72 31.98 2.5 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.005 179.445 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.452 ' CB ' HG12 ' A' ' 55' ' ' VAL . . . -75.86 -177.7 3.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.878 0.371 . . . . 0.0 111.604 -179.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.654 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -92.93 135.78 33.85 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.361 0.6 . . . . 0.0 110.703 179.705 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.747 ' O ' HG23 ' A' ' 64' ' ' VAL . 5.5 t60 -55.9 -44.39 78.17 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.783 -1.098 . . . . 0.0 111.883 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -61.58 -39.41 91.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.439 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -67.52 -43.07 81.7 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.225 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 59' ' ' SER . 48.4 t -63.79 -40.96 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.932 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.747 HG23 ' O ' ' A' ' 60' ' ' HIS . 48.8 t -65.97 -38.83 82.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 178.674 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -57.76 -42.64 84.45 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.822 ' CD1' HD11 ' A' ' 53' ' ' ILE . 12.0 mt -63.63 -42.26 98.19 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.647 179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.63 HG23 HD22 ' A' ' 74' ' ' LEU . 35.8 mt -63.42 -44.18 98.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.635 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.3 -12.52 84.14 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.793 179.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 41.3 tptt -68.19 -37.41 80.91 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -70.7 -52.46 20.9 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-O 120.811 0.339 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m 63.8 35.73 10.96 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.742 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.22 -44.35 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.295 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.3 p -163.15 138.24 1.4 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-O 121.014 0.435 . . . . 0.0 111.335 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.63 HD22 HG23 ' A' ' 67' ' ' ILE . 24.2 tp -114.24 146.79 39.95 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.376 -179.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.474 ' CD2' ' HG2' ' A' ' 7' ' ' GLU . 48.1 m80 -119.6 103.22 9.22 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.177 179.164 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.493 ' HG2' HG13 ' A' ' 50' ' ' VAL . 59.0 mtp -109.14 142.09 40.41 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.671 -179.272 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.3 t -115.06 97.05 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.926 178.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.643 HG22 ' HA ' ' A' ' 47' ' ' ILE . 10.3 pt -105.78 170.74 2.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.64 -179.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -136.94 145.73 44.59 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.941 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -86.43 112.89 21.92 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.774 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -106.45 46.31 1.19 Allowed Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.456 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -119.41 131.85 70.87 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-O 120.734 0.302 . . . . 0.0 110.858 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.694 -1.059 . . . . 0.0 112.976 -179.804 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.493 1.499 0 CA-C-O 120.419 0.091 . . . . 0.0 112.221 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.61 -46.93 3.72 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.533 -179.74 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.2 p 44.33 101.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.955 0.902 . . . . 0.0 112.636 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.26 146.66 47.08 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.727 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.1 m -102.21 154.73 18.75 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.213 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.699 HG11 ' HG ' ' A' ' 41' ' ' LEU . 20.3 t -140.29 136.2 36.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.355 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.428 ' O ' HG21 ' A' ' 39' ' ' VAL . 25.6 mt-10 -104.7 111.15 23.76 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.725 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.605 ' O ' HG23 ' A' ' 73' ' ' VAL . 6.7 t -104.43 119.94 54.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.251 0 CA-C-O 120.865 0.364 . . . . 0.0 111.475 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -90.32 92.28 8.85 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.066 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -49.5 125.07 10.51 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.646 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.69 -112.44 0.07 OUTLIER Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.818 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -115.39 -39.33 3.6 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.435 0.16 . . . . 0.0 111.328 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.9 30.61 6.38 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.388 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.59 -173.09 16.6 Favored Glycine 0 C--N 1.337 0.616 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.808 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.524 ' HD1' HG12 ' A' ' 8' ' ' VAL . 79.2 m-85 -79.34 -61.91 1.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.941 0.401 . . . . 0.0 111.013 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.43 59.22 0.26 Allowed Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.452 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.507 ' CD1' HD21 ' A' ' 27' ' ' LEU . 19.7 p90 -153.13 151.01 29.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 0.0 110.955 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -98.3 111.42 23.76 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.442 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.465 HD23 ' N ' ' A' ' 20' ' ' SER . 0.8 OUTLIER -99.95 133.49 44.25 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.951 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.465 ' N ' HD23 ' A' ' 19' ' ' LEU . 1.5 p -149.58 -174.26 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.762 179.697 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 107.28 85.43 1.77 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.3 -60.09 2.08 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.942 0.401 . . . . 0.0 110.799 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.892 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.41 -60.61 0.19 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.221 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.892 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.2 Cg_endo -87.69 95.35 0.44 Allowed 'Trans proline' 0 C--N 1.356 0.938 0 C-N-CA 122.692 2.261 . . . . 0.0 112.209 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 71.6 m -55.27 118.64 4.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.477 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.4 p -143.53 152.94 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.854 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.551 HD11 ' CE ' ' A' ' 76' ' ' MET . 1.0 OUTLIER -89.41 92.95 9.34 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.473 179.377 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -51.46 -39.93 58.43 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.504 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.67 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.6 t -169.07 161.43 10.46 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.961 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.432 HG13 ' HB3' ' A' ' 17' ' ' PHE . 18.5 t -124.8 154.35 32.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.431 179.556 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.3 mmt -85.58 98.0 10.4 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.227 0.537 . . . . 0.0 110.399 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.85 122.61 6.76 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.853 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.31 21.23 11.86 Favored Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.703 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.42 ' HB2' ' HD2' ' A' ' 35' ' ' PRO . 0.9 OUTLIER -115.31 166.68 11.43 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.712 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.443 ' HA ' ' CD2' ' A' ' 38' ' ' PHE . 9.7 Cg_endo -51.75 -29.55 34.25 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.962 2.441 . . . . 0.0 112.77 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.8 -46.19 46.89 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.992 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -64.01 -32.3 73.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.069 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.443 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.1 m-30 -60.04 -28.07 67.45 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.39 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.439 HG11 HG13 ' A' ' 6' ' ' VAL . 18.3 t -89.48 -26.21 5.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-O 120.469 0.176 . . . . 0.0 111.241 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.63 1.13 7.13 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.639 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.699 ' HG ' HG11 ' A' ' 6' ' ' VAL . 12.0 mt -67.93 116.96 9.18 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 117.378 0.589 . . . . 0.0 110.449 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.01 -150.36 0.43 Allowed 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.006 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.67 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -105.29 146.29 29.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.636 0.255 . . . . 0.0 111.299 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.82 -16.97 33.22 Favored Glycine 0 CA--C 1.523 0.56 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.152 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.434 ' CG ' HD12 ' A' ' 78' ' ' ILE . 1.3 m-20 -84.57 128.31 34.53 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 117.122 0.461 . . . . 0.0 110.822 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -82.38 134.01 35.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.486 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.42 ' CG2' HG22 ' A' ' 50' ' ' VAL . 22.7 mt -85.82 122.57 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.798 179.776 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -106.57 -47.55 3.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -124.08 136.25 54.11 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.993 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.42 HG22 ' CG2' ' A' ' 47' ' ' ILE . 3.0 t -135.51 105.71 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.096 179.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 75.92 37.8 0.37 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 72.32 -0.56 3.23 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.834 -179.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.665 ' CD1' HD22 ' A' ' 66' ' ' LEU . 8.0 pt -113.96 119.39 61.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 120.955 0.407 . . . . 0.0 111.01 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.493 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.0 m120 -68.53 130.32 42.53 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.081 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 63' ' ' VAL . 24.3 m -124.03 52.3 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.095 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.0 mttm -55.45 -45.65 76.83 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.543 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -136.48 32.42 2.8 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.095 179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.37 177.85 7.62 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 120.805 0.336 . . . . 0.0 111.275 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.676 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.7 OUTLIER -80.73 133.67 35.71 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-O 121.418 0.628 . . . . 0.0 110.665 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.704 ' O ' HG23 ' A' ' 64' ' ' VAL . 1.4 t-160 -54.49 -44.78 72.95 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.772 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -65.13 -41.91 94.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.693 179.547 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -64.34 -42.47 96.25 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.712 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 59' ' ' SER . 54.9 t -63.5 -43.34 98.3 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.124 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.704 HG23 ' O ' ' A' ' 60' ' ' HIS . 47.1 t -66.03 -39.73 85.34 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.162 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -58.79 -40.46 84.11 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.01 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.665 HD22 ' CD1' ' A' ' 53' ' ' ILE . 7.1 mt -65.53 -40.86 93.4 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.195 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 26.2 mt -69.55 -40.48 79.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.866 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -59.83 -27.82 64.87 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.278 179.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.69 -19.79 62.02 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.51 0.324 . . . . 0.0 111.668 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -98.54 100.89 12.18 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.408 0.623 . . . . 0.0 110.219 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.2 m -99.64 -29.16 12.83 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.975 -1.011 . . . . 0.0 111.663 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.05 -50.93 7.25 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.139 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.5 p -177.12 134.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.841 0.353 . . . . 0.0 111.487 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.408 ' HB2' ' OH ' ' A' ' 15' ' ' TYR . 1.2 tp -114.32 141.29 47.79 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.073 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -114.01 104.67 12.37 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.163 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.551 ' CE ' HD11 ' A' ' 27' ' ' LEU . 0.8 OUTLIER -107.19 148.5 28.8 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.211 -179.543 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.33 105.43 18.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.721 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.434 HD12 ' CG ' ' A' ' 45' ' ' ASP . 7.8 pt -100.98 173.58 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.208 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -155.86 124.73 6.05 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.666 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.32 120.84 41.16 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.639 179.206 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 128.27 -114.98 1.94 Allowed Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.187 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.6 t 57.2 90.39 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-O 121.034 0.445 . . . . 0.0 111.819 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.369 -1.239 . . . . 0.0 112.481 179.722 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo . . . . . 0 N--CA 1.49 1.272 0 N-CA-C 112.415 0.121 . . . . 0.0 112.415 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -61.72 89.21 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.925 0.393 . . . . 0.0 111.2 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.4 t -138.27 138.67 42.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.12 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -139.2 169.24 18.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.402 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -116.66 144.57 44.25 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.99 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.778 HG11 ' CD1' ' A' ' 41' ' ' LEU . 20.6 t -113.39 140.44 33.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.31 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.702 ' O ' HG21 ' A' ' 39' ' ' VAL . 30.8 mt-10 -112.68 108.05 16.94 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.973 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.7 t -102.66 126.23 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 111.277 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -92.39 92.24 8.03 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.979 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.468 ' HG3' ' CZ ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -52.92 122.53 9.44 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.972 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.83 -65.93 3.08 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 121.162 -0.542 . . . . 0.0 112.665 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -163.54 -48.74 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.568 0.223 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -131.93 26.36 4.62 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.455 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 179.71 164.69 32.49 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.607 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.674 ' CE2' HG22 ' A' ' 67' ' ' ILE . 40.1 m-85 -107.91 -73.72 0.68 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.65 0.262 . . . . 0.0 111.373 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.39 50.83 0.04 OUTLIER Glycine 0 C--N 1.33 0.242 0 C-N-CA 121.142 -0.552 . . . . 0.0 112.425 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.4 ' HB2' ' CD2' ' A' ' 27' ' ' LEU . 37.6 p90 -167.14 -177.08 3.57 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.428 0.156 . . . . 0.0 110.754 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -133.68 145.1 49.62 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 120.822 0.344 . . . . 0.0 111.353 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.4 mt -128.72 123.48 33.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.945 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.5 m -135.83 14.81 3.36 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.26 -0.427 . . . . 0.0 112.101 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -84.86 85.2 1.57 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.035 -0.603 . . . . 0.0 112.131 179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.02 -63.24 0.9 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 120.837 0.351 . . . . 0.0 111.074 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.24 -61.04 0.18 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.146 178.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.88 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 98.5 Cg_endo -86.75 93.26 0.53 Allowed 'Trans proline' 0 C--N 1.353 0.793 0 C-N-CA 122.825 2.35 . . . . 0.0 111.764 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.503 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.5 m -54.46 121.14 7.71 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.884 0.373 . . . . 0.0 110.806 -179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.4 p -145.79 146.74 19.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.85 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.589 HD22 HD23 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -81.55 92.24 6.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.707 179.843 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.83 -34.82 63.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.317 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.732 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 1.3 t -169.72 160.47 8.77 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 111.242 179.612 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.416 HG21 ' HB3' ' A' ' 41' ' ' LEU . 4.7 t -116.52 154.1 18.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.745 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 12.1 mmm -99.22 99.24 10.18 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 121.101 0.477 . . . . 0.0 110.818 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -50.2 126.85 15.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.118 -0.946 . . . . 0.0 111.276 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 97.05 24.2 13.37 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.028 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.458 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -127.52 169.58 12.05 Favored Pre-proline 0 C--N 1.33 -0.253 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.265 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.552 ' O ' HG23 ' A' ' 39' ' ' VAL . 19.3 Cg_endo -58.13 -17.7 33.19 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.673 2.248 . . . . 0.0 113.043 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.951 ' HB1' HD22 ' A' ' 41' ' ' LEU . . . -70.59 -50.91 32.18 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -72.07 -29.83 64.52 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.229 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.433 ' CD2' ' HA ' ' A' ' 35' ' ' PRO . 18.7 m-30 -59.18 -27.5 65.75 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.616 -0.266 . . . . 0.0 110.973 179.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.702 HG21 ' O ' ' A' ' 7' ' ' GLU . 22.4 t -89.64 -50.31 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.12 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.762 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 146.65 46.77 0.03 OUTLIER Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.068 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.951 HD22 ' HB1' ' A' ' 36' ' ' ALA . 1.0 OUTLIER -89.31 134.25 34.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.665 0.269 . . . . 0.0 110.412 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 16.4 mmt180 -144.91 120.38 10.34 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.732 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -45.97 125.74 6.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.449 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 125.33 -26.95 5.4 Favored Glycine 0 CA--C 1.517 0.189 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.322 -179.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.4 ' CG ' HD12 ' A' ' 78' ' ' ILE . 0.7 OUTLIER -67.1 121.1 14.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 120.593 0.235 . . . . 0.0 110.682 179.731 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.43 127.69 32.96 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.77 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.478 HG21 HG22 ' A' ' 50' ' ' VAL . 18.9 mt -82.65 119.31 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.569 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -97.11 -42.22 7.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -127.84 140.85 51.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.007 179.691 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.504 HG23 ' CG2' ' A' ' 55' ' ' VAL . 21.5 t -133.14 112.52 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.13 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.411 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 1.4 t30 76.34 31.06 0.64 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.672 -178.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 81.77 -3.76 1.57 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 115.174 -0.921 . . . . 0.0 112.713 179.64 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.501 HD12 HG13 ' A' ' 55' ' ' VAL . 1.1 pp -114.45 128.93 71.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.016 0.436 . . . . 0.0 111.397 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.561 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 3.1 m120 -64.27 132.69 51.0 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.439 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.58 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 7.8 m -136.36 58.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.452 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? -62.51 -40.2 95.98 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.422 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -132.92 31.11 3.94 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.208 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.58 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -78.04 179.92 6.5 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.771 0.32 . . . . 0.0 111.548 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.734 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.14 135.47 33.42 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.305 0.574 . . . . 0.0 110.951 179.881 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.76 ' O ' HG23 ' A' ' 64' ' ' VAL . 7.4 t60 -54.46 -44.63 72.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.815 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -62.63 -43.35 99.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.504 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -64.22 -41.38 97.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.543 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 59' ' ' SER . 47.0 t -64.94 -43.52 96.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.988 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.76 HG23 ' O ' ' A' ' 60' ' ' HIS . 45.0 t -65.76 -39.34 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -57.97 -40.98 81.94 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.01 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.625 HD12 ' HA ' ' A' ' 63' ' ' VAL . 4.5 mt -66.22 -42.43 88.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.668 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.799 HG23 HD13 ' A' ' 74' ' ' LEU . 18.5 mt -65.52 -42.92 94.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.51 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -77.98 -15.04 81.66 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.945 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -65.13 -39.79 93.56 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -62.72 -55.25 28.42 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.4 ' HA ' ' NH1' ' A' ' 10' ' ' ARG . 0.3 OUTLIER 65.94 35.03 6.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.903 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.29 -44.24 0.02 OUTLIER Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.554 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.7 p -160.72 138.86 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.784 0.326 . . . . 0.0 111.642 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.799 HD13 HG23 ' A' ' 67' ' ' ILE . 33.0 tp -105.8 143.18 34.31 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -128.56 96.8 4.5 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.191 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -121.66 154.59 36.62 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.43 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.1 t -111.63 110.87 33.77 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.746 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.428 HG12 HG23 ' A' ' 6' ' ' VAL . 7.6 pt -105.51 145.38 13.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.322 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -111.23 134.35 52.88 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.291 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -103.08 133.83 47.54 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 69.65 85.24 0.14 Allowed Glycine 0 C--N 1.333 0.404 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.459 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 21.7 t -67.54 116.2 6.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-O 120.711 0.291 . . . . 0.0 110.923 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.338 -1.257 . . . . 0.0 112.192 -179.842 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo . . . . . 0 N--CA 1.488 1.155 0 N-CA-C 111.565 -0.206 . . . . 0.0 111.565 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 71.91 148.52 0.09 Allowed 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 120.812 0.339 . . . . 0.0 111.062 -179.665 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.1 t -112.05 142.56 24.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -135.96 162.25 33.38 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.448 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.38 125.32 53.04 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.785 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.516 HG13 ' HB ' ' A' ' 39' ' ' VAL . 20.8 t -111.33 134.07 54.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.105 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.584 ' O ' HG21 ' A' ' 39' ' ' VAL . 16.9 mt-10 -105.71 112.87 26.11 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.404 ' O ' HG23 ' A' ' 73' ' ' VAL . 4.9 t -87.77 116.85 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 CA-C-O 120.84 0.352 . . . . 0.0 111.28 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.813 ' HB3' ' HB3' ' A' ' 35' ' ' PRO . . . -81.54 89.72 6.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.861 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.404 ' HG3' ' CE2' ' A' ' 15' ' ' TYR . 5.3 ttp180 -56.14 120.97 8.38 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.116 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.97 -88.1 0.29 Allowed Glycine 0 C--N 1.334 0.442 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.738 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -121.33 -73.5 0.65 Allowed 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.64 0.257 . . . . 0.0 110.76 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -121.11 31.96 6.15 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.111 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -178.26 -169.61 39.31 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.582 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.56 ' OH ' HG22 ' A' ' 67' ' ' ILE . 24.4 m-85 -133.17 -64.42 0.73 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 120.655 0.264 . . . . 0.0 111.27 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.03 47.24 0.08 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.814 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -156.73 172.31 18.83 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 120.708 0.289 . . . . 0.0 110.813 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.5 m -117.56 110.72 18.29 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.954 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.5 126.15 49.46 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.119 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 73.5 m -152.06 107.56 3.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.55 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.95 79.63 0.15 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.704 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.85 -45.88 30.57 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.03 0.443 . . . . 0.0 110.018 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.944 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -115.57 -67.35 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.24 178.523 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.944 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 90.3 Cg_endo -85.1 95.55 0.65 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 122.605 2.204 . . . . 0.0 112.155 179.158 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.635 ' SG ' HG21 ' A' ' 63' ' ' VAL . 80.8 m -53.27 118.91 4.16 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.679 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 p -146.79 149.63 15.65 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.393 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.463 HD22 HD22 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -87.48 93.61 9.46 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.319 179.401 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -46.91 -43.98 19.38 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.485 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.509 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 1.7 t -172.37 158.53 4.38 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.173 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.5 t -126.04 154.95 35.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.616 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 6.7 mtp -100.33 101.59 12.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 121.153 0.501 . . . . 0.0 110.66 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.1 mtm-85 -49.96 123.95 9.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.39 16.7 10.75 Favored Glycine 0 CA--C 1.523 0.583 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.75 -179.176 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -120.98 166.68 15.03 Favored Pre-proline 0 CA--C 1.531 0.221 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.486 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.813 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 71.0 Cg_exo -49.27 -31.39 22.25 Favored 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.989 2.46 . . . . 0.0 113.346 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.61 -49.06 51.63 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.587 -0.278 . . . . 0.0 111.139 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.36 -32.47 73.88 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.486 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 20.9 m-30 -58.06 -29.25 65.24 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.457 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.584 HG21 ' O ' ' A' ' 7' ' ' GLU . 18.7 t -89.53 -32.73 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.226 0 CA-C-O 120.696 0.284 . . . . 0.0 110.948 179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.45 51.39 0.16 Allowed Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.123 -0.56 . . . . 0.0 112.66 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.682 ' CD2' HD13 ' A' ' 78' ' ' ILE . 2.8 mt -116.55 129.3 56.1 Favored 'General case' 0 C--O 1.231 0.098 0 CA-C-O 120.574 0.226 . . . . 0.0 110.817 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -137.6 -152.9 0.46 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -99.58 148.14 24.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.799 179.6 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.3 -21.33 46.08 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.975 -0.631 . . . . 0.0 113.214 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.65 ' CG ' HD12 ' A' ' 78' ' ' ILE . 0.9 OUTLIER -69.9 116.86 10.77 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.883 0.341 . . . . 0.0 110.827 -179.853 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.53 132.09 37.06 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.425 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 27.2 mt -84.34 120.42 35.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.74 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.0 -40.37 5.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.402 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.512 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -128.88 135.99 49.83 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.626 0.25 . . . . 0.0 111.097 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.448 ' O ' HG13 ' A' ' 53' ' ' ILE . 4.8 t -135.73 110.09 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.186 179.53 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 75.99 33.71 0.58 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -178.73 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 77.6 -5.13 2.18 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 115.15 -0.932 . . . . 0.0 112.706 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.796 HD11 ' CD1' ' A' ' 66' ' ' LEU . 2.2 pp -116.71 130.82 70.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.948 0.404 . . . . 0.0 111.403 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -67.11 141.62 57.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.691 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.604 HG13 HD12 ' A' ' 53' ' ' ILE . 4.2 m -142.68 51.16 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.413 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.2 mtpp -58.16 -35.27 71.31 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.657 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -137.2 34.62 2.55 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.694 0.283 . . . . 0.0 111.03 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.537 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -78.13 -172.9 2.96 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.843 0.354 . . . . 0.0 111.556 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.616 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.4 OUTLIER -94.55 141.0 29.11 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.275 0.56 . . . . 0.0 110.791 179.738 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.697 ' O ' HG22 ' A' ' 64' ' ' VAL . 1.1 t-160 -52.86 -43.29 65.98 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.443 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.429 ' HA ' ' CG2' ' A' ' 64' ' ' VAL . 2.7 mt-10 -66.53 -35.06 79.32 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.457 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -71.59 -38.39 70.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.798 0.332 . . . . 0.0 110.286 179.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.635 HG21 ' SG ' ' A' ' 25' ' ' CYS . 46.6 t -66.47 -44.89 90.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.042 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.697 HG22 ' O ' ' A' ' 60' ' ' HIS . 2.9 m -66.42 -39.19 83.45 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.39 -39.18 82.57 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.972 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.796 ' CD1' HD11 ' A' ' 53' ' ' ILE . 14.3 mt -66.03 -41.99 90.19 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.864 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.924 ' HA ' HD13 ' A' ' 74' ' ' LEU . 31.5 mt -68.11 -41.41 84.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.762 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.74 8.73 19.64 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.954 178.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 2.0 tttp -111.61 -4.0 14.9 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 116.943 0.371 . . . . 0.0 111.071 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.469 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 26.4 p -50.62 -47.56 58.23 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 122.536 0.334 . . . . 0.0 111.71 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.8 t 68.74 31.71 4.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.004 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 150.02 -37.51 0.94 Allowed Glycine 0 C--N 1.335 0.499 0 C-N-CA 120.715 -0.755 . . . . 0.0 113.062 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.469 ' C ' ' HB2' ' A' ' 70' ' ' CYS . 7.8 p -172.05 138.07 0.35 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.234 0 CA-C-O 120.894 0.378 . . . . 0.0 112.012 -179.657 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.924 HD13 ' HA ' ' A' ' 67' ' ' ILE . 3.8 tp -111.04 139.77 46.12 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.111 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -100.95 101.52 12.33 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.29 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 35.5 ttm -103.44 125.1 49.84 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.97 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.512 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 40.5 t -97.86 103.61 14.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.511 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.682 HD13 ' CD2' ' A' ' 41' ' ' LEU . 14.7 pt -106.72 168.31 3.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.468 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -149.91 155.2 39.58 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.703 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.34 135.37 42.95 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -141.61 -87.98 0.12 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.449 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.0 t -86.3 -35.49 9.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.496 0.188 . . . . 0.0 110.975 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.27 -1.294 . . . . 0.0 112.624 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo . . . . . 0 N--CA 1.486 1.07 0 CA-C-O 120.147 -0.022 . . . . 0.0 112.087 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.39 178.83 0.13 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 120.869 0.366 . . . . 0.0 111.501 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 20.4 t -131.44 148.93 32.67 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.98 167.5 21.99 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.657 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 m -102.94 135.19 45.07 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.919 HG11 HD12 ' A' ' 41' ' ' LEU . 25.1 t -115.69 131.84 66.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.109 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -113.05 120.51 41.59 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.105 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 73' ' ' VAL . 12.7 t -104.92 134.18 47.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.179 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -103.55 98.79 8.62 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.039 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -48.84 124.11 8.04 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.268 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.41 118.43 0.45 Allowed Glycine 0 CA--C 1.52 0.353 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER 78.51 90.0 0.06 Allowed 'General case' 0 C--O 1.235 0.34 0 CA-C-O 121.393 0.616 . . . . 0.0 110.396 -179.22 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 71.15 34.26 1.85 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.548 -1.206 . . . . 0.0 111.569 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 -113.1 3.6 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.837 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.45 ' HB3' HG11 ' A' ' 8' ' ' VAL . 79.3 m-85 -110.64 -66.32 1.08 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.414 0.149 . . . . 0.0 111.171 -179.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.17 61.14 0.2 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.894 -0.67 . . . . 0.0 113.351 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -166.41 167.79 15.46 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 120.556 0.217 . . . . 0.0 111.183 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -120.34 150.84 40.11 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.007 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -137.62 124.32 21.08 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.363 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 m -140.15 15.74 2.43 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.092 -0.503 . . . . 0.0 112.021 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -85.65 84.36 1.59 Allowed Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.417 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -44.2 -61.98 1.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.795 0.331 . . . . 0.0 110.783 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.904 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -94.29 -62.81 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.881 178.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.904 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 92.0 Cg_endo -85.84 96.45 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.925 0 C-N-CA 122.76 2.307 . . . . 0.0 111.915 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.524 ' SG ' HG21 ' A' ' 63' ' ' VAL . 37.0 m -55.8 124.95 19.25 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.567 -179.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.16 143.8 17.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.395 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.771 HD22 HD22 ' A' ' 41' ' ' LEU . 0.4 OUTLIER -80.81 90.62 5.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.462 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 5.8 p -53.8 -38.44 64.52 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.473 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 8.1 t -161.75 153.41 18.89 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.836 0.351 . . . . 0.0 111.447 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.3 t -116.23 155.38 17.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.554 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.3 mtp -97.79 100.35 11.72 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 121.236 0.541 . . . . 0.0 110.791 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 1.4 mtm-85 -53.74 124.23 14.61 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.892 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.13 -24.04 21.88 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.534 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.414 ' CB ' ' HD2' ' A' ' 35' ' ' PRO . 0.4 OUTLIER -82.5 166.61 35.36 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 110.533 179.722 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 34' ' ' SER . 11.0 Cg_endo -53.95 -23.53 28.35 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 123.19 2.593 . . . . 0.0 113.186 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.59 76.91 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.887 0.375 . . . . 0.0 110.731 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -68.24 -27.1 66.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.194 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -55.97 -24.31 37.6 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 112.141 0.422 . . . . 0.0 112.141 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.748 HG11 HG13 ' A' ' 6' ' ' VAL . 34.8 t -89.09 -29.21 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 111.034 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.86 43.95 2.17 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.518 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.919 HD12 HG11 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -74.25 176.42 6.67 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 120.913 0.387 . . . . 0.0 110.762 179.857 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.519 ' H ' HD23 ' A' ' 41' ' ' LEU . 4.1 mtp85 -139.0 116.95 11.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.44 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.53 101.03 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.801 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.35 -21.26 3.47 Favored Glycine 0 CA--C 1.524 0.606 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.407 -179.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -58.24 123.31 15.62 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 120.633 0.254 . . . . 0.0 110.8 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -66.68 127.87 34.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.089 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.72 HD11 HD12 ' A' ' 27' ' ' LEU . 21.2 mt -85.27 125.89 40.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.573 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.492 ' N ' HD12 ' A' ' 48' ' ' LEU . 6.9 mp -98.76 -70.27 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.575 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.504 ' HA ' ' HA ' ' A' ' 54' ' ' ASN . . . -99.99 143.94 29.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.739 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.445 HG23 ' CG2' ' A' ' 55' ' ' VAL . 18.6 t -135.84 113.94 15.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.428 ' O ' ' HG2' ' A' ' 52' ' ' GLU . 5.1 t-20 76.38 33.05 0.55 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -177.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 78.74 -1.78 2.37 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 115.189 -0.914 . . . . 0.0 113.074 179.72 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.794 HD11 ' CD1' ' A' ' 66' ' ' LEU . 5.4 pt -115.65 133.0 63.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-O 120.817 0.342 . . . . 0.0 111.827 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.504 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 42.8 t30 -66.83 130.22 42.45 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.143 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.472 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 15.3 m -137.28 59.57 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.965 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 2.9 mmtm -51.91 -72.46 0.05 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.999 -179.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.2 mttt -111.72 39.55 2.34 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.255 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.472 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -73.86 -175.93 2.29 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.515 -179.462 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.632 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -88.44 134.67 33.78 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.443 0.639 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -53.04 -44.76 67.64 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.689 -1.142 . . . . 0.0 111.419 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.472 ' HA ' HG22 ' A' ' 64' ' ' VAL . 3.7 pm0 -66.36 -34.7 78.56 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.184 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.6 -39.31 70.6 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.728 0.299 . . . . 0.0 110.443 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 59' ' ' SER . 41.4 t -67.02 -43.36 89.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.497 ' HA ' HD12 ' A' ' 67' ' ' ILE . 29.8 m -65.93 -38.71 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 1.9 mtmp? -57.87 -39.38 77.67 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.881 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.794 ' CD1' HD11 ' A' ' 53' ' ' ILE . 7.5 mt -67.41 -43.28 81.65 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.761 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.83 HG23 ' HG ' ' A' ' 74' ' ' LEU . 13.8 mt -65.66 -38.03 81.36 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.981 179.564 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -86.61 3.77 86.76 Favored Glycine 0 CA--C 1.524 0.645 0 C-N-CA 120.913 -0.661 . . . . 0.0 113.015 179.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 4.6 tptm -86.91 -34.88 19.23 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.824 0.312 . . . . 0.0 111.25 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -71.66 -57.86 4.01 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.809 0.338 . . . . 0.0 110.86 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.1 m 64.65 36.02 8.61 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.072 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.13 -44.13 0.02 OUTLIER Glycine 0 C--N 1.331 0.296 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.434 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.1 p -162.12 137.08 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 CA-C-O 120.985 0.421 . . . . 0.0 111.385 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.83 ' HG ' HG23 ' A' ' 67' ' ' ILE . 1.9 mm? -112.6 134.37 54.17 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.523 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -117.09 96.36 5.41 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.999 179.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 16.5 ptt? -122.01 156.31 33.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.791 -179.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 19.7 t -111.42 109.73 29.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.735 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 pt -106.1 139.39 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.304 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -105.86 125.15 50.65 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.154 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -87.31 122.55 31.23 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.696 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.55 145.7 4.85 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.428 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m -67.82 95.1 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 120.976 0.417 . . . . 0.0 111.169 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.435 -1.203 . . . . 0.0 112.179 -179.624 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_endo . . . . . 0 N--CA 1.492 1.398 0 CA-C-O 120.943 0.31 . . . . 0.0 112.183 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 15.4 ttm-85 -105.6 -43.72 4.86 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.832 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -118.56 156.84 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.566 ' HD3' HD11 ' A' ' 78' ' ' ILE . 4.0 ttt85 -114.05 141.21 47.74 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 120.883 0.373 . . . . 0.0 111.1 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.0 m -110.9 137.16 48.88 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.664 179.518 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.756 HG11 HD22 ' A' ' 41' ' ' LEU . 16.7 t -111.8 136.01 49.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.756 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -134.59 100.84 4.76 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.535 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.645 ' O ' HG23 ' A' ' 73' ' ' VAL . 11.2 t -106.47 150.51 9.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.276 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -99.4 98.54 9.45 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.988 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 50.9 ttp85 -50.71 120.67 4.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.696 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.73 -107.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.705 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -118.28 -39.94 2.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.419 0.152 . . . . 0.0 111.249 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -111.3 32.19 5.53 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.668 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.11 -137.96 14.57 Favored Glycine 0 C--N 1.335 0.491 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.828 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.41 ' O ' ' HD2' ' A' ' 35' ' ' PRO . 80.2 m-85 -116.17 -83.33 0.63 Allowed 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.633 0.254 . . . . 0.0 111.19 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.61 55.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.265 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.525 ' HZ ' HG21 ' A' ' 67' ' ' ILE . 14.3 p90 -143.31 166.83 23.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.631 0.253 . . . . 0.0 110.756 179.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.1 m -113.92 142.03 46.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.943 0.401 . . . . 0.0 111.479 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 mt -133.89 122.87 23.78 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.943 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.8 m -146.92 169.37 19.29 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.31 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 121.91 -37.51 2.88 Favored Glycine 0 C--N 1.336 0.532 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.509 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.404 ' HA ' ' HB2' ' A' ' 60' ' ' HIS . 0.0 OUTLIER 81.55 -48.92 0.24 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.286 0.635 . . . . 0.0 111.493 -179.817 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.896 ' HB3' ' HD3' ' A' ' 24' ' ' PRO . . . -100.97 -65.09 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.438 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.896 ' HD3' ' HB3' ' A' ' 23' ' ' ALA . 91.5 Cg_endo -80.55 96.21 1.0 Allowed 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.292 1.994 . . . . 0.0 112.318 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 60.0 m -61.37 115.66 4.04 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.334 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.84 142.46 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.154 -179.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.648 HD12 HD11 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -75.87 90.98 2.96 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.468 179.743 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 69.4 p -53.2 -36.59 61.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.308 -179.715 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.443 ' HA ' ' HB2' ' A' ' 43' ' ' ALA . 3.0 t -167.22 158.63 12.13 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.237 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.592 HG21 ' HA ' ' A' ' 42' ' ' ARG . 11.8 t -119.08 154.97 21.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.858 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 30.8 mtt -98.28 101.85 13.42 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 121.21 0.529 . . . . 0.0 110.623 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 26.8 mtt-85 -51.84 123.69 10.82 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.22 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 106.07 -22.3 31.72 Favored Glycine 0 CA--C 1.521 0.438 0 C-N-CA 120.938 -0.649 . . . . 0.0 113.071 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.448 ' HB3' ' HD2' ' A' ' 35' ' ' PRO . 1.6 m -83.47 168.01 25.04 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.711 0.255 . . . . 0.0 110.658 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.448 ' HD2' ' HB3' ' A' ' 34' ' ' SER . 73.6 Cg_exo -50.43 -25.51 14.23 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 123.033 2.489 . . . . 0.0 113.448 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -62.26 -47.8 82.74 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 120.868 0.366 . . . . 0.0 111.024 179.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -68.96 -26.73 65.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.31 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.4 m-30 -54.98 -28.71 53.79 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 111.674 0.249 . . . . 0.0 111.674 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.763 ' HB ' HD23 ' A' ' 41' ' ' LEU . 22.6 t -89.43 -34.4 6.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.147 0 CA-C-O 120.83 0.347 . . . . 0.0 111.037 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.6 -11.81 15.88 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.747 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.763 HD23 ' HB ' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -64.58 127.59 32.16 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 179.918 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.592 ' HA ' HG21 ' A' ' 30' ' ' VAL . 1.7 mmm180 -115.51 -146.52 0.4 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.249 -179.687 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.443 ' HB2' ' HA ' ' A' ' 29' ' ' CYS . . . -95.11 159.19 15.13 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.926 0.393 . . . . 0.0 110.908 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.24 -33.52 6.1 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.577 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -61.39 118.56 7.11 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.79 0.328 . . . . 0.0 110.989 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.02 131.44 35.31 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.679 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.648 HD11 HD12 ' A' ' 27' ' ' LEU . 8.3 mm -87.38 124.55 40.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.5 179.68 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.439 HD22 ' N ' ' A' ' 48' ' ' LEU . 3.5 mm? -105.49 -46.51 4.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.352 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.561 ' HB3' ' HB ' ' A' ' 77' ' ' VAL . . . -120.49 139.2 53.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.195 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 53' ' ' ILE . 9.0 t -140.79 109.27 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.487 179.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.405 ' HB2' ' HB3' ' A' ' 66' ' ' LEU . 0.1 OUTLIER 76.54 34.21 0.48 Allowed 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.878 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER 76.02 -3.4 2.57 Favored 'General case' 0 CA--C 1.537 0.481 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.773 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.882 HD11 HD11 ' A' ' 66' ' ' LEU . 1.1 pt -114.27 120.5 64.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 CA-C-O 121.047 0.451 . . . . 0.0 111.312 179.501 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.559 ' HA ' ' HA ' ' A' ' 49' ' ' ALA . 2.5 m120 -64.71 131.84 47.98 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.054 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.503 ' HB ' ' HB3' ' A' ' 58' ' ' ALA . 5.8 m -131.11 55.97 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.355 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.9 mtmt -59.88 -40.5 88.94 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.188 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.0 mttp -136.35 30.84 2.92 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.061 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.503 ' HB3' ' HB ' ' A' ' 55' ' ' VAL . . . -75.93 -169.22 1.05 Allowed 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.272 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -92.01 135.0 34.3 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.47 0.652 . . . . 0.0 110.616 179.713 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.742 ' O ' HG23 ' A' ' 64' ' ' VAL . 4.9 t60 -54.44 -44.6 72.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.818 -1.083 . . . . 0.0 111.957 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -63.41 -38.11 89.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.811 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.4 -42.9 82.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.541 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 59' ' ' SER . 42.9 t -65.29 -42.18 93.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.754 179.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 60' ' ' HIS . 47.5 t -65.8 -39.08 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.244 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 178.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.6 mttt -57.64 -39.41 76.92 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.45 -0.796 . . . . 0.0 110.89 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.882 HD11 HD11 ' A' ' 53' ' ' ILE . 11.3 mt -66.57 -43.7 84.26 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.773 179.444 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.757 HG23 HD22 ' A' ' 74' ' ' LEU . 54.0 mt -63.16 -37.96 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.642 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -84.47 11.98 57.02 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.316 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.5 ttpm? -110.32 -16.23 13.77 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 122.406 0.282 . . . . 0.0 111.264 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . 0.403 ' HB2' ' C ' ' A' ' 73' ' ' VAL . 23.3 p -44.2 -50.85 8.61 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 122.576 0.351 . . . . 0.0 111.6 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.5 p 63.26 32.22 14.97 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.454 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.17 -36.73 0.6 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.993 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 8' ' ' VAL . 7.7 p -172.46 136.58 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.179 0 CA-C-O 120.995 0.426 . . . . 0.0 111.917 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.757 HD22 HG23 ' A' ' 67' ' ' ILE . 9.8 tp -114.45 145.0 42.41 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.827 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -119.37 107.11 12.96 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.16 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 1.1 ptp -122.71 135.04 54.46 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.012 0.434 . . . . 0.0 111.239 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.561 ' HB ' ' HB3' ' A' ' 49' ' ' ALA . 41.3 t -94.37 115.1 32.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.642 179.741 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.566 HD11 ' HD3' ' A' ' 4' ' ' ARG . 3.7 pt -107.06 167.05 3.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.551 -179.66 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.82 128.22 26.36 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -74.25 109.82 8.05 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.471 179.788 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 134.72 125.14 2.52 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.287 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m -65.09 120.25 11.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-O 120.814 0.34 . . . . 0.0 111.495 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.219 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.62 -179.91 . . . . . . . . 0 0 . 1 stop_ save_